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Abstract 
The primary aim of this project has been to identify paediatric tumour-specific MHC class I 
phosphopeptide antigens on lymphoblastoid cell lines LCLs (an in vitro model for PTLD) as 
well as paediatric hepatic tumour clinical samples. Tumour specific T-cells are notoriously 
difficult to maintain in long-term culture and as a result it is difficult to establish an ‘off the 
shelf’ T-cell product, however the secondary aim of this project was to explore potential 
modalities for capturing the T-cell receptor (TCR), important in recognising tumour specific 
antigens and the resultant product could be used to establish a non-patient-specific, but tumour 
specific product. In order to achieve this we have used T-cell hybridomas as one modality and 
also Human Induced Pluripotent Stem Cell (hIPSc) technology to immortalise tumour specific 
T-cells. Following on from this we have developed a technology for expanding these and 
differentiating them into a T-cell of interest with potential for future clinical application in 
paediatric tumours, using OP9 DL1 mouse feeder cell system to support differentiation of 
hIPSc towards haemopoietic lineage, demonstrating functionality of the end stage ‘T-cell 
product’. 
In summary we have identified a number of novel phosphopeptide antigens in vitro as well as 
on patient tissues. This information has been used to identify potential T-cell targets and by 
formation of hIPSc we have established a method for expanding specific T-cell’s in vitro. Using 
OP9DL1 cells we have also identified a method for differentiating these cells into lymphocyte-
like cells with T-cell functionality therefore representing a possible methodology for expanding 
tumour-specific T-cells for clinical application. 
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Chapter 1:  INTRODUCTION 
1.1 Background 
Cancer remains a significant challenge with current treatments being toxic and/or inefficient 
and therefore this is an area where research is thriving.  However, cancer as a disease has 
multiple forms and each tumour is different therefore the mechanisms of carcinogenesis and 
how tumours develop and evade the immune system vary from tumour to tumour.  Tumours of 
interest to this project are hepatoblastoma, hepatocellular carcinoma (liver tumours) and post-
transplantation lymphoproliferative Disease or PTLD – a lymphoma-like process occurring 
following organ transplantation.   
There are various mechanisms linked to the development of cancer which could form   potential 
targets for cancer therapies. The immune system plays a somewhat pivotal role in recognising 
pathogens and it is now understood to play a role in preventing tumour growth.  When this 
system is evaded, a tumour can propagate and grow, therefore this is clearly an area where 
much interest has been generated in attempting to identify an anti-tumour therapy.  One of the 
primary problems in tumour immunology relates to tumours developing from ‘self’ cells and 
therefore an appropriate target needs to be sought.  Phosphopeptides could be a new class of 
tumour-specific antigens and may therefore have potential and as a cancer immunomodulatory 
therapy. 
Major Histocompatibility Complex (MHC) class I restricted phosphopeptides have been 
identified as being a likely contributor to the anti-tumour T-cell response in cancer (Zarling, 
Polefrone et al. 2006, Cobbold, De La Pena et al. 2013, Abelin, Trantham et al. 2015) and 
therefore the first aim of this project was to identify phosphopeptides on the tumour surface 
and their role in tumour recognition (Chapter 3).  
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As identified as a valuable in vitro human model of post-transplant lymphoproliferative disease 
(PTLD) by Dr Penny of this group, lymphoblastoid cell lines (LCL) have been used to determine 
the relative proportion of the anti-tumour CD8+ T-cell responses that are thought to recognise 
phosphopeptides (Chapter 3). The use of phosphatases allows for discrimination of anti-tumour 
versus anti-viral peptide responses to be described.  In Chapter 4, specific MHC class-I restricted 
phosphopeptides associated with hepatoblastoma were identified and analysed, and their pattern 
compared to adult tumours (Hepatocellular carcinoma).  Following on from this, specific T-cell 
responses to tumour associated phosphopeptides were further explored in tumour-infiltrating 
lymphocytes (TILS) and peripheral blood from patients as well as in healthy donors with 
characterisation of healthy donor responses to target phosphopeptides identified. 
The second aim of this project was to identify mechanisms for promoting longevity in culture of 
T-cells.  T-cell hybridomas and viral transduction of T-cells were both explored as potential 
modalities for achieving this. 
 
1.2  Cancer 
Cancer remains the leading cause of death globally, and the World Health Organisation figures 
suggest that there were an estimated 12.7 million cases around the world in 2014 (WHO 2014, 
NIH 2015). This has been predicted to reach 21 million by the year 2030. Cancer is a collection 
of diseases with one thing in common – the ability of cells to multiply without any control 
mechanism and invade into surrounding tissues.  Usually cells divide and multiply in the 
healthy state, but are stopped from growing further (and needlessly) by contact inhibition.  
Cancerous cells lose this and therefore grow uncontrolled. These cells continue to survive 
becoming progressively more abnormal transitioning from metaplasia to dysplasia and 
eventually neoplasia (malignant change). This is considered to be a dynamic process, with 
reversibility exhibited in the early dysplastic changes. 
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Cancer cells can evade programmed cell death or apoptosis via a variety of mechanisms (Evan 
and Vousden 2001).  They are also influential on surrounding cells and blood vessels – therefore 
manipulating what is commonly referred to as the tumour microenvironment (Hanahan and 
Weinberg 2000).   
Hanahan and Weinberg first described the characteristics of cancer in 2000 where they 
identified six processes that a cancer collectively uses to survive and metastasize (Hanahan and 
Weinberg 2000).  In order to achieve sustained malignant change, a cancer must be able to 
sustain proliferative signalling, induce angiogenesis, evade growth suppressors, resist cell 
death, activate cell invasion and metastasis and enable replicative immortality. This original 
influential work was revised in 2011, and an additional two characteristics employed by cancer 
cells were described – the capability to modify cellular metabolism and thus effectively support 
neoplastic proliferation and allow cancer cell to evade immunological destruction (Hanahan 
and Weinberg 2011).   
The authors have subsequently expanded on the concept of ‘hallmark switching’ by which 
tumour treatments targeting just one of these hallmarks can be evaded by the tumour and 
resistance develops, and therefore they propose therapeutic ‘co-targeting’ of more than one 
hallmark in the evolution of cancer medicine – an area of research which is ongoing (Hanahan 
and Coussens 2012, Hanahan 2014).  This is not without controversy however. These original 
seminal papers were based around the concept of somatic mutation theory of carcinogenesis, 
which suggests successive DNA mutations in a single cell.  This relies on the assumption that 
(1) cancer is a defect of control of proliferation and (2) The default cell state is quiescence. 
Two recent papers have been critical of the original manuscript and have challenged this theory, 
proposing an alternative paradigm, including one paper suggesting that a number of the original 
'hallmarks' described by Hanahan could also be considered as being characteristic of non-
cancerous tumours as well. They went on to discuss that the only true hallmark of malignant 
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disease is actually its ability to invade adjacent tissues and metastasize further afield via 
induction of angiogenesis amongst other mechanisms (Lazebnik 2010). A further critique in 
2013 suggested the original data was flawed for the majority of the hallmarks as the processes 
described were at a cellular level and cancer itself is a tissue-level disease.  They concluded 
that these observations were therefore misleading. They proposed an alternative mechanism 
following re-evaluation of the original data (Sonnenschein and Soto 2013) whereby the default 
state of cells is that of proliferation, and carcinogenesis is related to a defect in tissue 
architecture. 
 
As a paediatric hepatology trainee working in a national tertiary transplant centre, I have chosen 
the focus of this PhD project to be on hepatoblastoma, hepatocellular carcinoma and PTLD. 
Each will be considered separately.  
 
1.2.1 Primary Hepatic Tumours in childhood are rare.  The incidence is quoted in the texts 
as being between 0.5-2.5 per million population. Locally within the West Midlands region, this 
has been noted to be in the region of 1.2 per million person years, with the incidence of 
hepatoblastoma and hepatocellular carcinoma being 0.77 and 0.09 per million person-years 
respectively (Mann JR 1990). To consider this in context, this equates to between 10-15 new 
diagnoses of hepatoblastoma and 1-2 new diagnoses of hepatocellular carcinoma per annum. 
The aetiology of hepatic tumours is well described, and summarised in table 1.1 below.  In 
hepatoblastoma, genetics plays a key role, whereas in hepatocellular carcinoma, chronic liver 
disease and environmental exposures appear to play a bigger role. 
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HEPATOBLASTOMA HEPATOCELLULAR CARCINOMA 
GENETIC 
o Beckwith Wiedemann Syndrome 
o Simpson-Golabi-Behmel 
Syndrome 
o Hemihypertrophy 
o Familial adenomatous polyposis 
(FAP) 
o Gardner Syndrome 
o Glycogen Storage Disease type 1 
o Trisomy 18 
GENETIC 
o Tyrosinemia Type 1 
o Progressive familial intrahepatic cholestasis 
type 2 
o Alpha-1-antitrypsin deficiency 
o Glycogen storage disease type I and IV 
o Neurofibromatosis 
o Familial Adenomatous polyposis (FAP) 
o Fanconi Anaemia 
ENVIRONMENTAL 
o Fetal Alcohol Syndrome 
o Prematurity 
o Low birthweight 
o Oral contraceptives 
o Gonadotrophins 
o Metals 
o Petroleum products 
o Paints/pigments 
o Meckel Diverticulum 
ENVIRONMENTAL 
o Any cirrhotic liver disease  
o Androgens 
o Oral contraceptives 
o Methotrexate 
o Aflatoxins 
 
INFECTIVE 
o Hepatitis B 
o Hepatitis C 
Table 1.1 An overview of aetiology of hepatic tumours in childhood 
1.2.2  Hepatoblastoma (HB) is a rare paediatric embryonal tumour (comprising ~1% of 
paediatric neoplasms (Otte 2010)), often affecting patients <4 years of age (91% cases) (Allan, 
Parikh et al. 2013).  Indeed, presentation >4y of age is considered a poor prognostic factor. 
There is a male preponderance of 3:2. Incidence of HB has been shown to be increasing over 
time, with annual incidence currently being 0-05-0.15 per 100,000 paediatric population in 
America (Allan, Parikh et al. 2013). Tumour cells have been shown to evolve from hepatic 
stem cells (HSCs). 
Presentation is most commonly with a mass, as well as non-specific symptoms of anorexia, 
pain, vomiting and rarely jaundice.  It is often associated with a raised α-fetoprotein (AFP).  
AFP is a glycoprotein which is 70kDa in size.  It is synthesized in the foetal yolk sac, and gut 
(Gregory and Finlay 1999).   Although it is a high plasma concentration of AFP which often 
signposts HB as a potential diagnosis, a low plasma concentration of AFP at diagnosis in fact 
confers a poor prognosis (Koh, Park et al. 2011).  AFP is thought to relate to tumour burden 
and therefore can be used as a monitoring tool to show responsiveness to treatment (Lovvorn, 
Ayers et al. 2010).  Histological classification of HB has recently been revised in an 
	
	
6	
international consensus group (Lopez-Terrada, Alaggio et al. 2014).  Here the disease is 
subdivided into (a) ‘Epithelial’ including foetal, embryonal, macrotrabecular small-cell 
differentiated, cholangioblastic or (b) ‘Mixed’ including stromal derivative or teratoid.  
Treatment options include chemotherapy (cisplatin) followed by resection or transplantation 
dependent on the extent of disease and whether there are any residual metastases following this 
treatment.  Although some patients present with resectable disease, the majority do not. 
PRETEXT is the classification given to hepatoblastoma and refers to the extent of spread of 
disease (table 1.2). Based on an original paper by the International Childhood Liver Tumour 
Strategy (SIOPEL) group, staging was interpreted using Couinaud’s segmentation model 
(Couinaud 1999, Abdalla, Vauthey et al. 2002, Roebuck, Aronson et al. 2007, Koh, Park et al. 
2011).  The liver is approximately divided up into 4 sections: right posterior (segments VI and 
VII), right anterior (segments V and VIII), left medial (segment IV) and left lateral (segments 
II and III).  Using this classification pre-chemotherapy, patients are divided into one of four 
groups.  Vascular involvement is also taken into account (Roebuck, Aronson et al. 2007). 
PRETEXT No. Definition 
I One section is involved only 
II One or two sections are involved, the 
remaining two sections are free of disease 
III Two or three sections are involved 
IV All four sections are involved 
Table 1.2 Definitions of the PRETEXT numbers, based on original definitions by the International Society of 
Pediatric Oncology (Societe Internationale d’Oncologie Pediatrique, SIOP). 
 
HB had a survival rate of 20-30% in 1970’s, however with the introduction of newer regimes 
comprising cisplatin and doxorubicin in the early 1990’s, this survival rate has improved 
markedly with newer drugs continuing to be introduced (Ninane, Perilongo et al. 1991).  
Overall survival is currently in the region of ~65% (Ruth, Kelly et al. 2010).  In 2000, a multi-
centre study reported a 5-year event–free survival of 66% and overall survival of 75%, 
following the introduction of combination treatment regimens consisting of four induction 
cycles of combination cisplatin and doxorubicin, followed by surgical resection of the primary 
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tumour/liver transplantation, if amenable, followed by two further courses of chemotherapy, 
(Pritchard, Brown et al. 2000). They also reported that of the 150 patients included, 118 
(78.7%) achieved at least a partial response to chemotherapy which is promising indeed to the 
overall improvement in survival rates.  Following this initial data, a further multi-centre study 
also considered introduction of combination cisplatin/doxorubicin.  This study found complete 
surgical resection of HB was possible in 115 patients (76.2%) either by partial hepatectomy 
(55.6%) or by primary liver transplantation (20.6%). As a result, an event-free (EFS) and 
likewise overall survival (OS) demonstrated at 3 years were found to be 65% (95% CI, 57% to 
73%) and 69% (95% CI, 62% to 77%) respectively for the whole group (Zsiros, Maibach et al. 
2010). 
Multiple signalling pathways have been implicated in HB carcinogenesis e.g. 
phosphatidylinositol 3 kinase-Akt (PI3K-Akt)  and the insulin-like growth factor 2 (IGF2) 
pathways (Tomizawa and Saisho 2006, Hartmann, Kuechler et al. 2009).  More recently, β -
catenin mutations (Wnt signalling pathway) have been implicated in the development of 
‘sporadic’ hepatoblastomas, occurring in up to two thirds of patients (Chen, Kozielski et al. 
2012).  β-catenin is an effector of Wnt-signalling, playing a role in cell-to-cell adhesion, 
growth, survival and differentiation. In the healthy state, β-catenin is complexed to E-
cadherin/α-catenin and found in the plasma membrane. GSK3-β and CK1 phosphorylate excess 
β-catenin at four cytoplasmic N-terminal serine-threonine residues.  The ubiquitin-proteasome 
pathway is able to degrade phosphorylated β-catenin. Wnt signalling inhibits GSK3-β activity, 
leading to stabilisation of the β-catenin allowing for nuclear translocation and subsequent 
activation of transcription factors including Tcf/Lef. In cancer, there are loss of function 
mutations which lead to constitutive activation of β-catenin (Peifer and Polakis 2000, Polakis 
2000). The Wnt/ β -catenin signalling pathway plays a pivotal role in embryonic development 
and has been shown to be necessary for stem cell maintenance.  It has been implicated in liver 
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development and regeneration, and has a possible role in constitutive activation and thus the 
aetiology of HB (Korinek, Barker et al. 1998, Korswagen, Clevers et al. 1999, Clevers 2006).  
It is perhaps not surprising then that this pathway is associated with hepatoblastoma given its 
embryonal origins (Armengol, Cairo et al. 2011). Aberrant Wnt signalling is considered a key 
feature of hepatoblastoma, related to mutations in the β -catenin gene.  As a result of mutational 
activation, HB may develop from HSCs or progenitors. Due to the finding in HB of 
mesenchymal derivatives a multipotent progenitor has been postulated with aberrant signalling 
appearing to disrupt/disturb the intricate relationship between proliferation and differentiation, 
resulting in the well differentiated foetal-type HBs. Fig. 1.1 demonstrates the possible 
mechanisms of action (Armengol, Cairo et al. 2011).   
 
Fig. 1.1 Schematic representation of the differentiation of hepatic stem cells. (a) Normal differentiation of 
hepatic stem cell into cholangiocyte and hepatocyte via hepatoblast stage (b) the effect of Wnt signalling on 
differentiation of cells at different stages of maturation results in development of a hepatoblastoma 
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1.2.3  Hepatocellular carcinoma is a very rare paediatric tumour (being more common in 
adults).  It differs from hepatoblastoma as it usually occurs in the context of chronic liver 
disease, rather than occurring in isolation (table 1.1).  It also tends to affect the older age group.  
Presenting symptoms are similar to those with hepatoblastoma, although jaundice has been 
more commonly reported in this group of patients.  The mechanism of development is scarring 
and regenerative nodules which have the potential to become malignant due to progressive 
dysplastic change.  It can also be found in association with hepatitis infection (fig. 1.2). 
Treatment is resection with adjuvant chemotherapy or liver transplantation in the absence of 
distant metastases.  Survival is ~50% with death occurring due to tumour recurrence 
(Thorgeirsson and Grisham 2002).   
 
Fig. 1.2 The transformation of healthy liver into hepatocellular carcinoma.  Liver is exposed to inflammatory 
processes such as chronic hepatitis B or C infection, metabolic dysfunction e.g. tyrosinemia, obstruction of bile 
flow.  This leads to inflammation of the liver (hepatitis) which if left will progress to cirrhosis and regenerative 
nodules.  This process can be reversible if the inflammatory trigger is removed, however ongoing inflammation 
will eventually lead to progressive dysplasia and eventual evolution into a hepatocellular carcinoma (HCC). 
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During the course of chronic liver disease several mutations are predicted to occur which 
subsequently accumulate in liver cells, resulting in a profound dysregulation of major 
signalling pathways that have been found to be important for malignant transformation. As a 
result, these pathways have become a major target for cancer treatments in hepatocellular 
carcinoma (HCC). For instance, the perceived survival benefits achieved with sorafenib, a 
kinase inhibitor, have been previously unheard of and serve to highlight the importance of 
understanding how signalling differs in malignant transformation. A number of key signalling 
pathways have become dysregulated in HCC, in particular those implicated in growth factor 
signalling, cell differentiation and angiogenesis – all of the pathways which have been 
implicated in other tumours, and those which are intimately related to the mechanisms 
described by Hanahan (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011). RAS and 
AKT/MTOR have also been identified as possible key pathways which could have a role in the 
development of HCC. A number of mechanisms have shown disordered pathway activation 
including point mutations, chromosomal aberrations, and down-regulation. Novel technologies 
such as next-generation sequencing (NGS) in HCC research identified a number of pathways 
which had not previously been associated with the development of HCC e.g. autophagy. 
Investing research time and effort into these newer pathways could potentially lead to 
alternative drug/therapeutic targets. 
Phenotypically altered hepatocytes have been demonstrated to have high epidermal growth 
factor receptor (EGFR) expression and also possess a number of potential epigenetic changes 
which are considered non-committal. These may go on to become dysplastic and show more 
committed genetic changes, e.g., increased telomerase activity. This may ultimately result in 
development of an HCC with additional genetic changes, e.g., an increase in c-myc and 
decrease in p16 expression, amongst others (Moeini, Cornella et al. 2012).  
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1.2.4  Post-transplant lymphoproliferative Disease (PTLD) is caused by B-cell proliferation 
resulting from necessary therapeutic immunosuppression after organ transplantation; with 
infection by Epstein-Barr virus (EBV) implicated as the trigger (fig. 1.3).  EBV interacts with 
its host in three ways: (i) EBV infects B-lymphocytes leading to proliferation of infected cells, 
(ii) subsequently, it enters a latent phase in vivo. (iii) Finally, it can be reactivated leading to a 
rise in the production of infectious material leading to infection of cells of the same cell type 
or transmission to another individual.  
 
Fig. 1.3.  Schematic representation to show effect of immunosuppressive agents on development of PTLD.  
(A) shows normal situation, where T-cells recognise transformed B-cells and eradicate them.  (B) shows the 
situation when immunosuppression is used such as calcineurin inhibitors, which work by reducing the number of 
circulating T-cells thus allowing for transformed B-cells to proliferate, leading to possibility of PTLD formation 
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B-cell immortalization and the lytic cycle leads to production of infectious particles. 
Polymerase chain reaction (PCR) analyses used in conjunction with fluorescent-activated cell 
sorting (FACS) has delineated the virus-host interaction in peripheral blood cells in vivo.  
It has been identified that in some patients, a malignant cell clone becomes the dominant cell 
type, and its proliferation results in development of B cell lymphomas (fig. 1.8). This was first 
described by Henle and colleagues in the 1960’s (Henle, Diehl et al. 1967, Diehl, Henle et al. 
1968). They identified that B-cells were induced by EBV to rapidly divide and proliferate in 
an exponential manner leading to an immortal B-cell clone and establishment thereof of a 
lymphoblastoid cell lines (LCL) in vitro. Based on this observation they established that these 
cells would form an ideal model to study EBV infection viral-induced tumour development 
(Keiff E 2001).  This process is intimately controlled by an intracellular transcription factor 
EBV nuclear antigen 2 (EBNA-2), which expresses its influence over 9 separate latent viral 
proteins and is driven by ‘The Growth Programme’ which refers to the pattern of gene 
expression seen in this process (Thorley-Lawson 2001).   
Healthy carrier individuals possess EBV-infected B-cells, but they are all memory B-cells 
which are considered latent or ‘resting’ and thus do not express viral protein (Miyashita, Yang 
et al. 1997, Babcock, Hochberg et al. 2000). Only those cells which possess the ‘Growth 
Programme’ have potential for tumour development and these cells are only found in the lymph 
nodes (Babcock, Hochberg et al. 2000, Joseph, Babcock et al. 2000). This pattern of B-cell 
viral segregation appears to be maintained in all individuals, including those who are 
immunocompromised.  It has been noted that the number of EBV-infected B-cells in an 
immunocompromised patient can be at least 50 times more than in a healthy individual with 
competent immune system. EBV has been postulated to be able to transform latently infected 
cells into actively proliferating blast cells, allowing for the conversion thereof of these cells 
into memory B-cells thus making them non-pathogenic.  
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EBV has been found to be associated with a number of diseases including autoimmune disease 
and cancer (Cohen 2000, Crawford 2001, Keiff E 2001). There is strong evidence for an 
association between EBV and cancer. For instance, immunosuppressed patients are at an 
increased risk for B-cell lymphoproliferative diseases, e.g. PTLD (Thomas, Hotchin et al. 
1990). Impaired cytotoxic T-cell response (due to immunosuppressive agents) allows for the 
unchecked growth of EBV-infected cells. Two events must occur to allow for expression of the 
growth program evolution of lymphoma (i) firstly the EBV-infected cell is not allowed to exit 
the cell cycle and therefore fails to transform into a resting memory B cell, resulting in 
continuous, unchecked proliferation due to a lack of effective T-cell immunity, and (ii) the 
cytotoxic T-cell response is prevented from destruction of lymphoblasts, proposed as resulting 
in the heterogeneity seen in this disease (Timms, Bell et al. 2003).  Even in those patients who 
are immunocompromised, this transformation has to be a rare event as very few actually 
develop a tumour. This bolsters the view that EBV-driven in vivo proliferation must be a closely 
regulated process.   
The incidence of PTLD is between 1% to 25% of solid organ transplant patients and it is 4 
times higher in paediatric transplant patients versus adults (due to their likelihood of being 
EBV seronegative pre-transplant compared to adult recipients).   It has been shown to occur in 
3% of liver transplant recipients and 18% of intestinal transplant recipients.  Prognosis is poor 
with overall 5 year survival between 25-65% (Haque, McAulay et al. 2011, Wistinghausen, 
Gross et al. 2013, Lee 2015, Dharnidharka, Webster et al. 2016). 
Cells possessing the oncogenic protein LMP-1 (which induces expression of BCL2 leading to 
inhibition of apoptosis) are kept in check by cytotoxic T lymphocytes (CTL’s) and Natural 
Killer (NK) cells, whereas cells without LMP-1 persist leading to latent infection with the 
potential for reactivation.  Following immunosuppression, cells which express the oncogenic 
protein LMP-1 are allowed to grow uninhibited due to reduction in circulating CTLs (as a result 
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of the immunosuppressive agents) and there is the potential for malignant transformation and 
resultant PTLD (Jacobson and LaCasce 2010). 
Tacrolimus and cyclosporin are calcineurin inhibitor agents used post-transplant as part of the 
immunosuppressant regimen to prevent organ rejection, by inhibiting T-cell function, therefore 
leading to unchecked B-cell proliferation. Anti-T cell antibodies (such as basiliximab, 
daclizumab) leads to T-cell depletion, and is often used in conjunction with standard 
immunosuppression protocols to prevent or treat organ transplant rejection, but at the expense 
of increased risk for the development of PTLD. The level of immunosuppression needed to 
prevent rejection is directly proportional to the risk of developing PTLD, i.e. in small bowel 
transplant trough tacrolimus levels are 3-4 fold higher than those needed in liver transplant for 
instance.  PTLD can spontaneously regress simply by reducing or stopping immunosuppressive 
agents.  It could also be treated with anti-viral agents, however in some cases it will continue 
to progress resulting in non-Hodgkin's lymphoma which can be fatal (Jacobson and LaCasce 
2010).   
 
1.2.5 Summary 
Cancer results in major morbidity and mortality, and although the cellular basis to each tumour 
type is varied as is its location, it has a number of common mechanisms for evading the immune 
system all of which can be potential targets for cancer immunotherapy (Hanahan and Weinberg 
2011).  By understanding the pathways involved potential targets may be identified. 
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1.3  The Basics of Immune System 
The immune system has evolved in order to provide protection from a growing number of 
pathogens, who themselves are likewise evolving. It is broadly split into two specific parts 
(Dranoff 2004) – the Innate and Adaptive Immune Systems (Table 1.3).   
 
Innate Immunity Adaptive Immunity 
Macrophage B-cell à antibodies 
Mast cell T-cell à CD4, CD8 cells 
Dendritic cells  
Granulocytes àNatural killer (NK) cells, 
basophil, eosinophil, neutrophil 
 
Γδ T-cells 
NK T-cells 
Table 1.3 Table to show the division of immune systems as described by Dranoff, 2004.  There is interplay 
between both systems with crossover demonstrated by γδ T-cells and NK T-cells, playing a role in both. 
 
1.3.1 Innate immunity is the first line of defence comprising the physical barriers to prevent 
infection e.g. tight junctions and mucus layers. It also comprises a variety of immune cells such 
as eosinophils, phagocytes and Natural Killer (NK) cells, all of which can produce 
proteinaceous materials which aid in the defence of the host against pathogen e.g. ficolins or 
complement. The innate immune response does not generate memory. 
 
1.3.2 Adaptive immunity comprises the responses resulting from somatic gene rearrangement.  
It comprises specialised B and T-cells.  Memory recall is the main feature of this type of 
immune response i.e. cells that persist in an apparently dormant state but have the ability to re-
express effector functions when challenged with the same antigen again in the future. T and B 
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lymphocytes express antigen-specific receptors on their cell surfaces.  Selection and expansion 
of these receptors can take up to 7 days. Two classes of response exist: B-cell antibody 
responses and the T-cell mediated responses.   
B-cells secrete immunoglobulins (antibodies) in response to antigen.  The antibodies circulate 
and bind to the specific foreign antigen (that had initially stimulated their production).  There 
are three main mechanisms of action:  (1) opsonisation, (2) neutralization and (3) complement 
activation. These antibodies are made up of heavy and light chains comprised of highly variable 
domains and constant domains denoted as Fab and Fc respectively (Delves P 2006), allowing 
complex interactions with other effector cells and immune system molecules. Light chains 
comprise both a single constant and a single variable immunoglobulin (Ig) fold domain which 
will be either κ or λ chains. Heavy chains are made up of a single variable and three or four 
constant domains. Heavy chains are responsible for determining the class and therefore 
function of the antibody (IgA, IgD, IgE, IgG or IgM).  As a result of Ig rearrangements, 
antibody diversity can be generated.  This can be achieved in a variety of ways for example (i) 
different combinations of heavy and light chains; (ii) recombination of different variable (V) 
gene segments on the heavy or light chains, diversity (D) segments or Junctional (J) segments; 
(iii) addition or loss of nucleotides at the VDJ junction or (iv) mutation of the variable regions 
of either heavy or light chains. It is the hinge region between variable and constant domains 
which allows for flexibility to bind with the antigen. 
 
1.3.3 T-cell ontogeny Haematopoietic stem cells are generated in the bone marrow and go on 
to form B-cells which are maintained there; whereas T-cells mature in the thymus, where they 
begin to express antigen receptors.  
Upon being released from the thymus, these cells are considered naïve due to no previous 
antigen exposure. However, once they recognise their cognate antigen in the secondary 
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lymphoid organs (spleen and lymph nodes) they mature to become potent effector cells capable 
of clearing infections.  It is likely development of an immune profile relates to environmental 
exposure.  There are 3 processes of lymphocyte development:  
(1) Proliferation of immature cells  
(2) Expression of antigen receptor genes  
(3) Selection of lymphocytes that express useful antigen receptors.   
The Nuclear factor-kappaB (NFKB) family of transcription factors has remained essentially 
unchanged throughout evolution, and they are thought to play a significant role in host immune 
responses to pathogen. Studies of NFKB deficient mice have identified its role in the 
development of T-cells and B-cells, ensuring lymphocyte survival at various developmental 
stages. In autoimmune disease, this function is bypassed leading to, for example, survival of 
self-reactive lymphocytes or tumour cells (Siebenlist, Brown et al. 2005).   
CD4-CD8- double negative (DN) thymocytes evolve into CD4+CD8+ double positive (DP) cells 
within the thymus and eventually to progress further to either CD4+ or CD8+ single positive 
(SP) thymocytes, which exit the thymus entering the peripheral circulation (fig 1.10). Double 
negative thymocytes progress through four stages of development: DN stage 1, at which they 
are CD25-CD44+; DN stage 2, CD25+CD44+; DN stage 3, CD25+CD44-; and DN stage 4, 
CD25-CD44-. DN cells in early stage 3 undergo TCR beta-chain gene rearrangement and 
expression. NF-kappaB appears to be important for this transition between DN stage 3 and DN 
stage 4. To investigate T-cell ontogeny further extra-uterine CD4 T-cell development was 
considered.  Previous studies have shown that the immune system develops rapidly in the first 
year of life and this is proposed to be due to extrauterine triggers (Kotiranta-Ainamo, Apajasalo 
et al. 1999, de Vries, de Bruin-Versteeg et al. 2000, Berrington, Barge et al. 2005).  During this 
early post-natal period, the development of immune phenotypes predict the risk of development 
of infective illnesses or  an immune-related disorder (Shearer, Rosenblatt et al. 2003, Zhu and 
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Paul 2008, Romero, Stolberg et al. 2013).  The relative proportions of basic lymphocyte subsets 
have been shown in a number of studies to vary with age.  Although data exists relating to this 
transition from birth to adolescence, there is a lack of longer term data to support the ongoing 
transition through older age (Rellahan and Cone 1990, Kozyrskyj, Bahreinian et al. 2011).  
T-cells comprise half the circulating lymphocytes in the early newborn period.  These cells 
have derived from precursors having undergone selection, and possess a low affinity for self-
peptides. The CD4-cells comprise two subsets: T helper cells and T regulatory cells (Treg).  
These T-cells tend to be naïve on the whole, however this population of naïve cells reduces 
during early infancy so that by age 6 months the memory CD4+ T-cells increase in numbers as 
immune challenges occur. Gender differences also occur which persist throughout the first year 
of life (Tsao, Chiang et al. 2002, Surh and Sprent 2008, Zhu and Paul 2008). 
 
1.3.4 T-cell responses – T-cells play a pivotal role in both humoral and cell mediated immune 
responses. T-cells recognise antigen presented to them via the T-cell receptor (TCR).  The TCR 
is similar in structure to immunoglobulin, however rather than recognising native protein, it 
recognises peptides complexed to major histocompatibility complex (MHC) molecules of the 
cell surfaces.  These antigens are presented by Antigen Presenting Cells (APC).  Variation of 
the TCR is generated in a similar fashion to a single antibody Fab fragment.  It is encoded by 
α and β polypeptide chains, each containing a single constant and variable region. TCR gene 
rearrangement initially relies on rearrangement of the β polypeptide chain, with Dβ to Jβ, 
followed by Vβ to DJβ.  This is then followed by α chain rearrangement.  In addition to αβ T-
cells, there is a distinct subset of T-cells possessing γδ chains instead of α and β polypeptide 
chains, thus called γδ T-cells. 
Following TCR rearrangement, T-cell selection occurs in the thymus.  Selection occurs in order 
to remove T-cells with non-desirable characteristics – i.e. to eliminate those T-cells which are 
	
	
19	
either harmful or ineffective.  The first stage is positive selection.  Here, TCRs are tested against 
self-peptide/HLA complexes which are expressed on the cortical epithelial cells.  Those TCRs 
which have moderate affinity for self-peptide receive a positive signal to continue growing and 
maturing.  Lack of interaction results in cell death.  Co-receptor expression is then modified to 
match MHC restriction.  The next stage is negative selection.  During negative selection, 
potentially autoreactive cells expressing TCRs with high affinity for self-peptide/HLA 
complexes are removed by apoptosis.  Cells surviving this second stage of selection then enter 
the circulation as mature naïve T-cells, waiting to be activated by professional APCs, such as 
dendritic cells (DC) to become functional. DCs work in three ways: (1) a signal is delivered by 
TCR engagement with the peptide/HLA complex and CD4 or CD8 ligation, (2) co-stimulatory 
molecules deliver a further signal to the complex (3) cytokines cause the differentiation of the 
T-cell into a specific type. 
One of the best characterised co-stimulatory molecules involved in the second stage signalling 
as described above are the B7 molecules.  These are homodimeric molecules of the Ig 
superfamily, specifically expressed on APCs. Two of the founding members of the B7 family, 
CD80 (B7-1) and CD86 (B7-2), each bind to the activating receptor, CD28, or the counter-
regulatory inhibitory receptor, cytotoxic T-lymphocyte antigen 4 (CTLA4). Ligation of CD28 
by B7 molecules is necessary for the clonal expansion of naïve T cells and induction of IL-2 
receptor expression. CTLA-4 is upregulated on T cells to dampen responses after activation, 
and reduce inflammation.  
Several tumour necrosis factor (TNF) family members that are expressed by APCs can co-
stimulate T-cell activation, by binding to specific TNF receptor family members expressed on 
T-cells. Most of these TNF receptor family members are upregulated on T-cell activation, 
indicating that the role of this family might be to amplify responses once initial T-cell activation 
has occurred. TNF receptors include: 4-1BB, which binds 4-1BB ligand; CD27, which binds 
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CD27 ligand (CD70); OX40, which binds OX40 ligand; and Light-R, which binds Light. The 
third signal varies between the different types of T-cells. For cytotoxic T cells, this can be IL-
2 provided by the T-cells themselves, but may also be IL-12 or type-I interferon (IFN) produced 
by other cells in the local environment. CD4 T-cells are capable of a much more diverse range 
of functions, and stimulation to differentiate into the different types of CD4 cells are provided 
by different cytokine profiles (Table 1.4). 
 
Table 1.4: Different T-cell subsets can be defined by their differentiation, cell marker and cytokine profiles, 
which thus determined their functions and targets.  Table modified from original by Dr S Penny, with permission. 
 
T-cells exert their effect through the production of effector molecules, such as perforin and 
granzymes, Fas-Ligand (FasL), and cytokines that induce activation of other cells. There are 
several classes of T-cells, defined by their stimuli, effector function, accessory molecule 
expression, and the type of MHC complex that they recognise (table 1.4). This thesis will focus 
mainly on cytotoxic (CD8+) T-cells. 
T-cell 
type 
Function Target Differentiation 
Profile 
Cell 
marker 
Cytokine profile 
Cytotoxic Kills infected 
cells 
Virus 
Bacteria 
Tumour 
IL-2, IL-12, IFN, T-
bet TF, Eomes 
CD8 MIP-3α, TNFα, 
IFNγ, IL-2  
TH1 Cellular 
Immune 
Response 
Bacteria 
Blood-borne 
parasites 
IL-2, IL-12, IL-18, 
IL-27, T-bet, IFNγ 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 
IL-2, IL-10, IFNγ, 
TNFα, TNFβ/LTα  
TH2 Support of B-
cells 
Extracellular 
parasites and 
toxins 
IL-2, IL-4, IL-6, IL-
25, IL-31, IL-33, 
GATA3 
IL-3, IL-4, IL-5, IL-
6, IL-10, IL- 13, IL-
25, IL-31  
TH9 Intestinal 
protection 
Parasite IL-4, PU.1/IRF-4, 
TGFβ  
IL-9, IL-10  
 
TH17 Defence against 
extracellular 
microorganisms 
Bacteria/fungi RORγt, TGFβ, IL- 
1β, IL-6, IL-21, IL-
23 
IL-17A, IL-17F, IL-
17AF, IL-21, IL-22, 
IL-26, GM-CSF, 
MIP- 3α, TNFα  
TH22 Tissue repair Skin/gut/lung IL-6, TNFα  CCL15, CCL17, 
FGF family, IL- 22, 
TNFα  
TReg Response 
suppression 
 FoxP3, IL-2, TGFβ  CD4, 
CD25 
IL-10, IL-35, TGFβ  
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In the peripheral circulation, two thirds of T-cells are CD4+, the remainder being CD8+. It is 
the CD4+ T-cells which have the ability to activate both humoral and cellular responses. 
CD8+ cells recognise and show cytotoxic activity towards intracellular pathogens or malignant 
transformed cells, they also have a suppressor cell subset which can down-regulate these 
immune responses. In response to antigen exposure and recognition, both CD4+ and CD8+ T-
cells are able to differentiate in order to mount a suitable response to target.  For instance, 
resting naïve CD4+ cells will only release limited amounts of cytokine prior to antigen 
stimulation however after stimulus IL2 is released and the cells progress from TH0 to TH1, 
TH2 and TH17 depending on the cytokines present.  TH1 cells release IL-2, IFN-γ, and 
lymphotoxin. TH2 cells release IL-4, IL-5, IL-9, IL-13, and GM-CSF as well as expressing the 
transcription factor GATA3. In general, TH1 cells can be considered to relate to cell-mediated 
immune responses, and TH2 cells are considered more the humoral and allergic responses. 
Cytotoxic CD8+ T cells also have discrete type 1 and type 2 cytokine responses, designated 
cytotoxic T cell type 1 and cytotoxic T cell type 2.   
Approximately 5% to 10% of T-cells in the peripheral blood, and secondary lymphoid organs 
are DN (CD4−CD8−). These cells use either αβ TCRs or γδ TCRs. These cells do not recognize 
antigen in the context of MHC class I or II directly, however some can recognize related antigen 
for example the MHC-class I–related protein CD1 which has been adapted to present the 
respective glycolipid components of various pathogens. A further example relates to the DN 
subset of γδ T-cells which recognizes the MHC class I chain–related proteins or MIC.  
Antigen-specific T-cells have proven clinical utility in a range of diseases from targeting 
tumours such as melanoma and leukaemia to the control of viral disease such as Epstein Barr 
virus (EBV), adenovirus, influenza (Flu) and Cytomegalovirus (CMV). However, highly 
expanded disease-specific T-cell populations are not very effective, which can in part be 
	
	
22	
explained by their gradual loss of function as a result of ex vivo processing of the patient 
autologous T-cells.   
In response to this limitation a number of techniques have been employed to try to establish a 
T-cell line which is stable and retains its features such as cytotoxicity and IFNγ release.  This 
has generated a vast amount of recent research interest in stem cells as a potential source of 
cells which despite controversy is a clear target for possible future investment. 
 
1.3.5 Major Histocompatibility Complex (MHC) - MHC molecules, also known as Human 
Leukocyte Antigens (HLA) present peptide antigen to T-cells.  The major histocompatibility 
complex (MHC) locus, also known as the human leukocyte antigen (HLA) locus, spans around 
4 Mbp on the short arm of chromosome 6 (6p21.3).  MHC-I molecules comprise a 45kDa heavy 
chain of three extracellular domains, covalently linked to beta-2-microglobulin (12kDa).  There 
is a peptide binding groove which can accommodate a peptide between 8 and 13 amino acids 
in length.  MHC-II molecules are similar but consist of an alpha (30kDa) and beta (33kDa) 
chain and possess an open ended binding groove with the ability to accommodate peptides of 
longer length.  Class I genes are expressed on all nucleated cells, whereas class-II associated 
genes are only expressed on the surface of antigen presenting cells (e.g. B cells or 
macrophages).  This study focusses primarily on MHC Class-I therefore class-II will not be 
discussed further at this stage. 
There are three major antigens of the human class I MHC system: HLA-A, HLA-B and HLA-
C.   The MHC heavy chains are located on chromosome 6 at 3 different loci named human 
leukocyte antigen (HLA) -A, -B and -C.  They are highly polymorphic, as there are well over 
1500 different heavy chains which have been identified, and each individual expresses six HLA 
alleles, two from each locus.  The peptide-binding domain is responsible for the polymorphism 
seen, as is the domain interacting with the TCR. This TCR will be peptide specific and domain 
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specific. Each HLA molecule has its own set of peptides to which it will bind, which is 
controlled by the physical shape of the peptide-binding groove. Molecules encoded by this 
region are involved in antigen presentation, inflammation regulation, the complement system, 
and the innate and adaptive immune responses, indicating the MHC’s importance in immune-
mediated, autoimmune, and infectious diseases. 
MHC-restricted antigen recognition, or MHC restriction, refers to the fact that a given T-cell 
can interact with both the self-major histocompatibility complex molecule and the foreign 
peptide that is bound to it, but will recognize and respond to the antigen, only when it is bound 
to a particular MHC molecule.  Foreign particles enter a cell and are broken down to smaller 
particles (peptides).  These peptides are then presented on the surface of the infected cell by 
MHC.	 MHC restriction is important for self-tolerance. As described previously, due to a 
process of selection in the thymus T-cells die by apoptosis if they express high affinity for self-
antigens presented by an MHC molecule or express too low an affinity for self MHC. MHC 
restriction allows TCRs to detect host cells that are infected by pathogens, contains non-self 
proteins or foreign DNA.  However, MHC restriction is also involved in presenting peptide to 
T cells in chronic autoimmune diseases and type IV hypersensitivity. 
Two models have been proposed to explain the imposition of MHC restriction. The Germline 
model proposes that MHC restriction results from co-evolution of TCR and MHC to interact 
with each other. The Selection model suggests that MHC restriction is imposed on TCRs by 
CD4 and CD8 co-receptors during positive selection.  Supporting the selection model argument 
is the observation that T cells genetically modified to not possess CD4 and CD8 co-receptors 
express MHC-independent TCRs (Tikhonova, Van Laethem et al. 2012, Van Laethem, 
Tikhonova et al. 2012). 
Of direct relevance to the current project is the concept of antigen cross-presentation by 
dendritic cells.  The presentation of exogenous antigens on MHC class I molecules, known as 
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cross-presentation, is essential for the initiation of CD8+ T-cell responses.  Naive antigen-
specific CD8+ T-cells, however, cannot directly eliminate transformed or infected cells. To 
become effector cytotoxic T lymphocytes (CTLs), naive CD8+ T cells need first to be activated 
by 'professional' antigen-presenting cells (APCs). When the APCs are not directly infected, 
they need to acquire exogenous antigens from the infectious agent and present them on MHC 
class I molecules, by a mechanism known as cross-presentation.  Cross-presentation is the 
ability of certain antigen-presenting cells to take up, process and present extracellular antigens 
with MHC class I molecules to CD8 T cells is required in order for immunity to viruses and 
tumours to develop (Bevan 1976).  It is also implicated in cancer vaccines where protein 
antigens are introduced to allow host immunity to develop. 
Cross-presentation allows the presentation of these exogenous antigens, which are normally 
presented by MHC II on the surface of infected dendritic cells to be also presented by MHC I 
without infecting the dendritic cell. Cross-presentation allows the dendritic cell to avoid using 
the endogenous proteasomal processing pathway.  Although this process primarily involves 
dendritic cells, macrophages, B-lymphocytes and sinusoidal endothelial cells have also been 
implicated. 
Two main intracellular pathways for the cross presentation of exogenous antigens have been 
described (1) the ‘cytosolic’ and (2) ‘vacuolar’ pathways. The cytosolic pathway is sensitive to 
proteasome inhibitors. The Proteasome-generated peptides are able to feed into the classical 
MHC class I mediated antigen presentation pathway.  This has been previously described as 
involving the transport of peptides into the endoplasmic reticulum (ER) by transporter 
associated with antigen processing 1 (TAP1) and TAP2 for loading on newly formed MHC 
class I molecules. This contrasts with the vacuolar pathway, which has previously been shown 
to be resistant to proteasome inhibitors and generally independent of TAP, but is sensitive to 
inhibitors of lysosomal proteolysis (Joffre, Segura et al. 2012).   
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1.4 The role of the immune system in tumour suppression The concept of immune 
surveillance was first described by Frank MacFarlane Burnet nearly 60 years ago where he 
described a process thus ‘in large long-lived animals, like most of the warm-blooded 
vertebrates, inheritable genetic changes must be common in somatic cells and a proportion of 
these changes will represent a step toward malignancy. It is an evolutionary necessity that there 
should be some mechanism for eliminating or inactivating such potentially dangerous mutant 
cells and it is postulated that this mechanism is of immunological character’ (Burnet 1957, 
Burnet 1957).  Since this first observation, there has been much debate as to this statement’s 
validity (Fuchs and Matzinger 1996, Smyth, Godfrey et al. 2001, Willimsky and Blankenstein 
2005, Senovilla, Vitale et al. 2012).  In 2001, in stark contrast to the theory of 
immunosurveillance it was proposed that cancer may even be promoted by inflammation – a 
concept introduced by Balkwill and further expanded over the succeeding years (Balkwill and 
Mantovani 2001, Mantovani, Allavena et al. 2008, Balkwill and Mantovani 2012).  
 
1.4.1 The role of the immune system in tumour suppression – evidence in mouse models  
Burnet wrote in relation to the theory of immunosurveillance that cancer should be more 
common in the face of immunodeficiency, a concept that can be explored in an array of mouse 
models for both primary and secondary immunodeficiency (Burnet 1957). There is compelling 
evidence that this prediction is true with a link between severe immunodeficiency and 
susceptibility to cancerous processes being demonstrated by a number of authors (Gatti and 
Good 1971, Smyth, Godfrey et al. 2001, Swann and Smyth 2007, Salavoura, Kolialexi et al. 
2008, Senovilla, Vitale et al. 2012). 
Schreiber’s work on the cancer immunoediting hypothesis has helped develop the concept that 
the immune system can not only recognise and remove cancers, but it can also drive them into 
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a dormant state, which in some cases, leads to enhanced malignant potential.  The focus of 
Schreiber’s research work was the concept of immunosurveillance in cancer pathogenesis. The 
original ‘immune surveillance’ hypothesis proposed that tumour cells arise naturally and are 
normally eradicated by the immune system (Burnet 1957). Tumours would, therefore, only 
arise if evasion of the immune system were possible, or if the immune system were 
compromised. This theory was tested by Stutman assessing whether athymic, nude mice which 
lack an adaptive immune system have an increased incidence of tumours (Stutman 1974).  He 
found no difference between nude mice and wildtype, which inevitably led to the theory that 
the immune system played no role in preventing the initiation or the prevention of tumours. 
With the knowledge that the innate immune system was intact in the nude mice that Stutman 
had used, Schreiber repeated these experiments using a strain of mice he bred to lack both 
innate and adaptive immunity. These mice lacked the recombination activating gene (RAG) 
required for adaptive immune responses and the STAT1 gene that is required for innate 
responses (Meraz, White et al. 1996).  In 2001, it was reported that RAG2 knockout mice, i.e. 
those which lack an appropriate adaptive immune system (T and B cells), had a far higher rate 
of development of malignancy compared to immunocompetent wildtype mice (Shankaran, 
Ikeda et al. 2001).  This led to the revival of the original hypothesis that the immune system 
somehow played a pivotal role in tumour surveillance and led to the proposed concept of 
‘cancer immunoediting’ the means by which tumours are able to escape the immune system 
recognition by losing their antigenicity (Dunn, Old et al. 2004, Dunn, Old et al. 2004, Dunn, 
Bruce et al. 2005, Dunn, Koebel et al. 2006). 
These studies have been critical in forming the scientific basis of many of the immune mediated 
strategies currently being tested in patients as anti-tumour regimens. Not only do these studies 
confirm that the immune system plays a hugely important role in tumour cell destruction, but 
they support the idea that better understanding of immunological recognition and regulation 
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will lead to breakthroughs in our ability to eradicate tumors using the immune system. Mice 
which have been genetically modified to lack certain components of the immune system such 
as RAG2 mice (which lack T and B-cells due to deficiency in the RAG2 - Recombination-
activating gene 2) are more susceptible to carcinogen-induced carcinomatosis.  Cytokines have 
also been demonstrated to be protective (in particular interferon α/β and γ) (Kaplan, Shankaran 
et al. 1998, Dunn, Bruce et al. 2005, Dunn, Koebel et al. 2006).  But are mice a good proxy for 
what happens in humans?  It is notable that in humans, they manage largely to avoid cancer 
until after the fifth decade of life on the whole, despite more than 1,000-fold greater cellularity 
and more than 20-fold longer life spans than mice.  This would suggest that the mechanisms in 
human are perhaps more sophisticated or at least more efficient than those in mice. 
 
1.4.2 The role of the immune system in tumour suppression – evidence in humans As is 
demonstrated in immunocompromised mice, immunodeficiency can be speculated to be 
responsible for development of tumours in humans also.  This is clearly demonstrated in 
patients with HIV for instance and PTLD. It is well described that patients with HIV are several 
thousand times more susceptible to Kaposi’s sarcoma (secondary to Human Herpesvirus 8 
infection) and at least 70 times more likely to acquire Non-Hodgkin lymphoma (due to EBV 
infection) – and it can be postulated that this may be due to a deficiency in the immune 
regulation and monitoring for disease.  Patients who have received an organ transplant and are 
prescribed immunosuppression are far more susceptible than their healthy counterparts to 
developing PTLD secondary to B-cell proliferation in response to viral infection (EBV).  It 
may therefore be postulated that these malignancies are secondary to an exaggerated viral 
response.  Although this may well be the case – it is also notable that these subsets of 
immunocompromised patients are in general more susceptible to tumours than the general 
population without a virus being implicated, which would suggest that it is not solely due to 
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viral responses (Cadranel, Garfield et al. 2006, Grulich, van Leeuwen et al. 2007).  The latter 
paper was a meta-analysis of a number of studies and found that there was an increased risk in 
patients who were post-transplant or with HIV/AIDS for certain types of epithelial tumour 
including lung.  In patients with immunodeficiency such as HIV/AIDs and those patients on 
immunosuppressive agents post-transplant for instance, increased rates of malignancy have 
been noted such as myeloma, renal, leukaemias and melanoma (Grulich, van Leeuwen et al. 
2007) – fig. 1.4. 
 
Fig. 1.4: Standardised incidence ratios  for development of cancers occurring at increased rates in 
HIV/AIDs or post-organ transplant – This demonstrates patients who are immunosuppressed increased risk of 
development of malignancy, suggesting an intact immune system will protect a patient from development of 
malignancy (Grulich, van Leeuwen et al. 2007) . 
 
1.4.3 The role of the Immune System in tumour suppression – Tumour Immune Evasion 
The fact that tumours have the ability to evade the host immune response makes designing any 
anti-cancer therapy challenging.  The mechanisms of immune evasion have been known about 
for a number of years, and they do indeed form the basis of Hanahan’s hallmarks of cancer 
(Hanahan and Weinberg 2011). 
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Two broad categories have been described as to how the developing tumour can evade the 
immune system: (1) tolerance induction by the developing tumour and (2) resistance to killing 
by activated immune effector cells.  These categories can be further subdivided:  
a) Downregulation of tumour antigen presentation 
Delineation of tumour from self, results from antigen recognition by T-cells.  Carcinogenesis 
is characterised by genetic instability which is believed to result from inactivation of p53 for 
instance. Neoantigens result from this genetic instability leading to tumour growth and 
progression (Stronen, Toebes et al. 2016).  As a result of deletion of b2-microgobulin genes, 
global loss of MHC I has also been noted, together with downregulation of Transporter 
associated with Antigen Processing (TAP) genes and components of the immunoproteosome 
such as the immunoproteosome subunit LMP-2. Downregulation of MHC class-I pathway has 
been identified in a number of solid tumours including  lung, breast and prostate (Salmaninejad, 
Zamani et al. 2016, Seliger 2016, Dunn and Rao 2017, Garrido, Perea et al. 2017, Reeves and 
James 2017). In the majority of cases, where the MHC class I processing machinery is 
downmodulated, it is usually rapidly upregulated by IFNγ, suggesting that the diminished 
expression is epigenetic in origin and reversible. Downregulation of tumour antigen 
presentation affecting the MHC I pathways has been described as a way that tumours are able 
to evade immune regulation (Johnsen, Templeton et al. 1999).  This downregulation leads to 
tumour expansion and metastasis due to non-recognition by CD8+ cytotoxic T-cells (CTLs).  
In addition to this, other suppressive cytokines such as TGFb, VEGF, CCL21 and IL-10 can 
also lead to reduced CTL functionality.  These factors can recruit or promote differentiation or 
expansion of suppressive immune cells such as Tregs, immature dendritic cells and tumour-
associated macrophages. 
b) Immunologic barriers within the tumour microenvironment  
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One definition of a tumour is its ability to invade normal tissue and metastasize.  Immune cells 
have an important role in inhibiting or promoting cancer through immune surveillance of 
tumours by the mechanism of immunoediting, immunoprocessing, and immunoevasion. 
Immunoevasion is one of the hallmarks associated for a tumour progression. Stromal cells in 
the tumour microenvironment can also actively hinder anti-tumour immunity by several 
mechanisms such as expression of inhibitory receptors, the production of immunosuppressive 
cytokines, production of molecules which induce T cell apoptosis or loss of HLA class 1, and 
costimulatory molecules.  
In both healthy tissues and solid tumours there are two distinct regions: the parenchyma (the 
tumour bed in the context of solid tumours) and a stromal region (part of the tumour 
microenvironment in tumours). The basal lamina, which normally separates these two regions 
in healthy tissues, is typically incomplete in solid tumours, which allows for interaction 
between the tumour and tumour microenvironment resulting in a range of processes such as 
microenvironment-derived factors can influence tumour cell survival, invasiveness and 
metastatic dissemination, as well as access and responsiveness to therapeutics.   
Evidence supports the idea that tumours actively inhibit the release and detection of specific 
‘danger’ signals in order to invade tissues and metastasize without evoking anti-tumour 
immune responses that would otherwise inhibit their growth, thereby converting inflammatory 
responses to those that could instead potentiate tumour growth. An example of where this 
occurs is the Stat-3 oncogenic signalling pathway.  It is constitutively activated in a number of 
tumours resulting in enhanced tumour cell proliferation and an anti-apoptotic effect  (Ok and 
Young 2017, Ok and Young 2017, Shrihari 2017).  In cancer, the Stat3 signalling pathway has 
been shown to inhibit the production of these pro-inflammatory signals and induces expression 
of factors that inhibit functional maturation of dendritic cells (DCs).  This observation makes 
Stat-3 a target for blockade and thus enhancement of the anti-tumour response. 
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c) ‘Disabled’ antigen presenting cells (DC’s) 
Some tumour-derived factors, including IL-10, IL-6, and VEGF, can induce Stat3 activation in 
DCs. This may directly inhibit NFkB signalling, with additional oncogenic signalling in 
tumours which may contribute to inhibition of DC activation within the tumour 
microenvironment as a whole.  
d) T-cell immune tolerance in carcinogenesis 
The immune system has evolved to avoid a CD4-mediated autoimmune reaction by means of 
thymic selection (Van Laethem, Tikhonova et al. 2012).  T cells are the master regulators of 
adaptive immune responses and maintenance of their tolerance is critical to prevent 
autoimmunity. However, in the case of carcinogenesis, the tumour microenvironment aids T-
cell tolerance, which contributes to uncontrolled tumour growth. The primary mechanism of 
self-tolerance is central deletion in which self-reactive T cells are eliminated in the thymus by 
negative selection. This process is incomplete however, and as a result further mechanisms of 
peripheral tolerance have evolved, divided broadly into two types: those that regulate the 
responding state of T cells intrinsically (anergy, apoptosis and phenotype skewing) and those 
that provide extrinsic control (Tregs and tolerogenic dendritic cells). 
Tumours can induce anergy by lacking expression of co-stimulatory signals – thereby engaging 
with the T-cell receptor but failing to stimulate it therefore leading to tolerance (Staveley-
O'Carroll, Sotomayor et al. 1998) i.e. failing to activate the CTL. 
e) Coinhibition 
T-cell activation and effector function is thought to potentially be controlled by a fine balance 
between costimulatory signals such as CD28 and co-inhibitory molecules (Chen 2004, Luo, 
Chapoval et al. 2004, Wang and Chen 2004).  This modulates TCR signals.  Ultimately this 
results in promotion or suppression of T-cell activation.  Timing and location of these 
molecules leads to positive or negative control of a number of functions including growth and 
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differentiation as well as functional maturation of a T-cell response.  These co-stimulatory and 
co-inhibitory molecules are termed receptors/ligands.  A ligand can be a co-stimulator or co-
inhibitor which results from which receptor it interacts with. A well described example is 
CD80/CD86 which following binding with CD28 is co-stimulatory for T-cell responses, but 
can also be a co-inhibitor by interacting with Cytotoxic T-lymphocyte antigen 4 (CTL4a).  A 
ligand also has the ability to become a receptor in certain circumstances if the appropriate co-
inhibitory or co-stimulatory signal is received (Chen 2004). 
f) Regulatory T-cells (Treg) 
CD4 T-cells that are also CD25+ have previously been shown to prevent autoimmunity, and 
infection (Yokokawa, Remondo et al. 2008).  These Tregs induce and maintain self-tolerance 
and immune homeostasis. Tregs prevent autoimmunity and infection, but have also been shown 
to promote tumours. 
There are two broad subsets of Treg (1) natural (nTreg) and (2) induced (iTreg).  Treg present 
in cancer is distinct from that which is thymus derived.  As a result, cancer-induced suppressor 
cells are also referred to as adaptive or inducible Treg (iTreg) and are believed to arise and 
differentiate in the periphery in response to environmental signals such as cytokines.  These 
iTreg have a number of functions including downregulation of anti-tumour immune cells or 
inhibition of tumour progression by reduction in inflammation (Whiteside, Schuler et al. 2012). 
Natural Treg (nTreg) was first described in the early 1990’s as representing a subset of CD4+ 
cells which were also CD25+ and capable of inhibition of immune responses to self and non-
self-antigen (Sakaguchi, Sakaguchi et al. 1995, Miyara and Sakaguchi 2011).  FOXP3 was 
identified as playing a role, as absence of FOXP3+ Treg results in autoimmunity (Miyara and 
Sakaguchi 2011).  It is crucial for the development and function of Tregs. In the healthy donor, 
whenever CD8+ effector and CD4+ helper Treg accumulate in response to local signals, the 
homeostatic balance is maintained by accumulation of FOXP3+ nTreg thus preventing potential 
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tissue damage. In contrast to this, as is seen in tumours, iTreg occurs, which results in 
generation of a pool of highly activated and indiscriminately suppressive inducible Treg, which 
results in the interruption of functions of anti-tumour effector T cells (Whiteside, Schuler et al. 
2012). 
Regulatory T-cells are known to decrease the activity of the immune system through direct and 
indirect interactions. In a study looking in ascitic fluid of women with advanced ovarian 
tumours, the presence of Tregs was associated with reduced survival (Curiel, Coukos et al. 
2004).  Tumour-associated Treg have also been found in a number of other solid tumours 
including lung, prostate, pancreatic, ovarian and breast (Yamamoto, Zou et al. 1995, Liyanage, 
Moore et al. 2002, Curiel, Coukos et al. 2004, Viehl, Liyanage et al. 2004, Zou, Chen et al. 
2004, Barnett, Kryczek et al. 2005). Tregs express chemokine receptors CCR4, CCR5 and 
CXCR1 which allows for migration into tumour sites.  In addition to this, TGFb in the tumour 
microenvironment has been shown to promote the conversion of naïve conventional CD4+ T-
cells to iTregs in tumour mass. Through cell contact-dependent suppression, competitive IL-2 
deprivation and secretion of immunosuppressive cytokines (e.g. IL-1,TGFb, Tregs are able to 
supress the functions of CD4 and CD8+ T-cells, NK cells, NKT cells, macrophages and 
dendritic cells. 
 
g) Immune editing  
Immune editing has been identified as one strategy by which tumours can evade immune 
surveillance/recognition allowing tumours to be present but inactive (and thus often 
undetectable) in patients for years through “equilibrium” and “senescence” before re-emerging. 
In addition, tumours exploit several immunological processes including regulatory T-cells, 
antigen presenting cells and the concept of immune tolerance is also exploited.  To date a 
number of anti-cancer medications exploit the underlying immune surveillance mechanisms 
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with some success including increased production of NK cell, γδ T cell responses or inhibiting 
functionality (Johnsen, Templeton et al. 1999, Swann and Smyth 2007).  These are thought to 
counter the genetic instability caused by tumours and promote anti-growth signalling – 
ultimately leading to tumour rejection. 
The concept of immune editing essentially describes how cancers can evade the immune 
system by virtue of the fact that the immune system is only able to recognise certain cancer 
cells due to their possession of tumour antigens, however as a result of genetic instability not 
all cells will possess these in equal amounts and results in a heterogeneous mix of cells not all 
as immunogenic as each other.  This results in clearance of the most active cells and the rest 
being in a state of equilibrium, dividing and accumulating further mutational variations (Swann 
and Smyth 2007).  There are three phases of immunoediting which describe the fine balance 
between tumour and the immune system: elimination, equilibrium and escape.  During the 
elimination phase, immune cells of the innate and adaptive immune system recognize and 
destroy tumour cells. If the immune system cannot fully eliminate the tumour, the equilibrium 
phase occurs, during which cells remain dormant and the immune system is not only sufficient 
to control growth, but also shapes the immunogenicity of tumour cells. This stage will remain 
or evolve to the elimination or escape phase. In the escape phase, tumour cells have acquired 
various strategies to evade the immune system and establish the dominant tumour immune 
tolerance. 
 
1.5 The role of the Immune System in tumour progression  The “progression model” is a 
well-recognised model which predicts cancers can develop and propagate as a result of a series 
of domino-like mutational events resulting in a number of these cells possessing metastatic 
potential (Nowell 1976, Fidler and Kripke 1977, Minn, Kang et al. 2005).   Angiogenesis and 
tumour seeding/metastasis is propagated by Vascular endothelial growth factor (VEGF) and 
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inducible nitric oxide synthase (iNOS). Control of cell survival, cycling and division is largely 
due to Nuclear Factor-κB (NF-κB) and its production of the pro-inflammatory cytokine TNF-∝  (also a promoter of angiogenesis) (Yamamoto, Zou et al. 1995).   This production of 
cytokines and chemokines allows for the progression of tumours, often at distant sites to the 
original primary tumour. 
 
1.6 Immunotherapies have been a major development in the effective treatment of cancer and 
reduction in morbidity and mortality. It is clearly well established that the host immune system 
can recognise pathogens/microbes such as bacteria/viruses due to their producing foreign 
protein.  However, tumour cells differ only marginally from host cells.  Mutated protein 
expression may account for some of this recognition, but essentially these tumour cells would 
normally use established biochemical pathways as normal cells would.   
 
1.6.1 The history of Immunotherapy and its possible role in cancer treatment 
Immunotherapy first came into existence in the 18th century when scientists explored the 
immune system’s role in fighting infection – most notable is the use of small pox vaccine by 
Edward Jenner.  By 1970’s the first biological agents had been used in humans for the treatment 
of breast cancer (Tamoxifen) (Kiang and Kennedy 1977).  
In 1987, researchers identified cytotoxic T-lymphocyte antigen 4 (CTLA-4) as playing a part 
in preventing T-cells from attacking tumour cells. It was proposed that blocking this could 
result in the immune system being able to actually target these tumours instead. This study 
found that patients with metastatic melanoma lived an average of 10 months whilst being 
treated with the antibody, versus 6 months without it. This randomised controlled trial was the 
first demonstration of enhanced life potential for patients with metastatic melanoma as a result 
of a new cancer treatment (Couzin-Frankel 2013).   
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It had previously been noted that dying T-cells expressed a molecule that was called 
programmed death 1, or PD-1 which was proposed as a blocker of anti-tumour T-cells therefore 
it was hypothesized that an antibody that targeted PD-1 should produce remission. In 2013, 
Couzin-Frankel et al reported that across the 300 cancer patients tumours included in their 
study, cancers had been demonstrated to have shrunk by at least half in 31% of those with skin 
cancer (melanoma), 29% with renal tumours and 17% with lung cancer (Couzin-Frankel 2013). 
In the mid 1990’s, the FDA approved rituximab as the first monoclonal antibody treatment for 
the treatment of follicular lymphoma, following extensive clinical trials (Coiffier, Haioun et al. 
1998, Davis, White et al. 1998). Following on from this, a further 11 antibodies have now been 
approved as adjuvant cancer therapies including alemtuzumab (2001), ofatumumab (2009) and 
ipilimumab (2011).  In 2003 IL-2-activated NK cells were administered together with IL-2 
with a good response noted in metastatic lesions (Yang, Hokland et al. 2003). They concluded 
that adoptively transferred activated-NK cells were able to eliminate even well-established 
metastases. To overcome the adverse effects of intravenously administered cytokines, in vitro 
expansion of cells against a tumour antigen, and reinjection of these cells with appropriate 
stimulatory cytokines was tried instead (Egawa 2004, Li, Li et al. 2005). Sipuleucel-T, was 
approved in 2010 as the first cell-based immunotherapy licensed for the treatment of prostate 
cancer (Waldmann 2003, Strebhardt and Ullrich 2008).  Sipuleucel-T is considered to be a 
personalised treatment for prostate cancer.  It allows the patient’s immune system to seek out 
cancer cells, acting as a therapeutic vaccine.  The treatment cycle has 3 stages: (1) APCs are 
extracted from the patient’s blood and (2) incubated with antigen prostatic acid phosphatase 
(PAP) – present in 95% of prostate tumours, as well as granulocyte-macrophage colony 
stimulating factor (GM-CSF) which aids APC maturation. Finally, (3) the activated blood 
product is reinfused into the patient. 
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After noting the success from harvesting T-cells from tumours, expanding them in vitro prior 
to re-infusion and the observation of reduction in tumour mass, the idea of redirecting the 
specificity of T-cells through genetic engineering was explored. This was first introduced by 
Zelig Eshhar, and has been further developed over time (Gross, Gorochov et al. 1989, Gross, 
Waks et al. 1989, Eshhar and Gross 1990, Eshhar, Waks et al. 1993, Hwu, Yang et al. 1995, 
Eshhar, Waks et al. 1996). Two approaches to improve the potency of the anti-tumour T-cell 
response have been devised; 1) TCR-engineered T-cells where the cells expressing the TCR 
ab heterodimers are modified and transferred and 2) Chimeric antigen receptor therapy, or 
CAR engineered T-cells where the cells are composed of antibody-binding domains fused to 
T-cell signalling domains.  With T-cell receptor (TCR) engineering, T-cells are made more 
potent in their recognition of tumour specific antigens by incorporating TCR constructs which 
activate and co-stimulate T cells in a coordinated immune response against tumour cells. The 
TCRs are engineered to recognise a tumour-specific peptide/MHC combination. With CAR-T 
cell engineering, T-cells are transfected with a CAR construct that combine the specificity of 
an antibody with the cytotoxicity properties of killer T cells. CARs are recombinant receptor 
constructs composed of an extracellular single-chain variable fragment (scFv) derived from an 
antibody, joined to a hinge/spacer peptide and a transmembrane domain, which is further linked 
to the intracellular T cell signalling domains of the T cell receptor. Both these strategies 
represent a shift in patient treatments and we are now entering an era where the drug is a cell 
product designed and repurposed through ex vivo genetic modification (Sadelain et al. Nature 
2017). 
CAR-T and TCR therapies are currently attracting vast amount of investment following 
encouraging clinical trial results and the first CAR-T cell therapy to treat adults with certain 
types of large B-cell lymphoma was FDA approved in October 2017. The basis of both these 
therapies involves the isolation of patient’s T cells, genetically modifying the T cell, expanding 
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them and then infusing the modified T cells back into the patient. The main challenges that lay 
ahead are how to manufacture these treatments in a cost effective and consistent way and how 
to manage some of the severe side effects that can occur.  
CAR-T therapy has until recently primarily focussed on B-cell malignancy as there is a clear 
target (CD19). However, solid tumours possess overall lesser sensitivity to T-cell mediated 
cytotoxicity and a tumour microenvironment with an array of immunosuppressive mechanisms 
which vary from tumour to tumour, thus leading to a relative paucity of suitable target antigens 
with a profile as favourable as that seen in CD19.  With advances in genomic screening, new 
tumour-specific targets are being discovered which will lead to these treatments being tailored 
for solid tumours (e.g. Sorronto Therpaeutics Autologous Anti-CEA CAR-T Cell Therapy for 
Liver Metastases Demonstrate Therpaeutic Activity in Stage IV Pancreas Cancer in a Phase 1b 
HITM-SURE Trial). Furthermore, combinational approaches to treatment such as combining 
a check-point inhibitor with a CAR-T/TCR therapy, are being considered to overcome this 
challenge.  
 
1.6.2 Immuno-oncology and its role in cancer treatment Based on the knowledge that 
tumour cells can avoid immune detection, the concept of immuno-oncology as an anticancer 
treatment was introduced. A raft of evidence has been gathered related to PD-1 and PD-L1 
antagonists in patients with a variety of cancers, identifying immune interventions in cancer 
treatment as invaluable. Data accumulated from agents that block checkpoint proteins such as 
CTLA-4 and PD-1, have provided a therapeutic level to which other therapies can be 
quantitatively and qualitatively compared. Key features include broad activity, rapid onset of 
response, relatively low toxicity and the possibility of T-cell memory resulting in durable 
responses differentiate this third generation of immuno-oncology agents from the preceding 
ones. However, these agents are still toxic, are very expensive, and are not currently curative. 
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In 2010, initial outcome data following use of Nivolumab, an  IgG4 PD1 antibody became 
available (Ascierto, Simeone et al. 2010) and it was subsequently FDA-approved to treat 
melanoma, lung cancer, kidney cancer and Hodgkin's lymphoma in 2014. Pembrolizumab 
(Keytruda) is another PD1 inhibitor that was approved to treat melanoma and lung cancer by 
the FDA in 2014 (2010, Kline and Gajewski 2010, Pardoll 2012, Reichert 2014, Barbee, 
Ogunniyi et al. 2015, Bex 2016, Cattrini, Dellepiane et al. 2016, Shreders, Joseph et al. 2016, 
Shukuya and Carbone 2016, Weber, Gibney et al. 2016).   
 
1.6.3 Identification of tumour antigens  T-cell clones can recognise and lyse specific target 
cells and cloning techniques exist to propagate these.  Peptide can be eluted from MHC 
molecules on tumour cells.  Tumour antigens should ideally only be expressed by tumour cells 
(and not healthy tissues) in order to be efficiently recognised by the host’s immune system.  
The reality is that they are overexpressed in tumour cells compared with healthy cells.  Tumour 
cells have the ability to employ ‘escape mechanisms’ allowing immune evasion.  An example 
of how a tumour can evade the immune system is for instance by altering production/sequence 
of a protein that contains an immunogenic peptide so that the epitope is no longer presented at 
the cell surface and hence not recognised by host immune cells. Furthermore, MHC can be 
down-regulated in various tumours and as a result the tumour antigens are not recognised by 
CTLs. 
 
1.6.4 Cancer Vaccines act in a variety of ways. Vaccines deliver proteins into the body. These 
proteins may be derived from infective materials such as viruses or from cancer cells 
themselves – but they are inactivated meaning they will not cause disease in the recipient.  As 
a result of introduction of these foreign proteins the immune system will generate antibodies 
and/or T-cells against them, allowing clearance of the vaccine particles, but also inducing 
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‘memory’, so that if there is a second interaction with the protein again, the immune system 
will react and clear this more efficiently.  This is essentially how vaccines against infections 
work. 
In cancer, two types of vaccine exist: 1) vaccines to prevent cancer 2) vaccines to treat cancer. 
An example of a cancer preventative vaccine would be the vaccine against human papilloma 
virus (HPV), implicated in cervical cancer. Other vaccines are currently being investigated for 
similar infective causes of cancer. The second form of vaccine, works by allowing the immune 
system to recognise cancer cells and form an appropriate response towards them, preventing 
growth and recurrence. There are a number of sub-category of vaccine including: Antigen 
vaccines, Whole cell (autologous) vaccines, dendritic cell vaccines, DNA vaccines and anti-
idiotype vaccines which relates to which part of the immune system is targeted in effecting 
tumour clearance. As a result of this new form of vaccine a number of FDA approved trials 
have been attempted or are ongoing (Gilboa 2004, Goldman and DeFrancesco 2009).  In 
regards to the whole cell (autologous) vaccines The FDA has recently approved a license for 
Sipuleucel-t (Provenge®) which is an autologous immune cell prostate cancer vaccine, shown 
to extend life for patients with otherwise untreatable prostate cancer by up to 4 months (Higano, 
Schellhammer et al. 2009, Higano, Small et al. 2010, Cheever and Higano 2011, Higano 2012, 
Higano, Sartor et al. 2015).  
Tumour-induced immune suppression is thought to be responsible for the failure of cell-based 
cancer vaccine attempts (Schabowsky, Madireddi et al. 2007).  Furthermore vaccination has 
been shown to induce antigen-specific Tregs (Curiel, Coukos et al. 2004, Curiel 2007, Curiel 
2007).  It has been predicted that the clinical response induced by some cancer vaccines may 
well be due to rapid induction of CTLs which overwhelm the deleterious effects of 
simultaneously generated Tregs, however these CTLs will apoptose with time and disappear 
leading to domination  by Treg (Curiel 2007).  
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It has been proposed that CD4+ Treg is a prognostic factor for survival in a number of tumours 
including ovarian (Wolf, Wolf et al. 2005), which would support the idea that depletion of 
tumour-associated Treg could be beneficial with tumour-specific immunotherapy.  
Conventional depletion of Treg with anti-CD25 antibodies, have been shown to eliminate only 
around 70% of Treg, which has failed to significantly reduce the growth of established tumours 
(Gu, Guo et al. 2015). Using an animal model (Foxp3.LuciDTR-4 mice), the authors 
demonstrated an impressive 90–95% Treg depletion resulting in complete regression of large 
established tumours (Li, Kostareli et al. 2010).   
Recently, Th17 T-cell infiltration has also attracted attention.  It has been shown to confer a 
more favourable outcome.  These cells have been positively associated with effector cells and 
negatively associated with Treg infiltration.  This has inevitably led to the question, could Th17 
be therapeutically induced or expanded by tumour vaccine or adoptive immunotherapy (Munn 
2009)?  There has been much study of this in recent years with conflicting evidence available 
in both support and against, as there have been a number of studies implicating IL-17 in 
promoting tumour growth and invasion (Murugaiyan and Saha 2009, Wang, Yi et al. 2009).  It 
is difficult in the face of conflicting evidence to adopt a rational opinion as to how to take this 
therapy forward as a potential cancer immunotherapy.  One viewpoint as to how these 
apparently conflicting observations may be reconciled is related to the important fact that like 
more immune responses, Th17 responses are unlikely to be homogeneous.  The new challenge 
therefore is to identify those responses which are anti-tumour and develop a mechanism for 
supporting and expanding these. 
 
1.6.5  Monoclonal Antibodies (mABs) In the quest to understand how antibodies work, early 
work by Milstein looked at the antibodies made by myeloma cells, and the observation was 
made that these appeared to be clonal – i.e. from one cell and lacked the diversity seen in other 
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cells (Milstein, Harrison et al. 1972, Kohler and Milstein 1975).  The American immunologist 
Klunkel has been credited for this observation.  Using mice as a model, Milstein further 
hypothesized that somatic mutation resulted in antibody diversity (Milstein, Harrison et al. 
1972).  Milstein was joined by the German scientist Kohler and together they sought to 
investigate somatic mutation of antibodies, in order to identify a means with which to create 
an antibody with the desired specificity. In order to achieve this a normal spleen-derived B-cell 
was fused with a mouse myeloma cell.  The normal B-cell was obtained from a mouse 
immunised with a known antigen, thus resulting in antibody production. By fusing these cells, 
this would lead to creation of a hybridoma, with the aim being to transfer the immortality from 
the myeloma cell to the antibody producing cell.  This resultant ‘hybridoma’ technology 
created a cell line capable of producing a seemingly limitless supply of highly specific antibody 
‘the monoclonal antibody’ having been derived from a single hybrid cell (Kohler and Milstein 
1975). 
As a result, monoclonal antibodies have become invaluable to a large number of clinical 
laboratory diagnostic tests such as ELISA.  Following on from this, in cancer, a number of 
mAbs have been developed and work in different ways.  Some mAbs recognise and attach to 
antigens on cancer cells. Others work by interrupting cancer cell signalling, thus putting a halt 
to cell division e.g. trastuzumab (Herceptin®) which blocks the Her2/neu receptor in breast 
cancers.  Conjugated mAbs are a subdivision of mAbs which are linked to a radioactive or 
chemotherapeutic agent, allowing delivery of said agent to the cancer cell in a targetted manner.  
Another example, and potentially most well-known of mAb is Rituximab, which recognises 
CD20 antigens expressed on lymphoma cells.  Rituximab is probably one of the more well 
established monoclonal antibodies.  It is a chimeric anti-CD20 monoclonal antibody.  It 
comprises human-derived IgG1 and κ light chain constant regions with murine-derived 
variable regions. Rituximab is used for treatment of a number of tumours. In a phase II clinical 
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trial of patients with B-cell lymphomas, rituximab was demonstrated to induce a response in 
half of the patients with low grade B-cell and follicular tumours (Maloney, GrilloLopez et al. 
1997).  In high grade tumours, rituximab had less well defined success, although remained 
better than conventional therapies with response rates of 37% and 33% in patients with high 
grade diffuse large B cell lymphoma and mantle cell lymphoma, respectively (Coiffier, Haioun 
et al. 1998). The mechanism of action is as a result of complement and antibody dependent cell 
mediated cytotoxicity, inhibition of cell proliferation, and induction of apoptosis (Coiffier, 
Haioun et al. 1998). 
 
1.6.6  Cytokine based immunotherapy             Cytokine therapy is an adjuvant 
chemotherapeutic, synthetically made.  There are 3 main types: 1) Interleukin boosts T- cell 
growth and division. IL-2 is an example of this.  It is essential for cytotoxic T-cell proliferation 
and differentiation, thus increasing responsiveness to tumours. 2) Interferon can suppress 
cancer cell growth. 3) Granulocyte-macrophage colony-stimulating factor (GMCSF) boosts T-
cell growth, allowing for increased effector cells to be present to target tumours (Dranoff 2004). 
There are a number of adjuvant cancer therapies available for use in the UK including 
Aldesleukin (IL-2) used in metastatic tumours including melanomas.  It has been shown to halt 
disease progression (Bhatia, Tykodi et al. 2009). 
As was the case in cancer vaccines, Tregs also play a role in the failure of these types of 
therapies also.  IL-2 for instance, expands and activates CTLs leading to an early clinic 
response to tumour, however it also boosts human Treg function in vivo which ultimately can 
inhibit the anti-tumour CTL response (Curiel 2007). 
 
1.6.7 Neoantigens  Many tumours express mutations. These mutations potentially create new 
targetable antigens (neoantigens) for use in T-cell immunotherapy. The relative number of 
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CD8+ T cells in cancer lesions, as identified using RNA sequencing data, is higher in tumours 
with a high mutational burden. The level of transcripts associated with cytolytic activity is 
positively correlated with mutational load as represented by NK cells and T-cells. For example, 
in non–small cell lung cancer patients who were treated with lambrolizumab (Domingues, 
Turner et al. 2014, Dang, Ogunniyi et al. 2016, Shukuya and Carbone 2016), mutational load 
shows a strong correlation with eventual clinical outcome. In melanoma patients who were 
treated with ipilimumab, any long-term benefit is also associated with a higher mutational load, 
although less significantly (Champiat, Ferte et al. 2014, Campesato, Barroso-Sousa et al. 2015, 
Van Allen, Miao et al. 2015, Marmarelis, Davis et al. 2016). The predicted MHC binding 
neoantigens in patients with a long-term clinical benefit were enriched for a series of 
tetrapeptide motifs that were not found in tumours of patients with no or minimal clinical 
benefit (Snyder, Makarov et al. 2014).  However, human neoantigens identified in other studies 
do not show the bias toward tetrapeptide signatures (Schumacher and Schreiber 2015, Stronen, 
Toebes et al. 2016). 
 
1.7 Phosphoproteins in Cancer If phosphorylation is so important to cellular control 
mechanisms, then it stands to reason that a loss of this control could be implicated in cancer.  
Entire pathways could be altered, many of which could be implicated in tumorigenesis.  
Hannahan described the many hallmarks of cancer, which when considered – phosphorylation 
plays a role in all of them (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011, 
Hanahan and Coussens 2012).  
 
1.7.1 Phosphoproteins as immune targets As already alluded to, immunotherapies are an 
attractive anti-cancer therapy, however until now, a lack of tumour-specific targets has 
hampered their potential use. Members of this group, based on Hanahan’s basic principles, 
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have identified MHC class I-associated phosphopeptides as representing a potential new class 
of tumour-specific targets (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011, 
Hanahan and Coussens 2012, Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 2013, 
Hanahan 2014, Abelin, Trantham et al. 2015). Posttranslationally modified antigens are 
increasingly being shown to play important roles in human disease. Phosphopeptide 
neoantigens have been identified on primary human malignant tissue and would be considered 
to be immunogenic in healthy donors or patients with cancer. MHC-I displayed 
phosphopeptides have been found to be over-represented on multiple leukemic malignancies.  
More aggressive malignancies display a greater diversity of phosphopeptides (Cobbold, De La 
Pena et al. 2013). Many of these tumour-associated phosphopeptides were found to be derived 
from oncogenes linked to leukemogenesis, making these of particular interest as 
immunotherapeutic targets. Dr Penny and Dr Cobbold found that by using the well-established 
autologous model of cancer in healthy individuals (LCL as an in vitro surrogate for PTLD), it 
can be demonstrated that phosphopeptides are the target of a significant proportion of all anti-
tumour cytotoxic memory T-cell responses. They showed that MHC class-I and class-II 
phosphorylated peptides derived from phosphoproteins are abundant on the surface of tumours 
(Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 2013, Abelin, Trantham et al. 2015).  
These antigens exhibit differential expression between healthy and malignant tissue with 
aggressive tumours displaying the most phosphopeptides.  Memory-like CD8+ T-cells against 
phosphoantigens are present in healthy donors, but are thought to be reduced in patients with 
cancer.  We propose that this may be the case for paediatric liver tumours and also PTLD.  To 
date no post-translationally modified tumour antigens have been identified from paediatric 
tumour samples.  Thus the discovery of phosphopeptides in the paediatric tumours would 
incorporate novelty in addition to providing a translational output for this project.   
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Many phosphorylated peptide antigens have previously been discovered in haematological 
malignancies, breast tumours, melanomas and colorectal tumours (Syka, Coon et al. 2004, 
Cobbold, Polefrone et al. 2007, Mohammed, Cobbold et al. 2008, Depontieu, Qian et al. 2009, 
Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 2013, Abelin, Trantham et al. 2015).  
Mass spectroscopy analysis of surface MHC-bound phosphopeptide display of EBV 
transformed B-cells (LCLs) has been performed with over 50 phosphopeptides identified.  One 
particularly interesting antigen is derived from the cytoplasmic tail of CD19 (pCD19, 
DPTRRFFKVpTPPPGSGPQ) which the Cobbold lab have shown to be highly immunogenic 
in healthy individuals.  pCD19-specific CD4+ cells can be expanded ex vivo and can target 
human lymphoma both in vitro and in vivo. 
 
1.7.2 Studying phosphorylation Sites  High throughput studies have advanced with the advent 
of mass spectrometry.  Precise localization of specific phosphorylation sites was made possible 
with the introduction of electron transfer dissociation (ETD) in the early 2000’s.  Enrichment 
of phosphopeptides by immobilised metal ion affinity chromatography or IMAC have allowed 
batch processing to become a reality (Syka, Coon et al. 2004, Abelin, Trantham et al. 2015).   
 
1.8 Summary  
The disease burden from cancer is largely underestimated.  Morbidity from the disease and its 
treatment options together with mortality associated with disease spread and recurrence has led 
to an identified need for development of new cancer therapies.  In paediatric hepatology key 
tumours of interest remain most commonly hepatoblastoma, more rarely hepatocellular 
carcinoma and the PTLD’s following organ transplantation. Although over time survival has 
improved, mortality rates remain relatively high, with overall survival from hepatoblastoma 
for instance being ~65%.  Traditional treatment options have been chemotherapy and organ 
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transplantation, which is not itself without risk of side effects which are often difficult to 
tolerate. 
Cancers have developed a number of mechanisms for overcoming immune recognition.  This 
was described in the seminal paper by Hannahan in 2000, and updated in 2011 to include newly 
identified mechanisms for evading immune surveillance.  This has even included the concept 
of hallmark switching where tumours change from one mechanism of evasion to another in 
order to avoid recognition which has fed into the idea of chemotherapy resistance (Hanahan 
and Weinberg 2000, Hanahan and Weinberg 2011, Hanahan and Coussens 2012, Hanahan 
2014).  This so called ‘Somatic Mutation Theory of Carcinogenesis’ has been debated by a 
number of authors, who appeared critical of the original data analysis, suggesting that the 
original ‘hallmarks’ were also characteristic of benign tumours (Lazebnik 2010).  Furthermore 
another review of the hallmarks proposed that cancer is perhaps a tissue based disease and the 
concept of ‘Tissue Organisation Field Theory’ was envisaged, where proliferation and motility 
are the default state of all cells, but it is the cell:cell interaction and cell:extracellular matrix 
interaction which has bearing on cancer development – i.e. cancer could be considered as 
disordered development ‘development gone awry’ (Sonnenschein and Soto 2013). 
Clearly there are a number of potential signalling pathways which may be involved in cancer 
development and propagation. Hence identification of proteins involved in these pathways 
could potentially result in identifying a target for cancer therapy. The immune system plays a 
key role in tumour recognition - in particular the adaptive immune system cell response to 
cancer.  MHC is also thought to play a pivotal role in this tumour recognition, resulting from 
cortical selection in the thymus, with those cells selected on MHC class I molecules becoming 
CD4-CD8+ cells and MHC class-II becoming CD4+CD8- cells. 
Immune surveillance was a concept initially proposed in the 1950’s, where it was suggested 
that as cells became older they would inherit more changes which may be a step towards 
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malignancy and the authors proposed that there was a mechanism for recognising and 
eliminating such cells in order to prevent tumour development (Burnet 1957).  However this 
theory has been questioned and more recently it has been proposed that inflammation may in 
fact be a cancer promoter (Balkwill and Mantovani 2001, Mantovani, Allavena et al. 2008, 
Balkwill and Mantovani 2012).  Perhaps evidence to support this is seen in mouse models 
where if Burnet’s initial theory were to be true, then we would expect immunodeficient mice 
to be more susceptible to cancer development.  A number of studies have demonstrated this 
and therefore would suggest that immunosurveillance was at least partially responsible for 
recognition and elimination of malignant change (Gatti and Good 1971, Smyth, Godfrey et al. 
2001, Swann and Smyth 2007, Senovilla, Vitale et al. 2012).  It is not just adaptive immunity 
however that plays a role and this was tested by Stutman looking at nude mice and comparing 
them to wildtype mice.  He found that there was no difference in cancer occurrence but this 
was proposed to be due to intact innate immune system – when tested again in RAG2 mice 
(which lacked the recombination activating gene (RAG) required for adaptive immune 
responses and the STAT1 gene that is required for innate immune responses) there was a large 
increase in tumour occurrence (Stutman 1974, Meraz, White et al. 1996, Shankaran, Ikeda et 
al. 2001), leading to a revival in the concept of immune surveillance being pivotal to tumour 
recognition and elimination. 
Further evidence is demonstrated in humans with immunodeficiency, who go on to develop 
malignancy e.g. Kaposi sarcoma in HIV/AIDs secondary to viral infection – although this may 
well be an exaggerated response to infection, patients with immunodeficiencies are 
significantly more likely to develop malignancy compared to the normal population with or 
without viral infection being implicated (Cadranel, Garfield et al. 2006, Grulich, van Leeuwen 
et al. 2007). 
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Immunotherapies have been a significant development in cancer treatment resulting in 
development of vaccines, monoclonal antibodies, cytokine treatments and the identification 
and targeting of neoantigens expressed on tumour surfaces (Coiffier, Haioun et al. 1998, Davis, 
White et al. 1998, Barnett, Kryczek et al. 2005, Curiel 2007, Curiel 2007, Bhatia, Tykodi et al. 
2009, Domingues, Turner et al. 2014, Marmarelis, Davis et al. 2016).  
Ultimately, the importance of identifying mechanisms by which a multitude of cancers can 
avoid immune mediated recognition and destruction, could lead to identification of potential 
targets for immunotherapy. This therefore forms the basis for this  PhD.  
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1.9 Project Aims 
The primary aim of this project was to assess the relative contribution of phosphopeptide-
specific T-cells to anti-tumour immunity. Initially, a well-established in vitro surrogate model 
of PTLD (LCLs) was used to assess the proportion of T-cell responses that are directed against 
phosphopeptides identified on these cells, and more importantly differentiate between tumour-
specific and non-specific phosphopeptides. We hypothesized CTLs recognised phosphopeptide 
expressed on tumour surfaces leading to T-cell activation and tumour recognition/destruction.  
 
The second aim of this project was to identify tumour-specific MHC class I-associated 
phosphopeptides displayed on hepatic tumours and PTLD. Phosphopeptides were extracted 
from patient samples and their counterpart normal tissue, or from established cell lines 
(HepG2) or LCL lines generated from healthy donors. Our collaborators in Virginia assisted in 
characterising these phosphopeptides, using their well-established nano-scale mass 
spectrometry techniques. Synthetic phosphopeptides were manufactured based on the 
phopshopeptide analyses of the tumour samples in order to determine if immunity targets 
phosphopeptides in cancer. We proposed phosphopeptides as an immune target, and therefore 
sought to identify tumour specific phosphopeptides involved in key cancer pathways.  We also 
hypothesised that certain phosphopeptides may be organ specific based on the observation that 
certain phosphopeptides were common to a number of tumour groups – e,g, the crossover 
between HB, HCC and hepatic secondary tumours identified by other members of this group.  
In order to reduce the risk of potential autoimmunity, phosphopeptide responses were also 
tested in healthy individuals, to allow for identification of potential targets.  This is based on 
the assumption that if healthy donors already have responses there should be a reduced risk of 
autoimmunity should these phosphopeptides be used in a clinical environment as a cancer 
chemotherapeutic for example.  
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The third aim of this project was to identify a process for immortalising tumour-
specific/phosphopeptide-specific T-cells to provide a constant supply of re-agents to study 
responses to specifically phosphopeptides and more generally other tumour specific targets. 
This is of particular importance when investigating the specificity and function of anti-tumour 
T cells as T-cells grown in culture long term lose specificity and function, preventing further 
understanding of their function in vitro.  Therefore, we proposed the use of Human Induced 
Pluripotent Stem Cell Technology (hIPSc) as a potential technique for overcoming this 
challenge.  This is a technique described previously by groups attempting to study T-cells 
specific to disease to prevent disease progression in AIDS and Malignant melanoma 
(Nishimura, Kaneko et al. 2013, Vizcardo, Masuda et al. 2013) and we therefore proposed this 
as a viable technique for expanding T-cells in vitro. A future application of this technology 
could be to have a source of tumour-specific iPSCs that could be used to re-differentiate into 
effector cells that could be infused into a patient as a cell therapy.  As this is a relatively new 
technique requiring some optimisation in experimental protocols, we sought to explore some 
older more well established techniques in order to probe the expression of antigen and 
phoshopeptides on both normal and transformed cell types in vitro including T-cell hybridoma 
technology (Taniguchi and Miller 1978) and the use of HVS (Biesinger, Mullerfleckenstein et 
al. 1992, Meinl, Hohlfeld et al. 1995, Fickenscher, Biesinger et al. 1996) to attain T-cell 
immortality. 
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Chapter 2:  MATERIALS AND METHODS 
It should be noted that a number of protocols included here are standard, well established 
protocols used within the Cobbold Group laboratory. In particular protocols 2.1-2.2, 2.4-2.14, 
2.16-2.17 are common protocols shared and incorporated by the group, including Dr L Morton 
and Dr S Penny. 
 
2.1 Cell Culture 
Cell lines were grown from commercially available stocks originating from the European 
Collection of Cell Cultures (ECACC, HPA, UK) and the American Type Culture Collection 
(ATCC, LGC, USA). All cells were stored in foetal bovine serum (FBS, obtained from Sigma 
UK) with 10% DMSO (Sigma, UK) at -80°C or in liquid nitrogen. The cells were managed in 
sterile conditions in a laminar airflow tissue culture hood, at all times, and incubated at 37°C 
with 5% CO2. For adherent cells (except iPS clones and OP9 mouse feeder cells), the media 
used was D-MEM (Dulbecco’s Modified Eagle Medium (1X) liquid (High Glucose) (Gibco, 
UK), 10% FBS, 1% penicillin/streptomycin (Sigma, UK) and the cells were grown in 25cm2, 
75cm2, 175cm2 and 1720cm2 vented tissue culture flasks, or sterile plates, with 20 mM HEPES 
(Gibco, UK) buffer added.  
For IPSc clones, the following medias were used (tables 2.1a and b): 
Table 2.1a: hIPSc media components 
 
 
 
 
 
 
 
iPSCs Medium - (KSR) 500ml Stock conc 
 
Final conc 
 
Volume 
 
DMEM/F12 (Life Technologies, UK)   400ml  
Knockout Serum Replacement (KOSR) 
Life Technologies, UK 
 20% v/v 100ml  
L-Glutamine (Sigma,  UK) 100x 2mM 5ml  
MEM-Non Essential AminoAcids (MEM-NEAA) 
(Sigma, UK) 
100x 1%  5ml  
2-Mercaptoethanol (Sigma, UK) 98% 0.007% 3.5µl  
Penicillin/Streptomycin (Sigma, UK) 100x 1%  5ml  
bFGF (FGF2)  (Life Technologies, UK) 4µg/ml  4ng/ml 500µl  
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Table. 2.1b: mIPSc/ESc media components 
Component Stock 
concentration 
Final 
concentration 
amount 
Knockout-DMEM (Sigma, UK)   425ml 
Knockout serum replacement (KOSR) 
Sigma, UK 
 15% 75ml 
L-glutamine (Sigma, UK) 100mM 1mM 5ml 
B-mercaptoethanol (Sigma, UK) 14.3M 0.1mM 3.5µl 
Penicillin/streptomycin (Sigma, UK) 100x 1x 5ml 
Leukaemia Inhibitory Factor (LIF) (Millipore, 
UK) 
107unit/ml 1000u/ml 50µl 
Non-essential amino acids 10mM 0.1mM 5ml 
GSK inhibitor 10mM 3µM 15µl 
MEK inhibitor 10mM 1µM 50µl 
 
For all suspension cells (except T-ALL 104), the media used was RPMI-1640 (high glucose) 
(Gibco, UK), 10% heat inactivated Foetal bovine serum (FBS, Sigma UK) (equivalent to 10ml 
in every 100ml complete media), 1% penicillin/streptomycin (Sigma, UK equivalent to 1ml of 
stock Penicillin/streptomycin (100x) every 100ml complete media), and the cells were grown 
in vented tissue culture flasks, or sterile plates.  
 
OP9 cells (obtained from Prof Anderson group, and recovered from -80c storage) were 
cultured in the following 'OP9 media'.  Minimum Essential Medium- Alpha (α-MEM) 
powdered media is used (Gibco, Life Technologies, Paisley, UK). The powder is added to 
900ml of sterile distilled water while stirring. The package is rinsed out at least twice. Once 
the powder has dissolved the following were added: 2.2g of Sodium Bicarbonate (Tissue 
culture tested) (Sigma, UK), 6ml of L-glutamine (200mM stock, Sigma, UK, 6ml of diluted ß 
–mercaptoethanol (Sigma, UK). Diluted 2-mercaptoethanol is made by adding 70µl of 2-
mercaptoethanol (Sigma, UK) to 100ml of sterile PBS or water. 5ml of penicillin\streptomycin 
solution (Sigma, UK, 50µg/ml final conc.) Top up to 1L with sterile dH2O Filter-sterilize using 
a 0.22µm bottle top filter.  Before use add 100ml of FBS to the 500ml bottle. 
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T-ALL 104 cells were cultured in Iscove's Modified Dulbecco's medium (IMDM, Gibco, UK), 
20% FBS (equivalent to 20ml in every 100ml complete medium), 1% penicillin/streptomycin 
(equivalent of 1ml of stock 100x Penicillin/streptomycin).  
 
Cell counts and viability were determined by the exclusion of Trypan blue dye (Sigma, UK) 
by light microscopy. All cell lines were tested for mycoplasma infection using the Lonza 
MycoAlert Mycoplasma Kit (Lonza, ME, USA). Cells infected with Mycoplasma infections 
were discarded. 
 
2.2 Plasma and cell preparation from whole blood 
Fresh blood samples were collected from healthy donors (as per agreed local ethics – see 
appendix). 50 ml of blood was collected using vacutainers containing lithium heparin (BD, 
UK) – fig. 2.1. In order to obtain peripheral blood mononuclear cells (PBMCs), the blood was 
mixed with an equal volume of plain 1640 RPMI, layered onto ficoll-paque (Sigma, UK) and 
centrifuged at 500 x g for 20 min, without a brake. The PBMCs were collected from the 
interface, washed twice in plain 1640 RPMI (500 x g, low brake), counted and resuspended in 
RPMI 10% FBS for use in experimental studies, or FBS 10 % DMSO at 1 x 107 cells/ml for 
storage at -80 C. 
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2.3 Immortalization of human B cells using EBV 
EBV-transformed B95-8 marmoset cell line was procured from ATCC, USA and the EBV 
stock prepared (with the assistance of Dr C Shannon-Lowe). 0.5x106 cells/ml were seeded in 
RPMI-1640, 15% FCS (Invitrogen, Carlsbad, CA), 200mM L-glutamine (Sigma, UK) and 1% 
penicillin/streptomycin (equivalent of 1ml of stock 100x Penicillin/streptomycin in 100ml 
complete media) (Sigma, UK). After 3 days, cells were spun down and the supernatant 
collected and passed through a 0.45µM filter.  This was subsequently aliquoted and frozen at 
-80°C. 
PBMC’s were prepared as described previously and were seeded in a sterile 24 well plate at a 
density of 1.5-2x106 cells/ml in Dulbecco’s modified eagles medium (DMEM) (Gibco, UK) 
containing 15% FCS (Sigma, UK), 200 mM L-glutamine (Sigma, UK) and 1% 
penicillin/streptomycin (equivalent of 1ml of stock 100x Penicillin/streptomycin) per 100ml 
complete media (Sigma, UK).  
EBV virus was added to PBMCs at 1:1 ratio (V/V) and placed in an incubator maintained at 
37°C with 5% CO2. After 2 hours, 5ml of complete medium was added containing cyclosporin 
A (final concentration of 0.5ug/ml).   Media was changed twice weekly and cells cultivated for 
Fig 2.1: Preparation of PBMC’s from whole blood.  Blood was obtained from subjects (50-60ml).  Equal volumes of warmed 
plain RPMI were added.   Fresh 50ml tubes were prepared with a base layer of 15ml of FicollPaque.  The Blood/RPMI mix was 
then carefully layered on top of the FicollPaque, being careful not to shake the samples.  They were then spun initially with no 
brake for 20 mins at 500 g.  The PBMC’s were collected from the interface layer, and transferred to fresh tubes.  These were 
topped up with more warmed RPMI and washed x2 at 500 g for 10 minutes on a low brake.  Finally the resulting pellet was 
resuspended in T-cell media and used for experimentation or frozen at -20c.
Plasma
PBMC	(interface)
Ficoll
RBC’s
Ficoll
500	g for	20’
No	brake
Plain	
1640
RPMI
Ficoll
PBMC’s
Wash	x2
500	g for	10’
Low	brake Resuspend in	
standard	T-
cell	media
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a further 4 weeks. Cells were mixed thoroughly to break clumps before splitting to ensure 
multiclonal population (Neitzel 1986) – fig 2.2. 
 
 
2.4 Flow cytometric analysis of T cell populations 
Flow cytometry provides quantitative multiparameter analyses on single cells based on the 
measurement of visible and fluorescent light emission. The cells to be tested were placed into 
a 5ml FACS tube and the relevant antibodies added (e.g. anti-CD3-APC and anti-CD4-FITC 
were added at 1:100 dilution (BD Biosciences, CA, USA)) and the mixture incubated for 20 
min at room temperature in the dark. The cells were then washed twice in 2 ml MACS buffer 
(Miltenyi, USA) (PBS, 2 mM EDTA, 2% FCS) and isolated by centrifugation at 500 x g for 
10 min. The cells were then resuspended in 200 µl MACS buffer and analysed on the flow 
cytometer (Fortessa20, BD, NJ, USA) using the BD FACSDiva software (BD, NJ, USA).  The 
exported files were then analysed using FlowJo (FlowJo LLC, CA, USA) software. 
 
2.5 Magnetic activated cell sorting 
Magnetic activated cell sorting (MACS) involves labelling cells with magnetic MicroBeads 
conjugated to the desired antibodies. The cells are then passed through a magnet via a plastic 
5%	CO2
37C
EBV
4-5	weeks CycA
Plasma
PBMC	(interface)
Ficoll
RBC’s
Ficoll
Fig 2.2: Generation of LCL’s from PBMC’s using EBV.  PBMC were generated using standard methods as previously 
described.  Cells were infected with EBV and incubated for 2 hours at 37c.  Following this media was changed and supplemented 
daily with cyclosporin to remove any T-cells which would otherwise target infected B-cells for destruction.  Media was changed 
twice weekly for 4 weeks, resulting in pure growth of LCL’s.
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column, and the magnetically labelled cells are thus separated from the unlabelled cells as the 
labelled cells remain in the column and the unlabelled flow out. The labelled cells are then 
eluted from the column by removing the magnet and applying kinetic energy, as per 
manufacturer guidelines (Miltenyi Biotec, Bisley, UK). The beads remain on the surface of the 
cell and are eventually endocytosed and degraded (they are non-toxic, biodegradable and 
biologically inactive) - fig. 2.3. 
 
 
2.6 Enzyme-linked immunospot (ELISpot) assay 
ELISpot assay is used for the detection of individual cells secreting specific cytokines/antigens 
(Czerkinsky, Tarkowski et al. 1984). The ELISpot PRO for human IFNγ kit (Mabtech, 
Sweden) was used for these experiments. Polyvinylidene difluoriden (PVDF)-backed 96 well 
plates were coated with a monoclonal antibody specific for human IFNγ were washed five 
times with sterile PBS (200 µl/well). The wells were then blocked by incubation with RPMI 
10% FBS for 30 min at room temperature. The medium was removed and a cell suspension of 
the PBMCs (5 x 105/well) or T-cells (1 x 105/well) of interest, in RPMI 10% FBS, or T-cell 
medium, added. The stimulating peptides were then added to the test wells, 1% 1x DMSO to 
CD8+ T-cells	eluted	from	
column
Plasma
PBMC	(interface)
Ficoll
RBC’s
Ficoll
PBMC	(interface)
Ficoll
CD8-
CD8+
CD8- T-cells	collected	 from	
flow-through
Fig 2.3: Schematic describing magnetic bead separation of T-cells.
PBMCs were obtained using standard methods as described previously. Magnetic beads are coated/labelled with CD8 antibody
and mixed with the PBMC’s. PBMC’s were then applied to a column set within a magnetic field. The CD8+ cells remain in the
column and can be eluted out with kinetic force after the mixture has run through the column. The non CD8+ cells will run
through the column and are collected in a tube for either experimentation or to be discarded.
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the negative control (as this was the solvent used to dissolve the peptides) or 10µg/ml 
phytohaemagglutinin (PHA) (Sigma, UK), as the positive control. The plate was incubated for 
16-24 hours at 37C. The cells were then removed and the plate washed five times with PBS 
(Sigma, UK) (200 µl/well). The one-step detection reagent (mAb 7-B6-1) was diluted 1:200 in 
1x PBS 0.5 % FBS and 100 µl added to each well and incubated at room temperature for 2 
hours. The plate was again washed five times with PBS (200 µl/well). Steptavidin-ALP was 
diluted 1:1000 in PBS 0.5% FBS and 100µl was added to each well and the plate incubated for 
a further hour.  The plate was again washed 5 times with PBS (200µl/well). The ready to use 
substrate solution (BCIP/NBT-plus) was filtered through a sterile 0.45 µm filter and 100 µl 
added to each well. When spots started to appear the plate was extensively washed with tap 
water and dried. Once dry, the spots representing individual IFNγ secreting cells were counted 
using an ELISpot reader (AID ELISpot Reader HR XL, Advanced Imaging Devices GmbH, 
Germany)) and images captured using the AID ELISpot Software 4.0 (AID GmbH, Germany) 
fig. 2.4. 
 
 
ELISpotIFNɣ coated	96w	plate
Washed	x5	
PBS
Blocked	
RPMI/10%	
FCS
Cells	 added	and	
incubated	 for	16-24h
Washed	5	times	 with	
PBS.	Detection	
reagent	added	 and	
incubated	 at	room	
temperature	for	2h
Washed	5	times	 with	
PBS.	Filtered	substrate	
reagent	added.		
Incubated	 at	room	
temperature	until	
spots	 have	emerged,	
then	 washed	with	
water,	dried	and	read	
on	appropriate	 plate	
reader		
Fig 2.4: Schematic describing the processes involved with EliSpot.
Pre-coated 96w plates were washed with sterile PBS and blocked using the same growth media that the cells to be tested were
being cultured in e.g. RPMI/10% FCS for half an hour. Plates were washed thoroughly with PBS again and required number of
cells added. Plates were transferred to an incubator for 16-24hours 5%CO2 37c. Following this, plates were thoroughly washed
with PBS x2 and a detection reagent added as per ELISpot kit used. Plates were incubated at room temperature for 2 hours and
washed again in PBS. Then a pre-made substrate (from the kit used) was filtered using 45µM filter and this was added to the
plates to enable detection of spots within the wells equating to cell activation i.e. detection of IFNɣ. Plates were washed with PBS
then distilled water and dried, and read on an appropriate plate reader as per manufacturer’s recommendations.
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2.7 Europium Killing assay (Perkin Elmer, via Fisher Scientific, USA)  
A fluorescence assay to study the loss of membrane integrity was used. In this assay, target 
cells are loaded with fluorescence enhancing ligand, BATDA, which penetrates the cell 
membrane quickly and is hydrolysed to form a hydrophilic ligand (TDA) that is released from 
cells only after cytolysis. In the presence of a solution containing Eu3+, the released TDA forms 
a highly fluorescent and stable chelate (EuTDA), whose levels are measured using time-
resolved fluorescence. Target cells were washed in the relevant medium and resuspended to 1 
million cells/ml. 2.5 µl/ml of the BATDA fluorescence enhancing ligand was added and the 
cells incubated for 30 minutes at 37 °C, humidified 5 % CO2. The cells were washed five times 
in excess medium. 10,000 target cells were added to each well of a V-bottomed 96-well plate. 
T cells at varying effector to target (E:T) ratios were added to the test wells. Lysis buffer was 
added to the wells. All well volumes were made up to 200µl. The plate was incubated for 2-5 
hours in a humidified 5 % CO2 at 37 °C. 20µl of each supernatant was transferred to a flat-
bottomed, white, 96-well plate and 200 µl of Europium solution was added. This was incubated 
for 15 minutes, shaking, at room temperature. The fluorescence was measured in a time-
resolved fluorometer (Tecan Infinite 200 PRO; Tecan, Switzerland). 
 
2.8 Fluorescence-activated cell sorting 
Fluorescence-activated cell sorting (FACS) was used to separate CD8+ T cells into cellular 
memory compartment. MACS selected CD8+ T cells were sorted into naïve (CD27+, 
CD45RA+), central memory (CD27+, CD45RA-), effector memory (CD27-, CD45RA-) and 
terminal effector memory compartments (CD27-, CD45RA+) using antibodies CD45RA-
PerCP and CD27-FITC (Becton Dickinson (BD), CA, USA). These cells were sorted slowly 
using the FACS Aria II to ensure accurate sorting (BD, NJ, USA). 
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2.9 Phosphatase treatment of LCLs 
LCLs were washed and phosphatase treated using Shrimp alkaline phosphatase (SAP) - 
(Sigma-Aldrich, Gillingham, UK). The reaction was performed in T-cell medium containing 
50 mM Tris-HCl and 5 mM MgCl2, with 10 units/ml of SAP, at 37 °C, for one hour (all 
components obtained from Sigma, UK). The LCLs for ELISpot were washed, then lightly fixed 
by a ten minute incubation in 1 % paraformaldehyde (Sigma, UK), which was quenched using 
0.2 M glycine (in house stock). The cells for use in the killing assay were washed and loaded 
with BATDA solution (as described in section 2.7). 
 
2.10 Isolation of HLA-associated Peptides  
MHC class I molecules were immunoaffinity purified and their associated peptides were 
extracted as previously described (Zarling, Ficarro et al. 2000) – fig 2.5. A billion cells were 
lysed in 10 ml CHAPS buffer (20 mM Tris-HCl pH 8.0/ 150 mM NaCl with 1 % 3-[(3-
cholamidopropyl) dimethylammonio]-1-propane sulfonate (CHAPS)/ 1 mM PMSF/ 5 µg/ml  
aprotinin/10 µg/ml leupeptin/10 µg/ml pepstatin A/ and 1:100 dilutions of phosphatase 
inhibitor cocktails II and III (to prevent potential dephosphorylation of peptides during 
extraction) (all components obtained from Sigma, UK)). The lysate was subject to 
centrifugation at 100,000 x g, for 1 hour, at 4 ºC, in an ultra-centrifuge (Optima LE-8K (Ti70 
rotor), Beckman-Coulter, UK). Supernatants were incubated with W6/32 antibody-bound NHS 
sepharose beads, specific for MHC class I molecules (Amersham Pharmacia Biotech). The 
beads were washed in lysis buffer, TBS (20mM Tris-HCl/ 150 mM NaCl pH 8), TBS2 (20 mM 
Tris-HCl/ 1 M NaCl pH 8), and 20 mM Tris-HCl pH 8. Peptides were eluted from the MHC 
class I molecules with 10% acetic acid and separated using a 5,000-dalton cut-off 
ULTRAFREE-MC filter (Millipore, MA, USA). Extracted peptides were stored at −80°C and 
shipped to Virginia, USA, on dry ice, for analysis. 
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2.11 Mass spectrometric analysis of phosphopeptides 
(Performed by Paisley Trantham/Stacy Malaker, VA, USA) 
HLA-associated peptide mixtures were dried to completion in a Centrivap and reconstituted in 
0.1 M acetic acid to a final concentration of 1x107 cell equivalents per microlitre. For tissue 
samples, it was assumed that 1 gram of tissue contained 1x109 cell equivalents. 
Samples were initially screened to assess peptide levels. The data from these screens was used 
in the plasma biomarker analysis. For phosphopeptide analysis, samples were standardised to 
similar peptide levels, using peptides identified in the JY cell line. A portion of each sample 
containing 1x107 cell equivalents with 100 fmol of two internal standard peptides, 
HSDAVFTDNYTR (vaso) and DRVYIHPFHL (angio), was pressure loaded onto a C18 
microcapillary pre-column (packed with 7 cm of C18 reversed-phase packing material (5-20 
µm diameter, 120 Å pore size)) and connected to an analytical column packed with an irregular 
C18 packing material (5-20 µm diameter, 120 Å pore size). 
1.		Tumour	
removed
2.		Healthy	
tissue/
tumour	
separated	
and	lysed
3.		MHC	Class-
I	complexes	
affinity	
purified
4.		MHC	Class-
I	peptides	
eluted
5.		IMAC	
enrichment	 of	
Phosphopeptides
6.		
Phosphopeptides
characterised	by	
LC-MS/MS
7.		
Phosphopeptide	
sequences	
manually	assigned
Fig 2.5: Schematic describing work-flow for tumour-specific, MHC class I-associated phosphopeptide discovery from
patient samples
Tumour and adjacent normal liver tissue were obtained from the same patient at tumour resection/explant. These solid tissue
samples were each lysed and the MHC class-I complexes affinity purified using the pan class-I antibody, W6/32. The MHC class
I-associated peptides were eluted in acid as per standard protocol at University of Birmingham within the Cobbold laboratory.
Our collaborators at University of Virginia enriched the phosphopeptides using IMAC. These phosphopeptides were then
characterised using CAD and ETD LC-MS/MS and the sequences manually assigned.
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Peptides were gradient eluted at a flow rate of 60 nl/minute, using an LC gradient of 0-60 % 
solvent B in 40 minutes (solvent A: 0.1 M AcOH in H2O; solvent B: 70% ACN, 0.1 M AcOH 
in H2O), through an electrospray tip directly into a LTQ-FT-ion cyclotron resonance mass 
spectrometer. MS data was acquired in the high-resolution Fourier transform mass analyser, 
and the MS2 data was acquired in the linear ion trap of the LTQ-FT-ion cyclotron resonance 
instrument using CAD and front-end ETD. 
Data analysis was performed using the Xcalibur software (Thermo Electron Corporation). The 
data file generated was searched against the RefSeq database using OMSSA (version 2.1.1). 
Searches of CAD and ETD data used the following parameters: no enzyme specificity, E-value 
cut-off of “1”, variable modifications oxidation of Met, phosphorylation of Ser, Thr, and Tyr, 
and ±0.1 Da and ±0.35 Da for precursor and product ion masses, respectively. OMSSA results 
were used to guide the analysis, but all peptide sequences were determined by accurate mass 
measurement and manual interpretation of the MS2 spectra. 
A normalised amount of sample was then cleaned, using another C18 column, prior to 
phosphopeptide enrichment. One hundred fmol of phosphopeptide standards DRVyIHPF 
(angio II phosphate (AIIP)) and STsLVEGR (STS) were added at the beginning and end of 
this process, respectively, to allow measurement of phosphopeptide recovery. These samples 
were then washed in methanol and dried to completion, thrice. The dried clean-up elutions 
were then esterified using methanolic HCl. This converts the carboxylic acid side chain of Asp 
and Glu to esters, to prevent the non-specific binding of peptides containing these amino acids 
to the IMAC column. 
An IMAC column packed with 5 cm of POROS® MC 20 imidodiacetate packing material was 
used to enrich for phosphopeptides. The IMAC column was activated using filtered 100 mM 
FeCl3. The column was equilibrated with 0.01% acetic acid, the sample loaded and the column 
rinsed in the same acid. Phosphopeptides were then eluted onto a C18 precolumn (5-20 µm 
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diameter, 120 Å pore size) with a pressure load of 250 mM ascorbic acid in water (pH 2) at a 
flow rate of 1 µl/min for 25 minutes followed by a 10 minute 0.01% acetic acid rinse at the 
same flow rate. As for the screen, the precolumn was connected to a C18 analytical column 
and the peptides eluted into the MS, using similar parameters. 
Data analysis was performed by using the Xcalibur software (Thermo Electron Corporation). 
The data file generated was searched against the RefSeq database using OMSSA 
(version 2.1.1). Searches of CAD and ETD data used the following parameters: no enzyme 
specificity, E-value cut-off of “1”, fixed modifications methyl ester of Asp, Glu, and C-term, 
variable modifications oxidation of Met, phosphorylation of Ser, Thr, and Tyr, and ±0.1 Da 
and ±0.35 Da for precursor and product ion masses, respectively. The data file was also 
searched using an in house program developed by Dina Bai called “Neutral Loss Finder” that 
identifies MS2 CAD spectra with the neutral loss of phosphoric acid (98 Da) characteristic of 
phosphopeptides. OMSSA and neutral loss search results were used to guide the analysis, but 
all peptide sequences were determined by accurate mass measurement and manual 
interpretation of the MS2 spectra. Manual interpretation of spectra was aided by another in 
house program developed by Dina Bai called “Fragment Calculator”. Fragment Calculator 
allows the user to calculate the b-, y-, c-, and z-type ions of hypothetical peptides so that spectra 
can be manually validated. 
 
2.12 Tumour Infiltrating Lymphocyte (TILs) isolation and expansion 
Tumour was obtained fresh from the Queen Elizabeth Hospital (QEH) Pathology laboratory 
and Birmingham Children’s Hospital (BCH) Clinical Histology, which was processed fresh in 
sterile saline, and shipped to the HBRC biobank based at the Queen Elizabeth Hospital, 
Birmingham for annonymisation and logging. In a laminar flow hood, the tumour was sliced 
into small (2 mm x 2 mm) chunks and each one placed into 2 ml T-cell medium, containing 
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extra antibiotics to eliminate gut bacteria and yeast (AIM-V/ 10 % Human serum/ 25 mM 
HEPES/ 6000 IU/ml IL-2/ 50 µg/ml neomycin/ 2 µg/ml micofungin/ 55 µM β-
mercaptoethanol/ 15 µg/ml metronidazole/ 20 µg/ml vancomycin) (all tissue culture reagents 
obtained from Sigma, UK). The TILs were maintained at 1x106 cells/ml in T-cell medium in a 
24-well plate for 14-21 days. The cells were subsequently FACS analysed to determine the 
proportion of CD8+ TILs and aliquots frozen. 
TILs were rapidly expanded using a standard rapid expansion protocol (REP) (Dudley, 
Wunderlich et al. 2003). A million thawed TILs were added to REP medium (200 million 
irradiated buffies/ 30 ng/ml OKT3/ 6000 IU/ml IL-2/ 50 ml RPMI 10% HS/ 50 ml AIM-V/ 50 
µg/ml neomycin/ 2 µg/ml micofungin/ 55 µM β-mercaptoethanol/ 25 mM HEPES). Half of the 
medium was exchanged on day 5. On day 7 the TILs were counted and their density reduced 
to 0.5 million/ml. Cells were maintained at 0.5 million/ml until day 14 when aliquots of up to 
30 million TILs were frozen, in FCS 10 % DMSO. 
 
2.13 Intracellular cytokine staining 
Cytokine production in response to specific stimuli can be measured using intracellular 
cytokine staining. Golgi inhibitors are used to prevent cytokine release from the cells and the 
cells fixed and permeablised to allow antibodies to access the intracellular compartments. The 
expanded TILs were thawed and plated at 200,000 per well of a 96-well plate, in TIL medium 
containing 5 µg/ml of Brefeldin A and monensin and 0.5 µg anti-human CD107a-FITC 
antibody (eBioscience, CA, USA), and stimulated with 50 µg/ml peptide. Unstimulated TILs 
were used as a negative control and TILs stimulated with PMA (5 ng/ml) and Ionomycin (400 
ng/ml) (Sigma, UK) were used as a positive control. The cultures were incubated for 5 hours 
at 37° C, 5% CO2 in a humidified environment. They were then harvested, washed with PBS 
and stained with a fixable viability dye (APC-Cy7) and the surface antibodies, anti-CD3 (APC) 
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and anti-CD8 (PerCP) (BD, Oxford, UK). The cells were then washed in MACS buffer, fixed, 
using 2 % paraformaldehyde, washed, permeablised, using 0.5 % saponin, and stained with 
anti-IFNγ (PE), anti-IL-2 (Pacific blue) and anti-TNFα (PE-Cy5.5) (BioLegend, Cambridge, 
UK) for 30 minutes at room temperature. Cells were washed again with MACS buffer and 
lightly fixed until they could be analysed on the FACS Canto flow cytometer (BD, Oxford, 
UK). 
TIL responses were expanded over 7 days, by incubating 200,000 TILs/well of a 48-well plate 
in T-cell medium supplemented with 6000 IU/ml of IL-2. TILs were rested overnight, and 
stimulated the following day with 10 µg/ml peptide. The positive control was stimulated with 
1 µg/ml PHA. On day 6 the TILs were all washed twice in RPMI 10 % FCS and resuspended 
in T-cell medium supplemented with 6000 IU/ml IL-2 and 5 µg/ml each of Brefeldin A and 
monensin. Each well was restimulated with 10 µg/ml of the relevant peptide overnight. They 
were then harvested, washed with PBS and stained with a fixable viability dye (APC-Cy7) and 
the surface antibodies, anti-CD3 (APC) and anti-CD8 (PerCP) (BD, Oxford, UK). The cells 
were then washed in MACS buffer, fixed, using 2 % paraformaldehyde, washed, permeablised, 
using 0.5 % saponin, and stained with anti-IFNγ (PE), anti-IL-2 (Pacific blue) and anti-TNFα 
(PE-Cy5.5) (BioLegend, Cambridge, UK) for 30 minutes at room temperature. Cells were 
washed again with MACS buffer and lightly fixed until they could be analysed on the 
FACSCanto II flow cytometer (BD, Oxford, UK). 
 
2.14 Enzyme-linked immunosorbent assay  
An enzyme-linked immunosorbent assay (ELISA) was used to assess the production of IFNγ 
by activated T-cells. Multisorb 96-well plates (Thermo- Fisher Scientific, Hereford, UK) were 
incubated at 4°C overnight with IFNγ as a capture antibody, and then washed 5 times with 
PBS. The wells were then blocked with a RPMI/10% FCS for 1 hour at room temperature and 
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washed, as before. The sample was incubated in the wells for 2 hours and then washed off. The 
primary antibody, was incubated for 2 hours at room temperature and washed. The alkaline-
phosphatase (ALP) linked streptavidin was then incubated for 1 hour at RT and washed. The 
chromogenic substrate, 3,3’,5,5’-Tetramethylbenzidine (TMB) (10 ml phosphate citrate buffer 
(pH5)/ TMB tablet/ 2 µl Hydrogen peroxide) (Sigma, UK) was added to the wells and positive 
wells turned blue. After 15 minutes, the reaction was stopped with 10% HCl and the plate read 
at 450 nm in a GloMax microplate reader (Promega, UK).  
 
2.15 Hybridomas 
Various techniques are described for the generation of a T-cell hybridoma, and these are 
explored below, using the basic concept of fusing a target cell to a fusion partner. 
 
2.15.1 Hybridomas – creation of fusion partner 
Jurkat-GFP cells were obtained from Dr Millar cultured as per standard conditions. 5-20x106 
were then taken to the irradiator and irradiated at 600 rads. Following this the cells were 
washed twice in RPMI and resuspended at a concentration of 20 million cells per well in a 12 
well plate (Corning, USA) in RPMI + 10% FCS with IL-2 at 100units/ml. Fresh media was 
exchanged daily for the first 3 days. Following this, cells were put on 6-thioguanine (Sigma-
Aldrich, USA) selection at either 1uM or 10uM made as per manufacturer’s instruction in fresh 
media. Cells were put on selection for 1 week, at which point they were centrifuged at 500 x g 
for 15 minutes with Ficoll-paque (Sigma, UK) to remove the dead cells and then media 
exchanged for fresh RPMI + FCS (without 6-thioguanine) for 7 days before being put back on 
6-thioguanine selection again. Following a second week on selection, media was again 
exchanged for fresh RPMI + FCS (without 6-thioguanine). This pulsing of 6-Thioguanine 
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continued for a further 2 rounds, following which cells were cultured in fresh RPMI + FCS 
and allowed to expand (fig. 2.6). 
 
2.15.2 Hybridomas – creation using PEG/DMSO (protocol described by Dr M Goodall, 
Clinical Immunology, University of Birmingham) 
Three days prior to fusion cells were optimised to a final density of 2x106/ml.  On day of 
fusion, cells were counted and plated into a 24-well plate at a density depending on 
experimental conditions.  Controls set up in triplicate: fusion partner, target cell line, mixture 
of fusion partner and target cell line.  Cells were suspended in suitable growth media 
(RPMI/10% FCS is a standard, however where using PEG (obtained from Dr Goodall) or 
PEG/DMSO, FCS should be omitted until cells washed). 
1x107 fusion partner cells were added to equal number of target cells in a 50ml falcon.  Cells 
were washed 3 times in RPMI (No FCS), 500 x g for 5 minutes.  Falcon was placed in water 
bath at 37°C.  PEG (or PEG/10% DMSO) was preheated in the same water bath.  200µl of 
Fig 2.6: Schematic describing creation of a fusion partner for T-cell hybridomas.
A malignant partner cell line was identified for use to generate T-cell hybridoma. This partner cell line was irradiated and
resuspended in fresh 1640 RPMI. On Day 3 following irradiation 6-Thioguanine was added at a concentration of 10µM. Cells
were incubated at 5%CO2/37c. Media changes were performed every 7days alternating between RPMI + IL2, or RPMI + IL2 + 6-
thioguanine for 35 days in total, allowing for selection of HPRT-enzyme deficient cells which are the cells which are resistant to
6-thioguanine.
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PEG was slowly added to the pellet using a transfer pipette over 1 minute, mixed by gentle 
shaking and incubated for 10mins. The mixture was gently mixed for a further 2 minutes, and 
then 20ml of plain RPMI was added over the following 5 minutes.  The mixture was then 
placed in the water bath and left for 5 minutes prior to centrifuging at 500 x g for 5 minutes.  
The supernatant was aspirated and the pellet was gently resuspended in RPMI/20% FCS and 
transferred to a T25 flask.  Selection with Hypoxanthine-aminopterin-thymidine (HAT) media 
(obtained from Dr Goodall) (100µM, 0.4µM, 16µM final concentration in DMEM 
respectively) was performed after 48hours. (Kohler and Milstein 1975) – fig. 2.7. 
 
2.15.3 Use of polycations and plant lectins 
Prior to hybridisation, polycation concentrations were calculated from stock. 
Polyvinylpyrrolidone (PVP, Sigma, UK) of various molecular weights (10,000, 40,000, and 
360,000) were dissolved in the autoclaved 1640 RPMI to prepare 9 g/l stock solutions, which 
were then filter-sterilized using a cellulose acetate membrane syringe filter (0.2µm).  The 
optimum dose of PVP was found to be 0.75g/l.  If the experiment was using PVP then this was 
added 40 minutes prior to polycation in each well.  Cells were not washed but polycation was 
added at desired concentration for 20 minutes. Cells were washed in plain RPMI and protocol 
Fig 2.7: Schematic describing formation of T-cell hybridoma.
Fusion partner cell line created as previously described and fused with target T-cell using standard protocols. Cells remained in
culture and had selection pressures applied HAT/6-thioguanine to remove any un-fused cells, leaving a pure population of fused
hybridoma cells.
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1x107 cells
Target	cell
1x107 cells
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6-Thioguanine	
removes	unfused	
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followed as per standard protocol above (Matsuya and Yamane 1985, Matsuya and Yamane 
1985).   
 
2.15.4 Transfection of hybridoma cells 
Equal numbers of target:fusion cells were set up as per experimental design (5x105 – 2x106 
unless stated otherwise). Lonza nucleofection solution (Lonza, UK) was added to the 
appropriate supplement as per manufacturer instruction (Kit-V was used as designed for 
jurkats). Cells were centrifuged in 1.5ml microtubes, 90 x g for 10 minutes. Pellet was 
resuspended in the nucleofection solution and transferred into manufacturer’s cuvette.  Target 
DNA was added at suitable concentration (3ug VSV-G obtained in house).  Cuvettes were 
nucleofected using Amaxa Nucleofector 2d (Lonza, UK) using programmes X-001 and X-005 
- this machine was kindly loaned by Professor Murray, Cancer Studies, University of 
Birmingham.  Cells were transferred back into 24 well plates and media was added (RPMI/10% 
FCS) to a final volume of 2ml and cells incubated at 37°C. 
 
2.15.5 Use of electroporation 
The ECM1000 (Harvard Apparatus, Boston, USA) allowed for the use of AC and DC current 
to achieve cell fusion.  AC current allows for cells to line up in chains due to electrokinetic 
energy.  A DC pulse then causes cell membrane pores to form and fuse.  
Equal numbers of T-cell population and fusion partner were mixed and resuspended in 
BTXpress Cytofusion media (Harvard Apparatus, Boston, USA).  Cells were washed twice 
(500 x g, 10 minutes).  Each reaction was then resuspended in 2ml of cytofusion media and 
loaded into the fusion chamber.  Electrodes were attached and programme set as per required 
parameters (e.g.  AC 65v for 30 seconds, 9 second pause, followed by a DC pulse of 2000v for 
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25µs). Cells were then left in the electroporation chamber for 10 minutes prior to being 
transferred to cell culture plate and topped up with regular cell media – fig. 2.8. 
 
 
2.16 Lentiviral Transfections 
Lenti-X 293T HEK cells (Clontech, CA, USA) were grown on a 24-well plate to 60-80% 
confluency. DNA of the gene of interest was co-transfected into the cells with gag-pol and 
VSV-G (1 ml Optimem/ 3 µg gag-pol/ 1 µg VSV-G/ 4 µg DNA GoI/ 8 µl PLUS reagent/ 15 µl 
LTX reagent), as per manufacturer’s instructions (Clontech, CA, USA). After 4 hours 
incubation, 3 ml D-MEM (Gibco, UK) (10% FBS/ 1% 1x penicillin-streptomycin (Sigma, 
UK)) was added to the cells. 24 hours post-transfection the medium was replaced with 3 ml of 
fresh D-MEM (10% FBS/ 1% 1x penicillin-streptomycin). This medium containing virus was 
then harvested at 48 hours post-transfection, fresh medium added and collected the following 
day. The virus was then concentrated 10-fold using the Lenti-X concentrator (Clontech, CA, 
USA), resuspended in phosphate buffered saline (PBS) and stored at -80 ºC. 
 
 
Fusion	partner
1x107 cells
Target	cell
1x107 cells
Cells	 mixed	in	 equal	
numbers	and	washed	x2	in	
BTXpress media.		Cells	
transferred	to	
electroporation	 chamber	
and	connected	 to	
ECM1000	
AC	current	applied	
leading	 to	cells	
lining	 up	in	polar	
fashion
DC	current	applied	
leading	 to	cell	
membranes	fusing
Fig 2.8: Simplified schematic describing formation of T-cell hybridoma using theECM1000 electroporator.
Fusion partner cells and target cells were washed x2 using manufacturer provided BTXpress media. They were then resuspended
in this and transferred to the electroporation chamber. This was connected to the ECM1000 and the pre-set programme start ed
(determined based on cells used). AC voltage allows for cells to rearrange in a linear fashion due to cell:cell polarity. DC current
allowed for cells in close contact to fuse. Following this process, cells were ‘rested’ in the electroporation chamber for 15 minutes
at room temperature within the laminar flow hood before being transferred to a suitable tissue culture vessel and transferred to an
incubator set at 5% CO2/37c.
	
	
71	
2.17 Lentiviral Transductions 
Cells to be transduced were plated at 5x105 cells per well in 24-well plates in D-MEM (10 % 
FBS/ 1 % 1x Penicillin-Steptomycin/ 10 mM HEPES - manufacturers as previously described) 
and grown to 60-80 % confluency. A spinoculation protocol was used to increase contact 
between the cells and virus as described by Dr Millar by personal communication. The plates 
were centrifuged at 500 x g for 5 minutes, the medium removed and virus containing medium 
added (1 ml D-MEM (10 % FBS/ 1 % 1x Penicillin-Streptomycin)/ 25 µl virus/ 4 µg/ml 
polybrene/ 10 mM HEPES). The plates were then centrifuged at 500 x g for 90 minutes at 
room temperature (RT). The medium was then renewed and the cells incubated for 48 hours 
before selection was initiated. Selection concentrations were determined using standard 
survival curves for individual cell types (Puromycin (Sigma, UK) at 2 µg/ml, G418 at 500 
µg/ml (Fisher, UK) for HT-29 cell lines). The cells were split in two and puromycin ± G418 
selection applied to half of the cells. The cells were grown on selection for two weeks, the 
medium changed weekly and this was stored and tested for protein production. 
 
2.18 HLA typing - HLA PCR (1% agarose gel). 
PBMC’s were prepared using Sigma-Aldrich GenElute DNA extraction kit (Sigma, UK). Cells 
were lysed with salt-containing buffer leading to adequate denaturation of macromolecules. 
Spin columns were used to bind the DNA to the column and the supernatent was discarded. 
Cells were then subjected to a number of wash steps to remove any cellular debris prior to 
DNA elution with DNA elution buffer (Sigma, UK). DNA concentration was then established 
using Nanodrop reader (table 2.2).   
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Forward primer Reverse primer Product size (bp) 
A1 GGA CCA GGA GAC ACG GAA TA A1 AGG TAT CTG CGG AGC CCG 575 
A2 TCC TCG TCC CCA GGC TCT A2 GTG GCC CCT GGT ACC CGT 940 
A3 AGC GAC GCC GCG AGC CA A3 CAC TCC ACG CAC GTG CCA 628 
B7 GGA GTA TTG GGA CCG GAA C B7 TAC CAG CGC GCT CCA GCT 1207 
B8 GAC CGG AAC ACA CAG ATC TT B8 CCG CGC GCT CCA GCG TG 606 
B40 CCA CTC CAT GAG GTA TTT CC B40 TAC CAG CGC GCT CCA GCT 1372 
Actin GCT CCG GCA TGT GCA A Actin AGG ATC TTC ATG AGG TAG T 541 
Table 2.2 HLA primers for PCR reaction 
PCR reactions were set up in 20µl reactions as per manufacturer instructions using Taq 
polymerase in a read- made mix (Bioline Reagents Ltd, London). Amplification conditions 
were established on a Gene Amp PCR system 9600 (Perkin-Elmer Corporation, Norwalk, CT, 
USA) or more recently on an MJ Research PTC 225 machine.  
The amplification products were visualised on 1% agarose gel containing 1x SybrSafe (Life 
Technologies, USA). The gels were run at 150 V for approximately 60 minutes in 1X TBE 
buffer and visualised using UV illumination. The results were recorded photographically. 
 
2.19 Herpesvirus Saimiri (HVS) 
A technique first described in 1992 (Biesinger, Mullerfleckenstein et al. 1992), the use of 
HVS has been investigated as a means to immortalize T-cells in much the same way that 
EBV immortalises B-cells.  Therefore, stocks of Owl Monkey Kidney (OMK) cells (provided 
by Dr H De La Pena, University of Birmingham) were used to generate virus for further 
investigation in this project. 
 
2.19.1 Production of HVS stock 
OMK cells were grown in Dulbecco’s Modified Eagles Medium (DMEM) (Life Technologies, 
Paisley, UK) + 10% FCS in T75 flasks. When the density reached ~70% confluence, the flasks 
were infected with HVS and incubated for 2 weeks at 37°C in 5% CO2. Clearing of cells will 
occur after 5-7 days and complete lysis will be seen by 2 weeks. Once the cells had been lysed, 
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cell supernatant and debris was harvested and spun down at 300 x g for 10 minutes, the 
supernatant collected and stored at -80°C in 1ml aliquots (to avoid repeated freeze-thaw 
cycles).  
	
2.19.2 Titration of HVS stock 
OMK cells were cultured as per standard tissue culture techniques. They were plated in 24 well 
plates at a density of 1x106 cells/ml on Day 0. On Day 1 Virus was removed from -80°C store 
and allowed to warm up to room temperature. Serial dilutions were made from neat virus down 
to a dilution of 1x10-14 in 15ml tubes by adding 1 ml of virus to 9ml of standard OMK cell 
media (DMEM (Gibco, UK) + 10% FCS (Sigma, UK)) and 1 ml was added to each respective 
well. A control well containing media with no virus was also set up. All experiments were 
done in triplicate. Virus handling was done in a category 2 tissue culture hood with standard 
precautions in place. The plates were then placed into a designated virus incubator and 
observed on a daily basis (NB no media change is necessary).  A note was made each day as 
to the degree of confluence. The experiment was terminated at 2 weeks, and the supernatant 
collected and spun down and frozen at -80°C. This process was repeated at 6 monthly intervals 
to confirm virus potency and degree of degradation over time (Grassmann, Biesinger et al. 
1990, Biesinger, Mullerfleckenstein et al. 1992, Nick, Fickenscher et al. 1993, Klein, 
Fickenscher et al. 1996, Daubenberger, Nickel et al. 2001, Vella, Zheng et al. 2002). 
Calculation of TCID50 in appendix 1. 
 
2.19.3 HVS infection of PBMC/T-cells 
100µl HVS (previously stored at -80°C) was added per 106 T-cells suspended in 1.6ml 
complete media (RPMI (Gibco, UK) + 10% FCS (Sigma, UK)). Cells had a media change 
twice per week with fresh RPMI 1640 supplemented with 10% FCS and 100 IU/ml of IL-2 
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(Sigma, UK). The success of the transformation was measured by using microscopy and Flow 
Cytometry (FACS) analysis and compared with the growth or death of a control culture.   
 
2.20 Human Induced Pluripotent Stem Cells (hiPS) cells derived from PBMC, T-cell lines 
and T-cell clones 
In depth protocols are available in the appendices of this project.  A brief schematic is produced 
here to describe the outline for the project (fig. 2.9). 
 
Fresh PBMC’s were obtained and cultured in ‘PBMC media’ comprising StemPro 34, 1% 
Glutamax, 100ng/ml SCF, 100ng/ml FLT-3, 20ng/ml IL3, 20ng/ml IL6) all obtained from Life 
Technologies, Paisley, UK.  Media was exchanged on alternate days for 9 days starting on day 
-9.  On day 0, cells were transferred to a suitable vessel and washed twice with plain StemPro 
34 media (no supplements).  A Sendai virus kit (CytoTune iPS 2.0 Sendai Reprogramming 
Kit, Life Technologies, Paisley, UK) was defrosted on ice and the correct volume (as per 
manufacturer’s guideline) was added to 1ml PBMC media per reaction.  Cells were transferred 
to a 12well plate and centrifuged at 300 x g for 90minutes.  1ml further of PBMC media was 
Fig 2.9: Schematic describing generation of hIPSc from T-cells, and PBMC’s.
PBMC’s were isolated and a T cell line generated from them as per standard methods as previously described. Cells were pre-
conditioned prior to transduction with sendai virus with a variety of cytokines as per kit guideline (CytoTune 2.0) and following
viral transduction, were washed in plain non-supplemented media and resuspended in standard growth media containing
appropriate cytokines to encourage iPSc formation. Detailed protocols available in text and appendix 1.
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added to each well and cells placed in an incubator (5% CO2, humidified).  The following day 
(day 1) cells were washed at 300 x g in StemPro34 media and resuspended in PBMC media 
and returned to cell culture plate and replaced in incubator.  On day 3 cells were washed at 300 
x g and resuspended in StemPro 34 media + 1% Glutamax (Life Technologies, Paisley, UK), 
without the addition of any cytokines, and transferred to a prepared MEF (mouse embryonic 
Feeder cell coated 10cm plate).  MEF cells were obtained from AMSBio, UK, strain CF1 
(irradiated at source).  Media was exchanged on alternate days. On day 7 cells had half the 
media replaced with ‘IPSc media’ (DMEM/F12, 10% Knockout-serum replacement, 1% 
Glutamax, 1% NEAA, 1% Penicillin/streptomycin, 0.1% FGF 0.007% B-mercaptoethanol – 
Life Technologies, Paisley, UK). Media was replaced daily until colonies emerged which were 
transferred to new 24w feeder plates (modified protocol (Takahashi and Yamanaka 2013). 
**Following production of hIPSC clones, further characterisation was made including ability 
to differentiate into different germinal layers, staining for alkaline phosphatase, confocal 
microscopy and qPCR (see appendix for protocols). 
 
2.20.1 Differentiation of mouse embryonic thymocytes into T-cells using OP9 DL1 cells 
Mouse embryonic thymocytes were obtained on day 13 gestation.  Thymocytes were 
transferred onto OP9 DL1 cells and grown in standard OP9 media (see section 2.1). OP9 DL1 
cells were grown in OP9 media (as standard protocol) and allowed to reach 70% confluence in 
6well plate. Media was changed every 3 days.  On day 6 the cells were reseeded on fresh 
OP9DL1 cells and the media supplemented with Flt3-L at 10ng/ml (Sigma, UK).  On day 10 
cells were harvested by gentle pipetting and transferred to fresh OP9DL1 cells.  Media was 
supplemented with Flt3-L 10ng/ml and IL7 1ng/ml (Sigma, UK).  Cells were cultured in the 
fashion with media changes every 3 days and transferred to fresh OP9DL1 cells weekly.  On 
day 40, cells were aspirated and analysed on Facs Fortessa (BD, UK) – fig. 2.10. 
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2.20.2 Differentiation of mouse induced pluripotent stem cells into T-cells  
Mouse IPSc were grown on standard Black-6 feeder (MEF) cells as per protocol above.  OP9 
DL1 cells were grown in OP9 media (as standard protocol) and allowed to reach 70% 
confluence in 6well plate. Mouse IPSc (obtained by Dr C Ward, School of Infection and 
Immunity, University of Birmingham) were gently removed from MEF cells using 1:1 volumes 
of collagenase and dispase (Life Technologies, UK) and transferred into pre-prepared 15ml 
falcon tubes containing plain knockout-DMEM (Gibco, UK).  Cells were allowed to fall by 
gravity and the supernatant removed.  Cells were washed in this fashion 3 times using 2ml 
Knockout-DMEM.  Cells were then resuspended in OP9 media and transferred onto the 
prepared OP9 DL1 feeder cells. Media was changed every 3 days.  On day 6 the cells were 
reseeded on fresh OP9DL1 cells and the media supplemented with Flt3-L at 10ng/ml (Sigma, 
UK).  On day 10 cells were harvested by gentle pipetting and transferred to fresh OP9DL1 
cells.  Media was supplemented with Flt3-L 10ng/ml and IL7 1ng/ml (Sigma, UK).  Cells were 
cultured in the fashion with media changes every 3 days and transferred to fresh OP9DL1 cells 
Day	13	embryos	
sacrificed	and	
thymocytes extracted
Transferred	
onto	 OP9DL1	
and	grown	in	
standard	OP9	
media	(aMEM
20%	FCS	and	1%	
Penicillin/
streptomycin )
Day	6	
supplemented	
with	 Flt3
Day	10	
supplemented	 with	
Flt3	and	il-7
FACS	D40
Fig 2.10: Schematic describing co-culture of mouse embryonic thymocytes on OP9DL1 cells.
Embryonic thymocytes were obtained on day 13 post vaginal plug identification (VP) in adult female mouse and resuspended in
standard OP9 media. These were then transferred onto a monolayer of pre-prepared OP9DL1 cells which had been cultured in 6
well plates and reached 70% confluency prior to thymocyte addition.
Media was changed every 3 days. On day 6 cells were resuspended in media supplemented with Flt-3 10ng/ml on fresh OP9DL1
cellls. Co-culture continued and on day 10 media was further supplemented with IL-7 1ng/ml. The cells continued to have media
changes every 3 days and continued in aMEM supplemented with Flt-3 and IL-7 until day 40,when they were harvested and taken
to the flow cytometer for analysis.
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weekly.  On day 40, cells were aspirated and analysed on Facs Fortsessa (BD, UK) (Nagata, 
Toyoda et al. 2009).  
 
2.21 Statistical analysis 
Statistical analysis was performed using Graphpad Prism 6.0 (GraphPad Software Inc, USA). 
SPSS 22.0 (IBM Analytics, USA) was used for the Fisher’s exact test. Unless stated otherwise 
in the text, error bars on figures represent SEM (standard error of mean). 
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Chapter 3:  THE ROLE OF PHOSPHOPEPTIDE IMMUNITY IN CANCER 
 
3.1 Introduction 
Cancer is widely accepted as an immune mediated process; however, the target of this immune 
response has for some time been the subject of much debate and continues to be a source of 
much scientific activity and investment. Infusion of cytotoxic T-cells (CTLs) has been used to 
target PTLD.  Viral epitopes have been proposed as the target used by CTLs  (Bollard, Savoldo 
et al. 2003, Chiereghin, Bertuzzi et al. 2016) (Bollard, Dotti et al. 2010, Heslop, Slobod et al. 
2010). The question remains if the responses seen by these cytotoxic T-cells are purely towards 
viral epitopes or whether there is another process driving this?  
Phosphorylation is termed a posttranslational modification.  It is both reversible and transient 
in nature. Proteins are phosphorylated by kinases and dephosphorylated by phosphatases.  
Intracellular phosphorylation can therefore be seen to have a number of important roles. It 
modifies protein stability, location or formation of complexes.  It clearly has a key intracellular 
role e.g. DNA transcription and is pivotal to intracellular signalling. Moreover, 
phosphorylation could be considered as a control mechanism, which exerts influence over a 
number of key functions (Ozlu, Akten et al. 2010).  If phosphorylation is so important to 
cellular control mechanisms, then it stands to reason that a loss of this control could be 
implicated in cancer.  Entire pathways could be altered, many of which could be implicated in 
tumorigenesis.  Immunotherapies are an attractive potential anti-cancer therapy, and have 
generated much interest scientifically, however until relatively recently; they have been 
hampered by a lack of specific targets.  
MHC class I associated phosphopeptides have previously been identified as a potential new 
class of tumour-specific target (Zarling, Polefrone et al. 2006, Cobbold, De La Pena et al. 2013, 
Abelin, Trantham et al. 2015, Penny, Abelin et al. 2012).  This is based on the observation that 
dysregulation of signalling in cancers can lead to dysfunctional phosphorylation. Using an 
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autologous model of cancer established in healthy individuals (LCLs derived from healthy 
donor PBMC's), as described by Dr Penny of this group, it was shown that phosphopeptides 
appear to represent a significant CTL target (Zarling, Polefrone et al. 2006, Cobbold, De La 
Pena et al. 2013) - fig. 3.1.  
 
MHC class-I and class-II phosphorylated peptides derived from phosphoproteins are abundant 
on the surface of tumours (Zarling, Polefrone et al. 2006, Cobbold, De La Pena et al. 2013, 
Abelin, Trantham et al. 2015).  These antigens exhibit differential expression between healthy 
and malignant tissue with aggressive tumours displaying the most phosphopeptides (Zarling, 
Polefrone et al. 2006, Cobbold, De La Pena et al. 2013).  Memory-like CD8+ T-cells against 
phosphoantigens are present in healthy donors, but are thought to be reduced in patients with 
cancer.  Many phosphorylated peptide antigens have previously been discovered in a multitude 
of cancers, including melanoma, breast cancer, colorectal tumours as well as haematological 
malignancies, all of which have been demonstrated in adults.  Post-translational 
RPPSTRVAM
P
RPPSTRVAM
TCR	recognition	 and	
binding	 of	phosphate	
group	on	
phosphopeptide
Fig. 3.1: Schematic showing showing recognition and binding of the phosphopeptide - a proposed method of
tumour recognition. (a) Recognition of phosphorylated peptide sequence by TCR, leading to binding of the phosphate
group. In the absence of the phosphate group (b) The TCR is unable to bind to the tumour. This is the process
underlying the hypothesised mechanism of tumour recognition by T-cells recognising phosphopeptide.
(a) (b)
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phosphorylation is a modality that a cancer cell uses to proliferate and evade immune control.  
It is therefore proposed that this is the means by which PTLD can evade immune recognition 
and destruction.  Previous studies by this group and others have shown MHC class –I 
phosphopeptides are differentially expressed on tumour surfaces compared to healthy tissue 
and therefore these would seem a logical step to target as a cancer immunotherapy (Syka, Coon 
et al. 2004, Cobbold, Polefrone et al. 2007, Mohammed, Cobbold et al. 2008, Depontieu, Qian 
et al. 2009, Li, Depontieu et al. 2010, Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 
2013, Abelin, Trantham et al. 2015). The overall contribution of phosphopeptides to T-cell 
immunity against transformed cells is not fully understood, and therefore it was our aim to 
investigate this further and assess their contribution to the anti-tumour response. The in vitro 
LCL model will be examined, whereby EBV-naïve individuals will be investigated as they will 
not possess an EBV viral response and thus any recognition and response from T-cells can be 
considered an anti-tumour phosphopeptide response.   
 
3.2 CD8+ T-cell responses to LCLs are found in EBV naïve individuals 
Healthy donors should be able to recognise transformed B-cells.  The question to be answered 
here is how do they manage this? We hypothesised EBV-naive individuals could recognise 
LCLs, and that this recognition would be due to malignant epitopes expressed on the 
transformed B-cell surface.  By virtue of their construction, LCLs are generated due to viral 
infection of B-cells by EBV and subsequent reduction in T-cells using cyclosporin (as 
described in chapter 2). Therefore, recognition of LCLs by T-cells is quite likely to be due to a 
viral epitope; however, it is unlikely this is the only form of recognition on the T-cell’s 
repertoire.  Therefore, to test this theory an EBV-naïve donor was selected as any response of 
these T-cells to the LCLs was proposed to be as a result of tumour recognition as opposed to 
viral epitopes as this donor had not previously been exposed to EBV.  
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As shown in Fig. 3.2a, PBMCs from an EBV naïve donor were obtained by standard techniques 
(as described in chapter 2) magnetically selected (CD8+ cells). These cells were then co-
cultured with irradiated, autologous donor-derived LCLs for up to 7 days.  
 
Fig. 3.2 An EBV-naïve healthy donor has T-cells recognising LCL-associated antigens.  (A) PBMCs, 
generated as described previously, from an EBV-naïve donor were mixed with antibody coated magnetic beads 
and were CD8+ selected and co-cultured with irradiated, autologous EBV-transformed B-cells (LCLs) for 7 days. 
In order to detect whether these cells recognised and became activated in response to these LCLs (B) an IFNg 
ELISpot assay was used to assess immunity of EBV-donor to autologous LCLs and (C) a 3 hour europium release 
killing assay was used to assess functional killing by these T-cells.  These graphs are representative of 3 repetitions 
of this experiment. Error bars represent SEM. 
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IFNγ ELISpot was used to determine their relative activation and subsequent cytokine release 
in response to the autologous LCLs (Fig. 3.2b).  (NB, an EBV peptide was used in order to 
demonstrate that the healthy donor control was EBV-naïve - designated negative-control on 
the figure). We were able to demonstrate a clear cell-number-dependent response to the LCLs, 
both immediately ex vivo (albeit small on day 1) and a more expanded response after 6 days of 
culturing with the irradiated, donor autologous-LCLs (Fig. 3.2b), thus demonstrating that these 
T-cells were recognising a non-viral epitope expressed on the transformed B-cell surface. This 
response appeared to plateau at 100,000 cells on day 6 which could suggest whatever target is 
expressed by the LCL has saturated the T-cell recognition and so no further activation is 
achieved.  It has been proposed that phosphopeptides represent the target for T-cells; and 
therefore if this is the case then this would suggest all T-cell receptors on the T-cells have bound 
to phosphopeptide. In order to explore this further, we assessed whether increasing the number 
of T-cells would increase functional killing.  We predicted that increasing availability of 
receptors on the T-cells (effector cells) would lead to increased target recognition and thus 
increased killing.  To test this a europium killing assay was performed whereby the anti-LCL 
T-cells which have been expanded in culture were used to target LCLs (Fig. 3.2c). This 
experiment demonstrated efficient killing in a ratio dependent fashion - for instance almost all 
LCLs had been destroyed by 3 hours when in a 10:1 effector:target ratio. The negative control 
in this instance was T-cells alone (i.e. without any target cells), thus demonstrating no non-
specific cell death.  
 
3.3 T-cell immunity to EBV-transformed cells targets phosphopeptides 
It has been demonstrated that there is a CD8 T-cell response towards autologous LCLs in an 
EBV-naïve healthy donor.  The T-cells are not recognising viral epitopes by virtue of the fact 
that the donor has not previously been infected by EBV and therefore there are no EBV-specific 
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T-cells within the circulating pool.  We wanted to see whether the responses seen in an EBV-
naïve donor were replicable in EBV-seropositive donors. We hypothesized that the T-cells in 
EBV-seropositive donors would recognise LCLs but that this recognition may largely be due 
to viral epitope recognition. In order to ascertain if there was a phosphopeptide response we 
phosphatase treated the LCLs.  We proposed that phosphatase treatment of LCLs would 
essentially remove any phosphopeptide response (by removal of phosphorylated peptides from 
the cell surface) and thus any resultant recognition would be due to other means i.e. viral 
recognition. 
We have established that the T-cells recognising antigens expressed on the LCLs were 
expandable in a healthy EBV naïve donor control. We therefore considered if this was 
reproducible in two age and HLA-matched EBV seropositive donors (Fig. 3.3A).  
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Fig 3.3 T-cells from two EBV-seropositive donors recognise LCL-associated antigens PBMCs from two EBV 
seropositive healthy donors were co-cultured with irradiated, autologous EBV-transformed B-cells (LCLs) for 7 
days. (A) After this period of 7 days, an IFNγ ELISpot assay was performed to assess the activation of T-cells in 
response to LCLs.  This represents the viral-derived and phosphoprotein derived immune reaction in both donor 
1 and donor 2.  (B) an IFNγ ELISpot assay to assess immunity of the EBV-seropositive donor 1 and 2 to 
respective autologous LCLs following phosphatase treatment (labelled Phosphatase Rx) in the same donors 
demonstrating a significant reduction (**) in IFNγ release as a result of removal of the phosphate group and thus 
removal of the phosphopeptide response.  (C) a 3-hour europium release killing assay showing dose-dependent 
killing. *** P<0.001  Graphs representative of 5 repetitions of these experiments, each done in triplicate. Error 
bars represent SEM. 
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We demonstrated that like the EBV-naïve healthy donor there is a dose dependent response of 
T-cells to LCLs, however again we note that there is a plateauing of this response at 100,000 
LCLs, suggesting that there is a ceiling to the effectiveness of T-cell:LCLs – an optimal number 
after which the recognition sites have become saturated and no further binding is possible.  
Donor 1’s response is more similar to the EBV-naïve donor’s responses in terms of 
SFU/100,000 CD8+ T-cells being a dose dependent concept with a gradual increase in SFU 
from 2, 8, 17, 27, 57 at 10,000LCL, 20,000LCL, 50,000LCL and 100,000LCL respectively.  
Donor 2 appears to have relatively poor responses at 7 days (little variation in SFU between 
10,000 and 50,000LCLs) until 100,000 LCLs are added at which point the response climbs 
from 20 SFU/100,000 CD8+ T-cells up to 49 SFU/100,000 CD8+ T-cells (fig. 3.3A).  
The T-cell response towards the LCLs may be wholly composed of an anti-EBV viral response. 
We hypothesised that there would be T-cell responses to other epitopes displayed on the surface 
of LCLs that could be used to identify a tumour cell.  The immune system has a variety of 
processes for recognition of transformed cells.  One characteristic of a transformed cell which 
the immune system recognises is phosphorylation, a so-called posttranslational modification.  
Furthermore, we proposed that these tumour epitopes may be phosphorylated peptides which 
could be an anti-tumour (and not anti-viral) T-cell response towards LCLs. In order to test this 
hypothesis, lightly fixed and phosphatase treated, or untreated, autologous LCLs were tested 
by co-culturing with T-cells, using IFNγ ELISpot (fig 3.3b). This revealed a significant 
difference (by two-way anova) between the response demonstrated in relation to 
phosphopeptide replete LCLs and phosphopeptide deplete LCLs (p<0.001).  Removing the 
phosphorylated peptide epitopes from the LCL cell surface using phosphatases led to a 67% 
reduction in recognition, activation and thus cytokine release as demonstrated by IFNγ release, 
suggesting that up to 2/3 of the memory responses to transformed self were against these 
phosphorylated epitopes i.e. phosphopeptides (B).   
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Fig. 3.3c demonstrates the effect of phosphatase on the ability of T-cells to kill LCLs using a 
Europium release killing assay in both EBV-seropositive donors. Phosphatase reduces the 
effectiveness of T-cell killing showing that killing of target LCLs is at least in part due to non-
viral epitopes.  Donor 1 showed reduction in killing by phosphatase by between 57-65% when 
compared to non-phosphatase treated p<0.005 by paired t-test.  Donor 2 showed a reduction 
by between 5.9% and 14%, however this is less efficient reduction in killing following 
phosphatases suggesting that killing in this cell line is largely viral-epitope driven. 
We hypothesised phosphatase-treating LCLs should have no effect on the anti-viral- response, 
only the anti-phosphopeptide response. Previously, it was shown that the T-cells responding to 
phosphopeptide will not recognise non-phosphorylated epitopes of the same sequence as would 
be demonstrated by phosphatase treating the LCLs (Cobbold, De La Pena et al. 2013).  
Therefore, it is the phosphate group that forms part of the TCR recognition and loss of the 
phosphate will result in loss of anti-phosphopeptide response. In order to test this hypothesis, 
a peptide-specific T-cell line was grown against the CMV-derived HLA-A2 binding epitope 
NLVPMVATV and cultured with HLA-matched non-autologous LCLs which had been pulsed 
with exogenous NLV peptide and phosphatase treated (fig. 3.4a).   
There appears to be a direct relationship between number of LCLs and number of SFU’s.  There 
is an increase in SFU between 20,000 LCLs and 50,000 LCLs from 21 SFU/100,000 T-cells to 
50 SFUs. The results plateau at 100,000 LCLs suggesting this is the point when all possible 
target binding sites have been exhausted.  Positive control was activation of T-cells with 
PMA/Ionomycin and negative was 1% DMSO (used as peptides were dissolved in this as a 
solvent)– with readout in terms of SFU being as would be expected for each.  There is not a 
significant reduction in T-cell activation following phosphatase treatment therefore confirming 
our prediction that the viral response is not significantly dampened by phosphatase treatment 
(fig. 3.4b). 
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Fig 3.4  NLV-viral peptide specific T-cells can recognise non-autologous LCLs despite phosphatase 
treatment  (A) LCLs from a donor with known CMV-viral peptide response were phosphatase treated and added 
to an NLV-viral peptide specific T-cell line (labelled NLV-T cell line on figure above).  (B) Cells were co-cultured 
for 7 days and an IFNγ ELISpot assay was used to assess immunity of the NLV-T-cell line to the NLV-peptide 
pulsed LCLs following phosphatase treatment (labelled Phosphatase Rx), thus demonstrating no loss of viral-
mediated immune response after phosphatase treatment. This graph is representative of 5 experimental repetitions, 
each done in triplicate. Error bars represent SEM. Positive control are cells stimulated with PMA + ionomycin, 
negative control were cells treated with 1% DMSO. The remainder of the cells were used for a Europium killing 
assay to demonstrate efficient killing in response to target cell (data not shown). 
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EBV naïve healthy donors demonstrated CD8+ T-cell responses to autologous LCLs 
(suggesting this was not a viral response).  As a result, we sought to establish in which 
compartment these CD8+ T-cell responses lay. Flow-cytometry sorting was used to sort the T-
cells into their discrete compartments making the following assumptions: Naïve - 
CD27+CD45RA+, central memory (CM - CD27+CD45RA-), effector memory (EM - CD27-
CD45RA-) and terminal effector memory compartments (TEMRA - CD27-CD45RA+) - fig 3.5   
After sorting (performed in Biosciences, University of Birmingham), using techniques as 
previously described by Dr Penny of this group (personal communication) these cells were co-
cultured with irradiated, autologous LCLs for 6 days, after which they were expanded and used 
in an IFNγ ELISpot assay in order to determine which T-cell population contained anti-LCL 
responses (Fig. 3.5b). Responses were observed in all memory compartments in the EBV-
seronegative donor, but the responses in the central memory and terminal effector memory 
compartments were demonstrably higher (5 and 12 SFU respectively versus 2-4 in the other 
memory compartments). 
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Fig. 3.5  The CD8+ T cell responses against LCLs reside predominantly in the central memory and terminal 
effector memory compartments   (A) CD8+ T-cells were FACS-sorted into Naïve - CD27+CD45RA+, central 
memory (CM - CD27+CD45RA-), effector memory (EM - CD27-CD45RA-) and terminal effector memory 
compartments (TEMRA - CD27-CD45RA+) phenotypes using antibodies to CD27 and CD45RA. (B) 100,000 
sorted cells of each phenotype were co-cultured for 6 days with irradiated, autologous LCLs. On day 6, an IFNγ 
ELISpot was performed to assess each compartment’s responses to the LCLs in an EBV-naïve healthy donor.  
(C) Effect of phosphatase on T-cell activation. ** P<0.01, *** P<0.001.  These graphs are representative of 3 
experimental repetitions, each repetition done in triplicate. Error bars represent SEM. Positive control are cells 
treated with PMA + Ionomycin, negative control are cells treated with 1% DMSO. 
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Having established which compartments the T-cell responses lay, we proposed that 
phosphatase treating the LCLs would lead to a reduction in T-cell activation, however we 
wanted to establish if this was the same for all compartments equally. Unfortunately, this assay 
was inconclusive and due to availability of cells, it was not possible to repeat this with this 
donor (data not shown). This was therefore repeated in an EBV-seropositive donor and the 
results demonstrated marked reduction in T-cell activation (fig. 3.5c). TEMRA compartment 
showed the largest reduction in response from 12 SFU to 2SFU, which is a significant 
reduction when paired T-test is performed (p<0.002).  These data in part validate the results 
seen in the EBV-naïve donor as in the EBV-naïve donor we saw the biggest activation in 
TEMRA and Central memory – which is the same trend seen in the sero-positive donor. The 
biggest reduction in activation was seen in both TEMRA and CM following phosphatase 
treatment suggesting the phosphopeptide response is the main contributor to this as 
compartmentalisation, i.e. viral epitopes have a lesser contribution to T-cell activation in this 
instance when recognising LCLs. 
Finally we considered whether using established anti-LCL T-cell lines in these experiments 
lead to skewing of the data – as these were lines which had been generated previously in 
response to autologous LCL i.e. had developed ‘memory’. We hypothesised that this could 
lead to data skewing and therefore in order to overcome this fresh PBMC’s were obtained from 
(one EBV-seronegative donor the two EBV-seropositive donors, donor 1 and 2 (fig. 3,6a, b) 
and co-cultured with autologous LCLs (already established).  LCLs were phosphatase treated.  
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Fig. 3.6  The CD8+ T cell responses against LCLs reside predominantly in the central memory and terminal 
effector memory compartments  
Fresh PBMC’s  obtained from an (A) EBV-naïve healthy donor and (B) two EBV seropositive donors were FACS 
sorted into naïve, central memory, effector memory and terminal effector phenotypes using antibodies to CD27 
and CD45RA as described previously. 100,000 cells of each type were co-cultured for 6 days with irradiated, 
autologous LCLs (phosphatase treated). On day 6, an IFNγ ELISpot was performed to assess each compartment’s 
responses to the LCLs.  These graphs are representative of 3 experimental repetitions, each repetition performed 
in triplicate. Error bars represent SEM. Positive control are cells stimulated with PMA + ionomycin. Negative 
control are cells treated with 1% DMSO. 
 
These data show a similar trend to the previous results seen in anti-LCL T-cells thus validating 
these previous results.  In the EBV-naïve donor (fig. 3.6A) there is the greatest response seen 
in the CM compartment (10SFU/100,000 CD8 T-cells down to 3SFU/100,000 CD8 T-cells), 
with TEMRA also demonstrating a large reduction from 12-6SFU/100,000 T-cells.  This is 
similar to that seen in the T-cells with regards to the two compartments implicated being CM 
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and TEMRA (although in T-cells it is TEMRA which shows the biggest reduction).  When 
assessing the EBV-Seropositive donors we can see a similar reduction in activation when LCLs 
are phosphatase treated.   
Using PBMC’s rather than T-cells lead to the biggest reduction in CM in all donors (seen more 
markedly in sero-positive donor 2) 12-7SFUs and 8-2SFUs respectively.  Both TEMRA and 
CM have been implicated as forming part of the phosphopeptide response; however in the T-
cell data (fig 3.5 C) we saw a larger reduction in TEMRA.  This may hint that culturing T-cells 
against autologous LCLs may lead to data bias.  
 
3.4 T cells from an EBV naive donor kill LCLs in a phosphopeptide dependent manner 
Having established that EBV naïve T-cells become activated in the presence of transformed 
B-cells, we sought to test if these cells had the ability to perform targetted killing.  It has long 
been established that CTL’s can be used for the treatment of PTLD (the in vitro model of which 
are LCLs) (Haque, McAulay et al. 2011, Ricciardelli, Brewin et al. 2013, Ricciardelli, Blundell 
et al. 2014, Stubbins, Peters et al. 2015, Chiereghin, Bertuzzi et al. 2016, Dharnidharka, 
Webster et al. 2016). We predicted that as viral epitopes do not play a role here, that 
phosphatase treating the LCLs would result in inefficient killing of the LCLs (Fig 3.7a).  This 
was tested by performing a europium killing assay comparing phosphatase treated cells to non-
treated cells in an EBV-naïve donor (fig. 3.7b).  This would be the case if the target for the 
effector cells is phosphorylated.  Interestingly we can see that there is still killing following 
phosphatase treatment, up to 40%, but this is markedly reduced compared to non-phosphatase 
treated cells which has efficiency up to 92% at an E:T ratio of 10:1.  This would suggest that 
the effector T-cells are recognising an alternative target on the cell surface – it is not 
immediately clear what this may be – but an alternative hypothesis may be that phosphatase 
does not completely eliminate phosphorylated peptides on the cell surface.  What is clear is 
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there is a significant reduction in target cell recognition by up to 50% (two way anova shows 
p<0.001) confirming our hypothesis phosphatase reduces killing efficiency and therefore 
demonstrating that phosphopeptides are the likely target epitope here (fig. 3.7b).  Put another 
way ANOVA was used to compare the regression lines (fig. 3.7c) and there was a significant 
difference demonstrated following phosphatase treatment of LCLs  (***) p=0.0011. 
 
Fig. 3.7 Anti-LCL T-cell lines can efficiently recognise and kill LCLs in a dose dependent manner and 
this effect is driven by a phosphorylated target.  (A) experimental protocol for testing the hypothesis that 
phosphatase will reduce efficient killing.  An anti-LCL T-cell line was used as the effector cells.  BATDA 
loaded autologous LCLs were used as targets.  Prior to BATDA loading half the LCLs were treated with 
phosphatase.  (B) Europium killing assay was performed as described previously and demonstrates a  
significant reduction in target killing when these cells are pre-treated with phosphatase. (C) Linear 
regression lines of same data demonstrating significant reduction in killing p<0.005. Experiments performed 
in triplicate. Error bars represent SD. 
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3.5 MHC class I associated phosphopeptides identified on LCLs 
Until now we have identified that phosphopeptides are likely HLA-associated, and that 
recognition of these phosphopeptides is one of the mechanisms by which T-cells can identify 
and kill transformed cells.  Using the commercially available and well established EBV-
transformed B-cell line JY, phosphopeptides presented at the surface of this cell line have been 
identified (table 3.1).  This was achieved by in vitro expansion, immunopurification using the 
antibody W6/32 and peptide acid elution.  Subsequently purification was achieved using IMAC 
and characterised further by LC-MS/MS and manual sequence assignment. 154 
phosphopeptides were identified as being expressed by JY(Zarling, Polefrone et al. 2006, 
Cobbold, Polefrone et al. 2007, Mohammed, Cobbold et al. 2008, Cobbold, De La Pena et al. 
2013, Abelin, Trantham et al. 2015). As some of this data is historical, absolute amounts of 
expression are not known as they were not quantified, however it can be seen that of the 
phosphopeptides which have been quantified, all except two are expressed at higher levels in 
JY than healthy control B-cells (spleen and tonsil).  Many more phosphopeptides were 
identified on JY compared to healthy B-cells – 154 vs 16 respectively.  As demonstrated in the 
table, a number of key cancer pathways appear to be implicated by these phosphopeptides; 
with source proteins including RAS, BCL2, LSP1, MAPK-II, Beta-Catenin.   
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Table 3.1 HLA A2 or B7 associated phosphopeptides identified on the LCL cell line JY compared to healthy 
control B-cells (healthy spleen and tonsil tissue was obtained from HBRC tissue bank, University of 
Birmingham). Small 's' or 't' denotes phosphorylation. This was achieved by in vitro expansion, 
immunopurification using the antibody W6/32 and peptide acid elution.  Samples were frozen rapidly in liquid 
nitrogen and subsequently packaged on dry ice and shipped to University of Virginia for further processing.  
Purification was achieved using IMAC and characterised further by LC-MS/MS and manual sequence 
assignment. Sequence sets were then returned and source protein analysed. 
 
 
 
 
 
Phosphopeptide Source Protein Predicted HLA binding JY Spleen (B cell) Tonsil (B cell)
RQLsSGVSEI Heat shock protein beta-1 A2
ALDsGASLLHL Receptor-interacting serine/threonine-protein kinase 4 A2
ALGsRESLATL RAS protein activator like-3 A2
ALYsPAQPSL Sphingomyelin phosphodiesterase 4 A2
AMAAsPHAV Heterogeneous nuclear ribonucleoprotein A0 A2
AMLGSKsPDPYRL Protein SON A2
AVIHQsLGL Protein CNPPD1 A2
AVVsPPALHNA Bromodomain-containing protein 4 A2
GLLGsPVRA M-phase inducer phosphatase 2 A2
GLLsPARLYAI Leucine-rich PPR motif-containing protein, mitochondrial A2
ILDsGIYRI Hermansky-Pudlak syndrome 5 protein A2
ILKsPEIQRA 60S ribosomal protein L4 A2
IMDRtPEKL Breast cancer anti-estrogen resistance protein 3 A2
KIFsGVFVKV 60S ribosomal protein L7-like 1 A2
KLDsPRVTV Family with sequence similarity 86, member A, isoform CRA_h A2
KLFPDtPLAL Interleukin enhancer-binding factor 3 A2
KLFsPSKEAEL Protein cramped-like A2
KLIDIVsSQKV Serine/threonine-protein kinase Chk1 A2
KLIDRTEsL Lymphocyte-specific protein 1 A2
KLLQFYPsL Linker for activation of T-cells family member 2 A2
KLLSSAQRtL Krueppel-type zinc finger protein A2
KLMAPDIsL BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 A2
KLMsPKADVKL Protein hinderin A2
KMDsFLDMQL NEDD4-binding protein 2 A2
KMYsEIDIKV 116 kDa U5 small nuclear ribonucleoprotein component A2
KVAsLLHQV TNFAIP3-interacting protein 2 A2
KVLsTEEMEL Mitotic-spindle organizing protein 2A A2
KVQVtSLSV unknown A2
LMFsPVTSL SET domain-containing protein 5 A2
mLAEsPSVPRL unknown A2
REAsIELPSM Lymphocyte-specific protein 1 A2
RLAsLNAEAL Bromo adjacent homology domain-containing 1 protein A2
RLAsLQSEV unknown A2
RLDsYVRS Trafficking protein particle complex subunit 1 A2
RLDsYVRSL Trafficking protein particle complex subunit 1 A2
RLLsPLS(+18)SA unknown A2
RLLsPLSSA Ribonucleoprotein PTB-binding 1 A2
RLQsTSERL ATP-dependent zinc metalloprotease YME1L1 A2
RLSsPLHFV Protein FAM134A A2
RLSsYVRS Trafficking protein particle complex subunit 1 A2
RQAsIELPSMAV Lymphocyte-specific protein 1 A2
RQAsLSISV Serine/threonine-protein kinase D2 A2
RQAsIELPSM unknown A2
RQAsIWLPSAAV unknown A3
RQIsFKAEV Ubiquitin-conjugating enzyme E2 J1 A2
RQIsFQAEV Ubiquitin-conjugating enzyme E2 J1 A2
RQIsQDVKL AMP deaminase 2 A2
RTYsGPMNKV Protein POF1B A2
RVPsPTPAPK Serine/arginine repetitive matrix protein 2 A2
SLLTsPPKA E3 ubiquitin-protein ligase TRIP12 A2
SMTRsPPRV Serine/arginine-rich splicing factor 8 A2
TLAsPSVFKST Protein aurora borealis A2
VLKGsRSSEL UPF0693 protein C10orf32 A2
VLLsPVPEL Anaphase-promoting complex subunit 1 A2
VLmKsPsPAL Probable ATP-dependent RNA helicase YTHDC2 A2
VMFRtPLASV F-box only protein 5 A2
YLDsGIHSGA Catenin beta-1 A2
YLDSGIHsGA Catenin beta-1 A2
YQLsPTKLPSI Nibrin A2
expressed, not quantified
0.05-0.5 copies/cell
0.5-5 copies/cell
5-10 copies/cell
10-50 copies/cell
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Phosphopeptide Source Protein Predicted HLA binding JY Spleen (B cell) Tonsil (B cell)
GPRSAsLLSL G-protein-signaling modulator 3 B7
HPRsPNVLSV Hypoxia-inducible factor 1-alpha B7
HPRsPtPTL Proline-rich protein 11 B7
KPRsPPRAL Retrotransposon-derived protein PEG10 B7
KPRsPPRALV Retrotransposon-derived protein PEG10 B7
KPRsPVVEL Beta-adrenergic receptor kinase 1 B7
KPSsLRRVTI Lymphoid-restricted membrane protein B7
LPRGsSPSVL Homeobox protein TGIF2 B7
MPRQPsATRL Mitotic-spindle organizing protein 2B B7
RPAKsMDSL Rho GTPase-activating protein 30 B7
RPAsAGAML Myocyte-specific enhancer factor 2D B7
RPAsPAAKL KAT8 regulatory NSL complex subunit 3 B7
RPAsPQRAQL unknown B7
RPDsRLGKTEL Histone-lysine N-methyltransferase SETD2 B7
RPFsPREAL Leucine zipper protein 1 B7
RPIsPGLSY Coiled-coil domain-containing protein 6 B35
RPKsDIVLL B-lymphocyte antigen CD20  (N to D conversion) B7
RPKtPPVVI Synapse-associated protein 1 B7
RPNsPSPTAL Serine/threonine-protein kinase tousled-like 1 B7
RPRANsGGVDL Ras-responsive element-binding protein 1 B7
RPRARsVDAL Lipolysis-stimulated lipoprotein receptor B7
RPRPHsAPSL Migration and invasion-inhibitory protein B7
RPRPVsPSSL Serine/threonine-protein kinase SIK1 B7
RPRsAVLL A-kinase anchor protein 13 B7
RPRsPRENSI Ataxin-2 B7
RPRsPRQNSI Ataxin-2 B7
RPRsPTGPSNSF Splicing factor 45 B7
RPRsPTGPSNSFL Splicing factor 45 B7
RPVsPFQEL unknown B7
RPVsPGKDI Transcription factor HIVEP2 B7
SPAsPKISL Ataxin-2-like protein B7
SPKsPTAAL Centrosomal protein of 55 kDa B7
SPRRsRSISL Serine/arginine-rich splicing factor 7 B7;C6
SPRsPGRSL unknown B7
SPR(s)P(s)TTYL Chromatin assembly factor 1 subunit A B7
TPRsPPLGL Mitogen-activated protein kinase kinase kinase 11 B7
APRKGsFSAL Cullin-4A B7
APRRYsSSL Rho GTPase-activating protein 17 B7
LPAsPAHQL Histone-lysine N-methyltransferase, H3 lysine-79 specific B7
RPKsNIVLL B-lymphocyte antigen CD20 B7
YPSsPRKAL Signal-induced proliferation-associated 1-like protein 1 B7
APRAPSAsPLAL MICAL-like protein 1 B7
GAQPGRHsV LIM domain-containing protein ajuba B7
GPRAPsPTKPL Sororin B7
GPRPGsPSAL RNA pseudouridylate synthase domain-containing protein 1 B7
GPRsPKAPP ARHGAP4 protein B7
HPKRSVsL BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like B7
IPRPLsLIGSTL Dedicator of cytokinesis protein 10 B7
expressed, not quantified
0.05-0.5 copies/cell
0.5-5 copies/cell
5-10 copies/cell
10-50 copies/cell
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Phosphopeptide Source Protein Predicted HLA binding JY Spleen (B cell) Tonsil (B cell)
KLRsPKSEL Tyrosine-protein phosphatase non-receptor type 22 B7
KPAsPARRL Microtubule-associated protein 1A B7
KPAsPKFIVTL Zinc finger CCCH domain-containing protein 14 B7
KPPYRSHsL Centrosomal protein of 95 kDa B7
KPRRFsRsL Arginine/serine-rich coiled-coil protein 2 B7
KPRsPPRALVL Retrotransposon-derived protein PEG10 B7
KPRsPPRALVLP Retrotransposon-derived protein PEG10 B7
KPYsPLASL Nuclear factor of activated T-cells, cytoplasmic 2 B7
LPAsPRARL Histone-lysine N-methyltransferase, H3 lysine-79 specific B7
LPIFSRLsI Zinc finger protein 36, C3H1 type-like 2 B7
LPKsPPYTAF Eukaryotic translation initiation factor 4B B7
MPREPsATRL Mitotic-spindle organizing protein 2B B7
MPRQPsATRL Mitotic-spindle organizing protein 2B B7
QPRsPGPDYSL Zinc finger protein Gfi-1 B7
QPRtPSPLVL Lymphocyte-specific protein 1 B7
RARGIsPIVF YTH domain-containing protein 1 B7
RPAFFsPSL Uncharacterized protein KIAA0930 B7
RPKLSsPAL Histone acetyltransferase p300 B7
RPKsNINLL B-lymphocyte antigen CD20 B7
RPPsPGPVL Sterol regulatory element-binding protein cleavage-activating protein B7
RPQRATsNVF Myosin regulatory light polypeptide 9 B7
RPRIPsPIGF Eukaryotic translation initiation factor 4E transporter B7
RPRsLSSPTVTL E3 ubiquitin-protein ligase NEDD4-like B7
RPRSLsSPTVTL E3 ubiquitin-protein ligase NEDD4-like B7
RPRsPGSNSKV General transcription factor II-I B7
RPRsPPPRAP Prickle-like protein 3 B7
RPRsPRQPSI unknown B7
RPSsLPDL AT-rich interactive domain-containing protein 1B B7
RPTsRLNRL Nuclear receptor coactivator 1 B7
RPVtPVSDL Krueppel-like factor 10 B7
RPWsPAVSA Ski oncogene B7
RPYsPPFFSL Protein FAM53C B7
RQAsIELPSMAV Lymphocyte-specific protein 1 B7
RQAsIELPSM Lymphocyte-specific protein 1 B7
SPGsPRPAL DNA replication factor Cdt1 B7
SPKsPGLKA CapZ-interacting protein B7
SPRAPVsPLKF Ribosomal protein S6 kinase beta-2 B7
SPRERsPAL Thyroid hormone receptor-associated protein 3 B7
SPRsPGKPM unknown B7
SPRsPSTTYL Chromatin assembly factor 1 subunit A B7
SPRTPVsPVKF Ribosomal protein S6 kinase beta-1 B7
SPSTSRSGGsSRL Arginine/serine-rich protein 1 B7
TPAQPQRRsL Targeting protein for Xklp2 B7
TPRsPPLGLI Mitogen-activated protein kinase kinase kinase 11 B7
TSPsYIDKL Serine/threonine-protein kinase Chk1 B7
VPREVLRLsL AT-hook-containing transcription factor B7
expressed, not quantified
0.05-0.5 copies/cell
0.5-5 copies/cell
5-10 copies/cell
10-50 copies/cell
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3.6 Discussion 
Treatment of PTLD using CTL’s was initially thought to target viral epitopes expressed at the 
cell surface (Haque, McAulay et al. 2011, Stubbins, Peters et al. 2015, Chiereghin, Bertuzzi et 
al. 2016). However, a competing hypothesis involves CTLs recognising an alternative target. 
It is likely that a combination of both viral and non-viral responses contributes to the targeting 
of PTLD.  As we have demonstrated here, EBV-naïve individuals do mount a response to LCLs 
and in fact removal of the phosphorylation of the peptide targets leads to inefficient killing – 
suggesting that phosphorylated proteins (phosphopeptides) are at least one of the classes of 
non-viral epitopes targeted.  This stands to reason given phosphorylation is a post-translational 
transformation seen in cancer cells and termed a ‘Hallmark of Cancer’ (Hanahan and Weinberg 
2011). 
In this chapter, we have demonstrated that EBV-naïve individuals do have a targeted response 
to autologous LCL (fig 3.2) which is probably not due to an anti-viral response given their 
EBV serostatus.  These T-cells demonstrate (i) an ability to expand in the presence of their 
cognate antigen and (ii) efficient killing of target LCL populations. A similar response has 
been demonstrated in EBV-seropositive donors (fig. 3.3) however, these donors have 
previously encountered EBV infection, and thus the activation seen in response to LCLs is 
likely to include this so called 'viral' response. In order to delineate this, cells were phosphatase 
treated (thereby removing the phosphate group from any presented phosphopeptides and 
consequently the phosphopeptide response) with the remaining cell responses considered 
virally driven. In order to assess this further we considered if viral non-EBV peptide-specific 
T-cells could recognise non-autologous LCLs following phosphatase treatment (Fig 3.4) 
therefore demonstrating that the T-cell activation is due to viral epitope not tumour, and also 
that phosphatase treatment does not affect the non-phosphorylated protein recognition. It was 
hypothesised that they should be able to, as phosphatase does not affect ability to recognise 
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non-phosphorylated proteins. To answer this question, CMV peptide-pulsed LCLs from a 
donor with known CMV-viral peptide response were phosphatase treated. They were added to 
a CMV-viral peptide specific T-cell line.  Following a period of 7 days of co-culturing, we 
were able to show that these cells were indeed not affected by phosphatase treatment and they 
continued to possess the ability to recognise and become activated by viral peptides expressed 
on the LCLs, thus confirming that T-cell activation towards LCLs in a non-autologous cell line 
was in fact viral driven not cancer epitope driven.  
Conventionally it is considered that it is the effector T-cells which are able to respond quickest 
to antigen stimulation, as demonstrated here by IFNγ release, and the central memory T-cells 
may also do this but at a slower rate as they will only actively do this when they have started 
to expand and differentiate. As a result of this observation, we decided to assess this 
presumption further, by analysing the memory phenotypes of the anti-LCL CD8+ T-cells, as 
demonstrated in an EBV naïve donor (fig. 3.5).  It was found (following FACS sorting) that 
the majority of responses were in the TEMRA compartment with similar frequencies of 
responses in both CM and EM cells.  Very few naïve CD8+ T cells were demonstrated. All 
four compartments showed expansion following stimulation with LCLs (Fig. 3.5b) when 
assessed in the positive control. This is in direct contrast to previous studies which had 
demonstrated a stronger CM response rather than TEMRA (Bhaduri-McIntosh, Rotenberg et 
al. 2008). Unsurprisingly phosphatase treatment of the autologous LCLs in the EBV-naïve 
donor drastically reduced the response to LCLs, with a reduction in TEMRA from 12-2SFUs, 
which would be expected as these cells should not possess a viral response to the LCLs by 
virtue of the donor being EBV-naive. Of note however, is that following phosphatase 
treatment, the central memory response was much less than the TEMRA response – and thus 
actually does confirm previous observation that CM is most involved in LCL recognition via 
phosphopeptides in the naïve donor (i.e. Phosphatase treatment has removed the 
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phosphopeptide response).  I wondered whether there was skewing the data obtained (due to 
using anti-LCL T cells rather than fresh PBMC’s), as by the nature of derivation of the anti-
LCL T-cell line, they were not truly ‘naïve’ and thus had the potential to have developed an 
anti-viral response. To test this theory the same experiment was performed with fresh PBMC’s 
which had been FACS sorted as previously into the different T-cell compartments (Fig 3.6a, 
b).  Phosphatase treatment once again significantly reduced the overall response to target cells 
in CM from 10SFUs to 3SFUs and TEMRA from 12-6SFU/100,000 T-cells, which confirmed 
that CM following phosphatase treatment was where the majority of the memory responses lie. 
Both TEMRA and CM have been implicated as forming part of the phosphopeptide response; 
however, in the T-cell data (fig 3.5 C) we saw a larger reduction in TEMRA.  This may hint 
that culturing T-cells against autologous LCLs may lead to data bias.  
In the EBV-seropositive donors we showed similar responses (Fig 3.6b), but phosphatase 
treatment allowed demonstration of the viral-targeted contribution.  This therefore confirms 
previous observation that there does appear to be an expandable, functional, cytotoxic T cell 
response to transformed-self, of a CM phenotype, which contrasts to the observation noted by 
Dr Penny which showed EM to be the predominant type. The implications of this finding are 
based on the assumption that these donors have a fully functional cytotoxic T cell response 
against phophopeptides and therefore they possess this T-cell response to protect them from 
cancer.  We would therefore hypothesise that the loss of this T cell response could result in 
them acquiring a B cell cancer (or other types of cancer if more than one cell type presents the 
same phosphopeptide). 
 Furthermore, it was demonstrated that these anti-LCL CD8+ T cells in EBV naïve individuals 
(and EBV-seropositive individuals in the presence of phosphatase treatment) were capable of 
killing (Fig. 3.3c and 3.7b,c). 
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JY is a long established cell-line which is derived from a patient with PTLD.  This was 
therefore used as a cell line model to study PTLD.  Phosphopeptides have been identified on 
this cell line (Table 3.1) as well as in healthy B-cells (spleen and tonsil).  However, it can be 
seen that there are far more phosphopeptides identified on JY than in healthy tissue, which 
again fits with the assertion that cancers possess post-translationally modified proteins, and 
phosphorylation thereof is a hallmark of this. This observation being accepted, it therefore 
stands to reason that tumour immunotherapy targets would be expressed on tumour and not 
healthy cells.  
Clearly, we have identified a vast number of phosphopeptides many of which could be 
implicated in cancer tumour pathways.  On analysing the source proteins we can see a number 
have previously been implicated in cancer pathways such as those which code for proteins 
MAP kinases, LSP1, NFAT and B-catenins. This will be investigated further in chapter 4.   
One key question to be answered is: is it likely that every patient with a tumour possesses at 
least one phosphopeptide on that tumour, allowing T-cells to target that tumour? The answer 
to this is likely to be yes given how many phosphopeptides we have identified on JY compared 
to healthy untransformed B-cells (10 fold more).  The next chapter explores overlap between 
tumours with regards to phosphopeptide expression, and will aim to come closer to answering 
this question.  Certainly previous studies have shown overlap between tumours but the fact 
that there are so many more phosphopeptides expressed on transformed cells compared to 
healthy controls would suggest that these are ‘cancer epitopes’. Related to this is the 
observation that healthy B-cells do possess phosphopeptides as well.  This could therefore 
point to a role for phosphopeptide outside of tumour recognition which is as yet unidentified, 
or it may purely be a coincidence – as we have seen that those phosphopeptides expressed by 
normal cells are on the whole expressed at a lesser level than transformed cells suggesting that 
this could be non-specific ‘background’ expression. Clearly phosphopeptides expressed on 
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healthy cells would be unhelpful in a cancer immunotherapy as they would  lead to T-cells 
targetting healthy cells – something clearly immunotherapies are aiming to avoid. One 
potential explanation is that these phosphopeptides are expressed on healthy tissues, and 
malignant transformation may lead to increased expression perhaps due to upstream 
upregulation of protein source. 
In conclusion, we have demonstrated that transformed B-cells express phosphopeptides at 
higher levels than healthy tissues.  We have also shown that T-cells derived from healthy 
donors are able to recognise phosphopeptides and perform effective killing.  This has therefore 
led us to believe that phosphopeptide-recognition could play a role in tumour recognition and 
destruction, and potentially play a protective role in healthy individuals, Based on this 
observation we can now go on to investigate whether these cells could form the basis of a 
cancer immunotherapy. 
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Chapter 4:  IDENTIFICATION OF TUMOUR-SPECIFIC MHC CLASS I-
ASSOCIATED PHOSPHOPEPTIDES 
 
4.1. Introduction 
In order for immunotherapy to work, tumours must express a specific target which can 
delineate healthy and tumour tissue.  Mutations and epigenetic changes accumulate in tissues, 
which finally lead to a dysregulation of major signalling pathways that are important for 
malignant transformation. Therefore, deregulation of signalling pathways with altered 
intracellular protein phosphorylation is a documented 'hallmark' of cancer. As established by 
this group, phosphoproteins involved in these signalling cascades can be degraded to 
phosphopeptides that are then subsequently presented on the cell surface by major 
histocompatibility complex (MHC) molecules and recognized by T-cells (Zarling, Polefrone 
et al. 2006, Cobbold, Polefrone et al. 2007, Penny, Abelin et al. 2012, Cobbold, De La Pena et 
al. 2013).  
Previously, it has been established that phosphopeptides could represent a likely target for T-
cell responses to malignant transformation. The aim of this study was to see what role these 
phosphopeptides played in paediatric cancer, and in particular (1) Hepatic tumours (i) 
hepatoblastoma and (ii) hepatocellular carcinoma and (2) Post-Transplantation 
Lymphoproliferative Disease (PTLD) as this was a key objective of this Phd, having worked 
in the liver transplant field, and aspiring to be a paediatric hepatologist.  
Clearly, with regards to PTLD, immunity plays a role, as it develops following initiation of 
immunosuppression in response to viral infection with EBV.  As discussed previously, LCLs 
are a useful in vitro equivalent to PTLD and a lot of what has already been established was 
based on the JY LCL as an in vitro model (Penny, Abelin et al. 2012, Cobbold, De La Pena et 
al. 2013, Abelin, Trantham et al. 2015). A role for the immune response and in particular 
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phosphopeptide response has also been identified in a number of other tumours including 
melanoma, leukaemia and colorectal tumours (Penny, Abelin et al. 2012, Cobbold, De La Pena 
et al. 2013).  
In hepatocellular carcinoma (a predominantly adult tumour) a role for recognition of tumour-
associated antigens is also evident (Stenner-Liewen, Luo et al. 2000, Thorgeirsson and 
Grisham 2002, Chen, Fu et al. 2008, Mizukoshi, Nakamoto et al. 2011, Liang, Ding et al. 
2013); however until recently very few of these antigens have been identified. In 
hepatoblastoma, there has been an implication that FAS/FAS ligand plays a role in apoptosis 
(Ozdemirli, ElKhatib et al. 1996, Scaffidi, Fulda et al. 1998, Yoshikawa, Toyohara et al. 1998, 
Allan, Parikh et al. 2013, Hsiao, Kao et al. 2013).  Wnt-signalling, B-catenins and NF-Kappa 
B also appear to play a pivotal role in development of tumour, and are targets for chemotherapy 
(Pritchard, Brown et al. 2000, Hartmann, Kuechler et al. 2009, Armengol, Cairo et al. 2011, 
Mokkapati, Niopek et al. 2014). FAS Ligand plays a key role in T-cell expansion during 
immune responses and it is also involved in cell responsiveness to chemotherapy as originally 
described in leukaemias. However, more recently it has been implicated in chemosensitive 
tumours such as hepatoblastoma, neuroblastoma and some brain tumours (Micheau, Solary et 
al. 1997, Muller, Strand et al. 1997, Fulda, Los et al. 1998, Scaffidi, Fulda et al. 1998).   
Many tumours are recognised by antigen specific MHC Class-I specific cytotoxic T-cells, the 
most extensively investigated being melanoma, with peptides identified as the targets for these 
CTL’s (Romero 1996, Wang, Gulden et al. 1997). This has even prompted a number of Phase 
I trials looking at cancer vaccines based around these peptides (Jager, Ringhoffer et al. 1996, 
Jager, Ringhoffer et al. 1996, Nestle, Alijagic et al. 1998, Rosenberg, Yang et al. 1998, 
Marchand, van Baren et al. 1999).  Therefore, there may be a role for phophopeptides in other 
tumour types including hepatoblastoma and PTLD, but as yet this has not been considered. 
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Immunotherapy is predicted to improve outcome in high risk hepatoblastoma patients who are 
more prone to developing chemoresistance.  The use of monoclonal antibodies to direct 
immunity towards tumour cells has recently been studied using humanised antibodies which 
recognised EpCAM or CD326 which is known to be overexpressed in hepatic tumour cells, 
with the data obtained suggesting improved targeting of cells and potentially better long term 
outcome (Armeanu-Ebinger, Hoh et al. 2013).   We therefore propose that recognition of 
phosphopeptide in conjunction with cancer vaccines or monoclonal antibodies, or indeed a 
combination thereof, may be a key cancer immunotherapy to be considered in the future. 
 
4.2 Characterisation of MHC Class-I phosphopeptides  
Leading on from these initial observations, we hypothesised that phosphopeptides are 
presented by MHC molecules in increasing amounts on the surface of altered hepatocytes. We 
further proposed that the immune system monitors the liver for malignant transformed 
hepatocytes and clears those cells with the help of phosphopeptide-specific cytotoxic T-cells.  
In order to test both of these hypotheses, MHC class I-associated phosphopeptides were 
isolated from tumour using techniques described previously (and adjacent normal tissue where 
available) and characterised in hepatoblastoma cell lines, primary liver tumours, PTLD cell 
lines and blood from a patient with PTLD, in order to identify tumour-associated 
phosphopeptides.   
 
4.2.1 Hepatoblastoma-associated phosphopeptides identified 
HepG2 is a well established cell line, which is known to be HLA-A2.  This cell line was grown 
to a density of 1x106 cells/ml, and the MHC class I complexes purified and the peptides eluted 
as per standard protocols (see materials and methods section 2.10). Using IMAC technology, 
phosphopeptides were purified from this mixture, which were further characterised by LC-
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MS/MS and manual sequence assignment by the Hunt laboratory in Virginia using their 
standard protocols (fig. 4.1).  
 
Fig. 4.1 Schematic describing work-flow for tumour-specific, MHC class I-associated phosphopeptide 
discovery from patient samples.  Tumour and normal tissue were taken from the same patient at tumour 
resection/explant. These were each lysed and the MHC class I complexes affinity purified using pan class-I 
antibody, W6/32. The MHC class I-associated peptides were eluted in acid and phosphopeptides enriched using 
IMAC. These phosphopeptides were characterised using CAD and ETD LC-MS/MS and the sequences manually 
assigned.  	
 
Additionally, four primary HB tumour samples, each with adjacent matched 'normal' healthy 
tissue were similarly processed and analysed. The HLA types of these samples, as obtained 
from records held by Birmingham Children's Hospital Liver Transplant Unit, are detailed in 
Table 4.1. Key HLA types investigated here were A2 and B7 as these were more commonly 
identified in the tumour tissues available to the project.  As already identified in chapter 3, 
phosphopeptides appear to be only expressed within a specific HLA type i.e. 'HLA specific', 
and therefore this influenced the subsequent healthy donor’s identified for this stage of the 
project. 
1.		Tumour	
removed
2.		Healthy	
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Table 4.1: HLA type of tumour samples and HepG2 the hepatoblastoma cell line.  HLA was assigned using 
standard PCR methods. Full HLA type not available. 
As per accepted 'in house' definitions, phosphopeptides were considered 'tumour-associated' if 
the levels detected in the tumour tissue were at least twice those levels detected on the normal 
tissue (corrected for weight of sample available). Only 11% of tumour-associated 
phosphopeptides were found at any detectable level in the healthy tissues. By using UniProt 
software (www.uniprot.org) the protein source for the phosphopeptide was assigned. Using the 
“MHC-I binding predictions” program from IEDB (tools.immuneepitope.org), along with the 
information available about the HLA type of the cell line/patient, peptide-HLA binding was 
predicted.  All patients undergoing liver transplantation had a HLA tissue typing conducted as 
part of their transplant preparation protocol.  This information was gathered by Ms Julie Taylor 
and shared as per our transfer agreement. The phosphopeptides identified, the protein which 
they originate from, their predicted HLA binding and their relative levels in each of the samples 
is described in tables 4.2 (HLA-A), 4.3 (HLA-B) and 4.4 (Unknown HLA). These were 
described in this way in order to make a further comparison to data available in other tumours 
as studied by other members of the laboratory including Dr Penny (colorectal, gastro-
Class I HLA Allele
Sample A locus B locus C locus
HB 02 A*02
A*29
B*07
B*27
C*06
HB 05 A*02
A*24
B*07
B*35
C*07
HB 06 A*02
A*29
B*07
B*57
C*06
HB 07 A*01
A*03
B*07
B*15
C*06
HepG2 line A*02
A*24
B*15
B*35
C*06
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oesophageal) and Dr Buttner (HCC tumours in adult samples) thus facilitating a direct 
comparison.  Small 's' or 't' denotes phosphorylation. 
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epatoblastom
a
sam
ples predicted to bind H
LA
-A
 continued 
C
ell line
H
epG
2
Phosphopeptide
Source Protein
Predicted H
LA
 binding
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
R
LSsPLH
FV
Protein FA
M
134A
A
2
R
LLsTD
A
EA
V
Transcription initiation factor TFIID
 subunit 7
A
2
A
V
V
sPPA
LH
N
A
B
rom
odom
ain-containing protein 4
A
2
A
LD
sG
A
SLLH
L
R
eceptor-interacting serine/threonine-protein kinase 4 (R
IPK
4)
A
2
R
LA
sY
LD
K
V
K
eratin, type I cytoskeletal 19
A
2
FLD
tPIA
K
V
Protein naked cuticle hom
olog 1
A
2
K
V
A
sLLH
Q
V
TN
FA
IP3-interacting protein 2
A
2
V
M
IG
sPK
K
V
Tensin 3 (TN
S3)
A
2
SM
TR
sPPR
V
Serine/arginine-rich splicing factor 8
A
2
K
LD
sPR
V
TV
Fam
ily w
ith sequence sim
ilarity 86, m
em
ber A
, isoform
 C
R
A
_h
A
2
STA
PPV
H
N
V
M
ucin 1, cell surface associated (M
U
C
1)
A
2
A
LSN
LEV
TL
Ferm
itin fam
ily hom
olog 1 (c20orf42)
A
2
ILA
PV
ILY
I
N
A
D
PH
 oxidase 1 (N
ox-1)
A
2
ILD
Q
K
IN
EV
O
rnithine decarboxylase (O
D
C
)
A
2
K
LM
D
LD
V
EQ
L
Proliferating C
ell N
uclear A
ntigen (PC
N
A
)
A
2
A
LFV
R
LLA
LA
Transform
ing grow
th factor beta 1 (TG
FB
1)
A
2
TM
A
sPG
K
D
N
Y
karyopherin subunit alpha 6
A
3
R
yQ
TQ
PV
TL
Supervillin
A
24
V
Y
TyIQ
SR
F
D
ual specificity tyrosine-phosphorylation-regulated kinase 4
A
24
K
SLsPSLLG
Y
N
uclear factor of activated T-cells, cytoplasm
ic2
A
29
R
PIsV
IG
G
V
SLY
Sperm
atogenesis-associated protein 13
A
29
Prim
aries
H
P02
H
P05
H
P06
H
P07
Not	detected
HLA	m
ism
atch
text
Tum
our	associated
text
Tum
our	specific
text
cell	line	only
text
non-specific
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Table 4.3: Phosphopeptidesidentified from
 H
epatoblastom
a
sam
ples predicted to bind H
LA-B 
C
ell line
H
epG
2
Phosphopeptide
Source Protein
Predicted H
LA
 binding
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
K
PFK
LSG
LsF
M
A
R
C
K
S-related protein
B
7
K
PA
sPK
FIV
TL
Zinc finger C
C
C
H
 dom
ain-containing protein 14
B
7
K
PR
sPV
V
EL
B
eta-adrenergic receptor kinase 1
B
7
TPR
sPPLG
L
M
itogen-activated protein kinase kinase kinase 11
B
7
R
PFH
G
ISTV
sL
D
EN
N
 dom
ain-containing protein 4C
B
7
R
PFsPR
EA
L
Leucine zipper protein 1
B
7
R
PV
sPFQ
EL
unknow
n
B
7
R
PW
sPA
V
SA
Ski oncogene
B
7
R
PY
sPPFFSL
Protein FA
M
53C
B
7
R
PLsPILH
I
Protein transport protein Sec24B
B
7
SPFK
R
Q
LsL
N
um
b H
om
olog (D
rosophila)-Like
B
7
SPFK
R
Q
LsL
cD
N
A
 FLJ53174, highly sim
ilar to N
um
b-like protein
B
7
R
PA
FFsPSL
U
ncharacterized protein K
IA
A
0930
B
7
TPR
sPPLG
L
M
itogen-activated protein kinase kinase kinase 11
B
7
R
PK
PsSSPV
IF
Poly(rC
)-binding protein 2
B
7
TPR
sPPLG
LI
M
itogen-activated protein kinase kinase kinase 11
B
7
Prim
aries
H
P02
H
P05
H
P06
H
P07
Not	detected
HLA	m
ism
atch
text
Tum
our	associated
text
Tum
our	specific
text
cell	line	only
text
non-specific
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Table 4.3: Phosphopeptidesidentified from
 H
epatoblastom
a
sam
ples predicted to bind H
LA
-B continued 
C
ell line
H
epG
2
Phosphopeptide
Source Protein
Predicted H
LA
 binding
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
R
PTK
IG
R
R
sL
adenosylhom
ocysteinase like 2 
B
7
R
PD
sA
H
K
M
L
Palladin, C
ytoskeletal A
ssociated Protein
B
7
R
A
H
sEPLA
L
D
D
B
1- and C
U
L4-associated factor 15
B
15
R
A
H
SsPA
SL
Y
A
P1 (yes-associated protein 1)
B
15
R
SH
sSPA
SL
W
W
 D
om
ain C
ontaining Transcription R
egulator 1
B
15
R
SR
sPLEL
D
N
A
 dam
age-binding protein 2
B
27
K
R
Y
sG
N
M
EY
Large Tum
or Suppressor K
inase 1
B
27
R
R
G
sFEV
TL
Selenoprotein H
B
27
R
R
PsLLSEF
N
uclear receptor corepressor 1
B
27
R
R
sSFLQ
V
F
Protein transport protein Sec23A
B
27
R
PIsPG
LSY
C
oiled-coil dom
ain-containing protein 6
B
35
R
PIsPPH
TY
R
oundabout hom
olog 1
B
35
R
Pm
sESPH
m
ZFP36 R
ing Finger Protein-Like 1
B
35
LPK
sPPY
TA
F
Eukaryotic translation initiation factor 4B
B
35
K
A
FsPV
R
SV
D
N
A
-binding protein inhibitor ID
-2
B
57
K
SG
ELLA
tW
salt inducible kinase 2
B
57
H
P02
H
P05
H
P06
H
P07
Prim
aries
Not	detected
HLA	m
ism
atch
text
Tum
our	associated
text
Tum
our	specific
text
cell	line	only
text
non-specific
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Table 4.4: Phosphopeptidesidentified from
 hepatopblastom
acells w
ith unknown H
LA
 binding
C
ell line
H
epG
2
Phosphopeptide
Source Protein
Predicted H
LA
 binding
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
Healthy
Tumour
RTHsLLLLL
Ribonuclease	4
U
RKSsIIIRM
Plasm
inogen-like	protein	B
U
Q
PRsPGPDYSL
Grow
th	Factor	Independent	1	Transcription	Repressor
U
ITQ
GtPLKY
Nuclear	Receptor	Corepressor	2
U
KPAsPKFIVTL
zinc	finger	CCCH-type	containing	14
U
RRPsLLSEF
Nuclear	Receptor	Corepressor	1
U
RFKtQ
PVTF
Anterior	gradient	protein	2	hom
olog
U
RTHsLLLLL
ribonuclease	A	fam
ily	m
em
ber	4	
U
KRLsVERIY
Topoisom
erase	(DNA)	II	Alpha
U
TRKtPESFL
Epsin	1
U
RRIsDPEVF
Filam
in	A	Interacting	Protein	1-Like
U
SFDsGSVRL
Interferon	regulatory	factor	6
U
RKPsIVTKY
ATP-dependent	helicase	ATRX
U
RRPsLLSEF
Nuclear	receptor	corepressor	1
C6
RRLsFLVSY
Glutam
ine--tRNA	ligase
C6
RRsSFLQ
VF
Protein	transport	protein	Sec23A
C6
KAFsPVR
DNA-binding	protein	inhibitor	ID-2
C6
KAFsPVRSV
DNA-binding	protein	inhibitor	ID-2
C6
RSAsFSRKV
Nephrocystin-4
C6
LSSsVIREL
Neuroguidin
C6
Prim
aries
H
P02
H
P05
H
P06
H
P07
Not	detected
HLA	m
ism
atch
text
Tum
our	associated
text
Tum
our	specific
text
cell	line	only
text
non-specific
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Initial observation of these tables suggests that the greatest number of phosphopeptides 
identified were on HepG2, the hepatoblastoma cell line.  This could be due to it being an 
established line generated a number of years ago and subsequent mutation of the line, although 
this can only be surmised.  Information was not available in relation to passage number of these 
cells.  It is likely this does represent a heterogeneous cell line however.  Hepatoblastoma 
tumour sample HP02 demonstrated a larger number of phosphopeptides (35) compared to 
sample HP05 (24), HP06 (19) and HP07 (13).  All tumour samples were normalised for tumour 
sample size.  The reason for this variation could be related to where the sample was obtained 
from (i.e. position within the tumour – central versus periphery) or how the sample was 
processed by surgical centre (i.e. different surgical teams, different histopathologist, time of 
day specimen was obtained – as many were obtained at liver explant during transplantation 
surgery and as a result samples may degrade as a result of short term storage if surgery occurred 
overnight/bank holiday/at the weekend.  Samples were to be processed ‘fresh’ (i.e. not fixed 
in formalin/wax or liquid nitrogen) and therefore any delay even small could result in tissue 
degradation.  To further emphasise this point, sample HB07 for instance was a sample which 
was taken during transplant surgery over a weekend period and therefore the sample was stored 
in a refrigerator for 36 hours prior to transfer to the Tissue BioBank (HBRC, University 
Hospitals Birmingham) prior to sample release, and this would therefore appear to have 
influenced the sample outcome.  However, in view of small numbers of clinical samples being 
available the decision was made to include this sample anyway. 
Overviewing the data there are a number of phosphopeptides expressed across a number of 
samples/HepG2.  In particular, the phosphopeptide RPWsPAVSA coding for the Ski oncogene 
is expressed in 3 of the hepatoblastoma tumour samples (HP02, HP05 and HP06).  This is 
therefore strongly suggestive of this being a potential T-cell target on  hepatoblastoma and 
therefore was considered a phosphopeptide of interest which was identified as one to 
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investigate further.  The phosphopeptide RTHsLLLL which codes for the protein ribonuclease 
4 is expressed in all samples both tumour and healthy tissue as well as the HepG2 cell line.  
This phosphopeptide is therefore discounted as a possible target phosphopeptide for this 
tumour group, as it is unlikely a tumour target would also be expressed at such high levels in 
normal healthy tissue. 
There were an increased number of phosphopeptides identified in the tumour samples 
compared with the healthy tissue, on average, 68 vs. 25 (fig. 4.2A).  This suggests that the level 
of phosphopeptide expressed on the cell surface would be higher in tumour tissue than healthy 
tissue (χ2 test p<0.01). Where phosphopeptides were found on both normal and tumour tissues, 
they were expressed at higher levels on tumour tissue suggesting they were ‘tumour 
associated’.  Fig 4.2b is a Euler diagram showing the overlap of phosphopeptide presentation 
on hepatoblastoma tumours, healthy tissues and hepatoblastoma (HepG2) cell line. This shows 
that 41 phosphopeptides have been found unique to hepatoblastoma and not on healthy tissue 
or previously in the HepG2 cell line.  There is an overlap of 16 phosphopeptides found on both 
tumour and cell line (HepG2).  If phosphopeptides are the target for immune cells to recognise 
tumour, we propose these targets will be in the tumour or tumour/cell line crossover.  We 
discounted those phosphopeptides found exclusively in the cell line, as these have not been 
seen in any other samples and hence validity as a target is in doubt, as we could not support or 
refute the suggestion that this is a tumour target as we have not demonstrated it on a tumour 
sample.   
Fig 4.2c demonstrated phosphopeptides found to be present in the healthy liver tissues were 
found at significantly different levels in the tumour tissue, p<0.001 Wilcoxons t-test, but 
weren’t significantly different to expression in the HepG2 cell line i.e. there were significantly 
more phosphopeptides found on tumours and the HepG2 cell line, and the numbers of copies 
per cell of phosphopeptide overall in the tumours and the cell line were significantly higher 
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than levels found in healthy tissues.  When considering the phosphopeptides identified in 
normal tissues (fig. 4.2D) we demonstrated that those found were not significantly higher in 
tumour than normal tissue, which further bolstered the idea that these phosphopeptides are 
unlikely to be an immune target as there is not a sufficient difference when comparing healthy 
and abnormal tissues (Wilcoxon signed rank p=0.802 (fig.4.2 D).   
Fig. 4.2e demonstrates the number of hepatoblastoma associated phosphopeptides identified 
on the hepatoblastoma tumour samples.  HLA-A2 and B7 were identified as being commonest 
amongst the samples obtained (three and four samples respectively) which is perhaps not 
surprising given the population sampled and hence selected to be explored further following 
this observation. 
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Fig. 4.2 Comparison of phosphopeptide levels in healthy and Hepatoblastoma tumour tissue samples The 
number of phosphopeptides identified by our collaborators at University of Virginia using techniques previously 
described was compared in hepatoblastoma tumour primaries and adjacent healthy tissue obtained at time of 
surgery from the same patient. (A) More phosphopeptides were seen in tumour than normal liver tissue χ2 
p<0.001. Phosphopeptides not identified were said to be at a level below detection (0.1 fmol/gram). Significantly 
more phosphopeptide was present in tumour tissue than healthy liver tissue, Wilcoxon signed rank p<0.001. (B) 
Euler diagram showing the overlap of phosphopeptide presentation on hepatoblastoma tumours, healthy tissues 
and hepatoblastoma (HepG2) cell line. (C) The phosphopeptides present in healthy liver tissue were found at 
significantly different levels in the tumour tissue, p<0.0001 Wilcoxons t-test(***).  (D) Phosphopeptides 
identified on normal tissue were not found at significantly different levels in tumour tissue by Wilcoxon signed 
rank p=0.802 (ns).  (E) Correlation between the number of phosphopeptides identified and the number of samples 
for each HLA type. 
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4.2.2 Characterisation of PTLD tumour-specific MHC class I-associated 
phosphopeptides  
MHC class I-associated phosphopeptides were isolated and characterised from three LCL cell 
lines (an in vitro equivalent to PTLD), and blood obtained from a patient with PTLD.  The 
patient was initially diagnosed with short gut secondary to antenatally diagnosed gastroschisis 
and subsequent multiple surgical resections necessitating combined small bowel and liver 
transplant for Intestinal Failure associated Liver Disease (IFALD) at the age of 3y 9 months. 
PTLD developed 7 months subsequent to this and was determined to be EBV-mediated.  
The cell line JY, as already discussed in chapter 3, which is natively HLA-A2 was grown to 
1x106 cells/ml and the MHC class I complexes purified as per standard protocols and the 
resultant peptides eluted. Using IMAC, phosphopeptides were purified and further 
characterised by LC-MS/MS and manual sequence assignment by the Hunt Laboratory in 
Virginia, USA. Additionally, two LCL cell lines were generated from healthy donors 
(designated donor 1 and donor 2), by methods described in chapter 2 which were similarly 
processed and analysed. All three cell lines and the patient sample were HLA typed (table 4.5). 
NB only one patient sample was obtained, HLA was already known as the patient had recently 
undergone solid organ transplantation 7 months prior to development of PTLD.  
 
Table. 4.5 HLA type of LCL/PTLD samples 
 
 
Class I HLA Allele
Sample A locus B locus C locus
JY A*02
-
B*07
-
-
Donor 1 LCL A*01
A*02
B*07
B*27
C*06
Donor 2 LCL A*02
A*02
B*07
B*13
C*06
PTLD 01 A*02
A*03
B*07
B*27
C*06
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Table 4.6 overleaf describes phosphopeptides isolated by our collaborators at the University 
of Virginia. Again, as per our agreed accepted 'in house' definition, phosphopeptides were 
considered 'tumour-associated' if the levels in the tumour were at least twice that of the normal 
tissue. The majority of tumour-associated phosphopeptides detected on the LCLs were not 
found at any level in the healthy B-cells (only 10% were found to be present). UniProt was 
used to identify the representative protein source of the phosphopeptide (www.uniprot.org). 
Prediction software was used to predict peptide binding to HLA - “MHC-I binding predictions” 
programme from IEDB (tools.immuneepitope.org), along with the information about the HLA 
type of the patient or healthy donors. The phosphopeptides identified, their protein, their 
predicted HLA-binding and relative levels in each of the samples is described in tables 4.6 
(HLA-A), 4.7 (HLA-B) and 4.8 (Unknown HLA). These were described in this way in order 
to make a further comparison to data available in other tumours as studied by other members 
of the laboratory including Dr Penny (colorectal, gastro-oesophageal) and Dr Buttner (HCC 
tumours in adult samples) thus facilitating a direct comparison. Small 's' or 'p' denotes 
phosphorylation. 
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Only twenty one phosphopeptides were identified on normal tissue (Spleen and tonsil) 
obtained from patients with a non-malignant pathology (tonsillar hypertrophy, patients with 
chronic Idiopathic thrombocytopenic purpura) compared to 152 on JY, 119 on healthy donor 
derived LCL lines and 75 on the patient tumour sample (fig. 4.3 A, B). Thus, there was 
significantly more phosphopeptide on tumour tissue than normal (Wilcoxon’s t-test p<0.001) 
(Fig. 4.3c). There were no significant differences in phosphopeptide expression demonstrated 
between (i) tumour (PTLD) and JY, (ii) tumour and healthy donor derived LCLs or (iii) JY 
and healthy donor derived LCLs (two-tailed Mann-Witney) – fig. 4.3C. Using unpaired T-test 
to compare phosphopeptides expressed in normal cells versus PTLD there is no significant 
difference between both data sets, suggesting phosphopeptides expressed in normal healthy 
tissues bare no significance to tumour development as expression levels are comparable in both 
healthy and malignant tissues supporting the idea that these phosphopeptides are not solely 
responsible for tumour development (Fig 4.3D). 
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4.2.3 Comparisons and analysis 
Identifying phosphopeptides on each tumour type was informative, and could represent a target 
for tumour immunotherapy, but as we found phosphopeptides on tumour and healthy tissues, 
perhaps more important are identifying those specific phosphopeptides that may represent 
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Fig. 4.3 Comparison of phosphopeptide levels in healthy B cells and PTLD cell lines and a PTLDpatient sample
The number of phosphopeptides identified was compared in a patient blood sample (newly diagnosed with PTLD) and the
commerci ally available PTLD cell line JY, as well as two LCL lines generated from healthy donors following infection with EBV
as per standard protocols. (A). More phosphopeptides were seen in tumour/tumour lines than healthy B cells χ2 p<0.001.
Phosphopeptides not identified were said to be at a level below detection (0.1 fmol/gram). Significantly more phosphopeptide was
present in tumour tissue than healthy B cells, Wilcoxon signed rank p<0.001 (*). (B) Euler diagram showing the overlap of
phosphopeptide presentation on PTLD tumour derived line, JY, Healthy donor derived LCL lines and healthy B cells. (C) The
phosphopeptides present in healthy liver tissue were found at significantly different levels in the tumour tissue, p<0.001
Wilcoxons t-test (**). (D) Phosphopeptides identified on normal tissue were not found at significantly different levels in tumour
tissue by unpaired t-test p=0.508.
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potential markers of an oncogenic process i.e. identification of a cancer phenotype – 
phosphopeptides that are integral to a cancer's existence, and are found on any tumour cell 
regardless of the organ type i.e. a marker of malignancy. On analysis of the phosphopeptides 
obtained from HB tissue, we noted that a number of these phosphopeptides had been identified 
on other tumours (fig. 4.4).   
 
Fig. 4.4 Phosphopeptides expressed on different tumour types which are also expressed on hepatoblastoma  
On analysis of phosphopeptide expression in hepatoblastoma tissue samples. Aa number of phosphopeptides were 
previously found to have been expressed on other tumour types. (A) Here we use a Euler plot to demonstrate 
crossover between different tumour types, where GI refers to oesophageal and colorectal adenocarcinomas (as 
studied by Dr Penny, Haem refers to all haematological malignancies (as studied by Dr Cobbold and Dr De La 
Pena), other includes other solid tumours  e.g. breast, melanoma and ovarian (data available from our collaborators 
in University of Virginia). (B) We also observed crossover between different liver tumours, both primary 
(hepatoblastoma and hepatocellular carcinoma) as well as liver metastases detected on patient samples collected 
from patients with GI malignancy. 
 
In order to identify what crossover there was, euler-venn diagrams were created.  Fig 4.4A 
shows a comparison of hepatoblastoma (HB) with gastrointestinal tumours (Colorectal and 
oesophageal adenocarcinoma), haematological malignancies (AML, ALL, T and B cell 
lymphomas) and other solid tumour primaries (including melanoma, breast carcinoma and 
ovarian carcinoma, termed ‘other’). The colorectal adenocarcinomas, as studied by Dr Sarah 
Penny also had a subset of patients with liver metastases, and on assessing phosphopeptides 
seen on these secondary malignancies a number were also identified on HB tumour samples, 
suggesting that these phosphopeptides may be involved in a hepatological development and 
tissue differentiation pathways.  They could play an important role in hepatic tissue dysplasia 
for instance (B). It is also noted that there are a number of phosphopeptides identified on adult 
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hepatocellular carcinoma samples (as studied by Dr Nico Büttner of this group), again 
bolstering this view of a role in hepatic dysplasia (Table 4.9).  
 
In order to understand their role in hepatic tumours a few of the key signalling pathways were 
further examined and proteins involved identified (fig 4.5) – signalling pathways of interest 
highlighted in red.  Interestingly these pathways have all been implicated in malignant 
transformation of cells, which would suggest that these are reasonable targets to investigate 
further.  
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Phosphopeptide 
Sequence 
Protein 
Pathw
ay 
M
echanism
 of action proposed 
K
T
M
sG
T
FL
L
 
Signal transducer 
and activator of 
transcription 2 
JA
K
/STA
T 
cascade 
regulation of transcription from
 R
N
A
 polym
erase II prom
oter 
R
Q
L
sSG
V
SE
I 
H
eat shock 
protein beta-1 
(H
SPB
1) 
M
A
PK
A
P kinase 
2 
C
ell m
otility; negative regulation of apoptosis and protein kinase activity; positive regulation of angiogenesis, blood 
vessel endothelial cell m
igration, interleukin-1 beta production, tum
our necrosis factor biosynthetic process, I-kappaB
 
kinase/N
F-kappaB
 cascade, m
R
N
A
 stability, translational initiation and the vascular endothelial grow
th factor receptor 
signalling pathw
ay 
R
Q
A
sIE
L
PSM
 
Lym
phocyte-
specific protein 1 
M
A
PK
A
P kinase 
2 
Phosphorylated by casein kinase II, protein kinase C
 and M
A
PK
A
PK
2. PK
C
 induced phosphorylation leads to 
translocation from
 m
em
brane to cytoplasm
. Phosphorylation by M
A
PK
A
PK
2 is thought to regulate neutrophil 
chem
otaxis. 
R
T
FsPT
Y
G
L
 
Synem
in 
 
interm
ediate filam
ent cytoskeleton organization and biogenesis 
R
Q
D
sT
PG
K
V
FL
 
N
uclear receptor 
subfam
ily 2 group 
C
 m
em
ber 1 
 
B
inds the IR
7 elem
ent in the prom
oter of its ow
n gene in an autoregulatory negative feedback m
echanism
. Together w
ith 
N
R
2C
2, form
s the core of the D
R
ED
 (direct repeat erythroid-definitive) com
plex that represses em
bryonic and foetal 
globin transcription. A
lso found to be an activator of O
C
T4 gene expression. A
s a result, it m
aybe involved in stem
 cell 
proliferation and differentiation. B
elongs to the nuclear horm
one receptor fam
ily. N
R
2 subfam
ily.  
K
A
FsPV
R
SV
 
D
N
A
-binding 
protein inhibitor 
ID
-2 
 
Im
plicated in the negative regulation of D
N
A
-dependent transcription, neuron fate com
m
itm
ent and the regulation of lipid 
m
etabolism
 
E
L
FSsPPA
V
 
N
uclear factor of 
activated T-cells 5 
T-cell receptor 
signalling 
pathw
ay 
R
egulates hypertonicity-induced cellular accum
ulation of osm
olytes. H
om
odim
er w
hen bound to D
N
A
, com
pletely 
encircles its D
N
A
 target. D
oes not bind w
ith Fos and Jun transcription factors. H
ighest levels in skeletal m
uscle, brain, 
heart and peripheral blood leukocytes. A
lso expressed in placenta, lung, liver, kidney, pancreas, spleen, thym
us, prostate, 
testis, ovary, sm
all intestine and colon.  
K
L
FPD
tPL
A
L
 
Interleukin 
enhancer-binding 
factor 3 
T-cell receptor 
signalling 
pathw
ay 
a double-stranded R
N
A
 (dsR
N
A
)-binding protein im
plicated in the regulation of gene expression. Phosphorylated in a 
double-stranded R
N
A
-dependent m
anner possibly by PK
R
.  
R
L
SsPL
H
FV
 
Protein 
FA
M
134A
 
 
B
elongs to the FA
M
134 fam
ily.  M
em
brane protein, m
ulti-pass; M
em
brane protein, integral 
A
V
V
sPPA
L
H
N
A
 
B
rom
odom
ain-
containing protein 
4 
G
1/S-specific 
transcription in 
m
itotic cell cycle; 
positive 
regulation of I-
kappaB
 
kinase/N
F-
kappaB
 cascade; 
positive 
regulation of 
R
N
A
 elongation 
from
 R
N
A
 
an atypical protein kinase of the B
rd fam
ily. C
ontains a double brom
odom
ain. B
inds to chrom
atin and regulates cell cycle 
progression at m
ultiple stages. A
ssociates w
ith chrom
osom
es during m
itosis. The cognate gene is the chrom
osom
e 19 
target of translocation t(15;19)(q13;p13.1), resulting in the B
R
D
4-N
U
T oncogene identified in a lethal carcinom
a of 
young people. B
inds to papillom
avirus E2 protein and is required for its transform
ing ability. Tw
o alternatively spliced 
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s have been described. 
Table 4.9: Phosphopeptides identified on prim
ary and secondary liver tum
ours 
Follow
ing identification of phosphopeptides on hepatoblastom
a tum
our sam
ples, correlation w
as m
ade w
ith previous hepatic tissues 
studied by this group.  K
ey pathw
ays w
ere identified including M
A
PK
inase, JA
K
/STA
T cascade, N
FK
appa-B
, T-cell receptor 
signalling, TG
F-B
 and W
nt/C
atenin B
 pathw
ays (inform
ation collected using U
niProt softw
are).   
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Of the 46 phosphopeptides that are shared between different hepatic malignancies in this list, 
23 (50%) were from established cancer pathways. It is therefore possible that these proteins 
are cancer specific, be it coded for by tumour suppressor genes, or oncogenes.  Their end result 
appears to be hepatic dysplasia and malignancy. 
 
4.3 T-cell responses to tumour specific peptides 
There is a clear need for immunotherapeutic targets in paediatric hepatoblastoma and PTLD, 
and prognosis following a diagnosis of malignancy is variable but typically morbidity is high 
with side effects of tumour therapies.  The aim therefore of this project is to identify a tumour 
specific target. Memory CD8+ T cell infiltration has been well described as being a key 
prognostic indicator in a number of tumours including colorectal adenocarcinoma and 
melanoma.  In a number of these tumours tumour infiltrating lymphocytes (TILs) have been 
implicated as targeting and destroying malignant-transformed cells, although how they achieve 
this has not been fully established (Pages, Galon et al. 2010, Emens, Silverstein et al. 2012, 
Galon, Pages et al. 2012). Phosphopeptides have been proposed as a possible epitope used to 
facilitate this tumour cell identification, based on the dysregulation of signalling in cancers 
which is known to lead to aberrant protein phosphorylation.  
As has already been described earlier in this chapter, we have identified 84 HB-associated 
MHC class I phosphopeptides on HB primary tumours and the HepG2 cell line. We found 4.4 
times as many different phosphopeptides on tumour-transformed cells than healthy tissues, at 
far higher levels (7.6-fold higher). A number of these phosphopeptides were found to be from 
proteins which are identified as pivotal in a number of already well-established and described 
cancer pathways, leading these to be considered as a marker of malignant potential. 
		 145	
Based on the initial observations of phosphopeptide expression we proposed that a significant 
part of the immune response to transformed cells is the targeting of phosphopeptides.  We 
considered if this may be related to eventual clinical outcome. Dr Cobbold, of this laboratory 
has previously described, in haematological malignancy, responses to phosphopeptides in both 
patients and healthy donors (Cobbold et al., 2013). He also noted that loss of phosphopeptide 
response which had previously been present was also a poor prognostic indicator.  
Healthy individuals possess mechanisms for recognising and eliminating tumour and we 
predict that phosphopeptides are one of the potential tumour recognition targets. We 
hypothesised that healthy donor T-cells could recognise tumour derived phosphopeptide.  We 
wondered if this may aid us in establishing whether phosphopeptide-specific memory T-cells 
could have a pivotal role in the functional immune response observed in malignant 
transformation. In order to test this hypothesis a number of phosphopeptides presented by 
HLA-A2 and B7 on tumour samples (both hepatoblastoma and PTLD/LCL) were selected for 
further analysis.   These phosphopeptides were pulsed onto appropriate target cells and cultured 
with HLA-matched healthy donor T-cells to establish if the T-cells could recognise these 
tumour-specific phosphopeptides (fig 4.6).  A number of the phosphopeptides chosen are 
considered ‘liver’ in phenotype – being consistently present on 
hepatoblastoma/HepG2/Hepatocellular carcinoma or liver secondary tumours. I also selected 
a number of phosphopeptides which were identified on the PTLD tumour samples also – 
keeping the same HLA group as the liver tumours in order to set up a panel of phosphopeptides 
to test on healthy donors.  
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Intracelllular staining techniques were employed to assess activation and response of healthy 
donor cells to tumour phosphopeptides on day 1 and day 7, demonstrated in representative 
plots fig. 4.7a,b and 4.8a,b (further plots for other donors are available in the appendix 1 fig. 
S2-S7, the data from which is used to compile fig 4.7c and 4.8b).  Combination gates were 
1.		Tumour	
removed
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tumour	
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and	lysed
3.		MHC	Class-
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affinity	
purified
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eluted
5.		IMAC	
enrichment	of	
Phosphopeptides
6.		
Phosphopeptides
characterised	 by	
LC-MS/MS
7.		
Phosphopeptide	
sequences	
manually	assigned
Fig 4.6: Schematic describing the work-flow for testing of healthy donor T-cell responses to tumour-specific, MHC class I-
associated phosphopeptides discovered in patient samples
Tumour and normal tissue were taken from the same patient at surgical resection. These were each enzymatically lysed (as per
protocol previously described in chapter 2) and the MHC class I complexes affinity purified using the pan class-I antibody, W6/32
(produced in house). The MHC class I-associated peptides were eluted in acid and phosphopeptides enriched using IMAC by our
collaborators at University of Virginia. These phosphopeptides were characterised using LC-MS/MS and the sequences manually
assigned. The phosphopeptides were then synthesised and the assignment verified.
Once phosphopeptides were identified, healthy donor PBMC’s were obtained from HLA-matched donors. These cells were
pulsed with these phosphopeptides in vitro on day 0 and day 6, and analysed by intracellular staining protocols (ICS) for evidence
of phosphopeptide recognition and T-cell activation. Cells found to recognise Phosphopeptide were expanded and T-cell lines
generated.
TILs were taken from the patient tumours at resection and expanded, using high-dose IL-2 (6000 IU/ml). TIL responses to the
phosphopeptides were then tested. TILs were stimulated with phosphopeptide and cultured for 5 days before being re-stimulated in
an intracellular cytokine staining assay assessing production of TNFα, IFNγ and IL-2.
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expanded	with	IL2	to	
generate	phosphopeptide-
specific	 T	cells
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then used to assess the individual expression of interleukin 2 (IL-2), interferon gamma (IFNγ) 
and tumour necrosis factor alpha (TNFα) – all considered markers of T-cell activation (fig 
4.7c, Fig 4.8b).  These plots demonstrated limited response on day 1across the range of donors 
in both the A2 and B7 responses, which were more marked by day 7.   We assessed the T-cell 
responses to the phosphopeptides using a 12 hour intracellular cytokine staining (ICS) assay 
to test production of cytokines (TNFα, IFNγ and IL-2). The responses at this time point were 
considered low (for three out of four of the B7 donors for instance, initial responses to 
phosphopeptide were all <2% at day 1) and therefore a further assay was performed at 7 days, 
with restimulation of cells with phosphopeptide at 6 days.   
We assessed the individual T-cell line's cytokine repertoires. We noted a degree of background 
staining seen in the TNFα and IFNγ staining in this assay in the negative controls for each line, 
which was considered low (e.g. in donor H when considering B7 responses at day 7, this donor 
had 0.844% IFNγ+ cells, 0.540% TNFα+ cells and 0.017% IL-2+ cells – combined total of 
1.401%) – but this was taken into account when assessing the phosphopeptide responses. In 
contrast positive controls (stimulation of cells with PMA/ionomycin as per methods chapter) 
resulted in an increase in positive cells to 18.1% IFNγ+, 27.3% TNFα+ and 0.120% IL-2+ cells 
respectively with a combined total of 45.52%). T-cell response to viral peptide was also tested 
and where demonstrated included as a further positive control. The same donor (H) also had 
good responses to the phosphopeptides tested at 7 days with totals ranging from 19.2% to 
42.6% polyfunctional responses to the peptides investigated.  In contrast donor C demonstrated 
only low responses to the phosphopeptides tested (ranging from 6.2% to 14.2%) on day 7, but 
with comparable positive and negative controls (fig. 4.7c). 
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
GPRSAsLLSL
RPAsAGAML
Fig. 4.7a:Phosphopeptide responses in Healthy Donor H (day 0) 
PBMC’s were generated from healthy donors as previously described and responses of these cells to tumour-associated 
phosphopeptides were then assessed using an intracellular staining (ICS) assay.  The FACS plots depicted show the gating strategy 
employed and representative IFNγ ,TNFα, and IL-2 responses (from left to right). NB notation on figures, IFNg = IFNγ , TNFa = 
TNFα. These are representative plots of cells obtained from donor H. Experiment performed in triplicate.
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Fig. 4.7a:Phosphopeptide responses in Healthy Donor H(day 0) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB notation on figures, IFNg = IFNγ , TNFa = TNFα. These are representative plots of cells 
obtained from donor H. Experiment performed in triplicate.
RPRsPRQNSI
SPRRsRSISL
TPRsPPLGL
RPWsPAVSA
RPQRA(ts)NVF
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RPAsAGAML
Fig. 4.7b:Phosphopeptide responses in Healthy Donor H (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB notation on figures, IFNg = IFNγ , TNFa = TNFα. These are representative plots of cells 
obtained from donor H. Experiment performed in triplicate.
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Fig. 4.7b:Phosphopeptide responses in Healthy Donor H(day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right) (See also fig s2-4). NB notation on figures, IFNg = IFNγ , TNFa = TNFα. These are representative 
plots of cells obtained from donor H. Experiment performed in triplicate.
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Fig. 4.7c: B7 Phosphopeptide responses in healthy donors
PBMC’s were generat ed from healthy donors as per methods previously described, and responses of these cells to tumour-
associated phosphopeptides were then assessed using an intracellular staining (ICS) assay. These were further analysed using
combination gates to assess the expression of IFNγ ,TNFα, and IL-2 (denoted IFNg, TNFa and IL2 on the plot)– see fig s2-4 also
for additional donor plots.
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Fig. 4.8a:Phosphopeptide A2 responses in Healthy Donor O (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right) – denoted IFNg, TNFa and IL2 on the plots. See fig S5-7 for additional donor plots.
		 155	
	
	
Fig. 4.8a:Phosphopeptide responses in Healthy Donor O (day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right) – denoted IFNg, TNFa and IL2 on the plots. See fig S5-7 for additional donor plots.
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RPWPAVSA and TPRsPPLGL emerged as potential targets of these healthy B7 donor T-cells, 
whilst in the A2 donor T-cells RQDsTPGKVFL appeared to be a possible target.  Across the 
healthy donors, a T-cell response was demonstrated to a number of phosphopeptides, but this 
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Fig. 4.8b: A2 Phosphopeptide responses in healthy donors at 7 days
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  These were further analysed  using combination gates to assess the expression of IFNγ ,TNFα, and IL-2 , and 
combinations thereof (denoted IFN-G, TNF-a and Il2 on the plots). See fig S5-7 for additional donor plots.
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response was noted to vary between donors, for example RPWsPAVSA produced a strong T-
cell response in the two older donors (P and H) 30.2% and 42.1% respectively, but minimal 
response in the younger donors (O and C).  H was the oldest donor at 61y of age and C the 
youngest donor at 34 years of age. Recognition of phosphopeptide was therefore proposed to 
be age related with a direct correlation between number of responses and amplitude of that 
response to phosphopeptide (fig. 4.9). However this is an assumption based on limited numbers 
(one donor in each of the 60y+ group and the 50-60y group, and two donors in the 40-50y 
group - fig 4.9), and further experimental analysis would be necessary to confirm this.  It does 
however correlate with observations seen by previous members of the group (by private 
communication). Wilcoxon paired t-test showed on comparison of the youngest donor with the 
oldest donor there was a significant difference (**) in recognition and stimulation of T-cells in 
response to phosphopeptide p=0.031.  
 
 
Fig. 4.9: Phosphopeptide B7 responses in Healthy Donor at 7 days  
Comparison was made of total cytokine expression (denoted activation on the figure above) of each healthy donor 
in response to individual HLA-B7 phosphopeptides as determined by the FACS analysis presented previously.  A 
significant difference was noted between the youngest and the oldest donor p=0.013 – Wilcoxon paired t-test 
(**).  
NB there was no significant difference between positive control response exhibited by either group when 
analysisng FACS data previously, therefore it was considered valid to compare each of the donors in this fashion.  
Overall numbers of healthy donors was small, with only one donor was in the 60y+ group and two donors in the 
40-50y group.   
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Likewise, on comparison of HLA-A2+ donors (fig. 4.10), it can be seen that there is a 
significant difference (**) based on age of donor, however as n=4 further analysis of this data 
is unlikely to be beneficial at this stage (i.e. one donor was in group 60y+, 2 donors were 30-
40y and one was 20-30y). It can be seen that the mean number of responses to phosphopeptide 
is much higher in the 60+ age group (31.8%) compared to the younger age groups (14.2% in 
40-50y age group) in the B7 responses at 7 days.  This trend was repeated in the A2 
phosphopeptide responses noted in healthy donors with the highest number of responses seen 
in the oldest age group (39.2%) versus 3.8% responses in the youngest age group (20-30y). 
 
 
 
Fig. 4.10: Phosphopeptide A2 responses in Healthy Donor at 7 days  
Comparison was made of total cytokine expression of each donor in response to individual phosphopeptides.  A 
significant difference was noted between the youngest and the oldest donor p=0.025– Wilcoxon paired t-test (**).  
NB the donor in age range 60y+ was included with caution in this analysis.  This is because the cytokine response 
to positive control was very different in this donor compared to any other donor (i.e. upto 75% CD8+ T-cells 
producing cytokine versus 10-40% in the other donors). One donor was age 20-30y, two donors were 30-40y and 
one donor was 60y+).  
 
4.3.1 Can phosphopeptide-specific T-cells recognise HLA matched tumour 
Having identified healthy donor T-cells that recognised tumour associated phosphopeptides, it 
was hypothesised that these cells could recognise HLA matched tumour samples. When liver 
tumour samples were first obtained, in addition to IMAC/MHC-I phosphopeptide extraction, 
		 159	
samples were also used to generate TiLs (using methods as previously described) and 
additional solid tumour sample and an aliquot of TiLs line were frozen.   
Healthy donor derived T-cells which recognised phosphopeptide were expanded in vitro with 
media which was initially not supplemented until the 10th day after phosphopeptide addition, 
when it was supplemented with IL-2 to maintain cell growth. These included hepatoblastoma-
specific phosphopeptides: RPWsPAVSA, TPRsPPLGL, RQDsTPGKVFL and 
ALDsGASLLHL.  The PTLD/LCL specific phosphopeptides assessed were: RPQRAtsNVF, 
RPQsAGAML and RPRsTRQNSI.  We also looked at a number of phosphopeptides identified 
on both tumour types: KAFsPVRSV, KLFPDtPLAL and SMTRsPPRV.  Once sufficient 
numbers had been grown an assay was set up to establish whether T-cells recognised tumour 
when pulsed with the relevant phosphopeptide and whether this response was the same as for 
TiLs lines already established in the case of hepatoblastoma.  We proposed that the TiLs 
response would be less than the phosphopeptide specific T-cell response as the TiLs line is a 
heterogenous line and so overall phosphopeptide specific cell number would likely be less as 
it was cultured with IL-2 alone which is a non-specific agent causing expansion of all T-cells, 
not just the T-cells which recognise the peptide of interest. The healthy donor-derived line 
should have more phosphopeptide-specific T cells in it as it was cultured with the peptide of 
interest initially and only supplemented with IL-2 following a 10-day period without so in 
theory the cells of interest should only be those stimulated by peptide.   
We wanted to establish that the tumour recognition wasn’t just a random response and so 
healthy donor B-cells were obtained from fresh PBMC’s using magnetic Beads (Miltenyi 
Biotec, UK). We considered if the phosphopeptide specific T-cells were able to recognise these 
B-cells as well as assessing response to non phosphopeptide pulsed cells (i.e. neither the 
healthy B-cells or the non-phosphopeptide pulsed cells should generate any significant T-cell 
activation if the T-cell response is specific to malignant target which we proposed was 
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phosphopeptide).  Samples of supernatent were taken at varying timepoints, and ELISA was 
performed to assess individual response to tumour (fig.  4.11a and b).  For the LCL/PTLD-
phosphopeptides no TiLs were available, however in order to assess tumour response versus 
viral response we tested LCL response of healthy donor cells – obviously this could potentially 
encompass a viral response and therefore to negate this we had an additional control of 
phosphatase-treated cells – as this would then represent the viral response of donor T-cells. 
Fig. 4.11a demonstrates the T-cell activation responses (release of IFNγ) as a response to 
different stimuli.  We considered whether the phosphopeptide-specific T-cell lines which had 
been generated previously were able to recognise HLA-matched tumour samples.  We 
hypothesised that pulsing the tumour samples with phosphopeptide would lead to T-cell 
activation, if the T-cells were using that phosphopeptide to target tumour.  In order to test this 
theory, we selected a number of phosphopeptide lines, and looked at response to 
hepatoblastoma and PTLD (LCL) lines.  When the hepatoblastoma tumour specimens became 
available, TiLs lines were also generated in conjunction with this and a sample of solid tumour 
frozen in liquid nitrogen.  We therefore considered if the phosphopeptide-specific T-cell lines 
were able to recognise the solid tumour samples and mount a response.  To do this, solid tumour 
samples were defrosted, cut into small pieces and digested enzymatically (collagenase).  Cells 
were counted and equal numbers of tumour to T-cell line were added to the respective wells.  
A number of controls were included:  
1) Phosphopeptide specific T-cell line alone (designated by the first 3 letters of the 
peptide sequence on fig. 4.11)  
2) Phosphopeptide-specific T-cell line with healthy B-cells (negative control) 
3) Phosphopeptide-specific T-cell line with LCL (positive control as cells will likely 
have a viral and phosphopeptide response) 
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4) Phosphopeptide-specific T-cell line with LCL (phosphatase treated therefore 
removing the phosphopeptide response resulting in any response being viral only 
5) Phosphopeptide-specific T-cell line with tumour (in the absence of phosphopeptide 
stimulation, cells should not be able to recognise tumour) 
6) Phosphopeptide-specific T-cell line with tumour and phosphopeptide 
These were compared to TiLs responses to the same tumours using the same conditions.  We 
also considered the responses of phosphopeptide-specific T-cells to LCL lines (B) but have no 
TiLs lines in this case.  Finally, we considered phosphopeptide-specific T-cell lines which had 
been identified as being expressed on LCLs and hepatoblastomas looking at the same 
conditions as listed above (C).  Cells were cultured as described and the supernatant sampled 
for ELISA analysis looking for IFNγ release (fig. 4.11a) and TNFα release (fig. 4.11b).  
Supernatent was sampled at 3 timepoints (day 1, day 7 and day 14). 
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Fig. 4.11a: ELISA data demonstrating IFNγ release from phosphopeptide specific T-cell lines compared to 
a TiLs obtained from HLA matched tumour. Phosphopeptide-specific T-cell lines were generated as per 
protocols described previously.  The cell lines were then compared to TiLs which were generated at the time of 
tumour harvest and snap frozen at -80c.  (A) Comparison was made of cytokine release of each phosphopeptide-
specific cell line, designated by the first 3 letters of the phosphopeptide sequence (shown in bold) (TPRsPPLGL, 
RQDsTPGKVFL, RPWsPAVSA and ALDsGASLLHL found in hepatoblastoma tumours compared to TiLs 
derived from HLA matched tumour using an ELISA assay and standard protocol. Phosphopeptide-specific cell 
line alone was considered background cytokine release.  The cell line was then tested with healthy B-cells 
(negative control), LCL lines (positive control), phosphatase treated LCLs (removing phosphopeptide response 
and thus demonstrating viral response), tumour (snap frozen at time of tumour harvest) and finally tumour with 
phosphopeptide (designated +PP on graph x-axis). Cells were samples on days 1, 7 and 14. (B) comparison made 
in PTLD-derived phosphopeptide-specific T-cell lines RPAsAGAML, RPQRAtsNVF and RPRsPRQNSI and 
(C) Derived from hepatoblastoma and PTLD lines KLFPDtPLAL, KAFsPVRSV and SMTRsPPRV  These 
graphs represent 2 repetitions of each experiment, performed in duplicate. Error bars represent SEM. 
 
 
A
TP
R L
ine
 alo
ne
TP
R L
ine
 + H
eal
thy
 B 
cel
l
TP
R L
ine
 + L
CL
TP
R L
ine
 + L
CL
 (ph
osp
hat
ase
 Rx
)
TP
R +
 Tu
mo
ur
TP
R +
 Tu
mo
ur 
+ P
P
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
RP
W L
ine
 alo
ne
RP
W L
ine
 + H
eal
thy
 B 
cel
l
RP
W L
ine
 + L
CL
RP
W L
ine
 + L
CL
 (ph
osp
hat
ase
 Rx
)
RP
W +
 Tu
mo
ur
RP
W +
 Tu
mo
ur 
+ P
P
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
RQ
D L
ine
 alo
ne
RQ
D L
ine
 + H
eal
thy
 B 
cel
l
RQ
D L
ine
 + L
CL
RQ
D L
ine
 + L
CL
 (ph
osp
hat
ase
 Rx
)
RQ
D +
 Tu
mo
ur
RQ
D +
 Tu
mo
ur 
+ P
P
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
AL
D L
ine
 alo
ne
AL
D L
ine
 + H
eal
thy
 B 
cel
l
AL
D L
ine
 + L
CL
AL
D L
ine
 + L
CL
 (ph
osp
hat
ase
 Rx
)
AL
D +
 Tu
mo
ur
AL
D +
 Tu
mo
ur 
+ P
P
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
TiL
S L
ine
 alo
ne
TiL
s L
ine
 + H
eal
thy
 B 
cel
l
TiL
S L
ine
 + L
CL
TiL
S L
ine
 + L
CL
 (ph
osp
hat
ase
 Rx
)
TiL
S +
 Tu
mo
ur
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
		 163	
 
 
  
RP
A L
ine
 alo
ne
RP
A L
ine
 + H
eal
thy
 B 
cel
l
RP
A L
ine
 + L
CL
RP
A L
ine
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
RP
A +
 LC
L +
 PP
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
KL
F L
ine
 alo
ne
KL
F L
ine
 + H
eal
thy
 B 
cel
l
KL
F L
ine
 + L
CL
KL
F L
ine
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
KL
F +
 HB
KL
F +
 HB
 + P
P
KL
F +
 LC
L +
 PP
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
RP
Q L
ine
 alo
ne
RP
Q L
ine
 + H
eal
thy
 B 
cel
l
RP
Q L
ine
 + L
CL
RP
Q L
ine
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
RP
Q +
 LC
L +
 PP
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
KA
F L
ine
 alo
ne
KA
F L
ine
 + H
eal
thy
 B 
cel
l
KA
F L
ine
 + L
CL
KA
F L
ine
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
KA
F +
 HB
KA
F +
 HB
 + P
P
KA
F +
 LC
L +
 PP
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
RP
R L
ine
 alo
ne
RP
R L
ine
 + H
eal
thy
 B 
cel
l
RP
R L
ine
 + L
CL
RP
R L
ine
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
RP
R +
 LC
L +
 PP
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
SM
TR
 Li
ne
 alo
ne
SM
TR
 Li
ne
 + H
eal
thy
 B 
cel
l
SM
TR
 Li
ne
 + L
CL
SM
TR
 Li
ne
 + L
CL
 (p
ho
sp
ha
tas
e R
x)
SM
TR
 + H
B
SM
TR
 + H
B +
 PP
SM
TR
 + L
CL
 + P
P
0
1000
2000
3000
4000
Day 1
Day 7
Day 14
pg
/m
l
B C
		 164	
Fig. 4.11b: ELISA data to show TNFα- release from phosphopeptide specific T-cell lines compared to a 
TiLs obtained from HLA matched tumour. Phosphopeptide-specific T-cell lines were generated as per 
protocols described previously.  The cell lines were then compared to TiLs which were generated at the time of 
tumour harvest and frozen at -80c.  (A) Comparison was made of cytokine release of each phosphopeptide-specific 
cell line, designated by the first 3 letters of the phosphopeptide sequence (shown in bold) (TPRsPPLGL, 
RQDsTPGKVFL, RPWsPAVSA and ALDsGASLLHL found in hepatoblastoma tumours compared to TiLs 
derived from HLA matched tumour. We assessed the phosphopeptide-specific cell line alone as considered 
background cytokine release.  The cell line was then tested with healthy B-cells (negative control), LCL lines 
(positive control), phosphatase treated LCLs (removing phosphopeptide response and thus demonstrating viral 
response), tumour (snap frozen at time of tumour surgery) and finally tumour with phosphopeptide (designated 
+PP on graph x-axis)  (B) comparison made in PTLD-derived phosphopeptide-specific T-cell lines 
RPAsAGAML, RPQRAtsNVF and RPRsPRQNSI and (C) Derived from hepatoblastoma and PTLD lines 
KLFPDtPLAL, KAFsPVRSV and SMTRsPPRV. These graphs represent 2 repetitions of each experiment, 
performed in duplicate.  
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Phosphopeptide specific T-cells can recognise HLA matched tumour samples, seen most 
noticeably at 14 days.  RPWsPAVSA, TPRsPPLGL, RPAsAGAML, SMTRsPPRV and 
KLFPDtPLAL specific T-cells all had demonstrable responses with IFNγ release of 
2200ng/ml, 1960ng/ml, 1135ng/ml, 990ng/ml and 960ng/ml respectively to tumour plus 
phosphopeptide in the case of hepatoblastoma or LCL plus phosphopeptide in the case of 
PTLD/LCL (an effective response in the LCL experiment showing that recognition was largely 
phosphopeptide-specific not viral specific as following phosphatase treatment there was a 
negligible response of the phosphopeptide specific T-cells).  T-cell responses to LCL were 
considered ‘false positive’ in RPQRA(ts)NVF, RQDsTPGKVFL, ALDsGASLLHL and 
KAFsPVRSV.  This is because although the phosphopeptide-specific T-cells are activated in 
the presence of LCLs, following addition of phosphatase, there is still T-cell activation seen, 
thus demonstrating viral recognition as phosphopeptide driven response would be removed by 
phosphatase treatment, yet levels of IFNγ and TNFα release is not significantly reduced 
following treatment with phosphatase.   
TiLs can recognise hepatoblastoma tumour, but this response is less than that seen in the 
phosphopeptide specific T-cells for reasons already stated, that the healthy donor derived lines 
should have more phosphopeptide-specific T-cells as it was cultured with the peptide of 
interest.  The TiL line will have less as it was cultured with a non-specific agent (IL-2) that 
will cause all T-cells to expand and not just the T-cells that recognise the peptide of interest. 
Due to availability of tumour tissue this was not possible to be repeated but provides reasonable 
proof of principle that these cells are able to recognise tumour. 
 
4.3.2 Can phosphopeptide-specific T-cells effectively kill tumour cells? 
After demonstrating phosphopeptide specific T-cells can recognise tumour pulsed with 
phosphopeptide, I proposed that these cells could also demonstrate effective killing, if as 
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predicted these cells use phosphopeptide as a target for killing. Although this is an artificial in 
vitro model system, using T-cells derived from healthy HLA-matched donors, the initial data 
would suggest that T-cells may use phosphopetide as a tumour target and this may induce these 
T-cells to kill target (tumour) cells. 
In order to test this theory two of the cell lines tested previously and shown to recognise tumour 
were used in a Europium release killing assay (RPWsPAVSA and TPRsPPLGL) alongside 
TiLs derived from hepatoblastoma tumour. Tumour cells were pulsed with phosphopeptide 
prior to the assay (fig. 4.12).  Fig 4.12a directly compares the two phosphopeptide-specific T-
cell lines with TiLs and assesses response to HLA-matched tumour. Two different E:T ratios 
were investigated as it was proposed that more Phosphopeptide-specific T-cell would lead to 
a greater killing response, but we considered if there was a ceiling effect to this.  The 
phosphopeptide specific T-cell lines were able to recognise and kill tumour cells, but this was 
far more efficient when pulsed with phosphopeptide.  RPWsPAVSA showed a greatest killing 
response (25.5%) when in a 3:1 E:T ratio with tumour pulsed with phosphopeptide, compared 
to 13.2% at a 1:1 ratio.  T-cells exposed to non-pulsed tumour showed no increase in killing 
response (3.1% vs 3.2% 1:1 and 3:1 respectively).  TiLs do demonstrate dose dependent killing 
of tumour cells, but this is only in the region of 9.7% and 12.2% respectively at 1:1 and 3:1 
ratios.  This shows that although the TiLs are a heterogeneous line, there are T-cells contained 
within this line that appear to be able to target the tumour.  The data obtained shows that 
addition of the phosphopeptide RPWsPAVSA to the tumour prior to addition of 
phosphopeptide specific T-cells did significantly increase effective killing from 3.2% to 25.5% 
(paired t-test p=0.0012)– which further suggests that T-cells target the tumour by means of 
phosphopeptide recognition (fig. 4,12b). Interestingly, T cells against the RPW peptide aren’t 
able to target the tumour without the addition of exogenous peptide. RPW peptide was found 
in three of the tumour samples by mass spectroscopy, therefore it would be expected that the 
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phosphopeptide-specific T-cells should recognise tumour cells without the addition of 
exogenous peptide. We propose that potentially this phosphopeptide was degraded during 
storage of the solid tumour sample, or that the process of generating a tumour cell line (by 
enzymatic digestion as described previously) led to loss of endogenous peptide, therefore 
necessitating the addition of exogenous peptide.  Linear regression shows a significant 
difference in tumour killing when phosphopeptide is added (p=0.0026).  There was also a 
significant increase in response to addition of exogenous TPRsPPLGL (p=0.0296) although 
not as marked as was seen for RPWsPAVSA. 
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Fig. 4.12: Europium Release Killing Assay demonstrating a dose dependent response of T-cells to 
phosphopeptide pulsed HLA matched tumour 
This experiment employed the Europium Release killing assay as described previously in chapter 2 to attempt to 
demonstrate recognition and killing of tumour cells by the effector cells. (A) Two phosphopeptide specific T-cell 
lines (RPWsPAVSA and TPRsPPLGL) derived from a healthy donor ‘P’ were tested in this assay (designated by 
the first 3 letters of the phosphopeptide sequence on the x-axis) using HLA matched hepatoblastoma-derived 
tumour cells (designated +tumour on x-axis) pulsed with phosphopeptide (designated +PP on the x-axis). TiLs 
derived from hepatoblastoma tumour were tested alongside these phosphopeptide specific T-cell lines.  E:T ratio 
of 1:1 denotes equal  numbers of phosphopeptide specific T-cells to tumour-derived cells. E:T 3:1 denotes 3x as 
many phosphopeptide-specific T-cells to target tumour-derived cells.  The effect of phosphopeptide pulsing on 
each individual cell line (B) RPWsPAVSA and (C) TPRsPPLGL are shown in these linear regression lines.  The 
addition of phosphopeptide (blue line) increases the killing efficiency significantly.  These graphs represent 2 
repetitions of each experiment, performed in duplicate. Error bars represent SD. 
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4.4 Summary 
Previously we have identified phosphopeptides as potential HLA-specific targets and this 
chapter sought to identify specific MHC class 1 phosphopeptides on hepatoblastoma tumour 
samples as well as HepG2 (a hepatoblastoma cell line) and also a small number found on 
healthy tissue.  It has been shown that there are an increased number of phosphopeptides seen 
on tumour samples compared to healthy liver tissue, and their expression level is also increased 
compared to healthy tissue.  This would suggest that as part of the tumour process proteins 
become phosphorylated resulting in more phosphopeptides being expressed.  It appears that it 
is these that may be targeted by CD8 T-cells. Therefore, it is a possibility that one of the reasons 
that the majority of people do not develop cancer is because these phosphopeptides allow 
tumours to be recognised and eradicated by the immune system.  Although none of the 
phosphopeptides identified on hepatoblastoma samples analysed here were unique, i.e. they 
had all been found on other tumour types including melanoma, colorectal adenocarcinoma and 
others (fig.4.4) and only 2 were unique on the PTLD sample, it is considered that their presence 
is indicative of malignant transformation and therefore a potential target for T-cell responses.  
Of course this is a broad statement to make and therefore this chapter sought to analyse 
responses of T-cells to tumour associated phosphopeptide further. 
A number of key cancer pathways were identified as being intimately associated with proteins 
the phosphopeptides were derived from, providing yet more evidence that these could be 
tumour associated. 12 phosphopeptides were identified as being implicated in a number of 
hepatic malignancies (hepatoblastoma, hepatocellular carcinoma, hepatic 
metastases/secondary tumours), and therefore these were chosen to be investigated further.  
HLA-matched healthy donors were identified, and T-cells magnetically selected.  These T-
cells were stimulated with phosphopeptide which had previously been identified on tumour 
samples and then these cells were cultured to see if over time they mounted a response to this 
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peptide stimulus and became activated.  This was to establish if healthy individuals had the 
ability to recognise tumour-associated phosphopeptide.  We predicted that they would, as this 
is the basis for the proposed hypothesis that T-cells have a tumour-specific target, and by nature 
of the fact that a healthy individual does not have that specific malignancy it would suggest 
that they are able to recognise that target and eradicate it.  
Responses to HLA-specific hepatoblastoma-associated phosphopeptides were tested in three 
HLA-matched healthy donors. Many of these phosphopeptides were identified on cell lines 
and were shared across other malignancies. RPWsPAVSA was seen on most HLA-B7+ cancer 
samples and not on healthy tissue; and healthy donor responses to this were seen in all three 
healthy donors to varying degrees. It was noted however that in older healthy donors, there 
appeared to be stronger and more plentiful responses to phosphopeptides in general – 
suggesting that possession of phosphopeptide responses is age dependent.  Three HLA-A2+ 
donors were also identified and their responses to tumour associated phosphopeptides assessed. 
Again age appeared to play a role in recognition; however, RQDsTPGKVFL consistently 
induced a response in these donors.  Due to limits on the amount of tumour tissue available 
these weren’t tested in more individuals, but in order to strengthen this observation it would 
be ideal to test this in more healthy donors.   
Unfortunately, we were only able to obtain one PTLD tumour sample as when diagnosing this 
disease process the majority of the biopsy specimen is used for histological analysis – and 
therefore the PTLD patient sample was derived from a blood sample obtained at time of 
diagnosis. As a proxy for PTLD, healthy donor PBMC’s were transformed into LCL lines by 
methods previously described and then these were used to identify phosphopeptides expressed.  
These were combined with data available from the commercially available cell line JY (190 
phosphopeptides identified on tumour tissue versus 23 on healthy tissue).  This provided 
further evidence that phosphopeptide expression was vastly different on tumour samples 
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compared to healthy tissue and could therefore be a potential target for tumour recognition.  
Phosphopeptides identified on LCL lines were used to test responses of healthy donor T-cells 
and we were able to demonstrate that a number of these phosphopeptides did lead to healthy 
T-cells becoming activated.   
 
4.5 Discussion 
This chapter sought to build on the knowledge gained in chapter 3 relating to phosphopeptides, 
and identify suitable targets on liver tumours and PTLD.  The questions to be answered 
included: (i) what is the target on tumours for T-cells; (ii) what role do these play in cancer; 
(iii) can healthy donors also respond to these phosphopeptides; (iv) can we generate a 
phosphopeptide-specific T-cell line and (v) can this phosphopeptide-specific T-cell line 
successfully target and kill HLA-matched tumour? 
82 tumour-associated phosphopeptides were identified on hepatoblastoma samples and 75 
tumour associated on the PTLD sample (152 on JY line and 119 on healthy donor derived LCL 
lines). This compares favourably with normal healthy tissues with far fewer phosphopeptides 
identified.  This could therefore suggest that phosphopeptides result from tumour formation 
and this then could result in T cell responses towards them.   
Previous work done by this group and our collaborators has identified phosphopeptides found 
on a number of other tumour groups including melanoma, breast cancer, leukaemia, colorectal 
tumours and others (Meadows, Wang et al. 1997, Wang, Gulden et al. 1997, Zarling, Ficarro 
et al. 2000, Syka, Coon et al. 2004, Zarling, Polefrone et al. 2006, Cobbold, Polefrone et al. 
2007, Mohammed, Cobbold et al. 2008, Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 
2013, Abelin, Trantham et al. 2015) 
There are cytotoxic T-cells present in tumours (TiLs).  We considered if  these T-cells were 
able to target the tumour-associated phosphopeptides identified during our initial experiments 
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and hence actually be a novel target for immunotherapy in paediatric liver tumours and PTLD? 
To test this hypothesis, 13 phosphopeptides from liver tumour samples (including those 
identified on cell lines, and those found previously on other hepatic tumours e.g. hepatocellular 
carcinomas and hepatic metastases) and PTLD/LCLs were generated and their immune 
responses were investigated in HLA-matched healthy donors of varying age groups (7 HLA-
B7+ and 6 HLA-A2+ phosphopeptides were selected).  It was not possible to test age-matched 
controls due to issues around consent.  The phosphopeptides tested had varying functions 
implicated in cancer including mRNA splicing, mRNA processing, DNA binding and protein 
binding. 
Initially, we considered the healthy donor T-cells responses to the target phosphopeptides. On 
day 0 (at 6 hours post-stimulation), responses to two of the target phosphopeptides identified 
were significantly higher than background (and at similar levels to viral control response) – 
RPWsPAVSA, from SKI oncogene, key in the TGF-beta signalling pathway, and TPRsPPLGL 
a MAP kinase involved in JNK signalling (Fig. 4.5, 4.7). We identified that RPWsPAVSA was 
the only peptide that generated a multifunctional response encompassing all three of the 
cytokines tested by ELISpot and FACS – IL-2, IFNγ and TNFα. The other peptides only 
elicited low/no responses compared to background. 
After a further 6 days of expansion, we identified more responses to the phosphopeptides in all 
6 healthy donors at varying levels (Figs. 4.7, 4.8). We also determined that some of these 
responses were multifunctional (with release of a combination of cytokines), which may 
represent cytotoxic potential, although this was not formally tested in this instance. In 
particular donor H had multifunctional responses to all HLA-B7 peptides tested (this donor 
was also the oldest donor tested).    Of particular note were the responses to RPWsPAVSA and 
TPRsPPLGL. Both of these HLA-B7 phosphopeptides were identified as potentially being 
implicated in hepatic malignancy, and interestingly every donor tested for these had a response 
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to them. However, RPWsPAVSA had good expansion when looking at day 0 and day 7 
responses, whereas TPRsPPLGL did not expand as well with similar levels seen to day 0.  It 
is slightly harder to identify a pattern in the HLA-A2 phosphopeptides assessed as the only 
donor with consistently high responses was donor H.  Donor H was the oldest healthy donor 
assessed hence leading to the hypothesis that possession of phosphopeptide responses may be 
directly proportional to age.  On further investigation it can indeed be seen that older healthy 
donors possessed a significantly higher number of responses than younger donors (fig. 4.9, 
4.10).   
We compared the cytokine responses seen before and after phospopeptide-induced expansion.  
This revealed a number of key differences in the various donors. An example of this is seen in 
the response to RPAsAGAML in donor H could not be seen at all pre-expansion, but expanded 
well over time, whereas the response to TPRsPPLGL in the same donor did not expand well – 
having been seen at baseline but not increasing over time. This could partly be explained by 
the fact that the protocol used different concentrations of phosphopeptide at different time 
points e.g. on day 0, 50 µg/ml was used, whereas on day 7, only 10 µg/ml was used (as per 
well established laboratory group protocols based on the assumption that higher concentrations 
may lead to overstimulation and death). T-cells with a high functional avidity only require a 
small amount of antigen to grow.  We predict that by using a higher concentration of peptide, 
the  T-cells with a lower functional avidity may demonstrate a better growth potential. Higher 
functional avidity is likely to be beneficial in cancer treatment, therefore we considered that 
the day 7 results are likely to be more meaningful (Zeh, Perry-Lalley et al. 1999, Xue, Gao et 
al. 2013, Zhong, Malecek et al. 2013, Rashin and Jernigan 2016). Whilst we were unable to 
demonstrate expansion of the responses to TPRsPPLGL, there were still multifunctional 
responses demonstrated by day 7, however, overall the responses seen were at a similar level 
to those seen on day 0 (Fig. 4.7c). This leads us to question whether it is the degree of individual 
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response or the quality (i.e. multifunctional versus not) that is most important. It has previously 
been proposed that multifunctional T-cells could be pivotal in controlling infection for instance 
(Betts, Nason et al. 2006). A further illustration of this point is seen on day 7 where a similar 
total amount of responses were seen to GPRSAsLLSL; however, we were unable to 
demonstrate any of these T-cells producing IL-2, IFNγ and TNFα (i.e. no multifunctional 
response), on day 0, only very limited responses were seen.  
Based on the phosphopeptide responses seen, can these T-cells recognise HLA matched 
tumour; and if they can, are they able to mount a response to it and perform effective killing?  
In order to answer this question, phosphopeptide-specific T-cell lines were generated from 
those donor T-cells which showed a good response to phosphopeptide stimulation, by rapid 
expansion with IL-2.  Cells were then applied to hepatoblastoma tumour to identify if 
phosphopeptide pulsing can induce T-cell activation and cytokine release as a surrogate marker 
of this (we also tested response to LCL, but were mindful of the fact that the responses here 
may well be due to viral epitope recognition).  A number cell lines were generated including: 
TPRsPPLGL, RQDsTPGKVFL, RPWsPAVSA and ALDsGASLLHL found in 
hepatoblastoma tumours; PTLD-derived phosphopeptide-specific T-cell lines RPAsAGAML, 
RPQRA(ts)NVF and RPRsPRQNSI and finally KLFPDtPLAL, KAFsPVRSV and 
SMTRsPPRV which were found on both hepatoblastoma and PTLD.  In addition, TiLs were 
rapidly expanded in the presence of IL-2 and their response compared to the phosphopeptide-
specific T-cell lines (fig. 4.12).   
Cells were assayed at day 1, 7 and 14 looking at IFNγ and TNFα release, and in the case of 
those phosphopeptides expressed on hepatoblastomas, compared with TiLs derived from these 
tumours.  Unsurprisingly TiLs recognised tumour, however their activation was limited with 
relatively low levels of IFNγ and TNFα release.  This is likely due to the line being rather 
heterogeneous and so a mixed population of cells targeting multiple different tumour surface 
		 176	
antigens.  When assessing the phosphopeptide-specific responses, it is possible that cells do 
recognise target tumour, albeit at low levels, and pulsing with phosphopeptide does appear to 
enhance tumour recognition and T-cell activation.  In particular, RPWsPAVSA had a good 
response at day 7 which was reproduced on day 14.  The other phosphopeptide-specific cell 
lines also appear to recognise pulsed tumour, but the level of activation appears lower in 
comparison, with levels of cytokine release similar to that seen with the TiLs.   
When assessing phosphopeptide responses in the PTLD-associated lines it was necessary to 
assess if recognition of LCL is tumour related or viral related. In order to do this, the T-cell 
line recognition of phosphatase treated LCLs was also assessed as the addition of phosphatase 
should remove the phosphopeptide response.  Therefore, any cytokine release in response to 
the phosphatase-treated cells would be due to a viral response present in the T-cell line. We 
therefore identified RPAsAGAML, RPQRA(ts)NVF and SMTRsPPRV as being 
phosphopeptide-specific T-cell lines which were able to recognise tumour and a demonstrable 
reduction in cytokine release following treatment with phosphatase suggesting this was partly 
phosphopeptide driven. 
In relation to functional avidity, it has previously been proposed that this could be intimately 
related to TCR affinity and its respective co-receptor interactions and thus there is a real risk 
of autoimmunity as it may be impossible to target epitopes present on healthy tissue,due to the 
presence of high affinity T-cells (Zhong, Malecek et al. 2013).  Our primary endpoint is an 
appropriate immune response with resultant killing of target cells. The ideal T-cell would be 
one which can produce cytokine in response to target phosphopeptide of interest and perform 
effective killing. Therefore, to answer this question, a Europium release killing assay was set 
up, using two of the phosphopeptide-specific T-cell lines used previously: RPWsPAVSA (due 
to its high cytokine release and multifunctional response) and TPRsPPLGL (lower cytokine 
release and non-multifunctional response).  Again these were compared to TiLs (fig. 4.12).  
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What is immediately obvious is addition of phosphopeptide unsurprisingly does induce better 
tumour recognition. The response seen in terms of killing is higher in RPWsPAVSA than 
TPRsPPLGL – which may add to the argument that high avidity cell lines are preferential in 
tumour killing. 
This remains a preliminary study of small size, with data only available on 6 healthy donors 
assayed for responses to phosphopeptide epitopes identified on both paediatric liver tumours 
and LCLs. The results would be greatly strengthened by increasing subject numbers in both 
healthy donors and their relative response to phosphopeptide as well as greater numbers of 
tumours to be analysed. The overall aim of increasing subject numbers would be to allow for 
identification of any possible association between the immune responses to these 
phosphopeptides and patient survival. This may also allow for confirmation of the role played 
by phosphopeptide immunity in patients.  
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Chapter 5:  T-CELL MANIPULATION – THE QUEST FOR IMMORTALITY 
 
5.1. Introduction 
Immunotherapies targeting tumour-specific antigens requires a ready supply of cells, and the 
study of in vitro cultured and manipulated T-cells are an exciting addition to the expanding 
field of cancer treatment. However, they are dogged by the issue that ex vivo culturing reduces 
the functionality of isolated T-cells (Nino, Kwan et al. 2016). Cryopreservation has been 
attempted but there have been concerns about possible effects on functionality (Coulie, Van 
den Eynde et al. 2014) and a lack of studies directly aimed at looking at this.   
It has been observed that T-cells grown in culture long term (>6 weeks) gradually appear to 
lose specificity and functionality. In mixed T-cell cultures, CD4 T-cells begin to outgrow the 
peptide-specific CD8 T-cells over a period of weeks which ultimately results in loss of cell 
line specificity. T-cell lines that aren't able to produce cytokines towards peptide-pulsed target 
cells over time lose functionality.  Anti-viral T-cells are the easiest to grow and can be cultured 
for few months as a cell line or longer as a clone but this can be very labour intensive with a 
lot of work required to achieve this.  Compare this with generating and maintaining a B-cell 
line (LCL), which requires cell-splitting once or twice a week and a very basic media – which 
is clearly less labour intensive and cost effective, which is therefore the aim with T-cells.  
Generating an immortal T-cell to allow further in vitro study would be of benefit to a number 
of therapies, but it would be desirable for it to have the ability to alter its makeup, such as 
transducing specific proteins into it therefore manipulating it to possess for instance an anti-
tumour response.  This becomes particularly important when considering the concept of T-cell 
exhaustion.  This chapter therefore covers techniques designed to overcome the challenges 
posed by culturing T-cells long term and thus provide experimental models for the study of 
patterns of antigen recognition in vitro.  
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With this in mind, this chapter has sought to explore some of these experimental techniques in 
order to generate a limitless supply of T-cell derived reagents with which we can pursue the 
study of phosphoantigen expression.  We selected 3 main technologies to explore further (i) 
T-cell hybridomas (ii) Herpesvirus Saimiri T-cell transduction and finally (iii) Induced 
Pluripotent Stem cell (iPSc) technology for differentiating T-cells into stem cells for in vitro 
expansion. Clearly these technologies vary in their complexity.  There are also biological and 
ethical considerations which need to be taken into account also.  Each will be explored in more 
detail in subsequent sections. 
HVS viral transduction and T-cell hybridomas would generate a theoretical T-cell model which 
can be manipulated in vitro with the aim of exploring antigen expression.  iPSc on the other 
hand have recently made their way into the clinical setting, and thus could be a potential 
clinical therapy (Kamao, Mandai et al. 2014).   
 
5.1.1 Generation of hybridomas 
Fusing cells to form a hybridoma was first conceived as an idea in the early 1970’s. The initial 
method described by Kohler and Milstein in 1975 incorporated fusing B-cells secreting 
antibody of one specificity with a continuously growing immortal plasmacytoma – the product 
being a hybridoma which expresses immunoglobulin genes from both the normal antibody 
forming B-cell as well as the plasmacytoma  (Kohler G and Milstein C, 1975). It inherits the 
potential for immortality and continuous growth from the plasmacytoma, and the antibody-
secreting potential from the B-cell. 3 years later the same technique was used to form T-cell 
hybridomas by Taniguchi and Miller by fusing antigen specific T-cells to a T-cell tumour line 
(Miller J and Taniguchi M, 1978). This technique allows for the production of immortal T-
cells with desired characteristics, to be studied in vitro, whilst using the fusion partner (often a 
tumour cell line) to maintain immortality. Previously, questions have been raised relating to 
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their genomic stability and potential loss of TCR complexes as well as IL-2 dependence and 
cytotoxic ability.  Due to the low yield and potential sporadic incorporation of cells, this 
technology has fallen slightly out of favour however if this could be improved then it poses a 
viable option for immortalising T-cells.   
The basis for the production of hybridomas gained Milstein the Nobel Prize for Physiology or 
Medicine in 1975. They described how B-cells were fused with myeloma cells by 
electrofusion. The myeloma cells were pre-selected so that they lacked the hypoxanthine-
guanine phosphoribosyltransferase (HGPRT) gene, making them sensitive to the HAT 
(hypoxanthine-aminopterin-thymidine) medium. Fused cells were incubated in HAT medium 
for up to 2 weeks. Aminopterin is the key to this mechanism working as a form of selection as 
it blocks nucleotide synthesis. Therefore, unfused myeloma cells die, because they lack 
HGPRT. Likewise, unfused B-cells die as they naturally have a short life span in culture unless 
they are fused with the immortal cancer cell line. In this way, only the B-cell-myeloma hybrids 
survive, since they will possess a functional HGPRT gene from the B cells. These cells produce 
antibodies (courtesy of the B-cells) and are immortal (a property of tumour cells). This 
therefore poses the basis for the development of T-cell hybridomas, formed in a similar 
fashion, but to be investigated in this project, we plan to irradiate the fusion partners (immortal 
cancer cell lines), select them with 6-thioguanine, and then reselect with HAT medium.  Of 
course no-one is actually going to insert a hybridoma in a clinical setting – this would never 
be ethically acceptable however it does form the basis of a hypothetical model which could at 
least demonstrate the effectiveness of T-cells in retaining desirable features and allow for 
further investigation of these cells in the experimental setting as well as potentially provide a 
limitless source of reagents with which we can pursue the study of phosphoantigen expression. 
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5.1.2 Viral transduction of human cells with Herpesvirus saimiri (HVS)  
HVS is a gammaherpes virus which naturally infects the Squirrel Monkey.  It is non-pathogenic 
in this natural host (virtually all Squirrel Monkeys are carriers) but has the ability to produce 
T-cell lymphomas in other New World Monkeys. It is distantly related to Epstein Barr virus 
which has also been shown to immortalise B-cell lines in a similar fashion. It was Biesinger et 
al in 1992 that first described the potential utility of HVS to transform human T-cells into 
stable culture lines. The virus persists as non-integrating episomes in human T-cells under 
restricted viral gene expression and without production of virus particles. The resultant 
transformed human T-cells are ‘not permissive’ to the virus, and reactivation of the virus has 
not so far been possible despite the efforts of a number of groups Worldwide. The T-cells 
which are immortalized in culture have the same phenotype as mature activated T-cells with 
normal CD4/CD8 expression. Also of benefit is that these cells will retain the parental cell’s 
antigen specificity therefore leading to a potential use in immunotherapy due to this 
preservation of specificity.  This model therefore again promises to be a useful basis for the 
study of antigen presentation and manipulation of cells in the experimental setting. 
 
5.1.3 The use of stem cells  
Stem cells are a generic precursor with the ability to become any tissue of the human body 
given the right growth conditions.  It is this ability that makes them attractive as a potential 
mediator for the generation of a target cell in vitro which can be used to make a desired cellular 
model for research. Embryonic Stem cells have been traditionally used; however their use has 
met with poor press due to their origin. Nevertheless they have been used in spinal cord injury 
and diabetes with mixed success (Thomson 1998). Therefore there has been a lot of recent 
research into the generation of Induced Pluripotent Stem Cells or iPSc’s. These are a stem cell 
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source created from adult somatic cells and their potential use is varied. The use of iPScs allows 
redifferentiation into effector cells that would then be infused. 
The availability of highly-effective “off-the shelf” T-cells with specificity against a portfolio 
of targets would be a step-change for the field. The recent demonstration that induced 
pluripotent stem cells (iPScs) can be generated from human antigen-specific T-cell populations 
offers a new therapeutic strategy for the expansion and delivery of such cells (Vizcardo et al 
2013, Nishimura et al 2013). Such an approach affords a potentially limitless supply of antigen-
specific T-cells to target a range of diseases that could be delivered in a scalable manner to 
reach all patients in need.  Recently, Masayo Takahashi at the RIKEN Centre for 
Developmental Biology, Japan has brought iPSc-derived cell therapies to the clinic, the results 
from which will hopefully validate the safety of using iPSc-derived cells in the clinical setting 
(Kumaro et al 2014) a potentially limitless supply of cells which have been shown to be both 
safe and stable in vivo.  They can be patient specific and therefore could negate the need for 
immunosuppression for instance in the right setting.   
These ‘‘rejuvenated’’ cells possessed antigen-specific killing activity and exhibited T-cell 
receptor gene-rearrangement patterns identical to those of the original patient T-cells.  These 
studies therefore demonstrate an approach to cloning and expanding functional antigen-
specific CD8+ T-cells that might be applicable to cell-based therapy of cancer.  
In order to understand why this is so important it is necessary to go back 8 years and see the 
first development of ‘Induced Pluripotent Stem Cells’ by Shinya Yamanaka and colleagues in 
Japan (Takahashi K and Yamanaka S, 2006). In the first few days after conception, an embryo 
consists of pluripotent cells which can develop into all cell types in the body. In 2006, Shinya 
Yamanaka found a new way to ‘reprogramme’ defined adult, specialized cells to turn them 
back into stem cells. He was able to do this following the observation of a number of different 
transcription factors which have been found in embryonic stem cells which were felt to 
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contribute to this cell’s pluriotency (Nichols J et al 1998, Niwa H et al 2000, Avilion A et al 
2003, Chambers I et al 2003, Cartwright P et al 2005). These factors comprised what we now 
refer to as the Yamanaka factors of Oct4, KLF4, C-Myc and Sox-2. These cells are described 
as being pluripotent – i.e. they have the ability to produce any type of cell in vivo - and are 
referred to as ‘induced’ as this isn’t a natural process, but they have been exposed to specific 
factors in order to undergo this change. Only embryonic stem cells are naturally pluripotent 
but their origin and general availability makes their use untangible. Yamanaka’s discovery 
meant that virtually any dividing cell of the body i.e. skin, blood, neurones can be turned into 
a pluripotent stem cell, and it went on to win him the Nobel Prize for Science and Technology 
in 2012. 
In order for this to be a possibility they must retain no genomic footprint from the virus used 
to generate them.  Initially retroviruses and subsequently lentiviruses were used in order to 
generate iPSc but these still retained a small genomic footprint (Takahashi and Yamanaka 
2006, Takahashi, Tanabe et al. 2007, Nagata, Toyoda et al. 2009, Takahashi and Yamanaka 
2013).  The introduction of sendai virus as a vector to insert the Yamanaka factors into the 
target cell has provided a means by which cells can be differentiated without any genomic 
footprint being retained, fig 5.1.  This is important when considering a system for clinical 
utility (Cao, Loh et al. 2012, Rao and Malik 2012, Malik and Rao 2013).  
 
Fig. 5.1: Comparison of different viral technologies for generating iPSc, abridged from Malik and Rao, 
2013.   
 
Use of hIPSc technology to immortalise T-cells was described recently by two groups, in order 
to overcome T-cell exhaustion (Nishimura, Kaneko et al. 2013, Vizcardo, Masuda et al. 2013). 
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The observations made by both groups led to our hypothesis that hIPSc may be used to 
imortalise phosphopeptide-specific T-cells. 
 
5.1.4 T-cell exhaustion  As a result of chronic infection or malignancy, a state of so called 'T-
cell exhaustion' may occur. This is characterised by T-cell dysfunction, loss of effector function 
and the expression of inhibitory factors.  This inevitably leads to a reduction in efficient control 
of infection or malignancy. EJ Wherry and subsequently his group proposed a model of 
hierarchical T-cell exhaustion (fig. 5.2), showing the gradual shift from highly polyfunctional 
CD8+ T-cells with little apoptosis, to a complete loss of function and increased apoptosis 
(Wherry 2011, Wherry and Kurachi 2015). Although this is described in virus infection, the 
same could be applied to how T-cells lose functional recognition of tumours.  Therefore, 
introducing a technique for propagating T-cells without loss of function in vitro would be 
beneficial.  
 
Fig. 5.2:  The effect of chronic infection of T-cell functionality – a model for T-cell exhaustion. Here it is 
demonstrated that during initial infection, naive T cells are primed by antigen, costimulation and inflammation 
resulting in differentiation into effector T cells. Clearance of infection and antigen results in a subset of these T 
cells to further differentiate into highly polyfunctional memory T cells. During chronic infection, infection 
persists after the effector phase. Cells progress through stages of dysfunction, losing effector functions and other 
properties in a hierarchical manner. There is an increase in the amount and diversity of inhibitory receptors 
expressed. Ultimately, if the severity and/or duration of the infection is high and/or prolonged, virus-specific T 
cells can be completely eliminated, leading to loss of virus-specific T cell responses. This model can also be 
applied to how T-cells recognise tumour (Wherry 2011). 
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This chapter therefore explores a number of techniques from early biotechnologies such as T-
cell hybridomas and viral transduction with herpesvirus saimiri to the use of more novel 
technologies such as generation of hIPSc using sendai virus.  All are predicted and have been 
shown previously to have the same desired end point and could all potentially be used to 
generate a stable T-cell line (Kohler and Milstein 1975, Taniguchi and Miller 1978, 
Grassmann, Biesinger et al. 1990, Biesinger, Mullerfleckenstein et al. 1992, Nick, Fickenscher 
et al. 1993, Meinl, Hohlfeld et al. 1995, Rao and Malik 2012, Vizcardo, Masuda et al. 2013, 
Nishimura, Kato et al. 2014).  Each of these techniques will be described in subsequent sections 
in more detail. 
 
5.2 T-cell hybridomas 
3 years after B-cell hybridoma technology was first described a similar technique was used to 
form T-cell hybridomas by Taniguchi and Miller by fusing antigen-specific T-cells to a T-cell 
tumour line (Taniguchi and Miller 1978). Based around the same technology a fusion partner 
cell (immortal tumour line) is fused with a T-cell of choice to generate an immortal T-cell 
which possess characteristics of interest, which is as was seen in B-cell hybridomas, fully 
selectable.  
This in turn does raise important considerations, such as genomic instability and potential loss 
of TCR complexes as well as IL-2 dependence and cytotoxic ability due to issues similar to 
those encountered with B-cell hybridomas relating to chromosome loss and mutations 
(Castillo, Mullen et al. 1994).  
The theory behind B-cell hybridomas is similar to that seen in T-cell hybridomas.  Cells are 
engineered to possess characteristics of interest which are selectable by adding selection agents 
to growth media, with the resultant pure culture of hybridoma cells.  The pathway involved in 
this technology relates to the gene hypoxanthine phosphoribosyltransferase 1 (HGPRT or 
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HPRT1), which codes for a transferase enzyme that catalyzes conversion of hypoxanthine to 
inosine monophosphate (IMP) and guanine to guanosine monophosphate (GMP), with 
resultant transfer of 5-phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate (PRPP) 
onto the purine. HGPRT plays a central role in the purine salvage pathway.  HGPRTase 
salvages purines from degraded DNA, reintroducing them into purine synthetic pathways. 
Hybridomas are immortal, HGPRT+ cells resulting from fusion of mortal, HGPRT+ plasma 
cells and immortal, HGPRT− myeloma cells. They are created to produce monoclonal 
antibodies in biotechnology. Hypoxanthine-aminopterin-thymidine (HAT) medium inhibits de 
novo synthesis of nucleic acids, leading to death of myeloma cells that cannot switch over to 
the salvage pathway, due to lack of HRPT1. The plasma cells in the culture eventually die as 
a result of cellular senesence, leaving a pure growth of hybridoma cells. HAT relies on the 
combination of aminopterin, (folate metabolism inhibitor), with hypoxanthine (a purine 
derivative) and thymidine (a deoxynucleoside) both of which are intermediates in DNA 
synthesis. The role of Aminopterin is to block DNA de novo synthesis, and therefore prevent 
cell division.  Hypoxanthine and thymidine work by providing the cells with a 'rescue' pathway, 
producing the necessary building blocks for bypassing the block placed by aminopterin and is 
hence termed the 'salvage pathway'. This is only possible if the correct enzymes are present 
which in turn is only possible if the gene or genes coding for them is in a functional state (fig. 
5.3). 
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Fig. 5.3: Generation of T-cell hybridoma by fusion of immortal fusion partner line with desired target T-
cell.  Selection with HAT-supplemented media and 6TG (6-thioguanine - used to remove any unfused T-cells as 
well as any fusion partner cells which do not possess the HPRT1 gene rearrangement) will remove all unfused 
cells, resulting in a pure culture of tetraploid cells with desired characteristics.  The resultant tetraploid cell is 
unstable however leading to high rates of cell death with very few cells reaching the hybridoma stage and even 
fewer that remain stable, with large numbers undergoing apoptosis as a result of genomic instability. 
 
One example of this is the enzyme dihydrofolate reductase, who's main role is the reduction of 
dihydrofolate to tetrahydrofolate (THF).  It is this enzyme which aminopterin blocks.  
This has a knock on effect on further downstream enzymes.  For example in the absence of 
THF, deoxyuridine monophosphate (dUMP) cannot be converted to thymidine monophosphate 
(TMP) via the precursor Thymidylate synthase. One function of dUMP is to be converted to 
thymidine triphosphate (TTP), and thus be used to make a nucleotide precursor and hence is a 
DNA building block.  However if dUMP is not converted then DNA synthesis is effectively 
blocked.  The only way of overcoming this is if an alternative TMP source is available.  One 
such source is found in HAT medium, as thymidine present can be effectively used, and is 
readily absorbed, and can be easily converted to TMP by thymidine kinase.  
Another role for THF is in the synthesis of IMP.  When this is blocked as described above and 
alternative route of production is by accessing hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT). Hypoxanthine is absorbed from the medium with PRPP.  
This leads to production of pyrophosphate, which via the salvage pathways is able to produce 
IMP (fig.5.4a). This therefore demonstrates the use of HAT medium for cell culture as a form 
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of artificial selection in cells containing functional forms of the enzymes TK and HGPRT. 
Addition of selection agents allows death of cells possessing the genes of interest (i.e. the 
unfused cells) and results in a pure culture of cells with desired characteristics - the tetraploid 
cells and development of hybridomas.  
 
Fig. 5.4a: HGPRT biochemical pathway. HGPRT is a transferase encoded by HPRT1 gene converting 
hypoxanthine to inosine-monophosphate and guanine to guanosine monophosphate.  This transfers the 5-
phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate (PRPP) to the purine.  It plays a central role in 
purine salvage pathway. 
 
In order to generate hybridomas, fused cells are incubated in HAT medium. Aminopterin, as 
described above leads to blocking of the de novo pathway. As a result of this action, any 
unfused fusion partner cells will succumb due to inability to produce nucleotides needed for 
DNA synthesis via either the de novo or salvage pathways – fig. 5.4b. Any unfused  T-cells of 
choice will likewise be lost as a result of cellular senescence.  As a result, only hybridoma cells 
(i.e. those that contain characteristics of both the fusion partner and T-cell of choice will 
survive selection with HAT media as it is only these cells which possess the appropriate 
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'machinery' to continue to survive in these conditions.  This forms the basis of production of a 
T-cell hybridoma. 
 
Fig. 5.4b: Demonstration of effect of HAT selection on hybridoma cells.  By exploiting the salvage and de 
novo pathways, the only cells to survive possess intact HGPRT (from target cell of interest) and immortality from 
tumour cell. 
 
Due to low yield and potential sporadic incorporation of cells, this technology has largely fallen 
out of favour.  However, if this could be improved then it poses a viable option for 
immortalising T-cells for use as an experimental model to assess patterns of antigen expression 
and probe their expression on both normal tissues and transformed cell types. 
 
5.2.1 Results:  Basic fusion protocol 
A number of T-cell tumour lines were selected as potential fusion partners including Jurkat (2 
lines were available, named 'JKA-NLV' obtained from Dr G Bendle, Cancer Sciences, 
University of Birmingham – a retrovirus-transfected jurkat line with insertion of a T-cell 
receptor which recognises the viral peptide sequence for the CMV peptide NLV and 'JKA-
GFP' obtained from Dr D Millar, School of Infection and Immunity, University of Birmingham 
– a lentiviral transfected line with addition of GFP expression and puromycin resistance), HPB-
ALL (DSMZ, Germany), SKW-3 (DSMZ, Germany), MOTN-1 (DSMZ, Germany) and CEM 
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(ATCC, USA).  Cells were irradiated and selected as described in chapter 2.  Irradiation serves 
to induce a mutation in the HPRT gene, leading to resistance to 6-thioguanine (6TG), allowing 
the immortal fusion partner cells to be selectable with 3 cell lines emerging as viable fusion 
partners (JKA-GFP, JKA-NLV and CEM) – fig. 5.5 shows the selection of JKA-NLV.   
 
Fig. 5.5: Demonstration of 6TG resistance in cell line 'JKA-NLV'.  (A) Cells were treated with 6TG and 
photographed on day 7, showing death of cells following administration of 6TG at 10µM or 20µM.  (B) These 
cells were incubated for a further week showing that despite death on day 7 they had recovered by day 14).  (C) 
Representative flow cytometry plot which revealed similar results with large numbers of cells dying at higher 
concentrations of 6TG at day 7, with recovery by D14 - dead Jurkats denoted as JKA-D and alive jurkats denoted 
JKA-A.  This is represented graphically in (D).   
 
Initially there was death observed amongst cells treated with higher concentrations of 6TG but 
these cells were maintained in culture, and resistant cells emerged and were allowed to expand 
and form a stable resistant cell line, whereas cells treated with lower doses of 6TG initially had 
high viability but as time progressed cells died – suggesting lower doses of 6TG were sub 
optimal for selecting a pure line – and thus a dose of 20µM 6TG was selected as the optimum 
dose for selecting suitable fusion partners. It was observed that the lines HPB-ALL and SKW-
A
B
C
D
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3 did not survive after irradiation, and it has therefore been proposed that these tumours are 
radiosensitive (Fig. 5.6).  They were therefore discounted from further input at this stage. 
 
 
Fig. 5.6: Growth kinetics following selection.  T-cell leukaemia lines were irradiated using standard protocols 
(described in chapter 2).  Following this they were pulsed with 20µM 6TG in order to obtain a pure growth of 
cells resistant to 6TG which can be used as a fusion partner for hybridoma formation.  Black rectangles represent 
times when cells were placed on selection (with 6TG).  Cell lines are all T-cell leukaemias.  'JKA-NLV1' and 
'JKA-NLV2' are two Jurkat lines which were retrovirally transfected by Dr G Bendle to include the TCR for the 
CMV-peptide (NLV).  'JKA-GFP' was transfected by Dr D Millar to have a GFP tag. In this example SKW died 
shortly after irradiation suggesting it is radiosensitive.  HPD-ALL also appears to be radiosensitive with a gradual 
decline in cell numbers.  JKA-NLV2 and JKA-GFP both initially appear to expand following 6TG selection, 
however numbers fell again at day 20.  In this experiment the only line which is 6TG resistant is JKA-NLV1. 
 
5.2.2 Efficiency evaluation 
In order to evaluate hybridoma formation efficiency, it was necessary to test standard protocols 
as originally proposed by Taniguchi and Miller.  Initial results were not promising and 
therefore the basic technique was modified as described in chapter 2. A Jurkat fusion partner 
line which had been previously modified by Dr Millar to contain a GFP tag (generated as 
described in chapter 2) was mixed with a viral-specific NLV-T cell line which was NLV-
tetramer stained.  Cells were FACS analysed on day 3 (fig. 5.7).  Controls included each cell 
line (target cell line and partner cell line) on its own, and a mixture of both lines without the 
addition of polyethylene glycol (PEG).  The hybridoma was formed by mixing 1x107 Jurkat 
(GFP) with an equal number of NLV-peptide specific T-cells, and PEG was used as the fusogen 
(as described previously in chapter 2).  FACS analysis of the cells was performed on day 3 and 
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demonstrated 98.9% GFP positivity of the Jurkat and 94.7% NLV-tetramer positivity of the T-
cells (Fig. 5.7A, B).  Both these controls had negligible double positive cells.  The hybridoma 
however showed 54.2% double positivity (shown by red circle) which represents the 
population of interest and potential hybridomas.  Jurkats are also known to be CD8-, and the 
T-cell line is 94.4% CD8+.  The resultant hybridomas would be expected to be CD8+ and GFP+ 
(fig. 5.7C).  Although hybridomas and T-cells would both be CD8+ and NLV-tetramer+, we 
can see a clear difference between the two when seen on FACS with a population of cells 
which may well represent true hybridomas (blue circle) and a separate mixed population of 
cells spanning tetramer+/- and CD8+/- but not both and therefore these cells are most likely the 
separate cell groups which are unfused – and therefore should be lost following selection.  Of 
note the NLV-T cells were a cell line i.e. heterogeneous and not clone derived – hence some 
cells are tetramer + but CD8-.  These cells were stained for GFP/CD8 also to see if a hybridoma 
population could be identified which were GFP+CD8+.   
  
		 193	
 
Fig. 5.7: Hybridoma formation using PEG.  NLV-peptide specific T-cells (denoted NLV-T cell) were fused 
with GFP-tagged Jurkat cells using standard protocols as described in chapter 2. Following this on Day 3 cells 
were analysed using FACS. (A) represents unselected Jurkats, T-cells, mix of cells (no PEG) and ‘hybridomas’ 
looking at NLV-tetramer positivity (trait of T-cell) and GFP positivity (trait of Jurkat). There is clearly a shift in 
population size (red circle) which may represent hybridoma formation.  (B) shows FACS staining for tetramer 
positivity (from T-cell) and CD8 positivity (from T-cell).  There is a discreet population of DP cells (blue circle) 
which may represent hybridoma cells. (C) Shows staining of the same cells for CD8 and GFP demonstrating a 
shift in the population of cells  upwards which may be representative of DP and hybridoma formation as there 
appears to be CD8/GFP + cells.  Selection will help to delineate this further as this should remove any non-fused 
cells.  
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Fig 5.7c demonstrates clear differences between the control cell lines and the 'hybridomas'.  
However it is not clear if these cells truly are hybridomas.  They would appear to be GFP 
positive and at least some of this population may be CD8+.  But this is by no means clear cut.  
The only way to actually identify what cells may be included in this population is to put them 
onto selection with HAT and 6TG.   
Although initially following selection with HAT there was a population of cells alive in the 
‘hybridoma’ plate, these cells were considered unstable, failed to expand and eventually after 
12 weeks of culture died (fig. 5.8).  It should be noted that cells were pulsed on day 3 and then 
every two weeks for 3 days with HAT in order to remove any unfused Jurkats.  Unfused T-
cells naturally died without selection, proposed to be due to senescence.   
 
 
 
Fig. 5.8: Absolute cell numbers following selection with HAT.  Following standard fusion protocols, cells were 
counted weekly using glass coulter counter and microscope.  Week 0 is the day the cells were initially set up at 
1x106/ml.  Cells were placed on HAT selection (20µM) on day 3 and counted initially after 1 week then at 2 
weekly intervals.  The jurkat line used 'Jurkat-GFP' is HAT sensitive and therefore in control showed a rapid 
decrease in viability at week 1 which never really recovered.  The T-cell line 'NLV T-cell' alone being HAT-
resistant survived in culture for 6 weeks (however gradually declined in number from week 2 due to natural cell  
death.  The cell mixture 'mix' (which comprised the jurkat line and T-cell line being mixed in equal numbers) 
likewise rapidly decreased in number, but when compared to FACS plot in fig 5.7c, it appears these cells were 
largely Jurkat in origin, so therefore following HAT selection unsurprisingly these cells succumbed.  'Hybridoma' 
cells appeared to survive until week 10 but cells did not expand in cell number. 
 
We wondered whether lack of cell expansion was due to chromosome instability by virtue of 
the hybridoma formation process.  Clearly a cell line which cannot expand has no potential for 
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clinical utility.  We therefore sought to improve the technique to make it both more efficient 
and scalable. 
 
5.2.3 Improving fusion efficiency 
Following the observation that a number of authors used dimethyl sulfoxide (DMSO) in 
addition to PEG we hypothesised this may improve fusion efficiency.  Although toxic, DMSO 
at low concentrations has been shown to be fusogenic over prolonged periods of time 
(Destgroth and Scheidegger 1980, Klebe and Mancuso 1981, Klebe and Mancuso 1982, 
Hundhausen, Laus et al. 1992). In order to test this hypothesis we chose to fuse PBMC’s which 
had been stained using CellTrace violet (CTV), with a Jurkat line which had GFP tag 'Jurkat-
GFP'. We made a direct comparison between PEG and PEG/DMSO in order to see if fusion 
potential was improved (fig. 5.9).   
 
Fig. 5.9: Comparison of PEG vs PEG + 10% DMSO as fusogen in creation of hybridomas.  Equal numbers 
of PBMCs (stained with CellTrace-violet were mixed with Jurkat-GFP using standard protocols as described in 
chapter 2.  PEG alone was directly compared with the combination of PEG/DMSO.  2.27% cells were DP when 
receiving PEG alone vs 2.44% of cells when receiving PEG/DMSO (NS). Of note there is a small population of 
PBMCs that were naturally GFP positive (1.32%).  These FACS plots were representative of 3 repetitions of this 
experiment, done in duplicate on each occasion.  
 
 
These experiments (pre-selection) showed no difference between both fusogen combinations.  
This was repeated with more cells (data not shown) however the overall fusion equivalents 
remained the same, therefore we concluded there was no difference between using PEG alone 
versus PEG combined with DMSO.  We wondered if there was any significant effect on these 
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cells following selection.  In order to test this; cells were set up in duplicate directly comparing 
those hybrids fused using PEG versus those fused using PEG/DMSO.  Each week cells were 
counted using Coulter counter and absolute cell numbers of live cells were recorded.  In this 
case we have demonstrated a similar effect on cell number compared to the initial experiment 
assessing overall efficacy of fusing cells (fig.  5.8), thus validating these initial data.  Using a 
two-tailed paired-t test to compare PEG with DMSO fused hybrids; there is no significant 
difference between both groups.  We did note an initial drop off in cell number at 1 week 
following fusion and this may be as a result of DMSO toxicity (fig. 5.10).   We therefore 
concluded there was no advantage to using DMSO + PEG over PEG alone. 
 
Fig. 5.10: Absolute cell numbers following fusion of PBMC’s and Jurkats using DMSO + PEG or PEG 
alone and subsequent selection with HAT.  Following standard fusion protocols, cells were counted weekly 
using glass coulter counter and microscope.  Week 0 is the day the cells were initially set up at 1x106/ml.  Cells 
were placed on HAT selection (20µM) on day 3 and counted initially after 1 week then at 2 weekly intervals.  
Jurkat-GFP line is a HAT-sensitive Jurkat line therefore unfused cells would be lost following selection.  PBMC’s 
which are unfused would naturally decline in the absence of IL2.  
 
5.2.4 Lentiviral transduction of the fusion partner cell lines was not feasible 
Having established that the basic fusion protocol is largely inefficient, and that fused cells are 
unstable, we proposed inserting an anti-apoptotic gene (BCL2) into the fusion partner cell 
lines.  We wondered if this would increase longevity of the resultant hybridoma cell line and 
prevent premature cell death thus improving the long term culture of hybridoma cells (fig. 
5.11).   
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Fig. 5.11:  Proposed improvement in hybridoma formation following insertion of anti-apoptotic gene BCl2 
(A) viral cassette containing BCL2 gene and puromycin resistance (B) using a lentivirus to incorporate the BCL2 
gene leads to incorporation of this DNA into fusion partner line, with (C)  resultant  proposal of reduced cell 
death.  Insertion of this cassette will also result in puromycin resistance of the fusion partner which would be 
useful for selection purposes. 
 
The cell lines transduced with BCL2 gene were the fusion partner lines: Jurkat-NLV (derived 
from the Jurkat line obtained from Dr Bendle which had already been transfected to contain a 
TCR specific for the CMV peptide NLV) and 'CEM' (derived from the commercially sourced 
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CEM line, ATCC, USA).  Unfortunately, 'Jurkat-GFP' could not be transduced as these cells 
were already puromycin resistant by virtue of their generation.  Standard techniques were used 
to package the virus ready for transduction and cells were transduced with virus in the presence 
of polybrene. Puromycin selection was used to isolate cells which had been transduced (a 
puromycin kill-curve was initially generated for each cell line).  Following this cells were 
pulsed with 6TG to obtain a pure line of 6TG resistant, puromycin resistant (and therefore 
BCL2+) cells. Unfortunately these cells did not remain viable despite multiple attempts (data 
not shown).  We proposed that this may be due to a number of reasons.  1) 'Jurkat-NLV' cells 
had already been genetically modified to include the TCR for the CMV-peptide NLV and 
therefore further modification makes the cell too unstable. 2) Irradiation of the cells in order 
to generate a line which is 6TG resistant is in itself mutagenic and therefore for the same reason 
these cells were non-viable.  In order to test these theories we transduced standard, non-
irradiated (and therefore non 6TG resistant) Jurkat cells and CEM cells.  These were selected 
with puromycin and a stable cell line was achieved.  However following irradiation neither cell 
line survived – suggesting that cell viability is dramatically reduced the more ‘genetic insults’ 
they receive.  We concluded that lentiviral transduction of the fusion partner cell lines was not 
feasible and therefore did not pursue this avenue further. 
 
5.2.5 Addition of mitogens to growth media was not advantageous 
Caspases are involved in apoptosis and cell death and therefore were a target to be investigated 
further with regards to preventing cell death in hybridoma cells and indeed T-cells in general.  
Previous work done in this lab (by Ms Lora Steadman) demonstrated there are a number of 
mitogens capable of supporting cell growth and increasing cell expansion when compared to 
standard media (RPMI + 10% FCS) – Fig. 5.12a, b.   
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This preliminary work suggested that addition of ZVAD, Calcitriol and Betulinic acid all 
appear to improve cell expansion and viability compared to control medias when tested in 
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Jurkat cells and therefore we proposed that this may help to expand hybridomas long term also 
(as these are a fusion of T-cells and Jurkat cells). In order to assess whether mitogens can 
improve cell growth Jurkat-GFP were fused with an NLV-T cell line. We predicted that the 
addition of mitogens would afford greater stability to the hybridomas based on the data seen 
in the Jurkat experiments.  We chose to assess the same concentrations as used previously in 
the Jurkat experiment (fig. 5.12) and also a 2x concentration, to see if doubling the 
concentration of mitogen could improve cell viability. Cells were stained for NLV-tetramer 
(tet), CD8 and GFP (fig. 5.13). ‘Hybridoma’ cells – i.e. tet+GFP+ were greater in the 
RPMI/10% FCS control media across all wells.  The prevailing cell line in each is also Jurkat-
GFP.  We concluded from this that the mitogens were preferentially supporting Jurkat growth 
but may not be supporting hybridoma growth.  We also observed that betulinic acid appears to 
be toxic to all cells.  It is not immediately clear why this should be the case when initial 
experiments did not show this, however we wondered if this may be as a result of mutation 
afforded by transduction of these Jurkat cells to be GFP+.  
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Fig. 5.13:  Comparison of media supplemented with mitogens.  A Jurkat fusion partner 'Jurkat-GFP' so called 
as it has been modified to have a GFP tag, was fused with a T-cell line known to be NLV-tetramer positive i.e. 
CMV-peptide containing, termed 'NLV-T cell' using standard protocols as described in chapter 2 using PEG.  
Immediately following fusion cells were resuspended in either control media (RPMI/10% FCS) or RPMI/10% 
FCS media supplemented with mitogen.  Cells were allowed to rest for 3 days in incubator 5% CO2 at 37c and 
then analysed using flow cytometry following staining for NLV-tetramer and CD8. (A) P1 is the %  target 
population.  These cells are considered alive. (B) Shows staining for tetramer and GFP. Hybridoma cells are 
considered to be the DP population in quadrant 2. 
 
 
A
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We wondered if longer term hybridoma cell growth would be better supported (i.e. after cells 
had recovered from initial fusion insult).  In order to test this theory we put cells onto HAT 
selection on day 3 (immediately after the first FACS analysis). Cells were then incubated for 
a week and repeat FACS analysis performed to see if there had been any recovery of hybridoma 
cells (Fig. 5.14). 
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Fig. 5.14:  Comparison of media supplemented with mitogens post HAT selection.  The same cell lines as 
described in fig. 5.13 were used for this experiment.  'Jurkat-GFP' were fused with 'NLV-T cells' using standard 
protocols as described in chapter 2 using PEG.  Immediately following fusion cells were resuspended in either 
control media (RPMI/10% FCS) or media supplemented with mitogen.  Cells were allowed to rest for 3 days in 
incubator 5% CO2, 37c and then put on HAT selection for a week.  (A) shows % target population i.e live cells 
potentially containing hybridomas. (B) Shows staining for tetramer and GFP. Hybridoma cells are considered to 
be the DP population in quadrant 2. (C) Shows staining for CD8/GFP, with hybridoma cells considered 
GFP+CD8+. 1x and 2x refers to the concentration of mitogen used, as first described by Ms Steadman. 
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Unsurprisingly the majority of Jurkats (which are HAT sensitive) have died following selection 
with HAT.  The NLV-tetramer+ T-cells are HAT-resistant and therefore survive.  Although on 
initial inspection of fig 5.14A it would appear there is a reasonable population of target 
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population cells (19.7%) in the control well containing RPMI+ 10% FCS. When analysed 
further, assessing tetramer and CD8 positivity it can be seen that these cells are largely tetramer 
and CD8 negative.  There is a population of cells which are GFP+CD8- which are presumed to 
be Jurkats (and further suggests that the fusion cell population is possibly mixed with not all 
possessing the HPRT1 mutation conferring HAT sensitivity and 6TG resistance. The 
alternative hypothesis is that these could be hybridomas fused with non-CD8+ T-cells as this 
is a heterogeneous cell line not a clone – however this is unlikely given these cells are also 
NLV-tetramer-). It is not immediately clear why HAT was so efficient at killing the Jurkat 
control, if this is also a heterogeneous line.  
One conclusion which may be drawn from looking at the other mitogens is that there is an 
increase in target population which is directly proportional to the amount of calcitriol 10.8% 
vs 19.2% respectively (although not better than control RPMI/10% FCS which was 19.1%) – 
Fig 5.14A. ZVAD also confers an increase in target population (which does not increase 
significantly when the amount of ZVAD is doubled – 29% vs 29.4% respectively).  However 
when observing tetramer positivity (B) it is clear that very few cells are GFP+NLV-tetramer+, 
and in fact the control well has a population of 10.1% cells which are double positive, which 
is far more than any of the mitogen wells. It was noted that the GFP+NLV-tetramer- population 
in quadrant 7 (considered to represent Jurkat cells) increased in the presence of mitogens – 
which would suggest possibly mitogens confer some resistance to HAT (fig 5.14.B). When 
analysing CD8+ there are very few cells which are CD8+GFP+.  There does appear to be a very 
small population in the ZVAD wells (red circle), but again the overriding cell line present 
appears to be Jurkat in origin. 
These data appear to suggest that mitogens support the growth of Jurkats but don’t appear to 
confer much of an advantage to hybridomas. We therefore concluded that addition of mitogens 
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to growth media was not advantageous to the culture of hybridoma cells and enhancing their 
stability. 
  
5.2.6  Nucleofection of the pre-mixed cells (PBMC + Jurkat) with VSV-G DNA is more 
efficient at generating hybridomas than standard protocols 
V-fusion has been proposed as a potential improvement to cell fusion technology as it reduces 
potential for toxicity, optimises efficiency and introduces flexibility (Gottesman, Milazzo et 
al. 2010).  We therefore hypothesised that use of VSV-G DNA could have the potential to 
enhance the hybridoma formation. Vesicular Stomatitis Virus G (VSV-G) can enhance DNA 
lipofection efficiency by interacting with liposomes to form fusogenic, serum-stable liposomes 
with enhanced transfection properties, which is reversible (Okimoto, Friedmann et al. 2001). 
We therefore predicted that the presence of VSV-G on fusion partners may allow for enhanced 
fusion with target cells.  In order to test this hypothesis, VSV-G DNA was used in combination 
with Lonza nucleofector 2d, nucleofection kit V (Amaxa, Germany).  Jurkat-GFP fusion 
partner cells were pre-treated with 6TG to obtain a near pure population of 6TG resistant cells 
and a sample aliquot of these cells was taken to test for HAT sensitivity with 99.2% death 
following this.  VSV-G DNA was added to populations of PBMC, Jurkat or a mixture of both 
and the cells nucleofected to introduce the DNA into the cell(s) of choice.  Addition of the 
second population of cells (i.e. Jurkats to the nucleofectd PBMCs or PBMCs to the 
nucleofected jurkats) was delayed for 2 hours to allow the nucleofected cells to express the 
VSV-G protein. It was noted that pre-nucleofection of PBMC’s and then addition of Jurkats 
resulted in very few double positive cells (0.59%) - fig. 5.15.  When this is reversed and Jurkats 
are pre-nucleofected we saw a higher percentage of double positive cells (2.82%) which is 
better than the standard hybridoma protocol with PEG as fusogen which saw only 1.61% DP 
cells.  Nucleofection (i.e. application of a current as per pre-selected programme) resulted in 
very few DP cells which would be as expected as in general application of a charge would 
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result in cell death and in the absence of a fusogen is likely to be detrimental to the cell 
population. When VSV-G was added to a premixed population of equal numbers of CellTrace 
violet-stained PBMC and Jurkat-GFP this produced the highest percentage of double positive 
cells (7.23% red circle Fig. 5.15).  We therefore concluded that nucleofection of the premixed 
cells (PBMC + Jurkat) with VSV-G DNA is more efficient at generating hybridomas than 
standard protocols. 
 
Fig. 5.15:  Assessment of the effect of nucleofection of cells with VSV-G.  (i) Control PBMC cells were stained 
with CellTrace-violet.  (ii) The control Jurkat fusion partner cell line was GFP+.  We compared (iii) a plain mixture 
of cells which were not nucleofected with (iv) the standard fusion protocol using PEG and also with nucleofection 
(v-x).  We considered nucleofection of PBMC with subsequent addition of Jurkats (vi) but the resultant population 
was largely comprised of PBMC alone (Q1). We also considered nucleofection of Jurkats prior to addition of 
PBMC (vii) which resulted in a mixed population of single positive cells (Q1 and Q3) and also a DP population 
(Q2) which were considered possible hybridomas (2.82% cells).  We predicted nucleofection in the absence of a 
fusogen or VSV-G would result in high cell death (viii).  Finally we considered mixing the PBMC with equal 
numbers of Jurkats and nucleofecting this mixture with VSV-G both with PEG (ix) and in the absence of PEG 
(x). This experimental protocol was peformed in triplicate on 3 separate occasions. Similar results were obtained 
with each. 
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5.2.7 Concentration of VSV-G DNA does affect fusion efficiency 
It was proposed that using higher concentrations of VSV-G may lead to higher fusion rates.  
The original protocol used 2µg of VSV-G DNA.  We therefore sought to identify the optimum 
concentration of DNA to lead to hybridoma formation with longevity in culture following 
selection.  We also set out to identify if the resultant DP cells were indeed hybridomas.   In 
order to test this theory, PBMCs were again stained with CellTrace Violet, and nucleofection 
protocol followed as previously with increasing concentrations of VSV-G DNA (0µg, 1µg, 
2µg, 3µg, 5µg).  Hybridomas were considered to be DP cells (i.e. GFP+CellTrace Violet+) 
following initial nucleofection (fig. 5.16a).   
However over time when cells proliferate they lose the violet colouration, therefore this could 
not be relied upon to identify the potential hybridomas after culturing for any prolonged period.  
Therefore the target population would be green (due to GFP+ from Jurkat) and HAT resistant 
(from the PBMC population).  Unfused PBMC’s die in the absence of IL-2 naturally (however 
a kill curve was used to establish puromycin toxicity for this line, and this was used to select 
out unfused PBMC’s) and unfused Jurkats die as a result of HAT sensitivity.  Cells were 
therefore pulsed with puromycin and HAT on D3 and D10 (post-nucleofection) and analysed 
using flow cytometry on day 3, 7, 14 and 21. Hybridomas were considered living GFP+ cells 
following selection (Fig. 5.16b).  Using paired t-test analysis we considered there was a 
significant difference (** on figure) between 2µg and 3µg VSV-G DNA (p<0.05). 3µg DNA 
was identified as the optimum concentration for demonstrating expansion of cells following 
selection. 
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Fig. 5.16:  Effect of different concentrations of VSV-G DNA on formation of hybridomas following 
nucleofection. Equal numbers of PBMC (stained with CellTrace-violet) and 'Jurkat-GFP' (Jurkats previously 
transduced with a GFP-tag) were mixed together.  They were resuspended in appropriate nucleofection solution 
and VSV-G DNA was added at 1µg, 2µg, 3µg, or 5µg.  Lonza 2D nucleofector was used with appropriate 
programme X-001. Cells were washed and resuspended in RPMI/10% FCS and analysed using flow cytometry 
on day 3 post nucleofection. (A) Hybridoma cells were considered to be those cells which were GFP+CellTrace-
violet+ i.e. double positive. Significnt differences can be seen in presence of addition of VSV-g DNA (**) (B) 
shows the same cells following selection with HAT and puromycin on day 3 and day 10.  Hybridoma cells were 
considered to be viable cells which were GFP+ following selection, as unfused Jurkats are HAT sensitive, and 
unfused PBMCs puromycin sensitive at established concentrations. At day 21, cells nucleofected with VSV-G 
DNA were significantly higher in number compared to those not (***) 
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5.2.8 Polycations and plant lectins do not improve fusion efficiency 
Previously it has been proposed that efficiency of fusion can be improved using polycations 
and lectins (Matsuya and Yamane 1985, Matsuya and Yamane 1985).  It has been reported that 
the use of PEG at high concentrations (>50%) is most effective, however this comes at the cost 
of viability and cytotoxicity.  Therefore the focus of this section is to try to identify a process 
which achieves effecicient fusion without loss of viability.  The mechanism of action of lectins 
on PEG-mediated cell fusion is not known.  One hypothesis proposed is that cell agglutination 
by lectins creates conditions of close cell-to-cell contact, thereby enhancing the possibility of 
any subsequent fusion, but the question still remains whether the lectins may induce a structural 
change in the cell membranes (Reeve, Hewlett et al. 1974, Mercer and Schlegel 1979, 
Schneiderman, Farber et al. 1979). 
Therefore we attempted to assess this protocol modification. As we identified nucleofection of 
VSV-G as a fairly efficient process we used this as our standard comparator.  Polyvinyl 
pyrrolidone (PVP) was also considered cytoprotective by Matsuya and therefore we also tested 
this as a possible additional modification to the protocol (see methods) - (Yoshii and Kaetsu 
1982, Matsuya and Yamane 1985, Matsuya and Yamane 1985).  
PVP has long since been used to block Southern blots, and is a known component of Denhardt's 
buffer.  It has also been demonstrated to absorb polyphenols during the purification of DNA. 
Polyphenols are commonplace in a number of plant cells, and they have the ability to deactivate 
a number of proteins/enzymes if not adequately removed.  As a result they may influence 
further molecular analyses such as PCR.  They are therefore an important consideration in 
molecuar biology. They have, as part of their make up, the ability to bind polar molecules, 
however the mechanism of cytoprotection in this instance is not clearly defined.   
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We compared (i) standard fusion with PEG, (ii) nucleofection with VSV-G and (iii) various 
plant lectins and polycations with and without PVP to assess if any were able to further enhance 
this protocol. Mixing the cells in the absence of any fusogen was taken as the background (false 
positive) and had a level of 2% DP cells (represented by black bar on graph).  Therefore, any 
DP cells above this threshold were considered to potentially represent hybridomas (fig. 5.17).  
There is limited effect of using the polycations, although this was slightly improved by the 
addition of PVP but this was still only in the region of 2-3% (i.e. limited improvement on just 
mixing the cells).  Plant lectins did not enhance the protocol and performed worse than mix 
alone. When compared with VSV-G nucleofection we demonstrated 6.45% DP cells, which 
remains the most efficient process for formation of hybridoma cells and remains significantly 
more efficient than standard PEG hybridoma protocols (paired t-test p,0.005). We therefore 
concluded that plant lectins and polycations do not improve on the established nucleofection 
protocol.   
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Fig. 5.17:  Effect of polycations, plant lectins and PVP on efficency of hybridoma formation. Control cells 
(grey) received no lectin/polycation or PVP.  Background DP was taken as 2% - the threshold of double positivity 
noted when cells were purely mixed together in the absence of any fusogen (represented by vertical black line).  
V-fusion is the standard nucleofection protocol with Amaza 2d nucleofector, programme X001, 3µg VSV-G 
DNA.  There is a significant difference between number of double positive cells formed as a result of standard 
fusion protocols using PEG when compared to nucleofection with VSV-G DNA (***).  There is limited effect of 
polycations, plant lectins or PVP on hybridoma formation above the background double positivity (NS). 
 
5.2.9 Hybridomas technology could potentially capture rare events 
Cancer cells are transformed cells which are considered rare in the heterogeneous mixture of 
cells of the human body.  Now we have established a technology which is more efficient than 
standard PEG fusion, and replicated this, we wanted to ascertain if this could be used to capture 
these infrequent target events – could this technology be used to immortalise T-cells capable 
of recognising these transformed cells? We hypothesised that potentially only a small 
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proportion of T-cells had the ability of recognising these tumours.  We have shown by our 
‘proof of principle’ experiments that nucleofection with VSV-G can potentially lead to cell 
fusion, resultant fusion cells can be selected and the resulting population expanded in culture.  
This protocol was therefore used on an HLA-A2+ PBMC population, from a donor with a 
known NLV-tetramer positive response of ~1% i.e. a rare event.  We proposed that hybridomas 
would be able to capture these rare cells and could be used as a technology to expand these in 
culture.  To test this hypothesis, we mixed 1x106 PBMC to equal numbers of fusion partner 
Jurkat cells which were GFP positive.  We would expect only low numbers of DP cells 
following fusion as background NLV-tetramer positivity in the PBMC population was 1% (Fig 
5.18A – red circle).  'Mix without VSV-G' referred to mixing target and fusion cells in equal 
numbers without the addition of VSV-G DNA or nucleofection, and  was included as a control.  
Cells were selected on D3 and D10 with HAT and puromycin to remove any unfused cells.  By 
D10 the nucleofected cells were proliferating, having expanded from a baseline of 0.834% 
NLV+ to 3.12%.  By Day 14 these cells had expanded further to 3.89% NLV+ which suggests 
viability following selection – and potentially these cells are fused hybridomas which 
demonstrate proliferation (fig. 5.18B).  Unfortunately all cells were dead at the end of this 3 
week period; however these results demonstrate the potential  of hybridoma technology to 
increase the tetramer positive cells (i.e. target cells) in a population i.e. can capture a rare event.  
They did not however lead to a stable cell line, despite 2 further experimental repeats, and 
therefore we concluded that hybridomas may not be the most efficient way of capturing rare 
events using the techniques investigated. This lead us to look at further experimental 
modifications to try to achieve this. 
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Fig. 5.18:  Can hybridoma technology be used to capture rare events?  (A) Equal numbers of fusion partner 
cells 'Jurkat-GFP' a jurkat already modified previously to contain a GFP tag were mixed with HLA-A2 PBMC 
(targets) with known NLV-tetramer positivity ~1%  (red circle).  (B) Following nucleofection with Lonza 2d 
nucleofector and standard protocol as previously described, cells were selected with HAT and puromycin on D3 
and Day 10 respectively. These figures represent 3 experimental repetitions, each peformed in triplicate, Error 
bar represents SD. 
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5.2.10 Cross-linking CD52 on the cell surface of lymphocytes with fusion partners pre-
treated with anti-CD52 does appear to facilitate hybridoma formation 
Clearly fusion of cells to form a hybridoma is reliant on a mechanism to bring cells together 
as cell-to-cell interaction is key to this process being successful. We proposed one such way 
of doing this would be to coat one of the cells (either fusion partner or target cell) with anti-
CD52, which is an antibody toward the CD52 peptide of 12 amino acids, anchored to 
glycosylphosphatidylinositol (GPI). Since lymphocytes naturally express CD52 we predicted 
the antibody should recognise and bind the CD52 expressed on the lymphocyte cell surface 
and result in bringing these cells into close contact prior to application of the nucleofection 
pulse.  A large excess of anti-CD52 antibody is needed to try to prevent both arms of the 
antibody from binding to CD52 on the same cell (i.e. one arm of the CD52 antibody binding 
to one cell and the other arm to the second cell forming a bridge). In order to test this 
hypothesis, the Jurkat fusion partner cells were first 6TG selected to remove any HGPRT+ 
cells, then pre-treated with anti-CD52 30 minutes prior to fusion and washed three times with 
PBS. Following this they were resususpended in appropriate nucleofection solution as per 
manufacturer guidance (Fig. 5.19a). PBMC were stained with CellTrace violet to allow 
visualisation on the flow cytometer.  Cells were then nucleofected using standard protocols 
and resuspended in RPMI/10% FCS.  On Day 3 and day 10 cells were put on HAT and 
puromycin selection to remove any unfused cells (Fig. 5.19b).  From this initial pre-selection 
data, antibody concentrations of 500ng and 1µg α-CD52 appeared to be optimal to allow 
possible fusion. 
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Fig. 5.19: Does crosslinking cells prior to nucleofection lead to hybridoma formation?  (A) Schematic 
overview of protocol for pre-treating fusion partner cells with anti-CD52 and predicted outcome.  (B) FACS 
analysis performed on Day 3 prior to selection with HAT or puromycin.  Top row represent control wells.  
Background double positivity is relatively high in this instance at 5.17% (Mix no nucleofection which represents 
control well where equal numbers of fusion partner and target cell are mixed together in the absece of antibody 
or nucleofection).  Therefore following nucleofection the DP cells must be greater than this value.  Nucleofection 
in the absence of CD52 antibody was low at 1.69% reflecting cell death as a result of electrical pulse delivered. 
Higher % DP cells were seen in 500ng and 1µg α-CD52 (20.3% and 14.3% respecitively).  Higher concentrations 
of antibody were less efficient at generating a stable 'hybridoma'. 
Cells were selected using HAT and puromycin on Day 3, 10, 21 and FACS analysis was 
performed.  As seen previously the CellTrace Violet is lost over time due to cell proliferation 
and therefore hybridoma cells were considered to be those alive following selection and GFP+.  
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In order to assess stability of cells, absolute cell number was calculated using microscope and 
manually counting an aliquot of cells at weekly intervals (fig 5.20) counting specifically live 
cells as determined using trypan blue staining.  Cells were also analysed by FACS looking at 
live cells, GFP+ and CD8+ (as Jurkats are GFP+CD8-, T-cells GFP- CD8+, and hybridomas 
considered GFP+CD8+).  Fig. 5.20 demonstrates cells following selection with HAT and 
puromycin on day 3.   
 
Fig. 5.20: Does crosslinking cells prior to nucleofection lead to hybridoma formation which is sustainable 
long term? As described previously, target cells were stained with CellTrace violet. Fusion partner cells (Jurkat-
GFP) were pre-mixed with cd52-antibody at various concetrations (1-5 µg).  These jurkat cells were then washed 
x2 with PBS and resuspended in culture media as previously described. Equal numbers of target cells and fusion 
partner cells were mixed and subsequently nucelofected. HAT and Puromycin selection pressures were applied 
on Day 3, Day 10 and Day 25. Cells were anaysed using FACS machine as well as manually counted using 
Coulter Counter and trypan blue staining in order to identify live and dead cell populations.  Cells were sampled 
sequentially over a period of 100 days. 
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It was noted that HAT leads to quick decline of sensitive cells, but puromycin appears to take 
longer to act – an observation seen previously.  Jurkat cells were all dead following HAT 
selection (plot not shown) at this time point. The trend which becomes clear is that cells 
initially expand well following hybridoma formation; however, they appear to slow down 
between days 50-75. In 5µg cd52-antibody wells there is an expansion at Day 75 but this is 
felt to be a spurious result as at day 100 the number of cells has fallen back to similar levels at 
day 50.  Therefore, due to lack of expansion and stable cell numbers we proposed that these 
cells were senescent. 
We considered if media supplementation with cytokines may start the proliferation process 
again.  We therefore selected a number of cytokines to test based on their properties 
intracellularly.  Initially we tested these cytokines on PBMCs obtained from healthy donors in 
order to look at their effect in vitro before attempting to use them on hybridomas (this was 
done because the hybridoma cell numbers were small and therefore we did not wish to lose 
any cells by testing out the different supplements (fig. 5.21).   
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Fig. 5.21:  Day 21 Assessment of different growth medias on growth/viability of PBMC’s.  (A) Fresh PBMC 
were obtained from healthy donors and were grown in RPMI/10% FCS with different cytokines added to enhance 
cell growth as indicated.  FACS was used to assess viability and visualise cell populations. Any combination with 
>40% live cells is shown in the FACS plots below.  The top two rows depict controls – either single cytokines  or 
all cytokines in combination.  The bottom two rows depict the best performers in terms of viability/live cells. (B) 
Any combination with >40% live cells is shown in the chart overleaf, with coloured squares representing cells 
which are more than 40% viable at different time points. Cells with >40% viable on Day 3 are shaded yellow.  By 
day 7 red, day 15 blue and day 21 green. (C) Shows individual effect on cell populations as assessed using flow 
cytometry. (NB. TiLS Exp Media is the standard T-cell media used for a expansion of TiLs as used in the 
phosphopeptide section of this thesis. We chose to test this media as well for potential to expand these often 
difficult to expand cells.  This media comprises: AIM-V, Human serum, IL2, Anti-CD3). (D) Breakdown of 
individual cell numbers by FACS analysis. Plots representative of 3 experimental repetitions. NB due to small 
cell numbers graph (C) was the result of a single sample from each well.  The student accepts this is difficult to 
draw conclusions from, however the results obtained on subequent repetitions of this experimental protocol were 
replicated.  This graph is a fair representation of the results obtained from this part of the experiemntal analysis. 
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Fig. 5.21A demonstrates the effect of the different cytokine combinations on cell viability/live 
cells on day 21.  Following the observation that IL-21 in particular was beneficial to cells 
grown long term (with >40% cells alive in all wells treated with IL-21 either on its own or in 
combination - fig. 5.21B) we decided to explore this cytokine further.  All test cytokine 
combinations were continued in culture for up to 4 weeks in order to identify which 
combinations supported growth and viability (fig. 5.21C) at set weekly timepoints.  As can be 
seen in fig. 5.21C - IL-21 only plays a role after 2 weeks of culturing, and prior to that other 
cytokines e.g. IL-2 were better at supporting cell viability. This suggested that both IL-2 and 
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CD27 24.1 46.2 16.5 31.3 53.9 2.55 26.5 60.1 1.63 25.4 53.7 1.54 28.2 54.1 1.45
IL21	+	GITR 22.7 47.4 18.6 31.7 54.2 3.26 29.1 48.6 2.08 33.2 46.2 1.98 34.6 47.9 1.87
IL21	+	CD30 23.8 50.1 16.4 29.6 52.6 3.45 27.8 49.8 2.49 29.3 53.1 3.01 31.2 54.3 3.11
IL2	+	IL21	+	GITR 23.8 43.4 19.5 20.7 20.2 2.23 27.5 44.7 4.58 28.2 45.3 4.11 29.7 44.9 2.88
IL2	+	IL21	+	CD30 21.2 46.6 17.9 20.7 46.2 2.96 15.3 49.5 4.15 20.3 45.99 2.22 22.8 47.3 2.01
IL2	+	IL21	+	GITR	+	
CD30 20.1 41.8 23.5 24.1 55.8 2.34 14 39.3 1.87 18.2 39.2 2.01 19.6 40.01 2.01
TiLs	Exp	Media 4.82 6.42 18.6 33.3 43.6 2.68 29 59.5 0.09 27.2 45.7 0 22.3 44.7 0
TiLs Media	+	IL21 4.66 5.92 20.6 30.6 39.9 3.22 28.7 57.33 2.22 28.1 44.9 1.22 33.6 53.6 1.05
C
D
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IL-21 may play a synergistic role in aiding cell growth. Interestingly, combinations of 
cytokines with IL-21 appear to support T-cell growth  long term at the expense of B-cell 
growth, however it is CD4+ cells which appear to predominate over CD8+ cells (fig. 5.21D). 
We predicted that addition of IL-21 to standard growth media (RPMI/10% FCS) would support 
growth and potentially lead to better cell expansion long term, but may need further 
modification to achieve high CD8 T-cell numbers. We also proposed addition of extra IL-2 
and changing the amount of FCS as viable options for restarting cell expansion from the 
senescent state they appear to be in. We screened a number of combinations, including some 
of the mitogens previously seen to be beneficial in Jurkat growth support (ZVAD) looking at 
effect on PBMC, Jurkat and hybridoma cells (fig. 5.22).   
Initially we proposed doubling the amount of FCS would improve cell growth (fig. 5.22A).  
PBMC’s were set up in triplicate and wells compared at different time points up to 28 days.  It 
was demonstrated that addition of IL-2 is certainly beneficial to growth of PBMC’s at a 
concentration of 100units/ml.  There is a significant increase in cell expansion/number when 
cells are exposed to IL-2 regardless of FCS concentration (p<0.02). We compared 10% versus 
20% FCS and were unable to demonstrate any significant benefit to increasing the amount of 
FCS supplementation to 20%.  
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Fig 5.22:  Effect of media supplementation on growth potential of cells.  (A) Initially we compared simply 
doubling the available FCS from 10% to 20% on standard PBMC’s.  Paired t-test demonstrated no significant 
difference between addition of 20% FCS compared to standard 10% FCS.  (B) Then we compared the addition 
of cytokines IL7 and IL21 to standard media as well as the mitogen ZVAD previously demonstrated to confer 
some benefit to cells in culture directly comparing PBMC to Jurkats and the cultured (senescent) hybridomas at 
7days. (C) Finally we looked at a comparison of cells and medias at 28 days to see if there is any longer term 
benefit to any particular media combination.   
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We sought to assess the impact of addition of IL-21, IL-7 and ZVAD to the standard media to 
see if this may be of benefit.  We predicted that IL-21 in addition to IL-2 would be beneficial 
as both cytokines have been shown to support cell growth and expansion. We also chose to 
investigate ZVAD further as we had previously shown it was of benefit for hybridoma growth 
(fig.5.14) and therefore proposed that ZVAD in combination with cytokines would support 
hybridoma growth and expansion.  We directly compared PBMC’s with Jurkats and 
hybridomas, and assessed their growth at 7 days and 28 days (fig 5.22 B, C).  At day 7 it was 
noted that RPMI/10% FCS unsurprisingly did not support expansion of cells with 50% less 
hybridoma cells being alive compared to standard RPMI/10% FCS + IL-2. We noted ZVAD 
was of limited benefit (38% live cells versus 20% in unsupplemented media) and ZVAD in 
addition to RPMI/10% FCS + IL-2 versus RPMI/10% FCS + IL-2 alone conferred no benefit.  
RPMI/10% FCS supplemented with IL-2 and IL-21 was not significantly better than 
supplementation with IL-2 alone. Jurkats and PBMC’s were included as control cells. By day 
28, the only media which appeared to be beneficial to hybridomas was RPMI/10% FCS + IL-
2 + IL-21 demonstrating a significant increase in live cells compared to any of the other medias 
tested (paired T-test comparing RPMI/10%FCS + IL-2 + IL-21 versus RPMI/10% FCS + IL-
2 + IL-7 which was the next best media performer showed significant improvement in cell 
viability p=0.0023). We concluded from these experiments that IL-21 supplementation does 
appear to be beneficial to hybridoma growth and may lead to improved cell survival. 
Following these observations we wanted to know if the cells were senescent.  Cells had been 
grown in culture for 4 months, with little evidence of cell expansion with regard to cell number.  
Cells were however alive – therefore we wondered if they were in a resting state or if rate of 
death was equal to the rate of division.  We sought to answer this question with a simple assay 
– staining the cells with with CellTrace violet – then sampling them weekly. We predicted that 
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if cells were proliferating we would see a loss of staining (fig. 5.23). Hybridoma cells were 
supplemented with IL-2 and IL-21 as demonstrated to be optimal for cell growth (fig 5.22).   
 
Fig. 5.23:  Are hybridoma’s actively proliferating?  Cells were loaded on day 0 with CellTrace CFSE violet 
and assessed using Flow Cytometry on Day 1 (blue line) and Day 7 (red line).  Cells were grown in standard cell 
culture media supplemented with IL2 (also with IL21 in the case of hybridomas).  Proliferation should lead to 
loss of CellTrace violet staining and a shift of the curve to the left, as demonstrated in the jurkat plot.   
 
Here we have demonstrated that hybridoma cells are not in an actively dividing state, as there 
is no reduction in CellTrace violet staining and therefore no cell division this is in contrast to 
the jurkat cells (control for actively dividing cells) which during the same time period have 
lost the CellTrace Violet staining which is considered to represent proliferation of cells.  PBMC 
were used as control of non-dividing cells.  We therefore concluded that the hybridoma cells 
appeared to be senescent. We have demonstrated that hybridoma cells are unstable and we 
therefore propose that senescence has resulted from loss of DNA during the formation of 
hybridomas and their subsequent instability. 
We questioned if these cells were able to mount a functional response towards standard T-cell 
stimuli (anti-CD3, PHA, PMA/Ionomycin).  We proposed if cells were senescent they may 
release cytokines in response to stimulation.  Cells were therefore set up in triplicate alongside 
a well-established T-cell line.  Cells were stimulated with anti-CD3, PHA or PMA+Ionomycin 
Day	1
Day	7
Jurkat-GFP PBMC Hybridoma
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on day 0 and day 6.  ELISPot was then performed on day 7 to assess release of IFNγ in response 
to stimuli.  DMSO was used as negative control (fig. 5.24).   
 
Fig. 5.24: Are hybridoma’s able to mount a functional response to T-cell stimuli?  Hybridoma cells were set 
up in triplicate  alongside  a well established viral T-cell line (termed NLV T-cell).  All cells were stimulated with 
anti-CD3, PHA or PMA/ionomycin on day 0 and day 6, and analysed using ELISPOT kits specific for release of 
IFN-gamma. Negative control was cells treated with DMSO. Jurkat controls also used, however at day 7 the wells 
were completely confluent therefore unable to interpret number.  Error bars represent SEM. Graph representative 
of 3 experimental repetitions performed in tripllicate. 
 
This demonstrated that although the response was not the same as that seen in the T-cell line, 
the hybridoma line did become activated by these same stimuli and therefore could be 
considered as being able to mount a functional response.  The evidence we have presented here 
suggests that hybridomas have been generated and they do appear to be functional, but in the 
absence of cell expansion, this clearly has limited potential as a mechanism for generating 
immortal expandable T-cells.   
 
5.2.11 Can ionic forces lead to improved cell fusion? 
Clearly for hybridoma formation to be successful there needs to be a method for allowing cells 
to be in close cell-to-cell contact and also a mechanism of cell membrane breach/fusion.  In 
this chapter, it has been demonstrated that the most efficient method so far for generating a 
hybridoma was by harnessing electrical pulse (nucleofection) to either insert viral DNA (VSV-
G) to aid fusion, or used after pre-treatment with anti-CD52 to the fusion partner allowing for 
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cross-linkage prior to application of electrical current which appeared to lead to cell membrane 
fusion.  
Part of this PhD was spent at Harvard University, Boston, USA.  As such we had access to 
equipment not previously available in UK.  One such instrument was the Harvard ECM 2001 
electroporator (BTXonline, Harvard Apparatus, MA, USA). This uses a AC current to draw 
cells together, followed by a pulse of DC current to breach the cell membranes and lead to 
fusion and proposed hybridoma formation. Because we had seen that nucleofection had been 
more efficient than standard protocols for fusion of fusion partner to target cells, we proposed 
that the ECM 2001 could also be used to fuse cells.  This had not been attempted before and 
therefore required optimisation of suggested protocols.  Cells were washed as described in 
chapter 2 and resuspended in BTXpress Cytofusion media.  Electroporation is based on a 
simple process. Cells are suspended in a conductive solution (BTXpress Cytofusion media), 
and an electrical circuit is closed around the mixture using a modified tissue culture plate with 
electrodes connected to the base unit. An electrical pulse at an optimized voltage and only 
lasting a few microseconds to a millisecond is discharged through the cell suspension which 
disturbs the phospholipid bilayer which comprises the cell membrane.  This leads to the 
formation of temporary pores.  As a result, there is potential for charged molecules e.g. DNA 
to cross the membrane in a fashion similar to electrophoresis - or in this case allows for the 
cells to fuse by merging their cell membranes via the cell pores.  A number of voltage 
combinations were attempted in order to allow enough time for target cells to come into close 
contact with the fusion partner cells, but not at the expense of cell viability.  High voltage 
would lead to higher cell death (fig. 5.25).   
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Fig. 5.25:  Use of electroporation to generate hybridomas.   Cell lines of interest were Jurkat-GFP and Jurkat-
A2.  (A) Cells were resuspended in BTXpress cytofusion media prior to application of an electrical pulse.  AC 
pulse was applied and cells lined up due to their polarity (B) forming chains of cells.  (C) Following application 
of DC pulse, fused cells (red circle/arrow) can be visualised using light microscope.  (D) Panel C was further 
digitally magnified 100x to demonstrate possible fusion of cell membranes.  Cells were allowed to rest at room 
temperature for 10 minutes prior to being transferred to appropriate tissue culture vessel and resuspended in 
RPMI/10% FCS supplemented with IL2 and IL21. (E) flow cytometry on day 3 following electroporation 
demonstrates good efficiency of hybridoma formation under a number of conditions – represented by red 
asterisk.Plots representative of 3 experimental repetitions performed in quadruplicate. 
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These data suggest that high DC pulses are needed to obtain efficient fusion of cells.  In the 
control wells it can be seen that a relatively high proportion of cells are double positive without 
any intervention.  It is assumed these are false positives, representing cell aggregation rather 
than true fusion.  This was taken as the baseline DP for cells and therefore we focussed on 
conditions which led to higher percentages of DP cells.  The most efficient combination of 
conditions, resulting in 74.2% DP cells was the lowest of AC voltages (65v) tested followed 
by the highest DC voltage (2500v).  It is likely that higher AC voltages resulted in increased 
cell death when used in combination with high DC voltage (potentially there is an additive 
effect).  Although 63.6% cells were DP when a combination of high AC (75v) is used with 
high DC (2500v), it can be seen that this is not a ‘clean population of cells but more a smear 
of cells from single positive GFP+ into the DP population (i.e. there is no clear distinction 
between the two as was seen in the mixture of cells in the absence of ECM, whereas the other 
tests which resulted in high DP cells – red asterisk – appeared distinct populations in a single 
quadrant only – not spanning two as a continuum.   It is likely that this smear of cells is 
therefore a mixed population of cells spanning from single positive GFP into DP GFP/A2, and 
is likely a combination of hybridoma cells as well as aggregated cells.  Due to cell line 
availability this experiment focussed on fusing two jurkat lines 'Jurkat-GFP' (obtained from Dr 
Millar, University of Biringham and previously modified to contain a GFP tag) to 'Jurkat-NLV' 
(obtained from Dr Bendle, University of Birmingham, a jurkat line modified to contain CMV 
peptide NLV-TCR)  as these cells were readily available.  This experiment represents a proof 
of principle that electroporation appears to be very efficient at generating hybridomas.  
Unfortunately, due to unforeseen circumstances these cells could not be analysed further as 
during transport from America to UK they were delayed in customs, leading to catastrophic 
cell loss. 
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In conclusion, T-cell hybridomas are not a new technology and the process of generating them 
is largely inefficient.  By modifying the protocol either by nucleofection in the face of a 
fusogen, or application of electrical current in the form of electroporation we have shown that 
hybridoma formation could potentially be made more efficient than standard protocols using 
PEG as originally described.  Unfortunately, although cells could be grown long term in culture 
they were not expandable, although did appear functional.  Despite media modification we 
were unable to expand these cells and therefore it was concluded that hybridoma technology 
is not efficient enough or scaleable therefore is not useful as an experimental model that can  
be used in the investigation of antigen expression of T-cells and was not investigated further.  
 
5.3 Viral transduction of T-cells 
After concluding fusion and hybridoma formation is not efficient we chose to investigate viral 
transduction as a possible means to immortalising T-cells.  This is also not a new technology, 
dating back to early 1990’s, but more recently has again been the subject of yet another Nobel 
prize in 2012 for Shinya Yamanaka for Science and Technology, for his work in Induced 
Pluripotent Stem Cells (Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007, 
Nagata, Toyoda et al. 2009).   
 
5.3.1 Herpesvirus saimiri transduction of human T-cells 
We chose to start with the gammaherpes virus Herpesvirus saimiri (HVS) which naturally 
infects the Squirrel Monkey.  It is non-pathogenic in this natural host (virtually all Squirrel 
Monkeys are carriers) but has the ability to produce T-cell lymphomas in other New World 
Monkeys. It is distantly related to Epstein Barr virus which has also been shown to immortalise 
B-cell lines in a similar fashion.  
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It was Biesinger et al in 1992 that first proposed the potential utility of HVS based on its ability 
to transform human T-cells into immortal culture lines (Biesinger, Mullerfleckenstein et al. 
1992). In New World Monkeys, HVS can induce T-cell lymphomas  as well as in rabbits.  
However Beisinger also demonstrated that it possessed the potential to  immortalise primate 
T-cells in vitro.  Sequences responsible for these effects have been localised to a region of the 
genome that varies significantly among the virus subgroups A, B, and C.  Only HVS (subgroup 
C) has the ability to transduce a variety of human cell lines.  Here the virus is seen to exist as 
a non-integrating circular episome, which has restricted gene expression and has a subsequent 
inability to produce virus particles. Of note, the transformed human cells do not allow viral 
reactivation despite the best efforts of a number of groups who have attempted to demonstrate 
this as being possible. The T-cells which are immortalized in culture are identical in phenotype 
as the mature activated T-cells from which they were derived,  with normal CD4/CD8 
expression. Also of benefit is that these cells will retain the parental cell’s antigen specificity 
therefore leading to a potential use in immunotherapy due to this preservation of specificity 
(Grassmann, Biesinger et al. 1990, Biesinger, Mullerfleckenstein et al. 1992, Meinl, Hohlfeld 
et al. 1995, Meinl, Fickenscher et al. 1997, Hall, Giles et al. 2000).   
Owl Monkey Kidney cells (OMK) were transfected with HVS as per standard protocols and 
the resultant supernatant used as a potent source of virus for infection of PBMC’s (fig. 5.26).   
 
Fig. 5.26: Infection of OMK cells with HVS. Infection with virus results in areas of clearing (arrow) emerging on the once
confluent adherent OMK cells. Virus particles are contained in the resultant supernatant. This supernatant is collected and
titrated in order to identify optimal concentration for infection.
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Following this we sought to investigate if we were able to maintain T-cells in culture and 
whether HVS could promote this.  We hypothesised that based on previous authors’ data, HVS 
should be able to immortalise T-cells.  In order to test this, fresh healthy donor derived PBMC’s 
were magnetically sorted and the CD8+ fraction were set up in 24 well plates in triplicate 
(1x106/well) - fig 5.27.  CD8+ cells were selected as we proposed these cells as being the 
phenotype that would be most useful to this project as we have sought to identify technologies 
for immortalising tumour-specific T-cells which we predict would be CTL’s.   
Virus was diluted in RPMI/10% FCS and added to the sorted PBMC’s.  Cells were then 
incubated at 37c/5% CO2 overnight. On day 1, the media was supplemented with 100 units 
IL-2. On day 5 cells were washed and resuspended in fresh media containing 100units IL-2. 
On day 7, cells were stained for CD3 and CD8 and analysed using flow cytometry (fig. 5.27a).  
This initial data appears to suggest HVS is capable of supporting CD8+ T-cell growth, with an 
optimum concentration of virus being 1:100 (see appendix for calculations).  41.3% of live 
cells were CD8+CD3+ T-cells, versus 30.3% in the non-infected cells. Using Student’s paired 
t-test, this is a significant increase (p<0.02) when compared to non-infected cells.  However, 
the number of live lymphocytes was drastically reduced as the amount of HVS increased by 
50% (fig. 5.27b) suggesting that toxicity of HVS outweighs any benefit conferred by this to 
propagating CD8+ cells, and the reality is these cells were all lost by day 21 in all wells, which 
we proposed was as a result of HVS toxicity. 
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Fig. 5.27:  Fresh healthy door-derived PBMC’s were magnetically sorted and the CD8+ fraction were 
infected with HVS on Day 0.  Cells were incubated at 37c/5% CO2 and (A) flow cytometry was used to assess 
CD8-positivity after 1 week incubation. (B) The number of live cells halved when comparing no virus control 
(46% lymphocyte) to 1:100 HVS (23.1% lymphocyte). Plots representative of 3 experimental repetitions. 
 
  
No	virus	(control) 1:10,000	HVS 1:1000	HVS
1:100	HVS 1:10	HVS
A
No	virus	(control) 1:10,000	HVS 1:1000	HVS
1:100	HVS 1:10	HVS
B
		 235	
5.3.2 Does cell number or media supplementation affect transduction efficiency?  
We sought to identify a process that could support cells in this early period after viral infection 
and attempt to overcome the cell death which is due to viral toxicity. We hypothesised that 
lower cell numbers may lead to better outcome, as this was based on the observation that cells 
appeared overcrowded shortly after viral infection, and we wondered if this may affect 
outcome. Also, based on the previous observation that PBMC’s and indeed T-cells grow better 
in the presence of IL-2 and IL-21, we proposed testing whether media supplementation may 
be able to maintain cells in culture following viral infection. Finally we questioned whether 
cells needed to be stimulated and therefore activated to be successfully infected.  Activating 
the T-cells allows them to enter the cell cycle and we hypothesised that this may allow infection 
of the T-cells by HVS.  In non-dividing cells, viral transduction doesn't work in all cases, so 
with retroviral transduction the cells need to be dividing to get the DNA into the genome.  
However, lentiviral transduction can be done in non-dividing cells so it is not the same for 
every virus.  Biesinger described activating PBMC’s with PHA yielding CD8+ T-cells. These 
are the phenotype of choice to this arm of the project and therefore we proposed that this would 
be beneficial, as  HVS transformation in the absence of PHA-stimulation appears to yield CD4 
T-cell lines (Biesinger, Mullerfleckenstein et al. 1992).   
 
5.3.3 Media supplementation with cytokines does not improve cell line longevity in 
culture. 
Standard media for growth of PBMC’s following HVS infection is RPMI/10% FCS 
supplemented on day 3 with 100 units IL-2.  Having noted previously that higher 
concentrations of IL-2 and addition of IL-21 benefitted T-cell growth (figs. 5.21, 5.22), we 
proposed that this may benefit HVS-transformed cells also.  Cells were set up in triplicate and 
supplemented with different concentrations of IL-2, IL-21 and a combination of both.  PBMC’s 
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were transformed with HVS at concentrations as previously determined (1:10,000, 1:1000, 
1:100 and no virus) – fig 5.28. Following viral transformation they were resuspended in 
standard media (RPMI/10% FCS) and supplemented on day 3 as described previously.   
 
Fig. 5.28: Effect of cytokine supplementation to T-
cell growth. It was proposed that as previously
cytokine supplementation can help maintain cells in
culture. This experiment assessed addition of IL2 and
IL21, separately and in combination to check for a
synergistic effect. Healthy donor derived PBMCs
were counted at weekly intervals using coulter
counter and microscope with trypan blue staining to
assess dead:live ratio. (A) are control PBMC cells.
(B) are cells infected with 1:10,000 HVS. (C) are
PBMC cells infected with 1:1000 HVS. (D) are
PBMC cells infected with 1:100 HVS.
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Firstly when comparing control to the virally transformed wells there is little difference in 
overall longevity of cells in culture – with only 1:1000 still having live cells at day 50 (wells 
supplemented with IL-21 or IL-2+IL-21) – fig. 5.28c. When considering the cytokines 
separately it is clear that IL-2 supports cells in the short term – but there is no significant 
difference longer term, with all showing death of cells by day 21, suggesting IL-2 is stimulating 
growth of cells in PBMC’s such as NK cells.  It can be seen that the 1:100 transformed well 
did have a good response to IL-2 100units at day 7 with 28% cells live compared to 22% treated 
with 1000 units IL-2, but not sustained. These results indicated that 100 units of IL-2 was 
optimal as when 1000 units was added, more cell death was observed which could be the results 
of ‘over-stimulation’.  In contrast IL-21 1000 units was demonstrably better than 100 units at 
supporting cell growth in all wells except 1:100 HVS, this effect appeared to start around D15 
peaking at day 30 before gradually tailing off again. We considered the synergistic effect of 
IL-2 with IL-21, and hypothesised IL-2 would support early growth and then the IL-21 would 
support latter growth of cells.  This was observed up until around day 35, after which IL-21 
1000units became the best at supporting cell growth (seen best in the 1:1000 wells – fig 5.28c).  
From these observations we can see that IL-2 and IL-21 do support growth and their effects do 
appear to be additive with regards to supporting growth/viability, however this is not 
sustainable long term. We concluded media supplementation with cytokines did not improve 
overall cell survival in the long term, although short term benefit can be seen.  The caveat to 
this is that it is difficult to ascertain if addition of cytokines that promote cell viability of 
transformed cells, also promote this in non-transformed cells. 
 
5.3.4 Cell density does not affect HVS viral transformation efficiency overall, however it 
does improve initial transformation 
Previous observations of cells transformed by HVS appear to show that the cell number reaches 
a peak which is quickly followed by a rapid decline.  In order to test whether this observation 
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was due to cell density within the culture plate becoming sub-optimal cells were set up in 
triplicate and starting cell number compared.  Standard cell transformation prior to this was 
performed on 1x106 cells/ml seeded.  On this occasion we compared 5x105 cells/ml, 1x106 
cells/ml 2x106 cells/ml and 5x106 cells/ml.  Cells were transformed with virus as previously 
described at concentrations of 1:10,000, 1:1000 or 1:100 versus no virus.  Cells were grown in 
RPMI/10% FCS and supplemented with IL-2 100units on day 3 (fig. 5.29 A-C).   
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Fig. 5.29: Effect of number of cells transformed
by HVS on overall longevity of line. Higher
numbers of cells may result in higher transformation
rate so initially we started with 5x105/ml (data not
shown as no cells viable at first timepoint), (A)1x106
cells/ml (B) 2x106 cells/ml or (C) 5x106 cells/ml. In
these initial experiments cells were grown in 24w
plates in RPMI/10% FCS supplemented with 100unit
IL2 and split as necessary based on cell number
(>10x106 cell/ml).
Higher cell numbers appeared to result in better
survival therefore further experimental wells were set
up starting with a cell number of 5x106 cells/ml and
compared either (D) not splitting the wells and
allowing the cells to continue in 1x 24w or (E)
splitting the cells at a set time point regardless of
number on day 10 and resuspending in a 6w plate. NB
cells received a media change on alternate days.
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This demonstrates that starting with a higher number of cells leads to better transformation 
potential with cells seeded at a density of 5x106 cell/ml and transformed with HVS at a 
concentration of 1:1000 appear to grow well, lasting longer than cells seeded at a lower density 
(cells start to decline between days 28 and 35 when seeded at density of 5x106 cell/ml, 
compared with days 21-28 in cells seeded at lower concentrations.  NB cells seeded at lower 
concentration (5x105/ml) were found to be non-viable following viral transformation (data not 
shown), suggesting that cells require at least a density of 1x106/ml at the start of viral 
transformation in order to have enough cells remaining following toxic viral insult. 
Based on the observation that cells initially grow well then appear to plateau we considered if 
this was as a result of over-confluence.  In our initial experiments cells were split when they 
reached 1x106 cell/ml.  In order to investigate this further, cells were set up in triplicate and 
direct comparison was made between cells that were left to grow in the same 24 well plate they 
were seeded in (and therefore by definition became overconfluent) compared to cells which 
were split on day 10 regardless of cell number (fig 5.29 D,E). This demonstrated that cells left 
to grow and become confluent grow much better than those split early.  Cells did appear to 
plateau again which suggested that the media components were being consumed, and following 
this cells rapidly declined in number between days 30 and 40 in those cells transformed with 
1:1000 HVS (fig 5.29D).  This led to the conclusion that there is an optimal concentration of 
cells above which cells are unable to be supported further.  From the data collected over this 
experiment and observed previously this number would appear to be 10x106 cells/ml, however 
as we have demonstrated previously, when cells are split when they reach this threshold that 
does not prevent them declining over time and therefore there remains the question as to how 
cells can be triggered to stay in culture over time. 
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5.3.5 Activation by media supplementation with PHA leads to increased numbers of 
CD8+ T-cells, but does not affect long term survival 
We hypothesised that supplementation with PHA would lead to better cell survival and 
longevity which would potentiate better virus infection and propagation. PHA 
(Phytohaemagluttinin) is a polyclonal T-cell activator, used as a mitogen to trigger T-cell 
activation and drive proliferation. It binds to the sugars on glycosylated cell surface proteins, 
including the TCR, and crosslinks them causing non-specific activation of the T-cells.  
We hypothesised that stimulation before infection with HVS could lead to more efficient 
infection with HVS as the T-cells would be dividing and may be more receptive to HVS 
infection. We also considered whether stimulation after infection would lead to better cell 
longevity.  It has been shown previously that stimulation with PHA could lead to preferential 
activation of CD8+ T-cells (Reeve, Hewlett et al. 1974, Mercer and Schlegel 1979) which is 
the phenotype of choice for this project and therefore we predicted pre-stimulation prior to 
HVS transformation was the optimum condition for propagation of T-cells long term. 
Fig 5.30 demonstrated that following stimulation T-cells are the predominant cell type in the 
previously heterogeneous soup of cells.  In unstimulated cells there is a peak in T-cell number 
on day 14, which likely corresponds to IL-2 supplementation to the media on day 3 as 
previously described, however there is a rapid drop off in T-cells in the following week with 
numbers reduced to zero by day 21-28 (A).  On assessing these cells further it was 
demonstrated that these cells are initially CD4 in phenotype (as demonstrated by CD4:CD8 
ratio – fig 5.30E), but this ratio changes by day 14 coinciding with T-cell peak with at this 
stage predominantly CD8 T cells, which gradually tail off to zero by day 28 when most cells 
are also dead. Cells stimulated 1 day prior to HVS infection (fig 5.30B) demonstrate 
persistently high T-cell numbers in cells which have been infected with higher concentrations 
of HVS (1:100 and 1:1000), which would suggest that pre-stimulation of cells does appear to 
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confer some protection of cells, potentially as a result of them being activated and in the cell 
cycle leading to better transformation potential.   
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Fig. 5.30: Effect of stimulation of PBMC’s on T-
cell counts over time, as demonstrated by CD3+ by
flow cytometry. Based on previous studies
suggesting PHA stimulates preferentially CD8+ T-
cells, it was proposed this could be beneficial in the
long term to propagation and support of T-cells.
PBMC’s were either (A) non-stimulated, (B)
stimulated 1 day prior to HVS transformation, (C) on
day 3 after HVS transformation, or (D) on day 7 aft er
HVS transformation. We first assessed total % T-
cells as % of live cells which were CD3+ by FACS
analysis.
Further, a CD4:CD8 ratio for each experimental
condition – (E) unstimulated, (F) stimulated 1 day
prior to HVS transformation, (G) 3 days after HVS
transformation or (H) 7 days after transformation –
overleaf.
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Uninfected and low concentration virus demonstrated rapid reduction of viable T-cells between 
Day 21 and 35 – the uninfected cell number falling off quicker than those with low 
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concentration HVS infection – suggesting there is a viral driven component to the T-cell 
survival.  Perhaps more interesting is the CD4:CD8 ratio demonstrated by these pre-stimulated 
cells (fig 5.30F). Here it is demonstrated that initially there are higher numbers of CD8 cells : 
CD4 cells (as predicted by the observation that PHA predominantly stimulates CD8 cells).  
This rapidly changes by Day 7 post-viral transformation where the predominant phenotype are 
CD4 cells, followed by another switch in T-cell phenotype back to CD8 cells by Day14, which 
persists in all but the uninfected cells until all cells are dead.   We proposed that CD4 cells 
proliferate following the initial expansion of CD8 T-cells (following stimulation with PHA) 
due to the subsequent increase in IFNγ levels, these are then exhausted leading to CD8 cells 
expanding as CD4 numbers drop. 
We considered if stimulation of cells after infection may be beneficial with the hypothesis that 
stimulating cells will lead to increased cell division, which may also encompass those cells 
transformed by virus and therefore lead to propagation of virally transformed cells.  Two time 
points were selected (day 3 and day 7 post viral transformation) – fig 5.30C and D.  Here we 
show that prior to stimulation, cells are predominantly CD4, which after infection changes to 
CD8+ within 1 week (for instance when considering the wells infected with HVS at a 
concentration of 1:1000, CD4:CD8 ratio 10.34 prior to viral infection, 5.12 by day 10, and 1.98 
by day 14) - fig 5.30E-H.  NB the starting number of CD4 cells was higher than expected 
(usually in region of 3:2) and it is presumed this donor may be recovering from a recent illness. 
This trend of being predominantly CD8 cells continues in all virally transformed cells until the 
point that all cells are dead.  Cells stimulated on day 7 with PHA showed a steady increase in 
CD8:CD4 suggesting CD8+ cells are potentially increasing in number in response to viral 
infection.  When the immune system first encounters a viral infection it is the CD8 T-cells that 
are first immobilised, this is then followed by a CD4 response, which is presumably the process 
occurring here in response to HVS.  Cell numbers in these wells are similar to those seen under 
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the other conditions tested so it is not the case that these cells were at lower baseline numbers, 
therefore the only conclusion possible is that viral recognition leads to a predominantly CD8 
phenotype due to antigen presentation with only CD8 peptides presented.  
We concluded from this set of experiments that pre-stimulation with PHA did indeed lead to 
predominantly CD8+ cells, which when infected with HVS, and we considered if this had any 
long term effect on cell number.   
Fig. 5.31 demonstrates what effect PHA stimulation has on the length that cells can be 
maintained in culture. Stimulation 1 day prior to viral transformation appears to confer the 
greatest benefit (fig. 5.31B) with cells infected with virus at a concentration of 1:1000 peaking 
in number on day 21, however this is not sustainable with rapid decline in cell number and 
eventual loss by day 49.  This is an improvement compared to cells not stimulated (fig. 5.31A) 
which shows loss of cells by between day 21-28.  However, long term sustainability was not 
maintained.  Stimulation of cells after viral transformation did not confer any benefit when 
stimulated on day 3 and appeared to be deleterious suggesting the initial viral insult lead to 
intolerance of the PBMC’s to further stimulation leading to apoptosis (fig. 5.31C).  Stimulation 
on day 7 conferred limited benefit (fig. 5.31D), and cells were sustained at high numbers for a 
shorter time compared to cells pre-stimulated 1 day prior to viral infection.  Therefore, we 
concluded that pre-stimulation with PHA was beneficial to viral transformation, presumably 
as cells had entered the cell cycle and therefore were easier to transform as actively dividing, 
however this benefit was shortlived and we were unable to maintain cells longer than 49 days 
in culture. 
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From these experiments we concluded that cell transformation with HVS was unlikely to have 
use as an in vitro model for T-cell antigen recognition in the longer term and therefore no 
further time was dedicated to this process.  
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Fig. 5.31: Effect of stimulation of fresh healthy
donor derived PBMC’s by PHA.
Cells were set up in triplicate as previously described
and grown in RPMI/10% FCS supplemented with IL2
100 units on day 3. (A) unstimulated cells were
included as a control. (B) are cells stimulated on day
1with PHA prior to HVS transformation as described
previously.
Stimulation after infection with HVS has a deleterious
effect if stimulated on day 3 (C) with rapid decline in
cell number already demonstrat ed by day 7
Stimulation at day 7 demonstrated a brief recovery in
cell number (D).
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5.4  Human Induced Pluripotent Stem Cells (HIPSc) – are reprogrammed adult somatic 
cells a useful addition to the field of immunotherapy? 
In the first few days after conception, an embryo consists of pluripotent cells which can develop 
into all cell types in the body. In 2006, Shinya Yamanaka found a new way to ‘reprogramme’ 
defined adult, specialized cells to turn them back into stem cells. He was able to do this 
following the observation of a number of different transcription factors which have been found 
in embryonic stem cells which were felt to contribute to this cell’s pluripotency (Nichols, 
Zevnik et al. 1998, Niwa, Miyazaki et al. 2000, Chambers, Colby et al. 2003, Cartwright, 
McLean et al. 2005).  
Following on from this initial discovery, there were questions raised as to clinical utility of 
hIPSCs, with doubts cast on our overall understanding of reprogramming and pluripotent 
potential (Okita, Ichisaka et al. 2007, Wu and Hothedlinger 2011).  Since then much work has 
gone into investigating the potential clinical reach of IPSc and also the means by which the 
Yamanaka factors are transduced.  Although initially retroviruses and lentiviruses were used 
to make IPSc, there has been a recent transition to use of sendai virus instead.  The reasons for 
this are many but the main benefit is that this is a non-integrating parainfluenza-like virus and 
is easily cleared from the system, and does not lead to gene mutagenesis (fig. 5.1).  For any 
system being considered for clinical utility, there needs to be no genomic footprint left behind 
and therefore this is a safe approach to consider (Cao, Loh et al. 2012, Rao and Malik 2012, 
Malik and Rao 2013). 
In 2013, two groups described the use of IPSc in regenerating or rejuvenating exhausted T-
cells, with clear clinical implications (Nishimura, Kaneko et al. 2013, Vizcardo, Masuda et al. 
2013). Both groups described exhaustion of T-cells and the subsequent technology used to 
generate iPScs from reprogrammed mature cytotoxic T-cells. These were subsequently 
redifferentiated into “rejuvenated” expandable T-cells which clearly has very broad 
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applications for adoptive immunotherapy in both cancer and infections such as HIV.  These 
two works have led to the belief that a focus on reprogramming of the immune system may 
provide a translational element to iPSc technology. Such an approach affords a potentially 
limitless supply of antigen-specific T-cells to target a range of diseases that could be delivered 
in a scalable manner to reach all patients in need and bypasses the issue of antigen-specific T 
cell exhaustion.  These ‘‘rejuvenated’’ cells were shown to demonstrate killing potential on an 
antigen-specific basis with similar TCR rearrangements as seen in the parent cells from which 
they were derived.  
hIPSc can be patient specific and therefore could negate the need for immunosuppression for 
instance in the right setting.  Alternatively using donors who had a haploidentical genotype is 
a potential option; however it may be advantageous to consider some of the newer technologies 
currently under intense investigation internationally to potentially knock out multiple HLA 
alleles such as CRISPR technology. 
Also in 2014 a number of controversial papers emerged revealing new techniques for making 
iPS cells, including a study where cells were exposed to extreme conditions (in this case acidity 
for a short period of minutes) and the emerging colonies 2 days later can be demonstrated to 
be iPS cells with the ability to be transformed into functional cells (Obokata, Wakayama et al. 
2014, Obokata, Wakayama et al. 2014, Obokata, Wakayama et al. 2014). Although these 
papers were subsequently retracted, it does demonstrate the global enthusiasm for development 
of a novel technology which can revolutionise this field.  
 
5.4.1 hIPSc can be derived from human T-cells 
Most immunotherapies rely on activated CTL’s, with the resulting cells exhibiting only partial 
killing efficiency, and as a result this is not usually sufficient to result in cure. This is partly 
due to the short lifespan of activated CD8+ T-cells, and this is hampered by antigen-induced 
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cell death (Willimsky and Blankenstein 2005, Mescher, Agarwal et al. 2007, Mescher, Popescu 
et al. 2007, Buschow, Charo et al. 2010).  The idea of using hIPSc to expand antigen-specific 
T-cells is appealing as it could overcome this inactivation.  Following the work by Nishimura 
et al and Vizcardo et al, where T-cells were rejuvenated by this method, we proposed that 
sendai viral transduction of the Yamanaka factors could be used to transduce antigen-specific 
T-cells with resultant cells demonstrated to have pluripotent potential and represent IPSc 
(Nishimura, Kaneko et al. 2013, Vizcardo, Masuda et al. 2013).  
In order to test this hypothesis, a viral NLV-specific T-cell clone was chosen and cells were 
transduced with the Yamanaka factors using a commercially available Sendai virus kit 
(Invitrogen, Paisley, UK), by methods described in chapter 2. Using protocols as developed by 
Professor Ludovic Vallier at Cambridge University (Vallier 2015), cells were grown in media 
which allowed optimal transduction for 9 days, after which they were infected with virus as 
per the MOI recommended based on batch number and then transferred to appropriate culture 
vessels (pre-coated with 1% gelatin, and a monolayer of CF6 Mouse Embryonic Feeder cells 
(MEF’s – Cambridge Biosciences, Cambridge UK) used to support emerging IPSc growth (fig. 
5.32).   
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Following emergence of IPSc colonies, it was necessary to characterise them to confirm 
complete differentiation and thus confirm pluripotency.  Pluripotent stem cells possess alkaline 
phosphatase on their cell surface when in the undifferentiated form.  Therefore staining cells 
for this enzyme is used as a surrogate marker for pluripotent potential (fig. 5.33).  
Immunodetection is used to stain for stem cell markers, including c-myc, Oct-4, Sox-2 (fig. 
5.34).  IPSc colonies were selected based on morphology and stained for genes indicative of 
being a stem cell, and included the Yamanaka factors which were transduced into the cells 
using SeV.  We proposed that if a cell had been adequately differentiated, then it would express 
alkaline phosphatase (a marker of pluripotent potential) as well as stem cell marker genes such 
as Oct-4, Sox-2, c-Myc.  Visualisation was performed with 4’, 6-diamidino-2-phenylindole 
(DAPI) a fluorescent stain that binds to DNA, providing a ‘photofootprint’.   
MEF	feeder	
cell	
monolayer
Day	8 Day	9 Day	10 Day	10
Day	13 Day	13 Day	13 Day	15
Emerging	
confluence	 of	
cells	
represents	
first	stage	of		
iPSc
development
Typical	iPSc
morphology
Fig. 5.32:  Typical appearance demonstrating the progression in change of morphology of emerging iPSc.  T-cells 
were transduced with sendai virus to incorporate the Yamanaka factors on day 0 and grown on a mouse embryonic feeder 
cell (MEF) monolayer. Typical first signs of an emerging iPSc colony are clumping of cells as seen in A and B.  These 
become more confluent as colonies emerge forming the typical iPSc shape by day 13.
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Finally qPCR was used to validate clones against the standard Human Embryonic Stem Cell 
(hESc) line H1 (fig. 5.35). hIPSc lines were selected based on their pluripotent potential and 
stem cell gene expression when compared to hESc H1, with the optimal lines being those with 
as close as possible expression to H1.  
Fig. 5.33:  Demonstration of pluripotent potential.  iPSc colonies 
were stained for alkaline phosphatase a marker of pluripotency – a 
key feature of iPSc.
DAPI C-myc merge
Fig. 5.34: Immunostaining for stem cell markers using confocal microscopy. iPSc colonies were selected
out based on morphology and expanded from the pool of emerging cells. These colonies were grown on
microscopic cover slips and stained as per standard protocols and fixed to microscope slide prior to analysis using
confocal microscope. Imaging performed with the assistance of Dr Maelle Lorvellec.
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Finally cells were differentiated into the 3 germ cell layers to confirm pluripotent ability (fig. 
5.36) by supplementing the growth media with various cytokines and growth factors (see also 
appendix 1 for scematic representation of germ layer differentiation) (fig. S1A-C): 
1) Mesoderm: Activin (cell proliferation), FGF2 (fibroblast growth factor family). The 
FGF family of proteins have the ability to induce mitosis and angiogenesis.  This is in 
part due to their binding of heparin.  As a result of thiese activities, FGF has an obvious 
role in a number of key cancer pathways including tumour growth as well as being 
implicated in other key biological processes such as neurological development. BMP4 
(a signalling molecule required for early embryonic differentiation and the 
establishment of a dorsal-ventral axis. BMP4 stimulates differentiation of overlying 
ectodermal tissue), Ly294002 (strong inhibitor of phosphoinositide 3-kinases (PI3Ks)), 
aminopyrimidine. Using CHIR99021, GSK-3β  activity is blocked resulting in 
embryonic stem cell renewal).  Differentiation was measured using relative protein 
expression for Brachyury (which is known to regulate mesoderm differentiation; and 
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Fig. 5.35: Expression of Stem Cell marker genes by 4 hIPSc lines derived from an NLV-viral T cell
clone (T26, T27, T31 and T32) compared to the hESc lineH1. Ideally hIPSc colonies should have a similar
expression of these stem cell marker genes (hOCT-4, Klf4, sox-2, c-Myc and Nanog) as the hESc. Too high
expression suggests overexpression of markers as seen in T27, therefore this would be discarded as expression
here is up to 10x that the standard set by hESc. Too low expression suggests incomplete transduction as seen
in T32. Two lines were taken forward to further expand – T26 and T31 as expression is very close to that seen
in hESc H1.
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Eomes (The Eomesodermin/Tbr2 gene), which is know to regulate a  number of 
developmental processes) - fig S1A. 
2) Endoderm: Activin, FGF2, BMP4, Ly294002, CHIR added at different time points in 
order to differentiate cells into endodermal germ layer. Bone morphogenetic protein-4 
(BMP-4) has the ability to vary it effects based on the duration of exposure.  For 
instance, short term it has been shown to induce mesoderm, whereas longer term it has 
been shown to differentiate endoderm. In order to measure its effects, the relative 
expression of FoxA2 was measured (due to its role indevelopment of endoderm 
systems). In addition to this we measured relative expression of hSox17 (This gene 
encodes a member of the SOX (SRY-related HMG-box) family of transcription factors, 
which plays a pivotal role in embryonic development and cell fate. It may act as a 
transcriptional regulator after forming a protein complex. It modulates transcriptional 
regulation via WNT3A and inhibits Wnt signalling. It is a probable transcriptional 
activator in premeiotic germ cells) - fig S1B. 
3) Ectoderm: SB431542 (is an inhibitor of transforming growth factor-beta), FGF2, 
Noggin (Noggin is a signalling molecule that promotes somite patterning in embryonic 
development. It is released from the notochord and regulates bone morphogenic protein 
during development. The absence of BMP4 lead to the patterning of the neural tube 
and somites from the neural plate in the developing embryo). This was measured by 
comparing relative expression of Nestin (necessary for cell survival and regeneration 
of neural progenitor cells) and hSox1 which is involved in regulation of the developing 
embryo and cell fate - fig S1C. 
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Pluripotent stem cell the lines should express protein at a similar level to the H1(fig 5.35, 5.36). 
From the clones tested, both T26 and T31 represent hIPSc that were closely resembling H1 in 
terms of protein expression, alkaline phosphatase secretion and the ability to be differentiated 
into the three germ layers (using paired t-test we demonstrated no significant differences 
between H1 and either T26 or T31) – fig 5.35. The clones were labelled T26, T27, T31 and 
T32 (T referring to them being derived from a T-cell and the number refers to the point they 
were selected from emerging colonies).  Clones T26 and T31 were selected to be expanded 
further and differentiated into the different germ line layers (fig. 5.37).   
Fig. 5.36: qPCR plots to show relative
protein expression of hiPSC lines
following differentiation into the three
germ layers: mesoderm, endoderm and
ectoderm compared to H1. This
demonstrates that both T26 and T31 have
similar levels of protein expression to H1,
this would suggest that the hIPSc do
closely mimic the H1 cells and could be
considered as true pluripotent hIPSc.
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Fig. 5.37:  Stem cell marker gene expression of hIPSc clones compared to the hESc clone H1.  H1 was taken 
as the standard to which the hIPSc should be compared.  Protein expression pre-differentiation was on the whole 
similar to the H1 cells.  After differentiation expression reduced (which would be as expected) across both hIPSc 
lines and also the hESc line H1. This demonstrates loss of pluripotent potential following differentiation. In this 
case cells were differentiated into endoderm and the relative protein expression of each line compared to 
undifferentiated cells and H1.  Similar plots were produced for the other germ layers. 
 
 
Clones T27 and T32 were discarded as the protein expression suggested possible incomplete 
transduction.  These cells were expanded exponentially in culture and intermittently sampled 
to check they still represented the early passages (data not shown). We concluded that 
differentiation of adult T-cells into hIPSc could be a valid method for expansion of T-cells in 
vitro of desired phenotype.  This is proposed as a method for immortalising T-cells.  Cells can 
be expanded exponentially, and with the right growth conditions this could continue 
indefinitely. We therefore proposed this as a method for the capture and expansion of desired 
T-cells.  The next challenge was to induce these iPS cells to be differentiated back along the 
haematopoietic lineage. 
 
5.4.2 OP9DL1 cell co-culture can support haematopoiesis in embryonic stem cells 
Following the demonstration that we can transform T-cells into IPSc using sendai viral 
transduction, and thus potential to be converted into any developing cell in the body, we 
therefore proposed that these IPSc could be expanded in this fashion providing a limitless 
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supply of cells with which to work.  Vizcardo and Takahashi both demonstrated it was possible, 
given the right growth conditions, to transform these IPSc into rejuvenated T-cells (Takahashi 
and Yamanaka 2013, Vizcardo, Masuda et al. 2013).  Both studies discuss the use of OP9DL1 
co-culture systems.  
The OP9 stromal cell line is a well established line  derived from the bone marrow of OP/OP 
Mice (Kodama, Nose et al. 1994), and found to be macrophage colony-stimulating factor 
(MCSF)-deficient. A number of studies have demonstrated its potential for lymphopoiesis 
from HSCs (Ueno, Sakita-Ishikawa et al. 2003) and ESCs (Nakano, Kodama et al. 1994). 
Stromal cells have also been implicated in diferentiation of haematopoietic cells, as a result of 
cytokine production.  It is MCSF which is pivotal to myeloid differentiation. It is the inability 
to perform this role by OP9 cells which led to B-cell differentation from ESCs, due to a 
reduction in ESC-derived myeloid cells, which otherwise would have interrupted 
lymphopoiesis.  
As a result of the observations above, OP9 cells have become a model system for the 
demonstration of lymphopoietic induction from a vast number of sources.  One issue identified 
in this system is with the lack of T-cells generated using this system.  It is however possible to 
do so in the presence of specialised cytokines, and it has been proposed that it is these that 
provide that missing link for supporting differentiation of T-cells from stem cells.   
Notch signalling has been shown to regulate cell fate (Artavanis-Tsakonas, Rand et al. 1999) 
- fig. 5.38.  
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There are a number of potential roles identified including cell survival and proliferation as well 
as having a role in cell fate of HSCs (Kondo, Weissman et al. 1997, Manz, Traver et al. 2001). 
Its role in acquired immunity is notable and it is thought that NOTCH signalling may influence 
the development of both B-cells and T-cells (Simpson 1998). 
Fig. 5.38: The Notch-signalling pathway is an evolutionarily conserved pathway that controls many cell-fat e decisions
throughout ontogeny. Notch signalling is initiated by the interaction of Notch receptors with Notch ligands on neighbouring cells.
In vertebrat es, these ligands consist of two gene families, jagged and delta-like. Notch ligands that are expressed by stromal cells
bind to Notch receptors on haematopoietic progenitors, inducing the presenilin-dependent gamma-secret ase-mediated cl eavage of
intracellular Notch (ICN). ICN translocates to the nucleus, where it interacts with a transcriptional co-activator (CoA, mastermind-
family member), which in turn displaces a co-repressor complex (CoR) containing silencing mediator of retinoid and thyroid
hormone receptors (SMRT) and histone deacetylase 1 (HDAC1) from its association with the DNA-binding protein CSL
(CBF1/RBP-Jkappa), to induce the transcriptional activation of T-cell-lineage-specific genes – taken from (Zuniga-Pflucker
2004).
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OP9-DL1 cells have been used as a system for the differentiation of mouse embryonic stem 
cells (ESCs) or hematopoietic stem cells (HSCs) into T-lymphocytes in vitro.  This variant on  
the OP9 cell line is able to express ectopic Notch ligand Delta-like 1 (Dll1) (Robey, Chang et 
al. 1996, Fowlkes and Robey 2002, Schmitt and Zuniga-Pflucker 2002, Kutlesa, Zayas et al. 
2009, Van De Wiele, Marino et al. 2010, Feng, Yang et al. 2012) - fig. 5.39.   
 
Although it has lost the capacity to support active lymphopoiesis of B-cells, it is able to induce 
the differentiation of progenitors into T-cells (both single and double positive CD4 CD8 cells 
(Schmitt and Zuniga-Pflucker 2002) (Radtke, Wilson et al. 2004). As a result of early studies 
which showed both γδ-TCR+ and αβ-TCR+ T cells are generated, and that these cells could 
Fig. 5.39: Thymocyte Differentiation. The thymic architecture is organized into discrete cortical and medullary
areas, each of which is charact erized by the presence of particul ar stromal cell types, as well as thymocyte precursors
at defined maturation stages. Thymocyte differentiation is charact erized by the expression of well-defined cell-surface
markers, including CD4, CD8, CD44 (or CD117) and CD25, as well as the status of the T-cell receptor (TCR).
Interactions between Notch receptor-expressing thymocytes and thymic stromal cells that express Notch ligands
induce a complex programme of T-cell maturation in the thymus, which ultimately results in the generation of self-
tolerant CD4+ helper T cells and CD8+ cytotoxic T cells, which emigrate from the thymus to establish the peripheral
T-cell pool. Taken from (Zuniga-Pflucker 2004).
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secrete γ-interferon following stimulation, it was felt that this was good evidence that Delta-
like-1 expression on stromal cells is necessary for the induction of T-cell lineage 
differentiation, and its associated functions such as progenitor expansion and TCR gene 
rearrangements in vitro (Deftos and Bevan 2000, Fowlkes and Robey 2002, Laky and Fowkes 
2008). This has demonstrated a clear role for Delta-like-1/Notch interactions by the thymus 
confirming its ability to promote lymphopoietic differentiation and the generation of T-cells. 
How this is achieved is likely to represent the interplay between a number of intracellular 
cytokines. These roles have not however been well defined.  
As previously described, T-cells undergo a series of well-documented differentiation steps, 
which relate to the cell surface expression of CD4 and CD8, with thymocytes progression from 
CD4-CD8- double negative (DN), which go on to become CD4+CD8+ double positive given 
the right growth conditions (DP), and finally either CD4+ or CD8+ single positive (SP) T-cells. 
Based on expression of CD25 and CD44, these stages can be further investigated (Zuniga-
Pflucker 2004) – fig. 5.39.  Wang et al suggested that differentiation of cells from the DN stage 
to DP stage was provided for by IL-7 which originated from the stromal cells, however any 
further transformation required addition IL7 from alternative sources. SCF was also 
demonstrated to induce DN cell proliferation of DN and the inhibition of the DP stage in a 
largely a dose-dependent manner (Wang, Pierce et al. 2006). In addition to this, they observed 
that blocking endogenous SCF also blocked progenitor cell proliferation but led to increased 
differentiation of T-cells.  They also showed that Flt3 ligand induced proliferation without 
having any noticeable effect on differentiation.  They concluded that IL-7 SCF and Flt3-ligand 
were necessary for the promotion of efficient T-cell differentiation.   
To test this suggestion, we proposed co-culturing developing mouse embryonic thymocytes 
harvested on day 13/14, which had not yet developed along any particular lineage with 
OP9DL1 cells (fig. 5.40).   
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These cells are 93.5% CD4-CD8-, and this was taken as baseline.  Previous observations 
suggested culturing on OP9-DL1 cells allowed differentiation of these cells down the 
haematopoietic lineage. Therefore we would expect transition of these cells through the various 
DN classes.  Cells were therefore cultured in the presence of IL-7 and Flt3L on OP9DL1 cells, 
as well as OP9 cells (lacking DL1) to demonstrate the role of DL1 in lymphocyte development 
(fig. 5.41a, b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.41:  Light microscope images (a) and Flow cytometry (b) plots of mouse thymocytes co-cultured on 
(i) OP9 cells or (ii) OP9-DL1 cells for 7 days in the presence of Flt3L and IL7.   Those cells grown on the 
OP9-DL1 cells appear morphologically to look like lymphocyte cells (A) and have progressed from a largely DN 
state to 23.6% CD4+CD8+.   
Fig. 5.40: Embryonic thymocytes were analysed using flow cytometry prior to co-culturing on OP9 cells. 93.5% of
cells are in the DN state, which represents baseline at day 0. Following this cells were co-cultured either on OP9 cells or
OP9-DL1 cells in standard cell media supplemented with Flt3L and IL7.
Day	0
A
(i)	OP9 (ii)	OP9-DL1
Day	7
B
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By day 14 (fig. 5.42) cells co-cultured with OP9-DL1 cells were predominantly CD4+CD8+.  
Cells grown on OP9 monolayer (in absence of DL1) did not survive.  
 
Fig. 5.42:  Flow cytometry plots of mouse thymocytes co-cultured on OP9-DL1 cells for 14 days in the 
presence of Flt3L and IL7.   Those cells grown on the OP9-DL1 cells have progressed from a 23.6% 
CD4+CD8+(DP) state to 63.8% DP.  Those cells grown on an OP9 did not progress, and were lost at day 10. NB 
DN refers to CD4-CD8-, DP refers to CD4+CD8+ 
 
This preliminary experiment demonstrates the ability of OP9-DL1 cells to support 
differentiation of stem cells down the haematopoietic T-cell lineage.  Having established this 
to be the case we proposed testing the system with IPSc. 
 
5.4.3 OP9DL1 cell co-culture can support haematopoiesis in induced pluripotent stem 
cells leading to development of single positive CD4+ and CD8+ populations 
We obtained a mouse IPSc line CD20.3, derived from a cross of C57BL/6 mice, generated 
using lentivirus with STEMCCA cassette (still being expressed) from Dr Carl Ward (Institute 
of Infection and Immunity, University of Birmingham). In order to confirm stem cell 
characteristic, this cell line was compared to the mouse Esc (line E4).  Because the IPSc was 
still expressing the STEMCCA cassette protein markers were selected that were not on the 
cassette (fig. 5.43).  
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Fig. 5.43:  qPCR plots showing relative expression of iPSc proteins NANOG, REX1 and SSEA1 in the 
mouse iPSc CD20.3 compared to the mouse ESc E4.  qPCR performed as per standard protocols.  Primers 
obtained from Dr Ward, School  of INFECTION AND IMMUNITY, University of Birmingham.  Expression of 
protein in both lines is relatively similar with no significant difference seen between the two, therefore confirming 
CD20.3 as a candidate iPSc.  Chimeric transformation of mice injected with blastocysts was confirmed by Dr 
Ward’s collaborators (data not shown). Error bars represent SEM.E4 taken as benchmark to which C20.3 was to 
be compared. Experiment repeated twice, these plots are representative of those obtained on both occasions. 
 
Using methods as described by personal communication with Dr Kyoko Masuda (co-author 
of one of these previous studies) we aimed to develop a system for differentiating mIPSc into 
T-cells (Vizcardo, Masuda et al. 2013) – fig. 5.44. 
 
Fig. 5.44:  Schematic representation of protocol for transformation of mouse iPSc to t-cells using OP9-DL1 
co-culture system.  This system was developed by Dr Matsuda and reproduced here with permission. 
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IPSc were cultured using standard techniques and transferred onto OP9 cells and OP9-DL1 
cells to test this protocol.  Media supplementation was as described and cells were observed 
and photographed at various time points.  Morphologically it can be seen that cells co-cultured 
on OP9-DL1 cells do appear to be differentiated from typical rounded colony appearance 
(similar to that seen of cells cultured on OP9 cells) to single cell with a more typical 
lymphocyte-like morphological appearance - fig. 5.45.   
 
These cells were analysed using flow cytometry.  The control adult thymocytes show clear cell 
populations in each of the DN's (fig. 5.46A) demonstrating single positive cell populations 
which were CD4+ or CD8+.  This compares to the mIPSc derived cells which had been co-
cultured on OP9DL1's (fig. 5.46B), and were predominantly DN, suggesting that the system 
had not fully differentiated these cells.  We had noted that initial experiments (fig 5.46c) had 
revealed a population that gated as ‘lymphocyte-like’ however were CD45- and therefore we 
considered that these cells possibly represented possible T-cell precursors. We therefore 
proposed that these cells had been insufficiently differentiated using the protocol described 
Fig. 5.45: Light microscope image of the mouse iPSc line CD20.3 grown on (i) OP9 cells and (ii) OP9-DL1 cells on
day 14 and (iii) cells co-cultured on OP9-DL1 cells on day 21. This demonstrates minimal morphological change of the
colonies grown on OP9 cells, however the typical colony formation is lost on cells co-cultured on OP9-DL1 cells, with
the emergence of single cells at day 14 (ii) which have expanded in number by day 21 (iii). Morphologically these cells
appear to be lymphocyte-like. (all cells viewed at same magnification x40).
?lymphocyte-like	
single	cells
mIPSc
like	
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previously.  Moreover we hypothesised modifying this protocol, by increasing the IL-7 
concentration 10 fold, and allowing cells to progress as previously with media changes as 
described, but harvested cells at varying time points for both ELISA (looking at TNFα and 
IFNγ) and also flow cytometry (fig. 5.47). 
 
 
Fig. 5.46:  Flow cytometry analysis of mIPSc-derived cells co-cultured on OP9-DL1 cells on day 17 
compared to adult mouse thymocyte control cells.  Here we can see progression of cells in the adult thymocyte 
control through the various DN’s 1-4 (A).  These cells show distinct populations, including single positive CD4+ 
and CD8+ populations (A).  No CD20.3 (miPSc)-derived cells have progressed and remain in DN (B) .  However, 
as denoted by the red circle in panel 2, row B, there is a population of cells which were gated as possible 
lymphocytes which are GFP negative (i.e. not OP9-DL1 cells which are GFP positive . Cells were re-gated on 
this population of cells (C).  There appears to be a separate population of cells (yellow circle) which may represent 
CD8 positive cells as the gates were set up using adult thymocyte controls which is not a perfect match size wise 
for those cells derived from iPSc, but due to cell numbers we were unable to set gates using iPSc derived cells.  
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By modifying the protocol in this fashion we can see that cells derived from mIPSc can be 
differentiated into T-cell like cells by OP9-DL1 co-culturing.  We assessed the cells at multiple 
timepoints (data not shown) and found cells cultured for 35 days on OP9-DL1 cells bore a very 
similar expression of markers to the adult mouse derived thymocyte control cells, with some 
subtle differences.  For instance, in both adult thymus derived control cells and the mIPSc 
derived cells, DN4 predominated, but in the adult cells more cells are DN3 than DN2, which 
is the opposite to that seen in the mIPSc-derived cells.  It is also noted that the mIPSc-derived 
cells showed a similar number of CD45+CD2+ cells (32.4%) versus 31.1% in the thymocyte 
control (NS), and higher CD45+c-Kit+ (36.4%) versus 27.8% seen in the adult thymocyte 
controls (fig. 5.47).   
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Fig. 5.47:  Flow cytometry analysis of mouse iPSc derived cells (B) compared to adult thymocyte control 
cells (A) on day 35 of co-culture on OP9-DL1 cells. miPSc show a similar DN distribution to adult thymocyte 
controls with 80.1% CD4+CD8+ cells in the mISPc derived cells versus 82.5% in the control thymocytes. (C) 
ELISA data showing cytokine expression following stimulation with PHA or PMA/Ionomycin 
 
This data is representative of n=4 repetitions of this protocol.  This suggests therefore that these 
cells have not as efficiently been differentiated into lymphocytes as the adult thymus derived 
cells. This is unsurprising as no in vitro system can completely mimic an in vivo process like 
thymic control of cell fate.  It was encouraging to see cells had started to differentiate and there 
was an increase in pre-cursors suggesting these cells could potentially become T-cells.  
Gating	 strategy
A
B
TNF-a
Me
dia
 al
on
e
un
tra
ns
for
me
d m
IPS
c
un
tra
ns
for
me
d m
ES
c
Tr
an
sfo
rm
ed
 m
IPS
c
Tr
an
sfo
rm
ed
 m
ES
c
0
2000
4000
6000
PHA
PMA + Ionomycin
-ve
pg
/m
l
IFN-gamma
Me
dia
 al
on
e
un
tra
ns
for
me
d m
IPS
c
Un
tra
ns
for
me
d m
ES
c
Tra
ns
for
me
d m
IPS
c
Tra
ns
for
me
d m
ES
c
0
2000
4000
6000
8000
PHA
PMA + Ionomycin
-ve
pg
/m
l
C TNF-alpha
		 266	
Unfortunately growing the cells for longer periods than this made no difference to the outcome 
(data not shown).   
We considered if these cells were able to function like a T-cell.  Therefore mIPSc-derived 
cell’s media were sampled, at similar time points to when they were harvested for flow 
cytometry, and ELISA tests run to see what effect stimulation with PHA or PMA/ionomycin 
would have. When stimulated with PHA or PMA/Ionomycin, these transformed cells do 
express TNFα or IFNγ as measured using ELISA at the same time point (day 35), suggesting 
the majority of cells were activated as a result of stimulation with PHA or PMA/Ionomycin, 
with release of cytokine as a result.  This preliminary data suggests that these cells functioned 
in a similar fashion to T-cells, although a limit of this assay is the inability to determine how 
many of the cells were capable of doing this (fig. 5.47C). 
Therefore, we concluded, from these experiments, that co-culturing mIPSc with OP9-DL1 cells 
supplemented with Flt3 and IL-7 is a potential system for differentiating IPSc into T-cells.  
Moreover, this system could be used to differentiate IPSc derived from mature T-cells with 
defined immunogenic repertoire, and thus IPSc system could be a valid method for expanding 
defined T-cell populations, given we have a method for converting those cells back into T-cells 
again which are functional. 
 
5.5 Discussion 
One of the primary aims of this study was to generate a tumour-specific T-cell line.  Following 
the identification of phosphopeptides exclusive to tumours, we selected a number for further 
investigation based on relative expression and HLA type.  Phosphopeptide-specific T-cell lines 
were generated based on responses to phosphopeptide pulsing, with FACS data demonstrating 
T-cell activation.  We proposed that these cells could be used as a cancer specific (and HLA 
specific) tumour therapy a so called ‘off the shelf’ cancer therapy which would be tumour and 
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HLA specific.  A key finding was that a number of these phosphopeptide-specific T-cells were 
capable of killing which is clearly a key attribute, as there is no clinical utility to establishing 
a phosphopeptide-specific T-cell line which is not able to eliminate its target.  
The follow-on to this is establishing the T-cells long term.  It is widely accepted that tumour-
specific T-cells are difficult to maintain in long term culture, with cells losing specificity or 
dying.  Therefore, the other arm to this project was establishing a modality for expanding these 
cells exponentially and maintaining them long term.  Having considered a number of 
techniques, we proposed that generating hIPSc from T-cells could represent a technology for 
overcoming this hurdle.  Although a relatively new technique having first been described in 
2013, we wanted to test the viability of this technique (Nishimura, Kaneko et al. 2013, 
Vizcardo, Masuda et al. 2013).  Having established T-cell lines, we transfected cells using 
sendai virus with the Yamanaka factors as first described by Yamanaka and colleagues when 
generating IPSc initially in 2006 and further characterised by the same group on a number of 
occasions since using multiple different virus vehicles including retrovirus, lentivirus and most 
recently sendai virus  (Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007, Nagata, 
Toyoda et al. 2009, Takahashi and Yamanaka 2013).  
Our initial findings have shown that using a T-cell line we can establish a stable hIPSc clone 
which readily expands.  This leads onto the obvious question of (1) how to transform an IPSc 
back into a T-cell, as hIPSc do not function like a T-cell and therefore expanding a cell line 
that is not functional is useless unless there is a way to transform it back and (2) will this T-
cell be functional?  Because of the relative novelty of this technique, the protocols for achieving 
this are still under development. Using methods as described by personal communication with 
Dr Kyoko Masuda (Kyoto University, and co-author of one of these previous studies) we aimed 
to develop a system for transforming mIPSc into T-cells (Vizcardo, Masuda et al. 2013) section 
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5.4.1.  mIPSc that were co-cultured on OP9-DL1 cells to provide a source of Notch Ligand to 
trigger T-cell development, do appear to be transformed from typical rounded colony 
appearance (similar to that seen of cells cultured on OP9 cells) to single cells with a more 
typical lymphocyte-like appearance.   
We can see that cells derived from mIPSc can be transformed into T-cell like cells by OP9-
DL1 co-culturing.  We assessed the cells at multiple timepoints (data not shown) and found 
cells cultured for 35 days on OP9-DL1 cells bore a very similar expression of markers to the 
adult mouse derived thymocyte control cells, with some subtle differences.  For instance, in 
both adult thymus derived control cells and the mIPSc derived cells, DN4 predominated, but 
in the adult cells more cells are DN3 than DN2, which is the opposite to that seen in the mIPSc-
derived cells.  It is also noted that the mIPSc-derived cells show greater proportion 
CD45+CD2+ (32.4%) versus 31.1%, and higher CD45+c-Kit+ (36.4%) versus 27.8% seen in 
the adult thymocyte controls.  This suggests therefore that these cells have not as efficiently 
been transformed into lymphocytes as the adult thymus derived cells. This is unsurprising as 
no in vitro system can completely mimic an in vivo process like thymic control of cell fate. 
When stimulated with PHA or PMA/Ionomycin, these transformed cells do express TNFα or 
IFNγ as measured using ELISA), suggesting the majority of cells were functional T-cells. 
Therefore, we concluded that co-culturing mIPSc with OP9-DL1 cells supplemented with Flt3 
and IL7 is an efficient system for transforming IPSc into T-cells.  We therefore concluded that 
this system could be used to transform IPSc derived from mature T-cells with defined 
immunogenic repertoire, and thus IPSc system could be a valid method for expanding defined 
T-cell populations, given we have a method for converting those cells back into T-cells again 
which are functional.  
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Chapter 6:  DISCUSSION AND FUTURE WORK 
Liver tumours (HB and HCC) and Post-transplantation lymphoproliferative disease (PTLD) 
pose a serious therapeutic challenge and novel approaches are being sought for the treatment 
of these tumours in the paediatric population. The immune system can specifically identify and 
eliminate tumour cells on the basis of their expression of tumour-associated antigens (TAA). 
This process is referred to as tumour immune surveillance, whereby the immune system 
identifies cancerous and/or precancerous cells and eliminates them before they can cause harm 
(Kaplan, Shankaran et al. 1998, Swann and Smyth 2007, Garrido, Perea et al. 2017). As a result 
of these observations, immunotherapy is considered a promising new treatment modality. A 
key aim of this project has been the identification of specific targets, which distinguishes the 
malignant cells from healthy cells. Very few immunogenic TAA have been characterised so 
far in general and even less for paediatric tumours in general, which is therefore a key outcome 
of this project. 
Malignant transformation results from dysregulation of signalling pathways which is predicted 
to be as a result of accumulated cell mutations and epigenetic changes.  One such change is 
deregulation of signalling pathways with altered and augmented phosphorylation of cellular 
proteins. Phosphoproteins involved in these signalling cascades can be degraded to 
phosphopeptides that are presented by major histocompatibility complex (MHC) class I and -
II molecules and recognized by T cells (Zarling, Polefrone et al. 2006, Mohammed, Cobbold 
et al. 2008, Depontieu, Qian et al. 2009, Li, Depontieu et al. 2010, Cobbold, De La Pena et al. 
2013, Abelin, Trantham et al. 2015). The contribution of phosphopeptide-specific T cells to 
immune surveillance in the development of liver cancer in chronic liver disease is unclear. 
We hypothesised that phosphopeptides are presented by MHC molecules with increasing 
amounts on the surface of altered cells with progression of cellular change towards 
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malignancy. We further hypothesised that the immune system monitors the liver for malignant 
transformed hepatocytes and clears those cells with the help of phosphopeptide-specific 
cytotoxic T lymphocytes. 
This project therefore had a number of key aims: (1) Identification of MHC class I-associated 
phosphopeptides that are presented on the surface of transformed cells using a mass 
spectrometry approach. (2) In order to show the immunogenicity of these novel identified 
tumour antigens, the second aim of this study was to characterise the T cell responses to these 
newly identified phosphoantigens in healthy individuals. (3) Finally we sought to identify a 
process for immortalising T-cells as a means of expanding a stable phosphopeptide specific T-
cell line which has potential for in depth in vitro analysis of these phosphopeptide specific 
responses.  Furthermore, the use of newer technologies such as iPSc technology, could benefit 
the development of a tumour-specific immunotherapy. 
 
6.1 Identification of MHC class I-associated phosphopeptides as novel tumour-specific 
antigens for HB and PTLD 
Several methods exist for identification of tumour antigens on the surface of cancer cells. In 
the past, most often a “reverse immunology” approach was used, in which the peptide 
sequences of the tumour antigens were predicted in silico. MHC presented peptides with low 
binding affinities or those carrying posttranslational modifications cannot be predicted with 
this approach. This project therefore implemented a more straightforward approach by directly 
isolating MHC-peptide-complexes from the surface of the tumour cells followed by 
sequencing of the peptides. The latter approach is necessary for the identification of 
posttranslational modified peptides. MHC class I-bound phosphopeptides were identified with 
the latter approach as described previously. This part was carried out in a collaboration with 
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the Department of Chemistry at the University of Virginia (laboratory of Prof. Donald Hunt). 
To date, we have discovered in total 68 HB-associated MHC-I-phosphopeptides and nearly 
200 PTLD-associated MHC-I-phosphopeptides. This data was acquired from 5 different HB 
samples and the corresponding adjacent healthy liver tissue and from a hepatoblastoma cell 
line (HepG2). In addition, we sampled the in vitro PTLD model (LCL) derived from healthy 
donors as well as some patient derived sample in order to understand phosphopeptide 
expression in this disease process. Sequence data from mass spectrometry is interpreted with 
the help of computer algorithms, but as no algorithm provided high enough confidence, the 
sequences had to be double-checked by hand, which led to limitations of this technique as it 
was as a result very time consuming to process each sample. This therefore limited the number 
of samples we were able to analyse for this current project. 
Greater varieties of MHC-I-phosphopeptides and on an average greater expression were 
presented on malignant tissue than on healthy tissue. Some of the identified MHC-I-
phosphopeptides have been previously found on other malignancies, e.g. colorectal and 
oesophageal cancers or on leukaemia (Zarling, Polefrone et al. 2006, Cobbold, Polefrone et al. 
2007, Depontieu, Qian et al. 2009, Penny, Abelin et al. 2012, Cobbold, De La Pena et al. 2013, 
Abelin, Trantham et al. 2015), further highlighting the importance of this novel class of tumour 
antigens for cancer growths.  
Many of the underlying proteins from the identified respective MHC-I-phosphopeptides can 
be directly linked to malignant signalling pathways, which highlight their importance as 
potential new immunotherapeutic targets. Several enriched clusters of proteins involved in 
transcriptional regulation, cell cycle regulation, regulation of metabolic processes, apoptosis, 
cell death, cell migration and many other biological processes, which have been associated 
with “hallmarks of cancer” have been identified in both the current study and also previous 
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studies by this group (Cobbold, Polefrone et al. 2007, Mohammed, Cobbold et al. 2008, Penny, 
Abelin et al. 2012, Cobbold, De La Pena et al. 2013, Abelin, Trantham et al. 2015). Several 
studies indicate a major role of the MAPK/RAF/MEK/ERK pathways in the tumorigenesis of 
liver tumours (Tomizawa and Saisho 2006, Hartmann, Kuechler et al. 2009, Armengol, Cairo 
et al. 2011, Esmaeili, Farimani et al. 2014, Mokkapati, Niopek et al. 2014, Wang, Lu et al. 
2016, Leichter, Sullivan et al. 2017). However, due to the small sample size, the data does not 
represent a complete picture of the involvement of phosphopeptides into important biological 
functions and their pathways yet. 
 
6.2 Characterisation of immune responses against MHC-I-phosphopeptides 
Preliminary data from our the current project and other members of the Cobbold group have 
indicated that T cell responses against phosphoproteins can be found in healthy individuals and 
to a lesser extent in patients with malignant diseases (Zarling, Polefrone et al. 2006, Penny, 
Abelin et al. 2012, Cobbold, De La Pena et al. 2013, Abelin, Trantham et al. 2015). These 
results suggested that individuals with a functional immune system create T cell responses 
against aberrantly phosphorylated peptides in order to eliminate those cells with signs of 
transformation. This may prevent further alterations and malignant transformation of the cells.  
According to our hypothesis we set out to identify CD8+ T cell responses against the newly 
identified MHC class I- associated phosphopeptides in healthy individuals and patients with 
HB. A number of the newly identified PTLD and HB-associated HLA-A*02-restricted 
phosphopeptides, as well as HLA-B*07 were selected for further immunological testing in 
HLA-A*02 positive healthy individuals. Responses were assessed using intracellular cytokine 
staining (ICS) and several cytokines and surface markers were assessed in parallel. After 7 
days of stimulation with the respective MHC-I-phosphopeptide and no other cytokines, CD3 
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and CD8 expressing T cells were stained for at least two different cytokines (IFN-γ, TNF-α). 
First peripheral blood mononuclear cells (PBMCs) from healthy donors were analysed 
(chapters 3,4).  
We demonstrated phosphopeptide-specific responses, which were clear memory responses 
with the added capability of killing (section 3.2-3.4).  We acknowledge that the number of 
healthy donors assessed was relatively small, and therefore in order to better understand the 
proportion of immune response targeting phosphopeptide, a larger cohort should be sought. 
We propose that this preliminary data, together with observations seen by other laboratory 
members, in their studies, suggest that these healthy donors have clear functional CD8+ T-cell 
responses to these transformation-dependent epitopes (Zarling, Ficarro et al. 2000, Zarling, 
Polefrone et al. 2006, Mohammed, Cobbold et al. 2008, Penny, Abelin et al. 2012, Cobbold, 
De La Pena et al. 2013, Abelin, Trantham et al. 2015). This brings us back to the concept of 
tumour immunoediting (Meraz, White et al. 1996, Shankaran, Ikeda et al. 2001, Dunn, Old et 
al. 2004, Dunn, Old et al. 2004, Dunn, Bruce et al. 2005, Dunn, Koebel et al. 2006). Therefore, 
we concluded that it is probable that the memory T-cell responses are to epitopes which the T-
cells have encountered before, and that these epitopes are likely to be phosphopeptides.  
We found that phosphopeptides were displayed on MHC class I at significantly higher levels 
in hepatoblastoma and PTLD than the corresponding healthy tissues (Section 3.5, Section 
4.2.1), an observation noted previously in other tumour types (Penny, Abelin et al. 2012). We 
identified 68 specific phosphopeptides associated with hepatoblastomas. Comparison of 
hepatoblastoma to healthy tissue and the cell line HepG2 shows that 41 phosphopeptides have 
been found unique to hepatoblastoma and not on healthy tissue or previously in the HepG2 cell 
line.  There is an overlap of 16 phosphopeptides found on both tumour and cell line (HepG2).  
The colorectal adenocarcinomas as studied by Dr Sarah Penny, of this group, also had a subset 
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of patients with liver metastases, and on assessing phosphopeptides seen on these secondary 
malignancies a number were also identified on hepatoblastoma tumour samples, suggesting 
that these phosphopeptides may be involved in a hepatological development and tissue 
differentiation pathways.  Their role could potentially be related to coding for proteins involved 
in hepatic tissue dysplasia for instance. It is also noted that there are a number of 
phosphopeptides identified on adult hepatocellular carcinoma samples (as studied by Dr Nico 
Büttner of this group), again bolstering this view of a role in hepatic dysplasia (Table 4.9).  
A similar picture was identified when studying PTLD and the in vitro surrogate LCLs.  
Although obviously limited by lack of patient samples, we can identify a number of 
phosphopeptides which are presented exclusively on malignant or transformed cells, and not 
on healthy tissues.  This has led to the suggestion that these tumour-associated 
phosphopeptides could be targets for immunotherapy.  
Phosphopeptide-CTL-responses were compared with responses to immunodominant viral 
epitopes from cytomegalovirus (NLVPMATV) and Epstein-Barr virus (GLCTLVAML). In 
many cases T cell responses against MHC-I-phosphopeptide are comparable in quantity and 
quality to viral immune responses. This is in contrast to the “classic” TAA. Here immune 
responses are often nearly not detectable (< 0.1 % of CD8+ T cells) and often show signs of 
exhaustion (Ramsay, Bates et al. 2008, Flecken, Schmidt et al. 2014).  
Phosphopeptide-specific T-cells produce multiple cytokines, mainly IFNγ and TNFα. The 
production of multiple cytokines (IFNγ, TNFα and IL-2) by T lymphocytes is in general 
associated with better disease control. Phosphopeptide-specific T-cells were found to be 
mainly CD27+ and CD45RA- and therefore most likely to reside in the memory compartment. 
This suggests that only individuals that have been previously exposed to the MHC-I-
phosphopeptide establish an immunological memory against these antigens. If healthy donors 
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are too young, we proposed that they haven’t had the chance yet to be exposed to MHC-I-
phosphopeptide tumour antigens.  
Finally, after establishing that healthy donor derived T-cells could mount a response to MHC-
I-phosphopeptides, we considered if these phosphopeptide-specific (and thus potentially 
tumour-specific) cell lines could recognise tumours.  This was performed on frozen tumour 
tissue as well as LCL-lines. From this series of experiments we were able to show that The 
Phosphopeptide-specific T-cell lines could recognise tumour and release cytokine as a result. 
Europium killing assay showed functionality of these cells.  We therefore considered how to 
propagate these phosphopeptide-specific T-cells. 
 
6.3 Establishing Phosphopeptide-specific T-cells 
This arm of the project looked at methods of maintaining T-cells in culture long term without 
suffering the complications of loss of antigen-specificity, T-cell exhaustion and cell death. 
Initially we looked at methods for assessing T-cells in vitro with the aim of their use as a tool 
to probe phosphopeptide expression on both normal and transformed cell types.  In order to do 
this, we explored the use of hybridoma-technology primarily with varying success.  The main 
barrier to this technique was efficiency which despite extensive manipulation of experimental 
protocols remained relatively poor. This is perhaps unsurprising given the observation that T-
cell hybridoma technology has largely fallen out of fashion as newer molecular biology 
techniques emerge. 
Building on prior knowledge and skills gained from previous projects, iPSc technology was 
investigated as a means of expanding T-cells.  This was based on two studies released in 2013, 
which showed success of iPSc technology in the rejuvenation of exhausted mature T-cells in 
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HIV and melanoma (Nishimura, Kaneko et al. 2013, Vizcardo, Masuda et al. 2013).  Using 
Sendai virus, we were able to demonstrate differentiation of mature T-cells into induced 
pluripotent stem cells which demonstrated all the characteristics of a stem cell with regards to 
gene and protein expression.  These cells have the potential to be differentiated into any cell 
type, and thus provide an ideal platform to be differentiated into a stable T-cell line. 
Preliminary data obtained during this project has demonstrated that iPSc cells derived from 
mature T-cells can be differentiated back into T-cell-like cells with the same cytokine 
expression and functionality as parent line.  Although only reproduced twice and in mIPSc, it 
does demonstrate a proof of principal and a step towards generation of a phosphopeptide-
specific T-cell line if a protocol could be established for hIPSc, given we have shown that we 
can generate an iPSc from mature T-cells. 
 
6.4 Adoptive cell transfer – TiLs vs iPSc 
It has been shown that adoptive cell transfer (ACT) of TILs can mediate cancer regression in 
patients with metastatic melanoma (Rosenberg 1984, Dudley, Wunderlich et al. 2003). In ACT 
autologous immune cells from a patient are removed, altered and/or expanded. A problem with 
this technique is that in order to generate a TiLs line from hepatoblastoma requires a large 
tissue sample, in order to get a sufficient number of lymphocytes to start a culture. That would 
mean that patients with HB or PTLD would need to have surgery before ACT in order to 
acquire enough tumour tissue. But that is not practical, considering the expected symptoms 
from liver disease, the need to initiate chemotherapy and time take to establish a culture.  The 
only reasonable approach to obtain liver tissue before immunotherapy could be a liver biopsy. 
Protocols have to be optimised in the future in order to obtain suitable T cell populations from 
liver biopsies, which remains a challenge in the paediatric population as it requires general 
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anaesthesia and could delay initiation of chemotherapy. Also there is a risk of tumour seeding.   
The time taken to generate this line is also a key consideration when using autologous cells.  
Other members of the Cobbold group have attempted to investigate this in hepatocellular 
carcinoma but with very limited success.  It was found that only very few and minor responses 
were detectable in all of the cultures. Background cytokine production was much higher in 
expanded lymphocyte cultures and therefore often genuine T cell responses were difficult to 
distinguish from background. Responses, which were demonstrated in the unexpanded 
cultures, were completely absent in the expanded T cell cultures (personal communication). 
Interestingly virus-specific T cell reactivity was not lost during expansion of T cells. This 
indicates that if expansion of T cells happens in a large scale and in an undirected way, virus-
specific T cells and tumour-unspecific T cells overgrow tumour-specific T cells. This might 
be one reason why ACT with T cells failed to induce clinical responses on a regular basis. 
Overgrow of virus-specific cells could be due to the fact that these cells are less exhausted and 
express lower amounts of inhibiting receptors.  
Recently iPSc have been proposed as a cell source for ACT (Minagawa and Kaneko 2014).  
Adoptive T-cell transfer is a potentially effective strategy for treating cancer and viral 
infections. However, previous studies of cancer immunotherapy have shown that T cells 
expanded in vitro fall into an exhausted state and, consequently, have limited therapeutic 
effect. One way to overcome this obstacle is to use induced pluripotent stem cells (iPSCs) as a 
cell source for making effector T cells. In recent years, there have been several reports on 
generating effector T cells suitable for adoptive immunotherapy. The reported findings suggest 
that using iPSC technology, it may be possible to stably derive large numbers of juvenile 
memory T cells targeted to cancers or viruses. 
Adoptive T-cell transfer has been successful in treating many cancer patients (Grupp and June 
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2011). We have shown that there is tumour-resident immunity to the tumour-specific 
phosphopeptides in HB patients. Therefore, if patients have T cells targeting these 
phosphopeptides, it may be possible to select these from the patient blood, using HLA- 
phosphopeptide tetramers and selectively expand them, before adoptively transferring them 
back into the patient, as is done with viral specific T cells after stem cell transplants (Cobbold, 
Polefrone et al. 2007).This could potentially be a relatively inexpensive personalised therapy, 
performed at the bedside. However, for this we require robust phosphopeptide multimers and 
these have proved more difficult to refold than viral peptide tetramers. 
 
6.5 Phosphopeptide-specific ImmTACs as potential immunotherapeutics 
The value of the TCR transfer approach is underscored by the many patients with either cancer, 
viral infection, or other life-threatening diseases, for whom it is not possible to expand T cells 
of therapeutic value. For such patients, the successful transfer of TCR genes would 
undoubtedly be a significant step in the development of improved T cell-based therapies. TCR 
gene transfer has been facilitated by retroviral and more recently lentiviral transfer.  Another 
potential therapeutic angle that could be used in targeting tumour-specific phosphopeptides is 
immune-mobilising monoclonal TCRs against cancer (ImmTACs). These are a set of new 
reagents engineered by Immunocore (Abingdon, UK). They comprise a tumour-specific TCR 
covalently linked to a CD3-specific single-chain antibody fragment (scFv). These thus engage 
specifically with tumour cells and induce responses from all of the CD3+ T cells in the local 
environment. They can be used to target cells expressing fewer than 50 epitopes, but it is 
essential that these epitopes are completely tumour-specific. Therefore, we would need to 
assess MHC class I-associated expression of the tumour-specific phosphopeptides in a range 
of healthy tissues. However, if we could find a selection of HLA- phosphopeptides that were 
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tumour-specific, this could be a treatment covering all cancers in all patients. To this end, we 
are attempting to clone phosphopeptide-specific T cells to sequence their TCRs. Furthermore, 
these reagents could be used in conjunction with the sHLA biomarkers for early detection of 
cancer. 
Cancer cells express MHC class I-associated phosphopeptides on their cell surface. ImmTACs 
specifically target these complexes with high affinity TCRs and stimulate all local T cells with 
the anti-CD3 scFv, redirecting T cell killing towards the cancer cells and clearing the cancer. 
In the more distant future, if we could ensure that the HLA-phosphopeptides were completely 
tumour specific, and we could develop an effective vaccine strategy, they may have potential 
as preventative cancer vaccines, used in a similar way to HPV vaccination. However, this 
would need extensive development and validation in multiple animal models to ensure against 
toxicity. 
 
6.6 The use of iPSC vs TCR gene transfer vs CAR-T 
An alternative to the iPSc process is use of either autologous cells or alloreactive cells and 
manipulating them using gene-transfer technology (e.g. lentiviral/retroviral or use newer 
“gene-disruption” technologies e.g TALENs -developed by Cellectis or CRISPR/Cas9). The 
focus of this project is specifically about phosphopeptide responses which are recognised by 
T-cells, therefore a CAR cannot be constructed, and it would be necessary to construct an 
engineered TCR.  This is because CAR-T cell therapies consist of an antigen binding region 
(usually drive from an antibody) which targets a surface protein on the tumour cell such as 
CD19 in B cell malignancies or MUC-1 on solid organ malignancies.  It would be very difficult 
and impractical to generate CAR-T cells against multiple phosphopeptide-MHC complexes.  
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With tumour-specific peptides such as phophopeptides or NY-ESO, WT-1, MART-1, 
MAGE3, TCR constructs must be generated and transferred to T cells. These transfected T 
cells subsequently recognise peptides on the tumour cells. TCR constructs act through the 
MHC pathway and recognize a processed epitope presented by the target cell`s MHC complex 
and thus are HLA specific. However, one of the major limitations of TCR gene transfer is due 
to MHC restriction in patients.  Those patients who express MHC class I alleles that can present 
a tumour-specific peptide may benefit from TCR gene transfer therapy but patients who do not 
express the correct MHC molecules cannot present the tumour-specific peptide and will 
therefore not benefit from this therapy.  
As already alluded to, there are different methods of introducing or adoptively transferring T 
cell immunity against phosphopeptides to a given patient. iPSCs would give a potentially 
unlimited supply of T cells with the only manipulation being the T cell>iPSC>T cell 
modification.  TCR gene transfer would require genetic manipulation of the patients harvested 
T cells, growth ex vivo and re-injection.  Numbers of injected T cells would depend on 
transfection efficiency and ex vivo growth.  Also, potential of new TCR alpha and beta chains 
pairing with the endogenous alpha and beta chains possibly altering T cell recognition.  
Potentially need to use non-autologous T cells for TCR transfer therapy meaning could have 
problems with Graft vs Host disease (GvHD) or host cells killing non-self T cells.   
As already suggested, CAR-T cells would probably not work as a phosphopeptide 
immunotherapy as these use an antibody variable region to recognise a protein on the cell 
surface e.g. CD19.  CAR-T likely would not easily recognise phophopeptide-MHC complex 
and would therefore not be useful in this setting. iPSc-based therapy would be tumour specific 
because of the restricted expression of the phosphopeptide so in theory it could target any 
tumour, haematological or solid organ.  At the moment, CAR-T are very restricted in their 
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targeting because they kill all cells expressing the protein they are targeting.  Therefore, they 
are mostly restricted to haematological malignancies because survival without their B cells or 
plasma cells is possible, but to specifically target liver cancer with a CAR-T therapy would be 
difficult as they would also kill healthy hepatocytes that express the CAR target antigen.   
Making any of these theoretical processes into this a patient therapy is going to be expensive 
and require a lot of resources.  For instance, with CAR-T, T cells are obtained from the patient, 
CAR-T construct is transfected in, subsequently the T cells are grown ex vivo and then re-
infused after 14 days (Couzin-Frankel 2013). iPSC therapy would be similar, where 
phosphopeptide-specific T cells are selected and used to generate iPSC, cultured and then 
differentiated back into T cells prior to being re-infused.  This is not dissimilar to CAR-T 
therapy so you could use that as a reasonable rationale for iPSC therapy moving forward.  
Many T cell therapies involve some sort of ex vivo T cell culture and a GMP facility facilitate 
this. Costs would be high for any of these therapies due to the rigorous controls necessary for 
a patient treatment, but would likely be comparable.  Although costs will initially be high, there 
is significant investment in this area by a number of leading companies (Norvartis, Giliad 
acquiring Kite, Juno) and it would be predicted that costs will inevitably come down once the 
field has been established. In terms of where production is best achieved there are two options: 
Is it going to be centralised in big cell manufacture factories or will it be closely linked with 
University hospitals. The current view from the field is that it will be a mixture of the two. 
Maybe autologous therapies being hospital based using automated machines and allogenaic 
therapies being centralised is a sensible division. 
 
6.7 The issue of HLA-restriction 
Discovery of a phosphopeptide specific T cell response and generation of an iPSC therapy 
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from it, would either be suitable for that patient or at best patients with the same HLA allele.  
This project has identified a number of tumour-specific phosphopeptides, however as is already 
known, these are HLA-restricted.  Although our focus here was on HLA A2 and HLA B7 (due 
to sample and time limitations), many other phosphopeptides were isolated on tumours which 
were of other HLA types.  If this iPSc based therapy were to be adopted as a patient treatment, 
one way to overcome the issue of HLA restriction could be to generate banks of cells lines 
with different HLA restrictions.	Alternatively, discovery of a phosphopeptide which binds to 
a non-classical HLA or similar may overcome this, but with the current phosphopeptides 
identified, MHC restriction is likely to prove an issue for the proposed therapy.  This will 
therefore make this a more expensive therapy and potentially a move towards personalised 
therapy. 
 
6.8 Summary 
Although anti-host reactivity may lead to unacceptable toxicity, immune rejection of non-
autologous T cells will most certainly reduce their efficacy. Therefore, critical to success of an 
‘off the shelf’ adoptive T-cell therapy is escaping immune rejection, ensuring sufficient 
persistence and possibly long term engraftment. One fairly obvious and perhaps necessary 
approach to this is to bank cells with common HLA haplotypes. This is still however limited 
by HLA matching and donor availability. Establishment of iPSC banks is another option which 
could be explored, although this also requires the generation of multiple iPSC lines from 
multiple donors.  This is not without its own limitations in terms of T-cell specificity, HLA 
restriction and the safety implications to name but a few.   
Stem cell reprogramming is however an attractive option as it offers the potential for 
generation of an unlimited source of therapeutic T lymphocytes, as well as a cell source for 
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further genetic engineering (Themeli, Kloss et al. 2013). The combination of iPSC technology 
and immune engineering could potentially lead to generation of T-cells with favourable 
characteristics such as phosphopeptide/antigen specificity, histocompatibility or a lack of 
alloreactivity.  
 
6.9 Future work 
As a result of this project and other studies, there are of course a number of important questions 
to answer:  
(1) Can phosphopeptide-specific T-cells be differentiated into hIPSc using the 
techniques described in Chapter 2?  
(2) Can techniques be established for differentiating hIPSc back to T-cells?  
(3) Will the resulting T-cells have the same specificity with regards to phosphopeptide 
as the parent T-cell?  
(4) These cells will be HLA specific – can we identify a technique for overcoming this, 
as not all patients with a specific tumour will have the same HLA?   
The answers to these questions form the basis of the future work.  We have identified 
phosphopeptides present on tumours, and developed techniques to generate phosphopeptide 
specific T-cells.  It would be useful to establish a larger cohort of tumours allowing for greater 
clarity of tumour-specific phosphopeptides identified. Can we narrow down more unique 
phosphopeptides for instance (novel phosphopeptides not identified on other tumours would 
be of particular interest as these could be truly considered ‘tumour-specific’, or ones which are 
expressed at much higher levels in tumour versus normal tissue.   In the case of PTLD, a larger 
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patient cohort is key to our understanding of this disease, as much of what we have established 
is from an in vitro proxy, so essentially a theoretical model.  
With regards to transforming hIPSc into T-cells, the protocol is constantly evolving, and as yet 
is not fully optimised.  We chose not to investigate this further in the current project as the 
mouse protocol was closer to being fully optimised, and with further modification with regards 
to cytokine supplementation and duration of co-culture we believe we have established a 
reproducible protocol for transforming mIPSc into T-cells.  The logical next step would be to 
do this in hIPSc and would be a key target of further work.  The clear focus of this would 
therefore be to establish a T-cell line from hIPSc, and then to identify if it is functional (i.e. 
capable of activation following stimulation) but perhaps most important is establishing if the 
resultant T-cell line has the same phosphopeptide specificity as the T-cell from which it was 
originally derived.  Again if the resultant T-cell is not phosphopeptide specific and therefore 
not tumour-specific then there will be no clinical utility.  Finally, we acknowledge that the 
system we have used is very artificial and only specific to a limited number of HLA types.  
Therefore, if more tumours were investigated more HLA specific phosphopeptides could be 
identified.  However as alluded to, not all patients have the same HLA type, and therefore 
focus could be to generate a non HLA specific T-cell line.  Could we determine a mechanism 
for removing HLA TCR of a T-cell line so that it could have functionality in more patients?  
One obvious technique currently receiving a vast amount of research activity across the world 
is CRISPR/Cas9 technology, which may indeed overcome the issue of HLA restriction. It is 
the subject of much investment in terms of time and knowledge by the Cobbold laboratory and 
collaborators in Harvard University in relation to phosphopeptide specific T-cells and 
manipulation thereof. We propose the use of CRISPR/Cas9 technology to remove the 
endogenous TCR, overcome HLA restriction and thus the risk for GVHD, and therefore we 
propose this as a technology for removal of endogenous HLA alleles from the T-cell to avoid 
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interaction in this third party setting. 
In summary, we have attempted to validate phosphopeptides as a potential new class of cancer 
antigen in a human cancer model. We showed that over half of the immune responses generated 
in healthy donors were directed towards phosphopeptides found on ‘transformed-self’. We 
isolated tumour-specific phosphopeptides from paediatric hepatoblastoma tumours and PTLD 
patient samples as well as cell lines. We also found that a number of these phosphopeptides 
were also expressed on other tumours e.g. breast, melanoma, gastrointestinal tumours, and 
haematological malignancies.  A key aim of this project was identifying what role 
phosphopeptide-specific T-cells played in the anti-tumour , which we achieved with the use of 
an in vitro model for PTLD which allowed us to assess the proportion of T-cell responses that 
are against phosphopeptides identified on LCLs as well as on paediatric liver tumour 
specimens.  We found these T-cells did appear to use phosphopeptide to target tumour and 
displayed functional killing as a result. We assessed a number of techniques for immortalising 
specific T-cells so these could be expanded exponentially in culture.  We established that 
generating induced pluripotent stem cells (IPSc) from T-cells appeared to be an efficient 
process for generating stable cell lines.  Following on from this we explored methods for 
converting these IPSc back to functional T-cells.  Using a mouse IPSc model we established 
that given the right growth conditions, co-culture with OP9 DL1 cells did allow for the IPSc 
to become T-cells which were capable of being activated following stimulation, leading us to 
believe that this method could be used to generate a stable T-cell line.  This proof of principle 
has allowed us to explore various techniques, with the ultimate aim to repeat this using IPSc 
derived from phosphopeptide-specific T-cells. 
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Appendix 1 
NB IPSc protocols were adapted from those provided by the Vallier Group, Cambridge 
University. All tissue culture vessels, media, supplements obtained from Sigma unless stated 
otherwise. 
 
A1.1.  Feeder-dependent IPScs protocols 
*For media recipes, please see chapter 2 materials and methods. 
Preparation of feeder plates  
Commercially available irradiated MEFs (IRR MEFs, GlobalStem, Cambridge BioScience, 
UK) were used.  
Tissue culture plates were pre-coated with 0.1% gelatin.  One vial of CF1 IRR MEFs from 
GlobalStem contains 4-5 x106 cells.  These were rapidly thawed cells in a 37°C water bath, 
and transferred to a 50ml conical tube containing 10ml MEF media * and centrifuge at 200g 
for 4 min. Cells were washed and resuspended in DMEM/10% FCS (GibCo, UK). Vessels 
were then transferred into an incubator set at 37°C, 5% CO2, for at least 24 hours prior to usage, 
but can be stored for up to 2 weeks. 
Table S1:  Densities for MEFs on Different Culture Dishes 
Cell culture vessel Surface area in mm2 # of MEFs  Optimum Volume For Plating 
(ml) 
Dishes/plates    
35mm plate 962 0.15 x 106 2 
60mm plate 2.827 0.4 x 106 3 
100mm plate 7.854 1.0 x 106 10 
Multi-well plates    
6-well plate 962 0.15 x 106 2-5 
12-well plate 401 0.05 x 106 0.5-2 
24-well plate 200 0.025 x 106 0.5-1 
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Picking hIPScs 
Picking of single IPScs colonies enables separation of clonal population of cells for further 
culture and propagation. 
MEF media (DMEM/10% FCS) was aspirated from the appropriate number of plates which 
were washed with PBS x2. 0.5ml IPSc media* containing 10µM ROCK inhibitor/Y-27632 
was added to each well.  Using 20µl pipette set to 15µl each colony was encircled. 
Subsequently, these were divided into clumps of 200-300 cells and transferred to the prepared 
feeder plates. Cells were subsequently incubated overnight, and media topped up after 24 hours 
(without ROCK inhibitor). 
 
Passaging hIPScs 
Human induced pluripotent stem cells need to be passaged in order to avoid overgrowth and 
to maintain them in undifferentiated state. 
Plates were washed x1 with D-PBS, following which equal volumes of collagenase and dispase 
were applied (1ml of each per well of a 6w plate).  Cells were returned to an incubator for up 
to 1 hour, but monitored for evidence of loosening (visible curling or thickening of colonies 
around edges).  15ml falcons were prepared with fresh DMEM/F12 =5ml per falcon (Gibco, 
UK). Colonies were aspirated and added to a falcon – one well per falcon. The lid was applied 
and the tube inverted x1.  Colonies were allowed to sediment and the media layer was gently 
aspirated.  Cells were washed x1 with 7ml DMEM/F12 and again colonies allowed to 
sediment. Feeder plates were washed with PBS and 1ml of IPSc media was added per well (6w 
plate). Colonies were resuspended in IPSc media and transferred to the feeder plates. 
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Non-integrating method of reprogramming PBMC with Sendai Virus (SeV) 
This protocol allows generation of integration-free IPScs from peripheral blood. Peripheral 
blood mononuclear cells (PBMCs) are cultured to expand the erythroblast (EB) population. 
They are then used to derive IPScs using four recombinant Sendai viral vectors, expressing the 
four reprogramming factors: OCT4, SOX2, KFL4 and c-MYC.  LifeTechnologies CytoTune 
2.0 kits were used.  Standard protocol as described below: 
Day –9: Plate peripheral blood mononuclear cells (PBMCs) at 5 ×106/ml in a 12-well plate in 
complete PBMC medium*.  
Day –8 to –1: Replace half of the medium per well with fresh PBMC media (with cytokines)*  
Day 0: Transduce the cells using the appropriate MOI as per the batch number and 
calculation on product website. Cells incubated overnight.  
Day 1: Media completely aspirated from the wells and replaced with fresh complete PBMC 
medium* to remove the 2.0 Sendai reprogramming vectors. MEF feeder plates prepared as 
described above.  
Day 3: Plate the transduced cells on MEF culture dishes in complete PBMC media without 
cytokines*.  
Day 4–6: Media replaced completely on alternate days.  
Day 7: Cells transitioned gradually onto IPSc media* by initially replacing half the PBMC 
media with complete IPSc medium.  
Day 8: Complete media change performed and complete IPSc media* added  
Day 9–28: Media changed daily.  
 
A1.2 Validation methods:  Detection of expression of endogenous pluripotency markers 
versus transgenes by RT-PCR 
Media was aspirated from IPScs and cells were pelleted from one confluent well of a 6-well 
plate and lyse with 250 lysis buffer. RNA isolation was performed as per manufacturers 
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protocols (GenElute mammalian total RNA miniPrep kit, Sigma, UK).  500ng of DNase treated 
RNA for reverse transcription according to SuperScript(R)II Reverse Transcriptase 
manufactures protocol (Life Tech., UK).  
Table S2:  MasterMix for Q-PCR was prepared according to the table below: 
Reagent Volume per well 
F primer [5µM]  0.6µl 
R primer [5µM] 0.6µl 
Sensi Mix (2x] 7.5µl 
Nuclease free water 1.3µl 
Total volume of the 
MasterMix 
10µl 
 
cDNA was diluted 30x in sterile water and 5µl of this mixture cDNA was mixed with 10µl of 
the MasterMix.  The Q-PCR was run with primers set for detection. 
Table S3: Endogenous genes encoding pluripotency markers 
Primers 
for detection 
Sendai virus 
transgenes 
Sequence Annealing  
Temp 
Product size 
Oct3/4 (p) F CCC GAA AGA GAA AGC GAA CCA G 55°C 483bp 
Oct3/4 (p) R AAT GTA TCG AAG GTG CTC AA 55°C 
Sox2 (p) F ATG CAC CGC TAC GAC GTG AGC GC 55°C 451bp 
Sox2 (p) R AAT GTA TCG AAG GTG CTC AA 55°C 
Klf4 (p) F TTC CTG CAT GCC AGA GGA GCC C 55°C 410bp 
Klf4 (p) R AAT GTA TCG AAG GTG CTC AA 55°C 
c-Myc (p) F TAA CTG ACT AGC AGG CTT GTC G 55°C 532bp 
c-Myc (p) R TCC ACA TAC AGT CCT GGA TGA TGA TG 55°C 
SeV F GGA TCA CTA GGT GAT ATC GAG C 55°C 181bp 
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In vitro differentiation of IPScs into three germ layers 
In order to validate differentiation capacity of IPScs, in vitro differentiation of IPScs into three 
germ layers: endoderm, mesoderm, neuroectoderm must be performed. 
 
Day	1
Activin +
FGF2	+
BMP4	 +
LY	+	
CHIR
Day	2
Activin +
FGF2	+
BMP4	 +
LY	
Activin +
FGF2	+
ENDODERM
Day	3 Day	4
Day	1
Activin +
FGF2	+
BMP4	 +
LY	+	
CHIR
Day	2
Activin +
FGF2	+
BMP4	 +
LY	+	
CHIR
Day	3
Activin +
FGF2	+
BMP4	 +
LY	+	
CHIR
MESODERM
Day	4
Day	1
SB431542		+
FGF2	+
Noggin
Day	2	
SB431542		+
FGF2	+
Noggin
Day	3
SB431542		+
FGF2	+
Noggin
Day	4
SB431542		+
FGF2	+
Noggin
Day	5
SB431542		+
FGF2	+
Noggin
Day	6
SB431542		+
FGF2	+
Noggin
Day	7
SB431542		+
FGF2	+
Noggin
Day	8
SB431542		+
FGF2	+
Noggin
Day	9
SB431542		+
FGF2	+
Noggin
Day	10
SB431542		+
FGF2	+
Noggin
NEUROECTODERM
Day	11
Fig.S1:  Differentiation of iPSc into the three germ layers according to media supplementation.  (A)Endoderm and 
(B)mesoderm have similar components but notably BMP4 is only required short term in endoderm but longer to differentiate 
cells to mesoderm.  Mesoderm also requires the presence of LY and CHIR.  (C)Neuroectoderm development is a lengthier 
process requiring 10 days of culturing in the presence of SB431542, FGF2 and Noggin in order to achieve differentiation.
A
B
C
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Differentiation into Endoderm (fig. S1A) 
Day 1 - after 24 hrs aspirate media and add 1ml per well of CDM-PVA containing: 
10µl Activin [10µg/ml] /ml  
20µl FGF2 [4µg/ml] /ml  
1µl BMP4 [10µg/ml] /ml  
1µl Ly [10mM] /ml  
1µl CHIR [3mM] /ml  
 
Day 2 - after 24 hrs aspirate media and add 1ml per well of CDM-PVA media 
containing: 
10µl Activin [10µg/ml]/ml  
20µl FGF2 [4µg/ml]/ml  
1µl BMP4 [10µg/ml]/ml  
1µl Ly [10mM]/ml 
 
Day 3 - after 24 hrs aspirate medium and add 1ml per well of RPMI media containing: 
10µl Activin [10µg/ml] /ml  
20µl FGF2 [4µg/ml] /ml  
 
After 24 hrs aspirate media and perform Q-PCR as described above.  
 
Differentiation into Mesoderm (fig. S1B) 
Day 1 - after 24 hrs aspirate media and add 1ml per well of 12-well plate of CDM-PVA 
containing: 
10µl Activin [10µg/ml] /ml  
5µl FGF2 [4µg/ml] /ml  
1µl BMP4 [10µg/ml] /ml  
1µl Ly [10mM] /ml  
1.66µl CHIR [3mM] /ml  
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Change media daily for two more days 
After 3 days of differentiation aspirate medium and validate with Q-PCR 
 
Differentiation into Neurectoderm (fig. S1C) 
After 24 hrs aspirate medium and add 1ml per well of 12-well plate CDM-PVA 
containing: 
1µl SB [10µM]/ml  
3µl FGF2 [4µg/ml] /ml  
1.5µl Noggin [100µg/ml]/ml  
 
Change medium daily for 10-12 days 
After 10-12 days of differentiation aspirate medium and validate with Q-PCR  
 
Detection of differentiation markers by immunostaining  
Cells were fixed with 4% paraformaldehyde.  Blocking solution was prepared by mixing 10ml 
D-PBS, 1ml Serum + 10µl Triton). Cells were covered with 0.5ml of D-PBS + 0.1% Triton X-
100 per well of 12-well plate and incubated at room temperature for 20 minutes to one hour. 
Primary Antibody Dilution was done in Dako Diluent (Cambridge, UK) according to the table 
below. 300µl of solution was added per well of 12-well plate (either 1% serum (or BSA), 0.1% 
Triton X-100 in D-PBS can be used for incubation with Primary Antibody).  Blocking solution 
was aspirated and replaced by the Primary Antibody.  Cells were incubated for 1 hour at room 
temperature.  The Primary Antibody was removed and replaced by PBS.  Cells were shaken 
for 5 minutes (gently) – table S4.  
The Secondary Antibody Dilution was prepared as follows: 
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1-1000 > 4µl Ab - 4000µl (Dako Diluent) per 1well of 12-well plate and 
multiply by number of wells to be stained 
1-2000 > 2µl Ab - 4000µl (Dako Diluent) per 1well of 12-well plate and 
multiply by number of wells to be stained 
 
PBS was aspirated from the cells and the Secondary Antibody was added.  Cells were incubated 
in the dark at room temperature for up to 2 hours.   
The Secondary Antibody was aspirated and replaced with PBS. In order to visualize cells 
(DNA) DAPI was added in first wash (DAPI 1µl -10 000µl PBS).  Cells were gently shaken 
for 2 minutes and PBS aspirated – this step was repeated x2.  Cells were then visualized using 
confocal microscope. 
Table S4: Antibodies used for pluripotency marker detection 
Primary Ab  Clonality/animal where Antibody  
raised 
Dilution Supplier/ 
Cat Number 
Pluripotency  
markers 
   
hNanog PolyIgG  Goat   1:100 R&D AF1997 
hSox2 PolyIgG  Goat   1:200 R&D AF2018 
hTRA-1-60 MonoIgM  Mouse  1:100 Santa Cruz sc-
21705 
hOct-3/4 (C-10) MonoIgG  Mouse  1:100 Santa Cruz sc-5279 
 
Alkaline Phosphatase staining 
10% neutral formalin buffer with formaldehyde was prepared (all reagents Sigma, UK 
unless stated otherwise) 
Na2HPO4 16g 
Na2HPO4:H2O 4g 
In	cold	room	as	stock	
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Dist water 1l 
Formaldehyde added to make final 4% solution. 
Substrate solution was prepared as follows: 
a) 0.0025g Napthol As Mx-PO4 (freezer) in 100ul N,N, DMF (dimethylforamide) 
12.5ml 0.2M pH8.3 Tris-HCl 
 
b) 0.015g Fast red violet (freezer) 
12.5ml distilled water 
 
‘a’ and ‘b’ were added together and filtered using Whatman Filter 1 paper. 
 
The cells were washed x1 in cold PBS and fixed in 10% cold NFB for 15 minutes.  They 
were washed x1 in distilled water (cold).  Water was replaced and cells left on ice for 15 
minutes. Following this the water was aspirated and the substrate solution added.  Cells 
were incubated in the dark for up to 45 minutes.  Following this substrate was aspirated 
and cells washed x1 with water.  Cells visualised by light microscope. 
 
A1.3. Additional figures for chapter 4 
Figures S2-S7 represent FACS data obtained from healthy donors, showing response of 
T-cells to phosphopeptides. They supplement data presented in Fig. 4.7-4.10. 
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
GPRSAsLLSL
RPAsAGAML
Fig. S2A: Phosphopeptide responses in Healthy Donor P(day 0) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα,.
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Fig. S2A:Phosphopeptide responses in Healthy Donor P(day 0) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα,
RPQRA(ts)NVF
RPRsPRQNSI
SPRRsRSISL
TPRsPPLGL
RPWsPAVSA
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
GPRSAsLLSL
RPAsAGAML
Fig. S2B:Phosphopeptide responses in Healthy Donor P (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα,
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Fig. S2B:Phosphopeptide responses in Healthy Donor P(day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα,
RPQRA(ts)NVF
RPRsPRQNSI
SPRRsRSISL
TPRsPPLGL
RPWsPAVSA
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
GPRSAsLLSL
RPAsAGAML
Fig. S3:Phosphopeptide responses in Healthy Donor C (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB no Viral response obtained. NB. IFN-G = IFNγ, TNF-a = TNFα.
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Fig. S3:Phosphopeptide responses in Healthy Donor C (day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
RPRsPRQNSI
SPRRsRSISL
TPRsPPLGL
RPWsPAVSA
RPQRA(ts)NVF
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Fig. S4:Phosphopeptide responses in Healthy Donor O (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
GPRSAsLLSL
RPAsAGAML
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Fig. S4:Phosphopeptide responses in Healthy Donor O (day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
RPRsPRQNSI
SPRRsRSISL
TPRsPPLGL
RPWsPAVSA
RPQRA(ts)NVF
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
RQAsIELPSM
RQDsTPGKVFL
Fig. S5: Phosphopeptide A2 responses in Healthy Donor H (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
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Fig. S5:Phosphopeptide responses in Healthy Donor H(day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
ALDsGASLLHL
FLDtPIAKV
SMTRsPPRV
KAFsPVRSV
KLFPDtPLAL
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
RQAsIELPSM
RQDsTPGKVFL
Fig. S6:Phosphopeptide A2 responses in Healthy Donor S (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
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Fig. S6:Phosphopeptide responses in Healthy Donor S(day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
FLDtPIAKV
SMTRsPPRV
KAFsPVRSV
KLFPDtPLAL
ALDsGASLLHL
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Gating strategy
Negative 
(DMSO)
Positive 
(PHA)
Viral control
QPEWFRNLV
RQAsIELPSM
RQDsTPGKVFL
Fig. S7:Phosphopeptide A2 responses in Healthy Donor N (day 7) 
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
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Fig. S7:Phosphopeptide responses in Healthy Donor N (day 7) cont..
PBMC’s were generated from healthy donors and responses of these to tumour-associated phosphopeptides were then assessed 
using an ICS assay.  The FACS plots depicted show the gating strategy employed and representative IFNγ ,TNFα, and IL-2 
responses (from left to right). NB. IFN-G = IFNγ, TNF-a = TNFα.
FLDtPIAKV
SMTRsPPRV
KAFsPVRSV
KLFPDtPLAL
ALDsGASLLHL
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A1.5. Calculation of TCID50 
Excel	calculator	courtesy	of	Dr	Marco	Binder,	Dept.	Infectious	Diseases,	Molecular	Virology,	Heidelberg	University.	TCID50	is	calculated	by	
the	Spearman	&	Kärber	algorithm	as	described	in		Hierholzer	&	Killington	(1996),	Virology	Methods	Manual,	p.	374.	
	
volume per well:  1000 µl  
replicate wells per dilution:  3  
dilution factor:  1: 10  
 
dilution in the first well:  1: 100  
 
dilution  number of   
 
wells with 
clearing >50%   
1:100  (10^-2) ## 3   
1:1000  (10^-3) ## 3   
1:10000  (10^-4) ## 3   
1:100000  (10^-5) ## 2   
1:1000000  (10^-6) ## 2   
1:10000000  (10^-7) ## 2   
1:100000000  (10^-8) ## 2   
1:1000000000  (10^-9) ## 1   
1:10000000000  (10^-10) ## 1   
1:100000000000  (10^-11) ## 0   
1:1000000000000  (10^-12) ## 0   
1:10000000000000  (10^-13) ## 0   
     
last complete infection at dilution: 10^-4   
 TCID50/ml: 5.5 +/- 0.47 log10 
TCID50/ml: 3.16E+05 
   +sd 6.20E+05  
   -sd 2.09E+05  
     
FFU/ml (aprx.): 2.18E+05 
   +sd 4.28E+05  
   -sd 1.45E+05  
     
 with FFU aprx. 0.69 x TCID50 
TCID50
stock	(Hugo)	
=3.16x10
6
/ml 
MOI
stock	(Hugo)
		 	 =2.24 
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Appendix 2: Research Outputs 
 
Presentations/Posters 
2017 5000 Livers International Symposium, Birmingham - Capturing T-cell Receptors.  A 
potential new modality for targeting hepatic tumours and Post-Transplantation 
Lymphoproliferative Disease – poster presentation 
2016 BSPGHAN, Bristol - Capturing T-cell Receptors.  A potential new modality for 
targeting hepatic tumours and Post-Transplantation Lymphoproliferative Disease 
(PTLD) – oral presentation and award of Alex Mowatt Prize for hepatology 
2016 ESPGHAN, Greece - Capturing T-cell Receptors.  A potential new modality for 
targeting hepatic tumours and Post-Transplantation Lymphoproliferative Disease 
(PTLD) – poster Presentation and award of Young Investigator Award and Poster prize. 
2015 ESPGHAN, Netherlands - Capturing T-cell Receptors.  A potential new modality for 
targeting hepatic tumours and Post-Transplantation Lymphoproliferative Disease 
(PTLD) – poster Presentation 
2014 EASL International Liver Congress 2014, London - GeneChip:  Identifying Incidence 
Of Inherited Metabolic Disorders In Patients With Infantile Liver Disease – oral 
presentation 
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2013 AASLD, Washington, USA – Annual meeting – (1)  Long term outcome of paediatric 
patients 15 years after liver transplantation – poster presentation.  (2)  The use of hIPSc 
in treatment of metabolic diseases affecting the liver – poster presentation.  (3)  
GeneChip:  Identifying Incidence Of Inherited Metabolic Disorders In Patients With 
Infantile Liver Disease – oral presentation. 
 
Awards and Prizes 
2017:  ESPGHAN Transplant School prize, Bergamo, Italy 
2016:  Alex Mowatt Hepatology Prize BSPGHAN 
2016:  ESPGHAN Young Investigator Award 
2016:  ESPGHAN poster award 
2014:  EASL Young Investigator Award 
 
